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A b st r a c t
Biopharmaceutical drug development is risky, lengthy, and expensive. Decisions in 
this delicate process are complicated by constraints on resources such as available 
capacity and uncertainties that include the risk of clinical failure. Hence, the impact 
of making sub-optimal decisions in this environment can be severe. Accordingly, this 
work explores the development of algorithms to support strategic drug development 
decisions and contains four results sections.
Firstly, a décision-support framework based on multi-criteria decision making 
(MCDM) is presented for assessing options when acquiring biopharmaceutical 
manufacturing capacity. An example ease illustrates the use of this framework where 
a biopharmaceutical company is faced with options for acquiring commercial 
manufacturing capacity. The development portfolio consists of three monoclonal 
antibody drugs at varying stages of clinical development with varying levels of 
demand. Capacity acquisition options include building in-house capacity, 
outsourcing, and partnering in addition to some hybrids of these. Deterministic and 
stochastic analyses showed that building manufacturing capacity ranked highest for 
the scenario considered when accounting for both financial and operational metrics. 
Secondly, the development of a stochastic combinatorial multi-objective optimisation 
framework is presented which confronts the problem of handling the multitude of 
decisions and trade-offs when designing portfolio management strategies, which 
results in extremely large decision spaces. The framework is considerate of strategic 
decisions that include the portfolio composition, the scheduling of critical 
development and manufacturing activities, and the involvement of third parties for 
these activities. The framework simulates development and manufacturing alongside 
the wider commercial environment. Machine learning and evolutionary computation 
techniques are also harnessed to characterise the conditional and probabilistic 
structure of superior decisions and evolve strategies to multi-objective optimality. A 
case study is constructed to derive insight from the framework where results
demonstrate that a variety of options exist for formulating nondominated strategies in 
the objective space considered, giving the manufacturer a range of pursuable options. 
The most preferred means for development across the set of optimised strategies is to 
fully integrate development and commercial activities in-house, however, alternatives 
include partnering during early stages of portfolio development and then coordinating 
outsourced and in-house activities for remaining drugs. Popular scheduling strategies 
tend to develop two drugs in close succession while spacing out the remaining drug 
development activities into longer time frames. Thirdly, this framework is expanded 
to explore the impact of the size of biopharmaceutical drug development portfolio and 
cash flow constraints on algorithmically formulated strategies. Illustrative examples 
suggest that naively applying strategies optimal for a particular size of portfolio to a 
portfolio of another size is inappropriate. Also, the size of the portfolio appears to 
have a larger impact on strategy than the magnitude of cash flow constraint. Fourthly 
and finally, the economics of biopharmaceutical manufacture are explored with the 
aim of developing equations that can estimate the cost of manufacturing for both 
monoclonal antibodies and antibody fragments using mammalian cell culture and 
bacterial fermentation respectively. The correlations, derived using multiple linear 
regression, allow the cost of goods to be estimated given the following inputs: the 
required annual output, fermentation titre, whole process yield, and the probability of 
achieving a successful batch.
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C h a p t e r  1
Liter a t u r e  Review
1.1 In t r o d u c t io n
Biopharmaceutical developers face highly significant challenges from the 
commencement of research and development through to the marketing stage of a 
therapeutic. The cost of drug development has been reported to be in excess of 
$800MM (DiMasi et a l, 2003; Adams and Bratner, 2006; Boston Consulting Group,
2 0 0 1 ); with development times from clinic to market typically being 6  to 1 0  years 
years (Too et a l, 2001; Ashton, 2001; Wemer, 2004; Reichert, 2003); and 
probabilities of success usually being below 35% (Pavlou and Reichert, 2004; 
Reichert et a l, 2005). Additionally, Ransohoff (2004) comments that 
biopharmaceutical products are also among the most technically complex to 
manufacture of any industry. These key points collectively convey that planning for 
successful biopharmaceutical development is non-trivial and that developers are 
forced to make optimal use of their resources through intelligent and thorough 
planning. Despite this Dabbah (2007) indicates that relatively few pharmaceutical 
and biotechnological organisations have been able to properly manage the interface 
between research and development and their overall organisation. This suggests that 
there is a significant opportunity for comprehensive portfolio management tools to 
assist industrial decision makers towards more effective strategy formulation and 
execution. Consequently, the underscored aim of this thesis is the development of a 
dmg development portfolio management tool that is capable of simulating and 
optimising strategic decision making in this challenging setting.
To establish a starting point for the development of décision-support algorithms for 
biopharmaceutical dmg development this introductory chapter explores published 
literature on the dmg development process, dmg manufacture, alternative options to 
in-house development, and computational fi’ameworks aimed at optimising decisions
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made during this process. Section 1.2 provides an overview of the biopharmaceutical 
drug development process that includes probabilities of success, economics, and 
timelines for development. Section 1.3 reviews pertinent aspects of 
biopharmaceutical manufacture which includes capital cost requirements, cost of 
goods figures, and implications for drug pricing. Section 1.4 explores outsourced and 
partnered approaches as alternative options to complete in-house drug development 
and manufacture. Section 1.5 highlights computational frameworks and approaches 
available in literature that are relevant to this work. Finally, the aims and organisation 
of this thesis are discussed in section 1 .6 .
1.2. B io p h a r m a c e u t ic a l  D r u g  D e v e l o p m e n t
Biopharmaceutieals are typically protein-based therapeutics agents produced by 
modem biotechnological techniques (Walsh, 2005; Schellekens, 2002), and have been 
described as described as therapeutics of the twenty-first century Tsuji (2007). 
Examples include hormones (e.g. insulin for diabetes), growth factors (e.g. 
erythropoietin for anaemia), and monoclonal antibodies (e.g. infliximab for 
rheumatoid arthritis). These have been produced in either genetically engineered 
microorganisms (e.g. E.coli) or animal cell-lines (e.g. Chinese hamster ovary cells). 
This group of therapeutics represents a noteworthy progression in the development of 
treatments for conditions and diseases whose counteraction requires the molecular 
targeting specificity that protein based dmgs have the capacity to provide. This thesis 
takes a particular perspective on addressing monoclonal antibody based therapeutics 
whose development, like all biopharmaceutieals, typically carries a higher risk of 
failure than success, requires significant expenditure in capital and operating costs, 
and is considerably lengthy. The development route for a biopharmaceutical is 
exhibited in Figure 1.1 and as it can be seen several stages of testing are required 
before a therapeutic can be approved for market.
Pre-Clinical \ \  Phase  I P hase  II Phase U.
Testing ^ iH ^ lin lc a lT r ia  DlinicalTm DllnicalTrials^ fUAKevie MarKet





Target identification is the stage where at least one disease target is identified with the 
complementary screening of therapeutic compounds that can demonstrate some 
acceptable level of potential in counteracting disease. Recently, techniques to 
facilitate this process have included combinatorial chemistry which can generate 
whole classes of compounds quickly, genomics which allows a greater understanding 
of disease targets at cellular and molecular levels, and high throughput screening 
which uses robotics to screen and obtain data on the potency of compounds (Monane, 
1998). Preclinical trials will test any promising therapeutics in animal models so as to 
study safety and toxicity. Patents are typically applied for upon successful 
completion of this period. Also, drug developers will apply to their respective 
regulatory body for legal permission to progress with testing on human subjects. In 
the USA this body is the Food and Drug Administration (FDA). In the UK the 
equivalent for this purpose is the European Medicines Agency (EMEA). Three stages 
of clinical testing ensue, with each stage requiring a larger number of human subjects 
than the previous. For phase I, II, and III clinical trials these numbers are typically 
and respectively 20-80, 100-500, and 1000-5000 (Pharmaceutical Research and 
Manufacturers of America, 2005). Phase I testing is aimed at determining safety and 
dosage information. Phase II clinical testing is used to demonstrate that the 
therapeutic carries a clinical efficacy that is statistically significant. Phase III trials 
are used to provide information for package labelling, such as side effects, and to 
make comparison to standard drugs used for treatment, if any exist. Upon successful 
completion of phase III clinical trials a drug developer will apply for a biologies 
license application (BLA), or the equivalent, for approval from the regulatory body to 
allow marketing of the therapeutic. Post approval, the drug developer is required to 
continue testing the marketed drug to study longer term effects on patients and to 
glean a detailed understanding of dosage requirements (Liang, 2002). This post 
approval testing is often referred to phase IV testing.
1 .2 .1 . P r o b a b il it ie s  o f  s u c c e s s
Biopharmaceutical therapeutics are typically subject to high failure rates when 
undergoing the development process. This is in part due to the highly structured 
nature of the approval procedure, and the stringent regulatory standards that exist for 
each stage of progression in the development process. Data for the transitional
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probabilities of success of selected biopharmaceutieals for each stage in the 
development route from phase I clinical trials onwards is presented in Table 1.1. 
Given that success rates from phase I clinical trials to market are typically are in the 
range of 10%-35%, these probabilities typically result in a development route that is 
more likely to fail than succeed for any one drug. For certain products, particularly 
monoclonal antibodies, Table 1.1 shows that phase II clinical trials carry the smallest 
likelihood of success. Literature explaining why this feature in clinical trial success 
rates exists has not been found. A survey conducted by Pavlou and Reichert (2004) 
indicates that for some groups of recombinant protein drugs the likelihoods of 
successfully traversing the entire clinical trial process and gaining approval for 
marketing have increased, though they do not provide a specific reason for this. 
These groups are diabetes and endocrinology, and anti-infectives. It is also seen in 
Table 1.1 that aside from anti-neoplastic (anti-tumour antibiotics) therapeutics, the 
monoclonal antibody products generally carry a lower probability of success than 
other recombinant protein products. Of the monoclonal antibody products shown 
chimeric products exhibit a stronger likelihood of progressing through clinical trials 
than humanised products. Reichert et al. (2005) comment that their research suggests 
the possibility that more stringent selection procedures were applied with chimeric 
products, particularly with the selection of drugs entering phase III clinical trials 
where a transitional probability of 1 is observed. Overall, it should be underscored 
that the number of drugs explored in the studies mentioned are relatively small and 
thus the probabilities of success observed are likely to be subject to some variance as 
more biopharmaceutieals enter the clinical trial process. Such data is relevant from a 
portfolio management perspective because intuitively a major factor in the selection 
of drugs for a research and development portfolio is the probability of success 
expected from a particular drug candidate. Rates of success for individual 
development phases are also likely to influence decisions that require the allocation of 
significant capital. For example, a drug developer may consider whether it is more 
appropriate to outsource commercial manufacturing instead of building in-house 




Table 1.1. Published clinical trial transition probabilities for biopharmaceutical therapeutics.
Phase I to Phase II to Phase III to Phase I to
Type Application n Phase II Phase III Market Market
Recombinant protein* D&E 22 0.91 0.84 0.81 0.69
AIID 15 1.00 0.73 0.63 0.46
CV/haemostasis 35 0.88 0.75 0.39 0.26
Anti-infectives 12 0.83 0.50 1.00 0.42
Anti-neoplastic 9 1.00 0.13 1.00 0.13
Chimeric’’ MAb All 39 0.69 0.36 1.00 0.25
Oncological 21 0.60 0.75 1.00 0.45
Immunological 9 0.67 0.36 1.00 0.24
Humanised” MAb All 102 0.80 0.51 0.69 0.28
Oncological 46 0.76 0.60 0.80 0.36
Immunological 34 0.88 0.43 0.80 0.30
Source; a. Pavlou and Reichert (2004), and b. Reichert et al. (2005). Notation: n -  number o f drugs 
included in the survey, MAb -  monoclonal antibody, D&E -  diabetes and endocrine, AIID -  arthritis, 
inflammation, and immune disorders, and CV cardiovascular. Chimeric products are antibodies 
where variable regions are murine and constant regions are human. Humanised products are 
constructed with mouse antigen binding regions derived and the remainder derived from a human 
source.
On the subject of controlling probabilities of success during clinical trials, Dutton 
(2007) suggests that these can be maximised with intelligent design and preparation of 
clinical trials throughout. This includes commencing clinical trials only when enough 
information is known about the drug compound, working with regulatory agencies 
before clinical trials take place, and diligent use of preclinical predictive models. 
Whilst such information is important for managing drug development effectively it is 
difficult to include in portfolio management tool considerations as the impact on 
probabilities of success is difficult to quantify. In many cases the decision maker can 
only account for appropriate and evidenced probabilities of success even if it is 
postulated that a superior approach to typical industry practices exist. From an 
alternative perspective it is critically important that upon the selection of a portfolio 
management strategy, project execution fully reflects the assumptions made on 
performance factors such as the probabilities of clinical trial successes. This means 




1 .2 .2 . D e v e l o p m e n t  e c o n o m ic s
Recent figures for the cost of development of a single drug have been indicated to be 
in excess of $800 million. DiMasi et a l (2003) have reported calculations that put 
this figure at $802MM. Adams and Brantner (2006) repeated this study and have 
reported their estimate to be $864MM. Boston Consulting Group (2001) reports their 
estimate to be S880MM. As an example of how these costs are allocated within the 
drug development process, sample cost data from DiMasi et a l (2003) are presented 
in Table 1.2. As expected, these costs increase considerably with each stage and the 
cost of phase III trials is nearly six times the cost of phase 1 trials. Interestingly, the 
data shows that the standard deviation for cost of development for each stage is 
comparable in magnitude to the mean and median values. With such variance, the 
meaning for drug developers taking a conservative perspective is that they can 
justifiably expect to spend double the mean and median estimates.
Table 1.2. Cost data for clinical trials.
Clinical Testing Phase Mean Cost Median Cost Standard Deviation
Phase I $15.2MM $13.9MM $12.8MM
Phase II S23.5MM $17.0MM $22.1 MM
Phase III $86.3MM $62.0MM $60.6MM
Source: DiMasi et al. (2003)
It is clear that the costs in Table 1.2 do not sum to the cost figures stated in literature 
that are in excess of S800MM. This is because the above figures stated in literature 
also account for the cost of failed drug development projects. DiMasi et a l (2003) 
and Adams and Brantner (2006) use the same calculation method but different 
databases, which are the Tufts Center for the Study of Dmg Development database 
and the Pharmaprojects database, respectively. Broadly, the average cost of 
progressing a drug through the approval stages is determined, which is then divided 
by the probability of obtaining marketing approval for a drug in phase I, and adjusted 
to reflect time value of money relative to when development commenced. The 
resulting figure is the total cost incurred in developing and approving one drug.
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1 .2 .3 . D e v e l o p m e n t  t im e l in e s
The average development time for a biopharmaceutical product has been reported to 
be as much as 12 years but is still consistently shorter than development times for 
their pharmaceutical counterparts (Ashton, 2001). Typical time to market figures for 
biopharmaceutical drugs are in the range of 6 to 10 years (Foo et a l, 2001; Ashton, 
2001; Werner, 2004; Reichert, 2003). Since 1970, the development time has 
exhibited a trend of increase over the long-term but more recently, since 2001, 
development times have become increasingly shorter (Reichert, 2003). Data 
published from the study conducted by Reichert (2003) is presented in Table 1.3 and 
show that development times for the therapeutics included in the study vary fi-om 5.8 
to 9.4 years. There appear to be no obvious trends that are specific to either 
recombinant proteins or monoclonal antibody therapeutics. For immunological 
applications monoclonal antibodies have shorter development times than recombinant 
therapeutics and the reverse is true for anti-neoplastic applications.
Table 1.3. Published development time data for biopharmaceuticals (years) developed during 1982- 
2001 .
Phase I, II, & III FDA Approval Total
Type Application n Mean Median Mean Median Mean Median
Recombinant protein Endocrine 10 4.3 4.7 1.4 1.1 5.8 6.1
Immunological 4 7.7 8.0 1.1 1.0 8.8 8.8
Cardiovascular 4 4.6 5.0 1.8 1.4 6.4 6.0
Anti-infective 3 8.2 7.1 1.2 1.1 9.4 8.2
Anti-neoplastic 4 3.9 4.3 2.3 2.3 6.2 5.9
Monoclonal antibody Immunological 4 5.5 5.7 1.0 0.6 6.4 6.5
Anti-neoplastic 4 6.7 5.5 0.8 0.7 7.5 5.9
Source: Reichert (2003). Notation: n ~ number o f drugs included in study.
1.3. B i o p h a r m a c e u t i c a l  m a n u f a c t u r e
Biopharmaceutical manufacture is a complex and delicate process that is typified by 
high capital costs for the building of facilities and necessary equipment, and high 
associated operating costs. Biopharmaceutical products are also among the most 
technically complex to manufacture of any industry (Ransohoff, 2004), take longer to 
manufacture than chemical entities, and require production operations that are more
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difficult to control (McGurk, 2004). In recent years, it has been reported that the 
biopharmaceutical industry has been faced with potential shortages in manufacturing 
capacity with decreasing revenue potential. This is also exacerbated by higher 
pressures fi-om regulatory bodies (Pisano, 1997; Molowa, 2001). Although 
anticipated shortages may not have been realised (Ginsberg et al, 2002) the 
importance of this issue to the biopharmaceutical industry was clearly displayed in the 
general level of concern generated at the time. Consequently and critically, this 
demonstrates a link between a drug developer’s manufacturing operations and its 
long-term business strategy. Published studies have indicated this in a more 
generalised context, for example see Brown (1998) and Demeter (2003). Brown 
(1998) provides evidence that manufacturing strategy is a principal factor in the 
success of new product development by linking it to operational capabilities that can 
directly guide the direction and scope of a business. Demeter (2003) surveys over 
700 companies and notes that return on sales figures are significantly higher for 
companies possessing a manufacturing strategy than for those who do not. For the 
biopharmaceutical industry in particular, aligning decisions with a business strategy 
forms a major factor in the decision of whether to make products in-house or to 
outsource their manufacture to a contractor (Ransohoff, 2004; Seymour and Galliher,
2002). Because of the significant costs and resources required, the manufacturing 
strategy undertaken is influenced by the approach to portfolio management and drug 
development issues. The size of the portfolio, success rates through clinical trials, 
doses and expected market demand for each drug dictate the potential production 
requirements. The budget, cost of drug development, and speed to market required 
constrain the amount of capital that can be allocated to manufacturing within a 
specific time-period and how long the company has to acquire manufacturing 
capacity. All of these factors increase the difficulty facing biopharmaceutical firms, 
especially smaller ones, in achieving success in the industry.
One driver of both capital and operating costs is that products such as monoclonal 
antibodies are usually required in high doses (Toi et al., 2004; Finesilver, 2003; 
Costello and Halverson, 2003) and emphasises the demand for the construction of 
facilities with high production capacities. This is further exacerbated by the 
increasing number of applications for biopharmaceuticals such as monoclonal 
antibodies (Lotgenberg, 2007, Reichert and Dewitz, 2006) which will require further
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increases in capacity for the manufacture of complex biologies. Reichert and Dewitz 
(2006) have reported that between January 2000 and June 2005 more than 130 
monoclonal antibodies entered clinical trials, and have noted the possibility that this 
number could reach 240 by 2010. Elsewhere, it has even been predicted that a 
shortage in manufacturing capacity would currently exist by as much as a quarter of 
demand (Molowa, 2001). More recently it has been noted that this expected shortfall 
did not materialise, rather it has actually been suggested that the industry currently 
holds an excess of manufacturing capacity (Thiel, 2004). Miller (2008) supports this 
view by reporting that in 2007 investments in biopharmaceutical manufacturing and 
laboratory facilities by the 15 largest biopharmaceutical corporations totalled $21.98, 
their highest since 2004. A survey conducted by Langer (2007a) provides further 
evidence of excess manufacturing capacity by reporting figures for the utilisation of 
full manufacturing capacity in industry. For mammalian expression systems 
utilisation during 2003, 2005, and 2007 was 76%, 69%, and 64% respectively. For 
bacterial expression systems these figures were 71%, 61%, and 62% respectively. 
Both sets of figures show a general decrease in capacity utilisation since 2003. The 
main reasons provided given for this by Langer (2007a) include improving titres, 
whole process yields, relationships with CMOs, and managerial competency. From a 
portfolio management perspective such drivers imply that integrating manufacturing 
capacity is becoming more attractive due to increasing productivity, finding contract 
manufacturing capacity may be easier than in previous years, and perhaps the gap 
between planning and executing strategies is becoming narrower.
Manufacturing processes for biopharmaceutical products will usually consist of an 
animal cell culture (using CHO cells for example) or a microbial fermentation (using 
E.coli or S.cerevisiae for example) procedure that aims to first grow the host cell 
responsible for the production of the desired protein and then to express that protein in 
the desired quantity. This procedure is also known as upstream processing. Of the 31 
therapeutic proteins approved between 2003 and 2006, 9 are produced in E. coli and 
17 are produced by mammalian cell lines (Walsh, 2006). Mammalian cell culture is 
technically complex, slow and expensive, but these cell lines are used due to their 
capability to produce large therapeutic proteins that require post-translational 
modification such as glycosylation. With specific regard to antibodies, mammalian 
cell culture manufacturing routes show greater promise for the production of whole
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fiilly-human monoclonal antibodies whilst bacterial cell culture appears to be most 
favourable for antibody fragments (Chadd and Chamow, 2001). As the product is 
initially crude it must be purified through a series of purification operations, 
eollectively known as downstream processing. At each stage some of the crude 
product is lost, so increasing the efficieney of produetion is a challenge that 
biopharmaceutical manufacturers across the industry are interested in meeting even if 
only for the sake of increasing profitability. Additionally, all facilities must meet 
striet guidelines that are certified to align with current good manufacturing practice 
(eGMP) and it is critical to note that this strietness is further supported by the premise 
that the process by which biopharmaceuticals are manufactured defines their function 
and activity (Griffiths, 2004). Hence, biopharmaceutical manufacturers are pressured 
to design the commercial manufacturing process correctly in the first instance. 
Alongside significant set-up and running costs as well as strict regulatory guidelines, 
there is considerable uncertainty that impacts manufacturing process deeisions. These 
include uncertainties in the necessity for glycosylation (Wemer, 1999), the clinical 
development timeline, the effieiency of manufacturing operations, and the annual 
output of the required product (Wemer, 2004).
Risk is an irremovable obstacle for the drug developer and it should be eonsidered in 
the proeess of planning for drug development. Mohs (2008) reeognises that there are 
three principal risks that can lead to failure in dmg development; target risk, clinical 
development risk, and market risk. Target risk poses an obstacle for the dmg 
developer in finding a disease target such that administration of the dmg leads to 
ineffective treatment of the disease. This risk is exacerbated by the biological 
complexity of the disease. Clinical development risks include the technical 
probabilities of success in bringing a dmg to market alongside uncertainties in 
development costs and the time taken to achieve market approval. Nicholson and 
Latham (1994) note that even a month’s delay in gaining marketing approval can lead 
to many millions of dollars in lost sales revenue. Market related risks include 
significant uncertainty in forecasted dmg prices partly due to lengthy lead 
development times which can impact profitability considerably. Also, determining 
expected levels of demand can introduce difficulty in planning the capacity design 
specifications for manufacturing. Ultimately, target uncertainties influence the 
difficulty of finding effective dmgs, developmental uncertainties can terminate
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development of a drug before a return can ever be realised, and market related 
uncertainties influence whether a marketed drug ever meets the revenue expectations 
of the developer. Brastow and Rice (2003) further consider uncertainties in 
manufacturing capabilities, such as whole process yields, and finding high quality 
outsourcing capacity, should this be relevant to the drug developer. Nicholson and 
Latham (1994) also mention government intervention in drug pricing and healthcare 
reforms as risks that can significantly influence profitability. When managing the 
impact of uncertainty it is of interest to biopharmaceutical companies to delay fixed 
investment costs till as late as possible, minimise development and production costs, 
and preserve the ability to meet demand when eventually reaching the marketplace. 
Hence, a major and ubiquitous problem confronting biopharmaceutical drug 
developers is how and when to best make and implement critical business decisions 
so that important rewards such as profitability are optimised. Yet more expensive, 
risky and complex is the development of a portfolio of drug candidates, especially 
under the limitation of constrained resources. Within the framework of a company’s 
pipeline, valuing one drug at a time is not sufficient and drug developers must 
consider the entire portfolio under technological and market uncertainty and resource 
constraints (Rogers et a l, 2002). Here the developer must also make decisions to best 
construct the portfolio such as to optimise the management of any resource and 
reward related trade-offs that each drug development project may introduce.
Other options for acquiring manufacturing capacity exist, such as outsourcing and 
partnering, and will be discussed later in this chapter. It is already observed that 
building frill manufacturing capacity gives the highest level of managerial control and 
intellectual property acquisition, but also requires the largest outlay of capital and 
carries the highest penalty in the event of failure. Because of the significant financial 
and operational impacts drug developers are forced to consider manufacturing 
strategies years in advance of construction and must ponder whether they should even 
be manufacturing the product themselves. It has been reported that building a 
commercial scale biopharmaceutical manufacturing facility can take at least three 
years (Ginsberg et a l, 2002, Wemer, 2004; Thiel, 2004). In light of this and 




1 .3 .1 . C a p it a l  C o s t  R e q u ir e m e n t s
Two broad classes of cost are of interest to drug developers in biopharmaceuticals, 
which are fixed capital investment and operating costs. The total fixed capital 
investment required includes the facility and equipment. The operating cost will 
typically include the cost of manufacturing materials, utilities, and wages. In this 
section, reported figures for these costs will be reviewed.
Pavlotsky (2004) conducted a study to approximate facilities cost, in which more than 
100 projects involving construction of a pharmaceutical facility between 1993 and 
2003 were investigated. Facilities in this study were considered in three sizes, 
100,000 sq.ft., 50,000 sq.ft., and 25,000 sq.ft and the findings are summarised in 
Table 1.4. From these figures it is immediately apparent that from this study the cost 
of constructing biopharmaceutical manufacturing facilities in the USA is more 
expensive than doing the same outside of the US. No explanation for this is given by 
Pavlotsky (2004).
Table 1.4. Construction cost for cGMP biopharmaceutical facilities.
Gross Size Net Size Cost Type USA Facilities Non-USA Facilities
100,000 sq.ft. 70,000 sq.ft. Total Cost S89MM $64MM
$/sq.ft. (gross) $893 $644
$/sq.ft. (net) $1258 $920
50,000 sq.ft. 30,000 sq.ft. Total Cost $43MM $31 MM
$/sq.ft. (gross) $862 $622
$/sq.ft. (net) $1437 $1036
25,000 sq.ft. 14,000 sq.ft. Total Cost $25MM $18MM
S/sq.ft. (gross) $984 $712
$/sq.ft. (net) $1757 $1271
Source: Pavlotsky (2004).
Pavlotsky (2004) also looked to identify patterns in the cost of constructing 
biopharmaceutical manufacturing facilities (Table 1.5). It can be seen that the base 
building cost and the equipment cost together comprise in the region of 50% of the 
total facility cost. Comparing to Lang factors (Lang, 1948) which linearly correlates 
the capital cost of equipment to the total capital cost of the facility, the figure seen in 
Table 1.5 for process equipment cost appears somewhat excessive. This figure would
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convert via its reciprocal to an equivalent Lang factor in the range of 3.3-3.7, whereas 
typical Lang factors for biopharmaceutical facilities have been considered to be from 
4 to over 8 times the equipment cost (Novais et al., 2001). This suggests that process 
equipment costs should comprise 13-25% of the total facility cost. It should be taken 
into account that such numbers should be treated as general guidelines and that it is 
the specific design of the facility that determines the appropriate Lang factor.
Table 1.5. Breakdown o f  construction costs.
Component Cost (% o f total facility cost)
Base building cost 22-25%
Process equipment cost 27-30%
Engineering, management and administration 13-16%
HVAC systems 9-12%
Process piping and utilities 8-11 %
Source: Pavlotsky (2004).
Additionally, Pavlotsky (2004) investigated factors influencing the cost of the 
manufacturing facility (Table 1.6). The most influential factor amongst these was the 
competence in constructing the facility, which can influence the cost of construction 
by up to 15%. The terms ‘luck of competence’ or ‘luck of ability to make decisions’ 
were not defined further in the publication. In context, these terms are respectively 
taken here to mean the chance that the skills required to complete construction are 




Table 1.6. Variables that influence the pharmaceutical cGMP facility construction cost (Pavlotsky, 
2004).
Component Variation (±)
Luck o f competence and luck o f ability to make decisions ±15%
Uniqueness o f process equipment, single source suppliers or competitive bidding ±7%
Materials o f construction ±5%
Utilities availability, requirements and constraints ±4%
Construction labour costs ±3%
Time-factor market constraints ±3%
Architectural concept, people movement and material flow organisation, open ^
process area or multiple compartments organisation
HVAC requirements: air changes, unidirectional or turbulent airflow, and air
pressure cascading, once-through air systems, active or passive differential ±2%
pressure control
Materials supply just-in-time or in-place warehousing ±2%
Interpretation o f validation or data acquisition requirements ± 1 %
Interpretation o f  life safety, fire safety, environmental safety, product safety and 
abatement requirements add or subtract 1%
± 1 %
Source: Adapted from Pavlotsky (2004)
It is clear that from Table 1.4 Pavlotsky (2004) correlates the floor size of the facility 
with the capital cost. An alternative approach of estimating cost might be based on 
the required output of therapeutic per year from the facility whilst accounting for 
additional technical manufacturing capabilities. Caleulations from Wemer (2004) 
with such an approach are displayed in Table 1.7. This clearly shows that significant 
cost savings in both capital expenditure and the cost of goods can result from 
increasing either the titre by which the therapeutic protein is expressed or the 
produetion yield. This highlights the importance of including such manufacturing 
characteristics into the eeonomics caleulations of biopharmaceutical manufacture. 
Wemer (2004) mentions that cost savings can also result from shortening the 
fermentation process time. This is intuitive because for a constant demand this means 
that more batehes would be produeed per year but requiring lower process volumes 
and smaller equipment requirements.
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Table 1.7. Facility cost calculations adapted from Wemer (2004).
Fermentation titre O.lgA Ig/L
Yield 40% 70%
Capacity required 62x10^ 3x10^
Number o f bioreactors 31 2
Capital cost $1,600MM SIOOMM
Cost o f goods per gram $1500 $260
Assumptions: 10,000L fermenters, 250kg/year biopharmaceutical therapeutic required, and $50K cost 
per bioreactor.
Surprisingly, considering the significance of the topic to the industry there are few 
studies in peer reviewed literature available on the economics of biopharmaceutical 
manufacture. It has even been reported that capital requirements are underestimated 
(Kessell and Frank, 2007).
1 .3 .2 . C o s t  o f  G o o d s
Equally as important as the capital expense ineurred in building a manufacturing 
facility is the cost associated with producing the product itself, otherwise known as 
the cost of goods. Studies on the cost of goods appear to be even lesser in number 
than capital estimates of biopharmaceutical manufacture despite it being one of the 
main drivers in the pricing of drugs (de Nohrona Pissarra, 2004). The principal cost 
driver in producing monoclonal antibodies is the bioreactor titre, even though 
chromatography may account for two-thirds of the downstream processing costs 
(Meyers, 2000). According to Meyers (2000), costs for monoclonal antibody 
production are approximately equally split between cell culture, purification, and 
support.
In a study published by Datar (1993) on tissue plasminogen activator (tPA) 
manufacturing, the operating costs and the distribution of the costs were analysed for 
mammalian and bacterial processes. An analysis of the annual production costs 
revealed that the annual direct manufacturing expense for the mammalian process was 
$70.9 million, approximately 60% of the total expense while that for bacterial $113
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million, approximately 47%. A detailed breakdown constructed by the authors is 
shown in Table 1.8.
Table 1.8. Annual operating expenses for the production o f tPA.
Mammalian production Bacterial production
Constituent Cost % Cost %
Fermentation $23,405,910 33% $1,129,670 1%
Recovery $7,801,970 11% $9,037,360 8%
Waste $7,092,700 10% $18,074,720 16%
Utilities $12,057,590 17% $22,593,400 20%
Labour and supervision $6,383,430 9% $24,852,740 22%
Pat./Royal. $12,057,590 17% $22,593,400 20%
Other $2,127,810 3% $14,685,710 13%
Total $70,927,000 100% $112,967,000 100%
Source: Datar (1993).
The analysis revealed that labour and supervision costs for the bacterial process were 
much higher than that for the mammalian process. This is most likely due to the 
complex recovery operations required following bacterial fermentations. The raw 
material costs were higher for mammalian processes, in part due to the expensive 
media required for the fermentation. One significant finding was the difference in the 
ratio between the cost of upstream processing and downstream processing for the two 
manufacturing routes. For the mammalian process this ratio was 3:1, while for the 
bacterial process it was 1:7, thereby highlighting the importance of the expression 
system in determining the distribution of costs within the cost of goods.
Similarly, Sommerfeld and Strube (2005) investigated the distribution of 
manufacturing expenses in the production of monoclonal antibodies (Table 1.9). In 
this study, a generic process flowsheet was established, based on existing monoclonal 
antibody production using mammalian cell culture methods in industry. To 
benchmark their findings they assume that the distribution of costs between the 
upstream and the downstream processes are in the range of 50-80% for downstream 
processes as suggested by Lowe (2001). Some important trends are demonstrated in 
Table 1.9 that are associated with an increase in fermentation titre. Within the 
distribution of the cost of goods attributable to downstream processing, equipment
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becomes less of a driver, consumables become more important, and the total cost of 
goods attributable to downstream processing becomes more of a determinant for the 
total cost of goods.
Table 1.9. Influence o f production rate on specific downstream costs.
Product Titre Concentration (g/L)
Downstream Cost Constituent O.lgA 0.3gA l.OgA
Equipment 65.7% 50.4% 32.7%
Consumables 16.8% 32.0% 49.1%
Waste 5.7% 7.7% 8.8%
Raw material 2.4% 4.2% 6.3%
Labour 8.1% 5.4% 2.7%
Other 1.3% 0.3% 0.4%
% o f total cost o f goods 45% 54% 70%
Source: Adapted from Sommerfield and Strube (2005).
1 .3 .3 . D r u g  P r ic in g
Appropriate drug pricing is essential for profitability. It is difficult to find 
information on the pricing of biopharmaceutical products but an empirical 
investigation into the sales price of monoclonal antibody drugs yields an interesting 
finding (Figure 1.2). It is clear from Figure 1.2 that there is an inverse relationship 
between drug price and annual demand in that the higher the demand the cheaper the 
sales price per gram of therapeutic. This is intuitive as revenues of the drug must 
cover fixed capital costs of manufacturing facilities, the costs of development, and the 
costs incurred candidates that have failed during the clinical trial process. An 
extreme example is Sim ulect^  which at the time of investigation was produced at an 
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Figure 1,2. Sales prices o f marketed monoclonal antibody drugs. Source: Drug prices adapted from 
International Pharmaceutical Services (http://www.intemationalpharmacy.com), accessed 2004.
1.4. O u t so u r c in g  a n d  Pa r t n e r in g
In-house development and production has been a traditional mode of operation for 
pharmaceutical and biopharmaceutical developers alike. In the earlier years of the 
biopharmaceutical industry patient and product demands were so high that production 
costs were of small concern, so the emphasis was simply on getting the therapeutic to 
the market to recoup the cost of development and generate profits (Kamarck, 2006). 
More recently, the need for alternative strategies has been emphasised in industry. 
One reason for this is that a biopharmaceutical manufacturing plant can cost $60MM 
to $600MM (Farid, 2006; Molowa, 2001; Wemer, 2006). Kamarck (2006) comments 
that the typical capital cost of a biopharmaceutical facility is more than five times that 
of a chemical plant. Understandably it is difficult for start-up biopharmaceutical 
developers to finance the constmetion of such a facility. A second reason for this is 
that stringent regulatory guidelines for biologic products impose the consideration of 
building a facility years in advance of when it is needed. Importantly, building 
manufacturing facilities while still in the clinical trial process is unlikely to provide 
sufficient evidence to assure the developer that after their construction, the existence 
of some set of approved dmgs will be awaiting manufacture. This is one of the 
reasons why building a biopharmaceutical manufacturing facility is perhaps regarded 
as the riskiest constituent of the dmg development venture (DePalma, 2008). 
Additionally, overarching pressures such as long standing issues with research and
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development productivity and investors demanding maintenance of profit growth 
(Belsey, 2007), stimulate the need to consider options outside of traditional drug 
development strategies.
Ultimately, existing alternatives to integrating all activities in-house can be appealing 
to drug developers as they allow for the risk and impact of failure to be mitigated as 
well as for expertise and productivity to be accessed expediently. Clinical 
development activities can be outsourced to a contract research organisation (CRO). 
Clinical and commercial manufacturing can be outsourced to a contract 
manufacturing organisation (CMO). Additionally, all of the capabilities offered by a 
CRO or CMO can potentially be offered by a single partner with the appropriate 
experience in the relevant technologies and the capacity to manage new projects. It is 
clear that the choice between any of these strategic routes is a key decision as 
biopharmaceutical companies must develop cost-effective development and 
manufacturing capabilities (Pavlou and Belsey, 2005) to assist in maintaining 
competitive advantages. Further, Langer (2007b) reports figures for organisations 
developing biopharmaceutical drugs fully in-house. For products manufactured via 
mammalian cell culture production in 2005 an 2006, 58% and 56% of organisations 
respectively conducted 100% of biopharmaceutical production in-house. For products 
manufactured using microbial expression systems these figures are 58% and 61% 
respectively. These figures indicate that biopharmaceutical developers have generally 
accepted alternative method to integrating manufacturing capacity in-house. The 
implications for portfolio management tools is that given this interest such tools 
should be capable of analysing what and when to oursource or out-license in order to 
meet manufacturing requirements.
1.4 .1 . C o n t r a c t  r e s e a r c h  o r g a n i s a t i o n s
CROs have the capacity to save development time and provide efficient access to 
expertise in the development of biopharmaceuticals. Additionally it is intuitive that a 
drug developer would be interested in limiting the requirements for significant upfront 
capital so that expenditures can be made and managed on a per-drug basis. Trends 
indicate that research and development costs incurred in bringing a drug to market 
have increased substantially with time. Undoubtedly this adds to the concern for
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maintaining efficient cost and cashflow management. For example, historically in the 
US this cost has been $125MM in 1989, $231 MM in 1993, and S450MM in 1997 
(PhRMA, 1998). As mentioned, more recently this has inereased to over $800MM. 
Outsourcing is not a new coneept for the industry. In the 1970s, pharmaceutical 
industry outsourcing included clinical trials and more recently in the 1990s 
outsourcing came to include the early stages of target identification (Crossley, 2002). 
They are becoming increasingly important because of pressures on drug companies to 
develop new technologies in a changing regulatory environment and to move products 
to market sooner to gain competitive advantage in the marketplace (Maloff et al, 
1997). In support of this view, DiMasi et a l (2003) report more recently that there is 
rapid growth in the outsourcing of research and development activities. Also, 
Liszewski (2007) reports that the CRO industry grew at an annual rate of 15% in 
2007, where one significant reason cited for this growth is that outsourcing clinical 
trials is cheaper and probably more effective than managing them in-house. The 
growth in outsourcing is not just limited to activities that have had a firm 
establishment in the outsoureing industry. It is also observed that the scope on what 
can be outsourced is increasing significantly. Currently virtually all stages of drug 
development can be outsourced (Clark and Newton, 2004; Crossley, 2004). Thus 
biopharmaeeutical developments are open to outsourcing as much or as little as they 
prefer. It has been reported in recent literature that outsourcing parts of the research 
and development effort has been a growing trend (Papadopolous, 2000) , and recent 
figures indicate that of all research and development conducted in the pharmaceutical 
and biopharmaceutical industries 30-35% is channelled to CROs (Crossley, 2002; 
Clark and Newton, 2004). Additional advantages for use of a CRO include the 
freedom to concentrate on core competeneies, greater flexibility, faeilitation of rapid 
exploitation of technologies, outsourcing of weaker projects that yet have some 
reasonable likelihood of success, and access to a global body of expertise (Piachaud, 
2002). An obvious concern about outsourcing is the risk of proprietary and 
commercially sensitive information being leaked to other companies. Such an event 
could substantially weaken a drug developer’s competitive advantage, especially if its 
pipeline is not technologically diverse. Understandably, it would be in the business 
interests of a CRO to guard against this because of disastrous repercussions. Piachaud 
(2002) finds that disadvantages of using a CRO include concerns about controlling the 
CRO, loss of critical internal skills, and difficulties in monitoring and evaluating the
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performance of the CRO. Additionally, CROs receive payment through upfront and 
royalty charges on marketed products so whilst it is cost-effective in the short term to 
utilise a CRO, sacrificing a percentage of future revenues may prove to be more 
costly in the long term.
1 .4 .2 . C o n t r a c t  m a n u f a c t u r i n g  o r g a n i s a t i o n s
In recent years widespread concerns over the ability of industry capacity to meet the 
global demand for biopharmaceuticals has assisted in spurring acceleration in the 
building of manufacturing capacity by CMOs. The factors and concerns mentioned 
when outsourcing to a CRO are shared by those for a CMO. The rate of growth of the 
contract manufacturing industry has been estimated to be at 14% per annum (de 
Nohrona Pissarrah, 2004). Thiel (2004) reports that at the time of publication there 
were mixed views on the ability of the industry to keep pace with the production 
demand for biopharmaceuticals. The publication suggests that the general perception 
in the industry is that there is an excess in manufacturing capacity but some specialist 
consultants believe that this could be short-lived due to the expectation that increased 
market penetration of blockbuster biopharmaceuticals may reverse this situation by 
2008. This excess is likely to be exacerbated by the finding that some 
biopharmaceutical drugs can be used in an expanded number of indications, or an 
increase in the rate of entry of drug candidates into clinical trials. Similar opinions 
held by biopharmaceutical developers may have spurred the use of CMOs at the time. 
Additionally, the impact of higher fermentation titres, especially those beyond 5g/L, 
for newer biopharmaceutical products entering development may improve the 
likelihood that industry-wide production capabilities are adequate for meeting 
demands.
As building a cGMP manufacturing capacity is capital intensive, outsourcing 
manufacturing responsibilities to a CMO reduces upfront fixed costs and converts 
them into flexible costs that are more manageable (Nâhri and Nordstrom, 2005). 
Typically the cost per gram of manufacturing a biopharmaceutical with a CMO will 
be more expensive than with in-house production, and control over manufacturing 
activities will be compromised to some extent (Rajapakse et al, 2005). One principle 
motivation for using a CMO is that it is difficult to accurately forecast the demand
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requirements for a particular therapeutic in the event that it reaches the marketplace. 
This carries the consequence that even if a drug successfully gains marketing approval 
the manufacturing facility can be significantly limited in its production capacity or be 
in excess of it. In such a circumstance the company is either limiting sales because of 
short manufacturing capacity or has spent too much on the facility and is incurring 
unnecessary operating and maintenance costs. It understandable that most small 
biopharmaceutical companies will choose to outsource manufacturing activities (Lias 
and Fogerty, 2002), however the option to utilise a CMO is not confined to smaller 
drug developers. Large biopharmaceutical companies are also using CMOs. For 
example, Genentech has outsourced some of its production requirements for 
Herceptin to Wyeth Biotech (Kamarck, 2006). Beyond concerns about manufacturing 
capacity lies the importance of access to skilled labour and the choice of expression 
systems, as the commercial scale production of biopharmaceuticals using mammalian 
cell culture is better understood than with using microbial systems (de Nohrona 
Pissarrah, 2004). One potential downside to using a CMO is that a contract must 
usually be secured much earlier than is needed (Nâhri and Nordstrom, 2005). Like 
CROs, CMOs receive payment through upfront and royalty charges. Molowa (2001) 
has suggested that such royalty charges are in the region of 15% of sales revenue.
1 .4 .3 . P a r t n e r s h ip s
Like the contracting industry for both CROs and CMOs, partnering is also becoming 
more popular amongst biopharmaceutical drug developers. In 2006 the value of 
alliances and mergers in the global biotechnology sector has been at its greatest since 
2002, for which an increase in alliances with pharmaceutical companies was a 
principal factor (Lawrence, 2007). Partnering strategies came about in the industry as 
recombinant protein drugs were met with high demand and biopharmaceutical 
developers struggled to keep pace so partnering became a solution to reducing fixed 
capital costs by sharing manufacturing capacity (Kamarck, 2007). Recently, 
relatively few biopharmaceutical companies have even had the financial resources and 
in-house expertise in clinical development and marketing to bring a 
biopharmaceutical therapeutic to market without the use of a partner (Ashton, 2001). 
Partnering with a company capable of providing manufacturing capacity allows 
expenses, operational and financial risks, and knowledge to be shared (George et a l.
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2001). It is likely that the most important of these benefits is the prospect of sharing 
finances as this strategic option is essentially a source of finance. Also, it reduces the 
impact of failure and allows for wider product pipelines to be pursued which thereby 
assists in accelerating product development. Currently, pharmaceutical companies 
have strong interests in partnering with biopharmaceutical developers. This is 
because across the industry pharmaceutical companies have been widely reported to 
be lacking productivity in the development of their product pipelines (Drews, 2003; 
Scherer, 2007), and partnering with biotechnology companies is a solution that meets 
this need (Kessel and Frank, 2007). Pharmaceutical companies in this circumstance 
may also be under pressure to partner because at some point the patents on their 
products will expire, with severe associated losses in sales as generic versions of their 
products enter the market. Kessel and Frank (2007), also show that the aggregate 
annual value estimate of pharmaceutical licensing deals has accelerated dramatically 
since 2004 where it was under $30B, until 2006 where it was under $90B. However 
the publication also shows that the annual number of deals has only increased by a 
comparatively modest proportion, indicating involvement with much higher value 
projects, as is commonplace with biopharmaceutical research and development 
projects. Jones and Clifford (2005) confirm this in reporting that average values of a 
partnership deal has risen in recent years, being $1 lOMM in 2003, S145MM in 2004, 
and $169MM in 2005. This trend is also supported by Jones (2007). The salient 
advantageous drivers that assist in forming partnerships appear to be shared by those 
for outsourcing. One important competency that large pharmaceutical companies 
possess which is not usually shared by contractors is in sales and marketing expertise 
alongside the access to established multi-national distribution networks. Downsides 
for the biopharmaeeutical developer include that profits must be shared, and such 
alliances can be difficult to manage (Koza and Lewin, 2000). Importantly, the costs 
are very different especially when a marketed product results from the partnership. 
On the front end there are a variety of deals that the biopharmaceutical company can 
enter into that give biopharmaceutical developers a range of options for managing 
cashflow. However it is beyond the scope of this thesis to discuss these in detail. On 
the share of revenue, pharmaceutical companies appear to take a much larger 
proportion of revenue than contractors. Based on a series of interviews with 44 CEOs 
and business developers Moscho et al. (2000) indicates that large pharmaceutical 
partners will take in the region of 62% of revenues. 81% of this figure is rationalised
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on the value of sales and marketing costs and expertise possessed by the partner. As 
these figures were ascertained through interviews with drug development chief 
executive officers it implies that industry sentiments agree that, in particular, it is 
difficult for smaller biopharmaceutical companies to replicate such competencies. 
Cunningham (2002) also discusses that smaller biopharmaceutical companies need 
access this type of expertise. 16% of the partner’s revenue is justified through 
manufacturing costs and expertise. The remaining 3% is aimed at covering the value 
of previous clinical trial development. The paper also indicates that a considerable 
portion of this valuation is not derived from rigorously defined methodologies, and 
one-third of the interviewees admitted to this. Of this one-third, 21% add an arbitrary 
margin to their expected costs, and the remaining 12% derived the valuation of deal 
terms based on best guesses. These findings suggest that at the time of publication an 
industry wide valuation methodology was not in place which in itself may create the 
opportunity for the smaller biopharmaceutical companies to negotiate the deal terms 
within reason. In support, Fisher and Wang (2001) note that the most favourable offer 
that can be negotiated with a pharmaceutical partner is an equal split of the revenue.
Results fi’om a study conducted by Danzon et al. (2005) which involved 900 
pharmaceutical firms between the years 1988-2000 indicate another strong reason for 
partnering, which is that alliances have historically tended to increase clinical trial 
success probabilities particularly in phases II and III especially if the partner is large 
(Table 1.10). It should be noted that their data does not allow them to distinguish 
between the effects of strategic or opportunistic project selection and the genuine 
effect of alliances. They suggest that any negative effects of alliances in phase I may 
reflect the decision of developers who have recognised early that a drug candidate is 
already performing below expectations and have decided to out-license it to reduce 
the impact of failure, assuming that partners are undisceming. Positive effects of 
alliances largely seen in later trials with larger partners may indicate that such 
partners are at least more competent in selecting good drug candidates to in-license or 
managing clinical trial processes at these stages. Alliances with small partners have a 
relatively small sample size and the negative effects seen in the dataset may be less 
robust. Danzon et al. (2005) also does not distinguish between effects concerning 
therapeutic protein and pharmaceutical candidates. Because of this it is difficult to 
use this data ubiquitously in modeling the impact of decisions made in the drug
43
LITERATURE REVIEW
development pathway. Nevertheless this study indicates that it is possible for 
alliances to influence the probability of success for a drug development project.
Table 1.10. Effect of alliances on probability of advancing in a clinical trial.
Size o f original developer Size o f partner Phase I Phase II Phase III
Small None 4 ,2 0 ,4 2 ,7
Small -4 ,4 7 ,7 -7,13
Medium -9,5 17,4 9, 10
Large -2,4 13,5 7 , 9
Medium None 4 ,2 -3,4 1,7
Small 5 ,4 -4, 10 -7, 14
Medium 2,3 0 ,7 15,8
Large -1,3 12,4 15,6
Large None -3,1 -1, -
All sizes 3 ,2 2 ,4 11,5
Source: Adapted from Danzon et al. (2005). Note: In columns for phases I, II, and III the first number 
represents the marginal effect o f the alliance and the second is the standard error, whilst means that 
the datum was not provided. The marginal effect is the additional impact on general probabilities o f  
success, and is measured in percentage points. Small, medium, and large firms respectively considered 
to have 1 to 3, 4 to 24, and more than 25 drugs in development.
1 .4 .4 . T i m in g  T h ir d  P a r t y  R e l a t io n s h ip s
After asking the question of when to include a third partner, the follow-on question 
entails which third party should be included. Literature that include some aspect of 
third party drug development tend to focus on the factors for doing so but do not 
usually discuss the stage at which third parties should be included. Arnold et al. 
(2002) looked at licensing deals in partnerships formed between large pharmaceutical 
companies and smaller biopharmaceutical companies. The study included a survey 
about the optimal time to commence a licensing deal. Their results showed that 60% 
of respondents believed phase II clinical trials to be the optimal time, 20% believed 
this to be phase I, and the remaining 20% believed this to be the phase III or later. 
They also analysed the value of licensing deals according to the stage of therapeutic 
development. Their results indicate that as drug candidates pass successive stages of 
clinical development there is a 22% increase in the value of the licensing deal. This 
preference for licensing during phase II is possibly due to most drugs failing at phase
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11, SO it is a means of gauging how successful the drug might be. Also, Arnold et al. 
(2002) comment that phase 111 trials are often too expensive for biopharmaceutical 
companies to conduct by themselves and in such cases the only choice is to license 
out the product. Intuitively, as drug candidates progress through clinical trials a 
reduced probability of failure is implied, so pharmaceutical companies are prepared to 
















Figure 1.3. Example o f  the constituents and possible goal o f a portfolio o f licensing deals. Source: 
Adapted from Geyer et al. (1999).
It should be considered that Arnold et al. (2002) researches licensing for a single drug 
and that possibly the decision on timing may change within a portfolio of 
partnerships, this is considered by Geyer et al. (1999). They stress that 
biopharmaceutical companies must strive for the correct portfolio of licensing deals as 
when time-wise cash flow characteristics are aggregated, distinctive cashflow profiles 
result for the company as a whole. The two studies mentioned in this section draw 
attention to the fact that timing the involvement of third parties is close to managing 
risks of product development and the expectation of cashflows. Clearly, different 
timing strategies have the capacity to produce different projected cashflows for the 
company. This is because different decisions made on the development of a drug will 
result in different payments being made at particular times. In the case of a licensing 
deal the biopharmaceutical company is open to different combinations of financing
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options that include signing the deal contract, royalty payments in the event that the 
therapeutic under contract upon market approval, milestone payments, and fees for 
services rendered by the third party. Also, in circumstances where it is solely the lack 
of capital that is restricting projected cashflows then any cash generated from 
previous licensing deals offers the option of covering the capital requirements for 
future projects. This would lead to a greater financial impact whether upon failure as 
well as upon successful approval of the therapeutic for marketing.
1.5. Co m pu ta tio n a l  D e c isio n  M a k in g  Fram ew orks
Computational approaches have been described in literature aimed at presenting a 
robust approach to optimising strategic decisions in pharmaceutical and 
biopharmaceutical development. Pertinent decisions that feature in such approaches 
include:
■ The size of the drug development portfolio.
■ The drug composition of the drug development portfolio.
■ The schedule of associated developmental activities for selected drugs.
■ In-house, outsourced, or partnered research and manufacturing.
■ Facility and manufacturing process decisions.
Decisions made on the size and composition of the portfolio may also be influenced 
by imposing resource constraints. Scheduling of critical development activities 
subject to a prioritised order of development based on considerations such as the 
identification of the most promising projects and accounting for strategic windows of 
opportunity in targeted drug markets. The decision to keep development and 
manufacturing activities in-house may be subject to monetary constraints but the need 
to manage of the impact of failure may be equally relevant. Ultimately, these 
decisions are explored by some algorithmic means to optimise at least one strategic 
criterion which is invariably a monetary goal such as net present value (NPV).
1 .5 .1 . P o r t f o l io  se l e c t io n  a n d  c a p a c it y  p l a n n i n g  m o d e l s
Portfolio selection problems pertaining to drug development have been addressed in 
literature and cover a variety of methodological features, technical problems, and 
scenarios. Broadly, these approaches will either be based on the analysis of a limited
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selection of strategic scenarios that are important to the drug developer, or based on 
the specification of a decision making super-structure over which an optimal strategy 
must be formulated by some strategic method of optimisation. Scenario analysis 
based approaches can offer significant depth of analysis to highlighted scenarios but 
optimisation-based approaches typieally offer a greater capacity to realistically 
represent the complexity of portfolio selection problems in drug development. Also, 
optimisation-based approaches typically feature much larger decision spaces than 
those presented in scenario analysis works and hence, can address solutions not 
considered by such methods. Varma et al (2008) present a method for optimising 
expected net present value (ENPV) through strategic scheduling and resource 
allocation for pharmaceutical research and development pipelines. The method 
consists of a joint simulation and optimisation based framework that incorporates 
mixed integer linear programming (MILP). Colvin and Maravelias (2008) describe a 
multistage stochastic programming formulation for the strategic planning of clinical 
trial scheduling in pharmaceutical research and development pipelines in order to 
maximise ENPV. Subramanian et a l (2003) develop a simulation-based optimisation 
framework capable of constructing research and development portfolios, ordering of 
necessary project activities within the chosen portfolio, and dynamically reprioritising 
activities based on real-time outcomes. They consider stochastic optimisation to 
maximise mean net present value (NPV) and the probability of delivering a positive 
NPV value, and their approach combines discrete-event simulation and MILP. Blau 
et a l (2004) consider project selection and prioritising the order of development 
based on maximising NPV and minimising the probability of achieving a negative 
NPV using discrete-event simulation and a genetic algorithm based optimisation 
procedure. They also consider the added complexity of a dependency structure 
between different drug groups that pertain to capital cost, revenue, technical 
probabilities of success, and experiential learning curves. Rogers et a l (2003) use 
stochastic optimisation via MILP to determine the size and structure of 
pharmaceutical drug development portfolios under budgetary constraints by using real 
options valuation (ROV) to make continue and abandonment decisions. Other 
relevant optimisation based approaches in this area include Choi et a l (2004), 
Subramanian et a l (2001), Blau et a l  (2000), and Jain and Grossmarm (1999).
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There are contributions that address the issue of capacity planning in the 
pharmaceutical industry using optimisation based approaches. For example, internal 
planning decisions of a company and the recognition of market opportunities have 
been considered by Gupta and Maranas (2004). Cheng et al. (2005) provide an 
approach to capacity planning and inventory control. A mathematical programming 
approach to capacity planning for the pharmaceutical industry was presented by 
Gatica ei at. (2003). Levis and Papageorgiou (2004) provide a mathematical 
programming method for long-term, multi-site capacity planning under uncertainty 
for the pharmaceutical industry. Additionally, Maravelias and Grossman (2001) 
present a framework for the simultaneous optimisation of capacity planning and new 
product development. Other examples include Lakhdar et al. (2005) and Gatica et al. 
(2002). The majority of such approaches pertain to drug developers who have or plan 
to have integrated their development and manufacturing infrastructures in-house, 
however there are some who develop frameworks for wider settings. These can offer 
a more realistic setting as there are a significant number of biopharmaceutical 
companies that manufacture at least some of their drugs externally (Langer, 2004; 
Rogers, 2005). For example, Rogers and Maranas (2005) consider an approach for 
optimising the stage at which a drug developer should enter into a partnership 
licensing deal, the investment policy taken for each deal, and the portfolio structure of 
licensing deals to be held given a budgetary constraint using real option value (ROV) 
and mixed integer linear programming (MILP). Oh and Karimi (2004) develop a 
MILP technique for capacity expansion planning that considers decisions to expand 
existing manufacturing facilities, build new capacity, or outsource given regulatory 
factors. Rajapakse et al. (2005) present a framework based on scenario analysis and 
discrete-event simulation to evaluate scenarios for the developer to build 
manufacturing capacity early, build late, or outsource to a CMO. Further work in 
Rajapakse et al. (2006) provides some extension to this by using efficient frontier 
analysis to prioritise portfolio construction against resource constraints.
Approaches have been reported in the literature for the development of frameworks 
that incorporate both the problems of portfolio management and manufacturing 
capacity planning simultaneously. Intuitively, such approaches represent an 
important advancement while also presenting more challenging and realistic large- 
scale optimisation problems that offer vast extensions to the lines of inquiry for either
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of the two problems in isolation. Levis and Papageorgiou (2004) develop a 
hierarchical approach based on MILP for maximising net present value (ENPV). The 
decisions to be optimised include product portfolio structure, the manufacturing 
network and investment strategy over multiple sites, design specifications for each 
manufacturing site, as well as sales and inventory plans. Maravelias and Grossman 
(2001) consider a MILP approach that the optimisation of NPV given decisions that 
include portfolio structure, sequencing and assigning resources to activities, 
outsourcing of activities, building new manufacturing capacity, and expanding 
existing manufacturing facilities. Their work features Lagrangean decomposition as a 
heuristic solution to the problem. Papageorgiou et al. (2001) present a MILP 
technique for optimising portfolio selection, proprietary manufacturing capacity and 
production plan design, schedule, and sales and inventory plans.
1 .5 .2 . Fa c il it y  a n d  m a n u f a c t u r in g  p r o c e s s  d e c is io n s
Examples focused on facility and manufacturing process decisions in the 
biopharmaceutical industry have been featured in literature. Farid et al. (2001, 2005a) 
developed a tool to capture the technical, financial, and risk related aspects of 
competing biopharmaceutical manufacturing strategies. The tool combined process 
economics and logistics via discrete-event simulation, object-orientated programming, 
and uncertainties via Monte Carlo simulation. The work highlights a decision making 
framework based on multi-criteria decision making (MCDM) to reconcile pertinent 
financial attributes such as fixed capital investment, and non-financial attributes such 
as operational flexibility. Lim et al. (2005a, 2005b) further developed this approach 
to capture regulatory compliance activities as well as continuous production-related 
activities and applied it to evaluate the process economics of fed-batch or perfusion 
culture in mammalian cell culture processes. Mustafa et al. (2004) presents an 
approach for comparing the business impact of packed bed and expanded bed 
absorption chromatography operations.
1 .5 .3 . S t o c h a s t ic  O p t im is a t io n  A p p r o a c h e s
Stochastic models often offer a realistic representation of a given decision making 
environment. When developed for real situations such models result in large-scale
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optimisation problems that can be difFicult to solve. For problems featuring decision 
making under uncertainty there are two broad classes of solution scheme: multi-stage 
stochastic programming and stochastic optimal control (Cheng, 2005).
Stochastic programming usually involves two stages where the first stage accounts for 
strategic decisions made whilst the second stage accounts for the consequences of 
strategic decisions which manifest the performance of the strategy (Sahinidis, 2004). 
Optimisation-under-uncertainty problems are commonly formulated under such an 
approach where some form of linear programming such as MILP is also a popular 
solution scheme, as seen in section 1.5.1. Multi-stage stochastic programming 
extends this concept via the introduction of some set of procedures to enhance the 
efficiency of the optimisation approach.
Stochastic optimal control, or a Markov decision process, considers a model for 
sequential decision making that accounts for the outcomes of both current decisions 
and future decision making opportunities, (Cheng, 2003). Decision makers are 
intended to choose an action according to the state of the environment that they are 
currently in according to an optimal control policy. Dynamic programming 
techniques provide a means by which for this optimal control policy can be solved. 
For example, Cheng et al. (2003) utilises multiobjective stochastic dynamic 
programming as a solution scheme to optimal decision making for a chemical 
production plant.
Although both types of technique can be applied to the same problem but with 
different perspectives emphasised, Cheng et al. (2005) comments that stochastic 
programming is better suited for long-term strategic planning problems such as 
capacity planning. A well known barrier to either type of approach when using 
solution schemes that guarantee optimal solutions is the curse o f dimensionality, 
which refers to the explosion in the number of possible combinations of decision 
variables as the number of decisions to be considered increases. Because of this a 
guaranteed optimal solution for some problems cannot be found as the problem has 
far outgrown current computational capabilities. In such cases heuristic approaches, 
which use some set of heuristics to reduce the decision space, are the next best option. 
Examples of heuristic approaches include simulated annealing (Kirkpatrick et al.
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1983), TABU search (Glover and Laguna, 1997), genetic algorithms (Goldberg, 
1989), and Lagrangean relaxation and decomposition (Fisher, 1981).
Strategic decision-making in the biopharmaceutical industry is considerably complex 
and represent large-scale optimisation problems, particularly when regarding 
strategies for research and development portfolio selection, scheduling, and the 
involvement of third parties. The types of problems that will be explored in this work 
will feature such decisions under a stochastic programming approach. Furthermore, 
features designed into the problem such as dependencies mean that problem is 
difficult to decompose because the performance of certain decisions is linked to other 
decisions. This is explained further in chapter 3. Due to the size and complexity of 
this problem heuristic techniques that aim to learn the structure of the problem are 
explored here. One reason for this is the anticipated computational efficiency offered 
by such approaches for such large-scale problems. A second reason is that such 
models have the capacity to give insight to the decision maker on the problem itself, 
which is rarely found in alternative methods.
1 .5 .4 . H a n d l i n g  m u l t ip l e  c r it e r ia  a n d  o b je c t iv e s
In problems involving capacity acquisition and expansion there may be many 
conflicting criteria to be considered for decision-making. The usefulness of extending 
the criteria considered was demonstrated by Farid et al. (2005b) who used multiple 
quantitative and qualitative criteria to assess the use of disposable components when 
building a biopharmaceutical manufacturing facility. This was supported by a 
framework that used multi-criteria decision making (MCDM). Additionally, Chhatre 
et al. (2007) presents a simulation-based approach to evaluate the impact of 
alternative process configurations under uncertainty using MCDM to amalgamate 
multiple criteria. Generally, the available types of methods for reconciling between 
multiple objectives include: transforming the multi-objective problem into a single 
objective problem, the lexicographic approach, and the Pareto approach. The field of 
MCDM offers numerous techniques that transform multi-objective problems into 
single-objective ones. This often involves assigning a weight to each objective so that 
relatively more important objectives contribute more to the output score of each 
alternative. In cases where a score is derived and in its simplest application, the most
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preferred candidate solution will yield the optimal score. The lexicographic approach 
involves assignment of a preference order to each objective and then optimising each 
objective in order of preference until a non-dominated solution is found (for example 
see Sawik, 1997; and Volgenant, 2002). The Pareto approach (e.g. Cheng et al, 2003) 
compares each solution against each criterion and results in a set of Pareto optimal 
solutions that are said to be non-dominated. A solution is considered Pareto optimal 
if there is no other existing solution that can improve the value of one criterion 
without degradation in any other criteria. A key advantage of using lexicographic and 
Pareto approaches over transforming multiple objectives into a single objective is that 
they compare solutions according to each criterion. However, for numerous criteria it 
can be difficult for the decision maker to prioritise each individual objective, as in the 
lexicographic approach, without having a reasonable understanding of each one. 
Additionally, having a set of Pareto optimal solutions means that the decision maker 
still has the task of selecting a solution from this set. This can be especially difficult 
if there are more than two criteria as multiple trade-offs may exist between individual 
objectives. For these reasons the simpler technique of transforming multiple 
objectives into a single objective is focused on first in this work. Following this, 
exploration of a technique that includes Pareto optimal solutions will be explored. 
The use of multiple criteria as a basis for analysing decisions can be supported 
effectively through MCDM which is one of the most well known branches of 
decision-making (Triantaphyllou, 2000). Its potential ability to support the selection 
of strategies in biopharmaceutical manufacturing lies in the flexibility it provides to 
reconcile both the financial and operational concerns of the decision maker. There are 
many methods available in MCDM which have been used to process financial and 
non-financial data. For example, Platts et al. (2002) used the weighted sum method 
(WSM) to analyse the decision to invest in internal manufacturing capabilities or to 
outsource these activities. Additionally, Steuer and Na (2003) have published a 
review of 265 publications that focus on utilising MCDM to aid decision-making in 
financial contexts.
1.6. A im s  a n d  O r g a n isa t io n  of  T hesis
An overview of the economics of biopharmaceutical development and manufacture 
has been presented alongside pertinent strategic decisions that must be made in this
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process. In addition, published eomputational frameworks that have been developed 
for deeision-support in this industry have been diseussed. What is yet to be seen in 
literature or in the commercial software industry is the development a computational 
framework that unifies:
■ Simulation of biopharmaceutieal development and manufacture.
■ Simulation-based estimation of the economics of biopharmaceutical 
development and manufacture.
■ Optimal seleetion of therapeuties for a portfolio of a given size.
■ Optimal order and year-by-year seheduling of drug development and 
manufaeture such as to optimise the management of eashflows and inherent 
risks of failure.
■ Optimal selection of CROs, CMOs, and partners if at all across the entire 
range of eritical activities for the development and manufacture of 
therapeutics.
■ Optimal year-by-year schedule for assignment of third party to critical 
development and manufacturing activities.
■ Optimisation against multiple and possibly conflicting criteria.
Accordingly, the principal aim of this thesis is to develop a computational tool that is 
attentive to all of these features and incorporates them into a single framework. The 
ultimate aim of this work is the creation of a computational, intelligent, stochastic, 
combinatorial, and multi-objective deeision-support framework that can optimise a 
strategic map for the year-by-year planning o f critical development, manufacturing, 
and marketing activities for an entire portfolio o f biopharmaceutical therapeutics, 
where key related findings in the development of this framework will also be distilled.
Chapter 2 develops the use of simulation and multi-criteria deeision making (MCDM) 
as a means for gleaning and utilising diverse information about strategies for the 
manufacture for monoclonal antibodies that involve the use of third parties. The use 
of MCDM is inclusive of financial and operational criteria that are combined into a 
holistic framework that outputs a score. Use of the framework is illustrated in a 
scenario analysis example.
Chapter 3 develops a framework that unifies the concepts and strategic concerns 
described earlier in this section into a stochastic combinatorial multi-objective
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optimisation framework. A super-structure for the formulation of a strategic 
development and manufacture plan is presented. The development and manufacturing 
environment is described. The optimisation algorithm is based on estimation of 
distribution algorithms (Mühlenbein and Paass, 1996) which are a recent development 
in the computer science discipline. An example case is formulated to demonstrate the 
use of the optimisation framework.
Chapter 4 extends the use of the framework presented in chapter 3 by exploring the 
impact of cashflow constraints and portfolio size on the algorithmic formulation of 
drug development and manufacturing strategies and their associated quality.
Chapter 5 explores the use of the manufacturing model for the development of 
straightforward equations for estimating key economics of biopharmaceutical 
manufacture within acceptable error margins. Equations are developed for both the 
manufacture of whole monoclonal antibodies in animal cell culture processes and 
antibody fragments in microbial processes. The equations are developed using 
multiple regression to learn geometric relationships between model outputs and 
inputs.
Chapter 6 explores the commercial considerations of this work and illustrates the 
economics of translating this work into a viable business venture. Chapter 7 discusses 
issues associated with validating this work. Chapter 8 provides the salient 
conclusions of this thesis and highlights avenues of investigation for extensions of this 
work. Finally, papers by the author published during the course of this work are 
attached in Appendix C.
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C h a p t e r  2
A  M u lti-C r it e r ia  D e c is io n -M a k in g  Fr a m e w o r k  fo r  
THE S elec tio n  o f  St r a t e g ie s  fo r  A c q u ir in g  
Bio p h a r m a c e u t ic a l  M a n u f a c t u r in g  C a pa c it y
2.1. I n t r o d u c t io n
This chapter investigates the design of a deeision-support framework for the 
stochastic analysis of options for acquiring commercial-scale manufacturing capacity 
in a biopharmaceutical setting. It is recognised that acquiring biopharmaceutical 
manufacturing capacity is typically risky, expensive, lengthy, complex, and that 
relevant decisions are commonly based on a single metric, net present value (NPV). 
Hence, the overarching motivation behind this work is to explore whether the 
extension of decision-making criteria captured within a holistic framework can aid the 
decision maker towards making more informed choices regarding strategies for 
acquiring biopharmaceutical manufacturing capacity. The framework considers 
decisions faced by the drug developer and multiple criteria pertinent to decision­
making in this setting. Decisions are mapped in a model that simulates their impact in 
the environment for capacity acquisition alongside salient uncertainties. One clear 
challenge is how to structure such a framework as different types of criteria may be 
relevant to the decision maker. Such criteria might be broadly categorised as 
financial, referring to the stability of the financial balance sheet and how effectively 
finances are used, or operational, broadly pertaining to implications of a more 
managerial nature. Within these two broad categories it is demonstrated that further 
categorisation exists. Because of these issues a multi-criteria decision-making 
(MCDM) technique is utilised here as a means for organising and reconciling multiple 
criteria. Hence, the overall deeision-support framework combines a stochastic 
simulation model with a MCDM technique.
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This chapter is organised as follows: section 2.2 details the architecture of the 
deeision-support framework, section 2.3 describes the case study used to illustrate use 
of the framework, section 2.4 discusses the results, section 2.5 details the conclusions 
regarding the obtained results, and section 2.6 lists the nomenclature used in this 
work.
2.2. D écision-S upport  Fram ew ork
The deeision-support framework was designed to model the financial and operational 
perspectives of strategies for acquiring commercial manufacturing capacity. 
Microsoft Excel was used for its implementation and an overview is presented in 
Figure 2.1. A hierarchical approach was applied to facilitate a clear and detailed 
representation of the business and manufacturing processes involved. This approach 
also offers the ability to rapidly change assumptions so that a wider variety of 
scenarios can be captured and analysed. The framework has four elements: a 
biomanufacturing process model, a profit and loss model, an MCDM technique, and a 
set of criteria used to distinguish between the strategic options.













Figure 2.1. An overview of the MCDM framework.
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A decision-making scenario is comprised of a set of alternative options with each one 
representing a capacity acquisition strategy. Each option is defined as a collection of 
probability distributions to be inputted to the model. These inputs can be split into 
teehnieal, commercial, business and qualitative categories. Technical inputs 
describing the manufacturing capabilities, sueh as the fermentation titre and the 
overall process yield, are directed to a biomanufacturing cost model. These technical 
inputs are used to generate data such as the cost of goods sold per gram (COGS) and 
the capital investment required. Commercial inputs include the market eapture and 
the market lifetime of each drug. These inputs are used to define the production 
capacity required and expected sales revenue. Inputs from the business category 
define the structure of any contractual agreements sueh as royalty payments and the 
terms of any partnerships formed. Qualitative aspects of each option include the 
suitability of the location, control and flexibility over the projects considered, and the 
expected acquisition of manufacturing knowledge. Qualitative scoring is used to 
describe most of the operational aspects. The outputs of the biomanufaeturing cost 
model are directed to the profit and loss model. The outputs of the profit and loss 
model determine the values of the financial criteria used to discriminate between the 
alterative options. Subjective operational inputs are fed directly to their 
corresponding criteria. Details of the biomanufaeturing model and the profit and loss 
model will be discussed in further detail in sections 2.2.1 and 2.2.2 respectively.
2 .2 .1 . B io m a n u f a c t u r in g  P r o c e s s  M o d e l
The framework used to model the manufacture of biopharmaceutical products (Figure 
2.2) is based on work reported by Farid et al (2000, 2005a) and Lim et al (2005a and 
b). Figure 2.2 represents a typical manufacturing route for monoclonal antibodies. 
Ineluded in the model are the main process and ancillary tasks involved in the 
manufacturing process as well as equations for calculating the utilisation of 
equipment, materials, utilities, and labour. The cost calculations are supported by a 
database of unit costs for equipment and materials used in the manufacturing process.
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Figure 2.2. The biomanufaeturing process model. Abbreviations: DSP - downstream processing, 
QC/QA -  quality control / quality assurance, PCI -  fixed capital investment, COGS -  cost o f goods 
sold. Demand is the annual product demand determined from the market analysis and depends on 
market size, market capture and the drug dosage per patient per year. Titre refers to the titre o f crude 
product (g/L) that is expected to be achieved in the fermenter. The DSP yield is the overall yield after 
all downstream processing steps have been completed. The batch success rate refers to the likelihood 
of batch success given the chances o f  contamination or equipment failure. The manufacturing 
operations and the ancillary tasks have been modelled to determine estimates o f  utilisation of major 
cost components. Utilisation estimates are combined with an extensive cost database to determine the 
PCI and COGS values.
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The overall input parameters to the model are the annual demand, the expected 
fermentation titre, the overall product yield and the anticipated success rate of each 
batch. Each unit operation has a process model comprising of design equations and 
mass balances. These are used to size equipment, determine the composition of the 
output streams and the amount of materials required (e.g. chromatography buffers). 
More details on these models can be found in Farid et al. (2007). Equipment sizes are 
determined by matching processing requirements such as volume to a database of 
equipment dimensions available at the time of writing. If the processing requirements 
require an equipment size that is in excess of available equipment dimensions then the 
sizes of equipment allocated will be such that all units will be of equal size with 
number clearly being sufficient to handle process requirements. The outputs from this 
model are the fixed capital investment for the manufacturing plant as well as the 
COGS. The fixed capital investment was estimated by the Lang Factor method 
(Lang, 1948) which correlates this figure to the equipment cost. The COGS model 
employed is shown in Table 2.1.
Table 2.1. COGS model breakdown.
Cost Category Description
Direct raw materials f(utilisation) (2 .1)
Miscellaneous materials 0.5 X direct raw materials (2 .2)
Direct utilities f(utilisation) (2.3)
Direct
Cost
Operating labour f(utilisation) (2.4)
Supervisors 0.2 X operating labour (2.5)
oj Goods
Quality control and quality 
assurance
1 X operating labour (2 .6)
General management 1 X operating labour (2.7)
Maintenance 0.1F7 (2 .8)
Indirect Local taxes 0.02F7 (2.9)
Cost o f Insurance O.OIFF (2 .10)
Goods Capital charge F  (1 + rate o f interest) ^ C * (2 .11)
General utilities Cost per unit area per year x Facility size x Y (2 .12)
Total Cost o f  Goods Direct Cost o f  Goods + Indirect Cost o f Goods (2.13)
Total Cost o f  Goods per Gram (COGS) Total Cost o f Goods / Annual Production Output (2.14)
Note; Where F  is the fixed capital investment, Y is the project duration in years, and C is the capital 
charge period. Source: Mustafa et al. (2004).
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2.2.2. P r o f i t  a n d  L o s s  M o d e l
Table 2.2. Profit and loss model.
Year Year t
Income
Dose per Patient per Year 
Target Population Size 
Market Capture, /j .
Annual Product Demand, I 4  ,





fftj, M, to) 
h .t h ,t  h .t
5 9 .83 2 / 4 '^^ ^^^






Total Annual Income, It bt + h .t (2.19)
Expenses
Capital Investment E u
COGS Vt
General and Administrative, E2 ,, g h . t (2.20)
Royalties, r h . t (2.21)
Total Plant Expenses to be Paid, E 4 J Pe(Eu +E2 ,, +Eu  + u j (2.22)
Profits owed to paitner, £ 5 , P(^t -  E 4 J (2.23)
Convertible Debt Repayments cL (2.24)
Total Annual Expense, E , Es.t + Ee,, (2.25)
Profit
Profit Before Interest and Tax, ? i , It - E, (2.26)
Depreciation P 2 .t
Taxable profit, P i , (2.27)
Tax, P i , mPs.t (2.28)
Profit after Interest ad Tax, P , E t -  (P 2 .t + P4.t) (2.29)
Net Present Value
Annual Present Value, P p y  , PtOt (2.30)
Net Present Value, Pnpv.i Y ^ P p V jr=l
(2.31)
Expected N et Present Value
Transition Probability Kt
Cumulative Transition Probability,
Y l ^ t (2.32)
Expected Net Present Value, P enpv.i PNPV.t (2.33)
Note: ÎR is the ramp period from commercialisation to peak market capture, M  is the peak market 
capture, and to is decay period after peak market capture, g  is the proportion o f sales that are expected 
to be spent on general and administrative costs, r  is the proportion o f sales that will be used to pay 
royalty fees, is the proportion o f expenses that the company is obligated to pay, p  is the proportion o f  
profits it owes to any partners, c is the coupon rate payable on the par value o f the issued convertible 
debt L, and m is the tax payable as a percentage of profit, and a is the discount factor.
* Derived by correlating sales price versus demand for therapeutic monoclonal antibodies.
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A profit and loss model was built to process income and expense data (Table 2.2) and 
to generate values for the decision-making criteria. It was found that the sales price 
data for monoclonal antibody therapeutics could be explained by a geometric 
regression model:
P  = 59.382D (2.34)
where P -  sales price, D -  annual demand of the therapeutic. The coefficient of 
determination = 0.8055 for this relationship meaning that over 80% of the data 
seen can be explained by the geometric model. In addition to the business revenues 
achieved from the sale of therapeutics other sources of finance are also modelled. 
These additional sources of finance include an initial public offering (IPO) and the 
issuance of convertible debt. It is assumed that this will be in the form of convertible 
bonds which are issued in the same year as the IPO. The holder of any convertible 
bonds can convert them to common stock of the issuing firm according to conditions 
specified by the firm prior to issuing the bonds (Kimura and Shinohara, 2006). The 
static conditions are the term of the bond, its coupon, the probability of conversion 
and the conversion premium which is the amount the bond holder must pay the firm 
in order to convert. The only variable condition is the year of conversion, providing 
this happens, which is modelled as a triangular distribution. Additionally, the year of 
conversion is expected to coincide with the successful commercialisation of the first 
drug which is reflected in the probability distribution. The amount of finance required 
to be raised through the issue of this instrument is calculated. The model assumes that 
there are no possibilities of negative cashflows. If the cashflow in any year for any 
scenario falls below $5million then enough is raised to correct this with an upper limit 
of $10 million for the same year. It is assumed that there are no restrictions to issuing 
convertible debt at the time of need.
2 .2 .3 . C r it e r ia
The criteria used in the framework (Table 2.3) were chosen to represent a broad 
spectrum of values that may be important when considering detailed financial and 
operational perspectives. Also, each criterion is intended to capture a certain aspect 
of each option over its lifetime from an overall perspective. In the financial category
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five categories of criteria are considered: profitability, asset utilisation, liquidity, long­
term solvency and capital structure. In the operational category four categories were 
considered: productivity, the suitability of the location, control and flexibility over the 
projects considered, and the expected acquisition of manufacturing knowledge. The 
qualitative component of the productivity category includes the ease of training 
manufacturing personnel. The location category includes the ability of the local 
infi-astructure to support operations and logistics, and the access to qualified 
manufacturing personnel. The flexibility category includes the ability to control its 
drug manufacture projects, the ease of expanding operations, and the ease of 
consolidating manufacturing operations. The manufacturing knowledge category 
includes the readily available manufacturing expertise, the number of company 
personnel assigned to manufacturing, the potential to acquire manufacturing 
knowledge, and the control over any manufacturing knowledge acquired.
When applying these criteria to a decision-making scenario a higher criterion value 
represents a stronger position. Some of these criteria, such as those based on costs 
had to be inverted to reflect stronger positions as higher values rather than as lower 
values.
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Table 2.3. Criteria used in the MCDM framework.
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Note: For symbol definitions refer to the Nomenclature section.
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2 .2 .4 . T h e  W e i g h t e d  S u m  M e t h o d
The weighted sum method (WSM) was chosen to evaluate the criteria shown in Table
2.3. These criteria are not all measured in the same dimensions and thus result in a 
multi-dimensional decision-making scenario. For comparisons between options to be 
drawn meaningfully and usefiilly the criteria values must be converted into an 
equivalent set of dimensionless numbers (e.g. Triantaphyllou, 2000). Normalisation 




where is the value of i criterion of the alternative option and Xy is the 
normalised rating of attribute i for the alternative option j.
Each criterion is given a weighting that can be configured by the decision maker to 
reflect how important each criterion is in the decision-making process. These weight 
values must also be converted to an equivalent set of dimensionless numbers. The 
normalised weight value is:
(2.52)
where z, is the weight value of the criterion.
The score generated by the WSM method can be represented as:
-^ 7 = Z ^'^'7 (2.53)
/=!
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where w, is the normalised weight assigned to attribute i, and Xÿ is the normalised 
rating of attribute i for the alternative option j . The preferred alternative option has 
the highest score.
2.2 .5 . U n c e r t a in t y
To determine the stochastic ranking configuration, input values were specified as 
triangular distributions characterized by minimum, maximum, and most likely values. 
These inputs were subjected to a Monte Carlo simulation and the options were ranked 
according to their mean WSM score. Subsequent analyses were conducted to identify 
any tradeoffs linked to these mean scores.
2.3. Case  St u d y  D esc r iptio n
A hypothetical case study was formulated to illustrate and examine the use of the 
framework in capturing the financial and operational perspectives of decision-making 
scenarios in the acquisition of commercial scale biomanufaeturing capacity. The 
example is based on a biopharmaceutical company that needs to acquire commercial 
manufacturing capacity and has three monoclonal antibody drug candidates in its 
product pipeline. One has just recently entered late stage clinical trials whereas the 
others are still in the early stages of clinical testing. The first, second and third drugs 
are required in medium, high, and low demands respectively. Given the progress of 
the drug portfolio toward commercialisation the necessity to acquire commercial 
manufacturing space is urgent. The company’s Initial Public Offering (IPO) has 
raised $100 million. The following possible options have been identified:
■ ‘Partner’ option: Partner with a large pharmaceutical company and split the 
expenses and profits.
■ ‘CMO’ option: Outsource all manufacturing requirements to a contract
manufacturing organisation (CMO).
■ ‘Build’ option: Build a new facility and undertake all of the manufacturing by 
themselves.
■ ‘Partner/Build’ option: A hybrid option involving following through with the
partnership but only for the first drug. The remaining drugs will be manufactured 
by the construction of a new facility.
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■ ‘CMO/BuilcT option: A hybrid option involving a contract manufacturer but only 
for the first drug. The remaining drugs will be manufactured by the construction of 
a new facility.
Table 2.4. Market and development characteristics o f drugs in the case study.
Characteristic Drug 1 Drug 2 Drug 3
Dose (grams per patient per year) 6 3 1
Annual Market Size (patients) 100,000 200,000 25,000
Clinical Trial Stage Phase III Phase I Phase I
Expected Time to Market Entry (years) 5 8 8
Expected Market Lifetime (years) 10 10 10
Table 2.5. Input values used for the case study.
Input Partner CMO Build
Expected market capture -  Drug 1 (%) Tr(5.5, 11, 16.5) Tr(5, 10, 15) Tr(5, 10, 15)
Expected market capture -  Drug 2 (%) Tr(16.5,33,49.5) T r(15,30,45) Tr(15, 30 ,45)
Expected market capture -  Drug 3 (%) T r (ll ,2 2 ,3 3 ) Tr(10, 20 ,30) Tr(10, 20, 30)
Ramp time to peak market capture 
(years) Tr(3, 2, 1) Tr(4,3,2) Tr(4,3,2)
Decay time from peak market capture 
(years) Tr(3, 2, 1) Tr(4,3,2) Tr(4,3,2)
Transition probability -  Phase I to 2 0.7 0.7 0.7
Transition probability -  Phase 2 to 3 0.5 0.5 0.5
Transition probability -  Phase 3 to FDA 0.8 0.8 0.8Review
Transition probability -  FDA Review to 1 I 1Approval
Discount Rate 0.12 0.12 0.12
Fermentation titre (g/L) Tr(0.6, 0.8, 1.2) Tr(0.8, 1.0 ,2 .0) Tr(0.4,0.6, 1.0)
DSP yield (%) Tr(55, 60, 65) 65 Tr(50, 55, 60)
CMO’s mark-up on COGS (%) - 80 -
CMO’s royalty charge on sales (%) - 15 -
Profit paid to partner (%) 60 - -
Expenses paid by partner (%) 50 - -
Ease o f training staff Tr(5, 7, 9) T r ( l , l , 3 ) Ti(3, 5, 7)
Ability o f the local infrastructure to
Tr(6, 8, 10) Tr(6, 8, 10) Tr(8, 10, 10)support operations and logistics.
Ability to acquire manufacturing 
personnel Tr(6, 7, 9) Tr(8, 10, 10) Tr(3, 5, 7)
Ability to control and manage drug 
manufacture Tr(3, 5, 7) Tr(8, 10, 10) Tr(8, 10, 10)
Ease o f manufacturing expansion Tr(4, 5, 7) Tr(5, 7, 9) Tt(3, 5, 7)
Ease o f manufacturing consolidation Tr( l ,3 , 5 ) Tr(I , l , 3 ) Tr(8, 10, 10)
Readily available manufacturing 
expertise Tr(5, 7, 9) Tr(8, 10, 10) Tr(l, 1,3)
Potential to acquire manufacturing 
knowledge Tr(5, 7, 9) T r ( l , l , 3 ) TK3, 5, 7)
Control over manufacturing knowledge Tr(2,4, 6) T r ( l , l , 3 ) Tr(8, 10, 10)
Note: For each input the first, second and 
best case scenarios respectively. Where 
through all scenarios.
third numbers represent the worst case, most likely case and 
only one number is present, that value remains constant
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Probability o f  conversion before expiry date 0.5 
Year o f conversion 2, 7, 10
2 .3 .1 . M e t h o d
The commercial and development characteristics of the drug candidates are outlined 
in Table 2.4. The input values for the ‘Partner’, ‘CMO’ and ‘Build’ options are 
detailed in Table 2.5. These values were determined based on assumed differences in 
capabilities between the options. For example, the CMO option was assumed to offer 
the highest titres due to their specialised expertise in the manufacture of 
biopharmaceuticals. Advice from industrial experts was solicited to ensure sensible 
assumptions were made. For the ‘Partner/Build’ option, manufacture of the first drug 
is modelled on the input values for the ‘Partner’ option and manufacture of the 
remaining drugs are modelled on the ‘Build’ option. Similarly, for the ‘CMO/Build’ 
option, manufacture of the first drug is modelled on the input values for the ‘CMC ’ 
option and manufacture of the remaining drugs are modelled on the ‘Build’ option. 
The convertible debt instrument is the same across all scenarios and the input values 
can be found in Table 2.6. The expected values were used to generate a deterministic 
ranking configuration. By default the financial criteria and operational criteria were 
assigned equal aggregate weightings. The weighting of each group of financial 
criteria is equal. Likewise, the weighting of each group of operational criteria is 
equal.
The base case input values were processed through the deeision-support framework to 
generate deterministic scores. A sensitivity analysis, based on the best and worst case 
values, was used to identify the most influential factors. A stochastic analysis was 
conducted using triangular distributions based on worst, most likely, and best values 
of manufacturing, commercial, and operational variables. Here, 1000 iterations of a 
Monte Carlo simulation were found to be sufficient to represent the stochastic 
behaviour of each option considered for the purposes of comparability.
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2.4. Results a n d  D isc u ssio n
2 .4 .1 . B a s e  C a s e
Table 2.7. Deterministic results.
Option ENPV ($MM) WSM Score Rank
Build $855 0.2157 T*
Partner $641 0.2062 2nd
Partner/Build $683 0.2026 3rd
CMO/Build $829 0.1960 4*
CMO $764 0.1795 5*
Table 2.8. Deterministic rankings o f the options considered within each decision-making category.





Profitability 5 3 2 4 1
Asset Utilisation 3 1 5 4 2
Financial Liquidity 2 5 3 1 4
Long-term Solvency 1 5 3 2 4
Capital Structure 5 3 1 4 2
Productivity 2 1 3 5 4
Operational
Location 5 1 3 4 2
Flexibility 4 5 1 2 3
Manufacturing Knowledge 3 5 1 2 4
The deterministic results are presented in Table 2.7, which for each option includes 
the WSM score, the assigned rank, and the ENPV generated. Table 2.8 highlights 
how the categories of criteria contribute to the score of each strategic option.
The Build, Partner and Partner/Build options scored higher than the average WSM 
score. The Build option scores highest indicating that is the most preferred option. 
This option generates the greatest ENPV value as well as the highest total value of 
assets which contribute highly in the capital structure category. Additionally, the 
highest degree of flexibility and the greatest expected gain in manufacturing 
knowledge are associated with this option.
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The Partner option ranks second place. The sharing of expenses results in its total 
liabilities being the lowest of all the options and contributes to a high score in the 
long-term solvency category. The Partner option also involves sharing profits 
making it the least profitable option. The smaller profits result in a smaller equity 
value when compared with other options contributing to a low score in the capital 
structure category. This option also scored low in the flexibility category because the 
partnering company has been granted some control over the manufacturing projects.
The Partner/Build option scores lower than the Partner and Build options even 
though it is a combination of both. The benefits that the Partner/Build option gains 
fi'om the Build option are counteracted because these benefits happen halfway into the 
lifetime of the project. This is relevant because the discount factor and the transition 
probabilities used to calculate the ENPV cashflows have the resultant effect of giving 
events occurring soonest the highest degree of impact on this figure. This will 
consequently impact the WSM score. Similarly, the fixed assets that are gained fi'om 
building manufacturing capacity are used to generate highly discounted profits and 
hence lower equity. This results in a low score in the asset utilisation category and 
the capital structure category. Additionally, the Partner/Build option scores lowest in 
the productivity category as the labour force is not used as efficiently as with the 
Partner or Build options.
The CMO and CMO/Build options score the lowest overall. Contributors to these 
scores include the higher COGS and royalty charges associated with both of these 
options. This results in significantly higher current liabilities and lower equity values 
than any of the other options and gives rise to low scores in the liquidity and long­
term solvency categories. Contracting out manufacturing obligations means that these 
options compromise some of the potential to build manufacturing knowledge so these 
options achieve lower scores in manufacturing knowledge. The CMO/Build option 
scores low in the productivity category as the labour force is not used as efficiently as 
with either the CMO or the Build options.
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2.4 .1 . S e n s it iv it y  a n a l y s is
This analysis displays the maximal sensitivities across all options. For individual 
options these values will change as may the order of these factors. The analysis 
revealed that the most significant factor affecting the deterministic WSM score was 
the market eapture achieved by the company (Figure 2.3). It was found that the most 
critical drivers were associated with commercial factors. These are similar to results 
from research conducted by Rajapakse et al. (2005) and Stonebraker (2002).
Expected Market Capture 
Price Deviation Factor 
Titre 
Average Yield 
Ramp Time to Peak Market Capture 
Decay Time After Market Capture 
Batch Success Rate Î
- 6 - 5 - 4 - 3  -2 -1 0 1 2 3 4 5 6
% Change in Base Case WSM Score
Figure 2.3. Tornado diagram illustrating the overall maximal effects o f best 
financial inputs on base case options.
and worst (■) case
2.4 .2 . Ex pe c t e d  N et  P r e s e n t  V a l u e  (E N P V )
Use of the WSM proved to be highly useful in its ability to aggregate many aspects of 
the financial analysis and the operational evaluation. Furthermore, analysing the 
options under uncertainty via a Monte Carlo analysis also proved to be highly 
informative in revealing the expected performance of each option. Figure 2.4 
demonstrates that the CMO/Build option is the most profitable and has a marginally 
greater upside potential in generating profit. The reason why the Build option does 
not generate the most profit in all circumstances is mainly due to its less developed 
technical manufacturing capabilities. In this case study the option to build has 
significantly less efficient technical manufacturing capabilities than with outsourcing
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to a contractor. This can create a greater barrier to generating profits in the Build 
option than the COGS premium and royalties charged will do in the CMO/Build 
option. When considering the Build and CMO options alone it can be seen that the 
Build option demonstrates a better performance in ENPV which is consistent with 
research by Ginsberg et al (2002). Additionally, it is shown that in this scenario 














500400 600 1100700 800 900 1000
ENPV ($Millions)
Figure 2.4. Distribution o f  the Expected Net Present Value for the Partner (—■ —), CMO (' 
Build ( A ), Partner-Build (- ■  ■) and CMO/Build (“ ♦  ") options under uncertainty.
2.4.3. S t o c h a s t i c  WSM s c o r e s
The stochastic WSM score highlights the holistic value of the option to the decision 
maker as defined by the deeision-support methodology. Figure 2.5 reveals the 
difference in this case between an analysis based entirely on ENPV and one based on 
multiple criteria. In particular, the CMO/Build option which came first in the ENPV 
analysis is one of the lowest scoring options in the WSM analysis. Another notable 
difference is that none of the ranking positions achieved with the ENPV analysis are 
the same with the WSM analysis. In contrast, the stochastic WSM ranking positions 
are the same as the deterministic WSM ranking positions (Table 2.7 and Table 2.8).
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Figure 2.5 also highlights a distinction between the top three options, Build, Partner, 
and Partner/Build and the remaining alternatives. By regarding the peaks of each 
distribution alone, the Build option can be considered to be most preferential and 
more certain, but not entirely distinct from the Partner option. The Partner/Build 
ranks closely behind the Partner and Build options but not close enough to be 
preferred over either. To draw further distinction between the Partner and Build 
options a two-sample two-tailed t-test assuming equal variances demonstrated full 
confidence that both samples are completely dissimilar. What needs to be determined 
from this point is the extent to which the WSM valuation can be relied upon to 
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Figure 2.5. WSM Score o f the for the Partner (—■ —), CMO ( ^  ), Build ( A ), Partner-Build 
(■ ■  ■) and CMO/Build (" ♦  ") options under uncertainty.
2 .4 .3 .I . R is k s  a n d  R e w a r d s
It is useful to quantify the impact of uncertain variables for each option on the WSM 
score. Here, the risk refers to the semi-standard deviation and the reward refers to the 
stochastic WSM score. Further, deviations above the mean value are not considered 
to be undesirable risk so the standard deviation which includes values both above and 
below the mean value, is not an appropriate metric. Figure 2.6 plots the semi­
standard deviation versus the reward of each option and also displays the initial 
expenditure for each option. It is ideal to have options in the lower rightmost
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quadrant. The Partner/Build option is shown to perform within this quadrant. The 
Build option performs approximately at the average semi-standard deviation value 
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Figure 2.6. Risk versus reward o f considered options. The vertical dotted line and the horizontal 
dotted line are representative o f the mean reward and risk values respectively across all options. The 
size o f each bubble is proportional to the initial expenditure required to exercise each option.
The Build option is also shown to require the highest initial expenditure. If the 
company could not afford this option then it would have to reeoneile between the 
tradeoffs seen with the other options that perform above the average reward. As 
demonstrated in Figure 2.6, these options would be the Partner and Partner/Build 
options. The Partner option offers a higher reward than the Partner/Build option but 
is also eoupled with signifieantly higher risk.
This risk and reward analysis allows the deeision maker to draw elearer distinetions 
between the Build and Partner options than was possible with Figure 2.4 or Figure 2.5 
exelusively. Figure 2.6 makes elear that although the rewards are above average for 
the Build and Partner options, the Build option incurs a significantly lower risk. The 
Build option has the advantage of offering over 14% lower risk with nearly a 4% 
greater reward than the Partner option. It is intuitive to attaeh little advantage to this 
gain in reward however this is not neeessarily an aecurate association to make. As
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seen in this case, a gain of nearly $200 million in ENPV is a contributor to this 4% 
advantage in reward.
2 .4 .3 .2 . F i n a n c i a l  a n d  O p e r a t i o n a l  A g g r e g a t e  S c o r e s
While analysing the holistic value of the WSM score reveals the overall worth of the 
option to the decision maker it is important to discern the factors that have been most 
influential in score’s determination. This is especially significant in confirming 
whether or not the characteristics attributable to the highest ranking option are aligned 
with the business strategy. Due to the structure of the MCDM based model it is 
possible to breakdown the WSM value of each option into scores that relate 
specifically to financial and to operational criteria. Figure 2.7 demonstrates the 
balance of operational to financial scores for each option in this scenario. A high 
financial score suggests a highly sustainable investment and likewise a high 
operational score suggests a high level of practicality and manageability. Hence, the 
most desirable option is the one that lies most to the upper rightmost quadrant. The 
Build option performs fully above the group average for both scores. Comparison 
between the Build and Partner options demonstrate that the Build option is most 
valuable both financially and operationally.
Under uncertainty it is also highlighted that there is greater variance with the financial 
aggregate scores than with the operational scores. Because of the subjective nature of 
scoring for many of the operational attributes it would not be accurate to say that this 
would necessarily translate to a lower operational risk.
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Figure 2.7. Operational versus financial aggregate scores o f the Partner (■), CMC (♦ ), Build (A), 
Partner-Build (□) and CMO/Build (O). Each data point is representative o f its deterministic value. 
The X and y error bars each signify one standard deviation either way o f the data point. The vertical 
line intercepting the financial aggregate score axis is the mean financial aggregate score. The 
horizontal line intercepting the operational aggregate score axis is the mean operational score. The 
diagonal line shows the profile o f financial and operational scores that are equally balanced.
2 .4 .3 .3 . O p e r a t i o n a l  t o  F i n a n c i a l  R a t i o
The relative weighting of the operational aggregate score to financial aggregate score, 
R, is the final analysis considered in this chapter and is demonstrated in Figure 2.8. 
The previous analyses were under the presumption that operational and financial 
characteristics were of equal value to the decision maker. In Figure 2.8, values of R 
ranging from 0 to 2 were used to investigate the stability of the ranking configuration. 
Within this range, it was found R did not have an effect on the top ranking option 
demonstrating that this option dominates the other options when considering both the 
financial and operational aspects. It can be seen fi-om Figure 2.7 that the ‘CMO’ 
option stochastically dominates all other options in operational scoring so as the value 
of R increases this option becomes increasingly preferred and is most preferential at 
values of R above 6.02.
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Figure 2.8. The impact o f the ratio, R, o f  operational to financial aggregate weightings on the mean 
overall aggregate score for the Partner (■), CMO (♦ ), Build (A), Partner-Build (□) and CMO/Build
(O).
2.4 .3 .4 . S u m m a r y  o f  S t o c h a s t ic  R e s u l t s
The results indieate that all options are finaneially and operationally viable but 
aeeording to all analyses the Build option is most preferential. Although there were 
many eonflieting attributes assoeiated with the seleetion of any option, it is important 
to be aware that the Build option is the option most aligned with the eompany’s 
business strategy. Overall, the faetors defining the deeision proved to be its ability to 
exereise the option along with its willingness to aeeept the inherent tradeoffs. It is 
important to remember that the results are speeifie to the assumptions made in the 
ease study; for example, if tighter budget constraints were assumed, this eould 
influence the ranking of the option to build capacity and might even rule it out 
completely as infeasible.
Comparing the results presented, an investigation by Rajapakse et al. (2005) 
contained similar investigations with regard to risk and ENPV analysis. The paper 
involved the comparison of the construction of a biopharmaeeutieal manufacturing 
facility and the utilisation of a CMO. Similar to the results shown here was that the 
CMO displayed a significantly lower performance in ENPV when compared with 
building a new facility. Contrary to the results demonstrated here, was that the CMO
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was found to be less risky than the option to build. It is difficult to compare results 
accurately as there are many differences between the case studies, assumptions and 
architectures of the models. For example, the drugs used in this case study are at later 
stages of development so the portfolio risk will be lower than a portfolio of drugs all 
entering early stage clinical trials as in Rajapakse et a l (2005). This reinforces the 
fact that the results are case-study specific.
One issue still to be resolved is that of the weightings of the criteria and their 
respective categories. In the case study equal weighting was assigned to all criteria 
and their categories but this configuration will conflict with the preferences of a 
decision maker that is more aggressive on generating profits. The line of inquiry 
following this is then in determining a suitable weighting configuration between the 
group, their categories, and their individual criteria to best represent the preferences of 
the decision maker. This consideration is outside the scope of this chapter.
Finally, the decision maker needs to be aware that, by definition, the normalisation of 
criteria values distorts or removes any meanings associated with their original 
magnitudes. Additionally, further distortion of the original magnitudes is exacerbated 
by the amalgamation of criteria values into a score and thus caution is required when 
interpreting the value of that score. As demonstrated earlier, the Build option 
outperformed the Partner option by a modest percentage in its WSM score but a 
significant gain in ENPV was a contributor in this performance.
2.5. C o n c l u s i o n s
The development of a décision-support framework to assist decision-making in 
strategies for the acquisition of biopharmaeeutieal manufacturing capacity has been 
presented. The framework provides a structured and transparent method of analysing 
such scenarios through the utilisation of MCDM and Monte Carlo simulation. 
Additionally, several financial and operational criteria were considered to provide a 
broad and detailed analysis from both perspectives. A hypothetical case study was 
formulated to demonstrate the usefulness and limitations of the framework.
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The WSM proved to be highly suitable for data handling and for the analysis of 
results. The Monte Carlo simulation was valuable in highlighting the probability 
distributions and variance of base case values. Use of the model has highlighted that 
the employment of a single criterion in making strategic manufacturing decisions of 
this nature may not allow the decision maker to be aware of other important criteria. 
However, use of multiple criteria analysed under uncertainty provided a successful 
approach in identifying and confirming the best option. The analytical approach 
required highlights the complexity that can be involved in making decisions similar to 
the one analysed. Ultimately, a thorough and accurate analysis of financial and 
operational data is essential to make confident distinctions between feasible and 
attractive options.
2.6. N o m e n c l a t u r e






E total annual expense
El capital investment
E2  cost of goods sold
E2  general and administrative
E3 royalties
E 4  total plant expenses to be paid
E5  profits owed to partner
F  fixed capital investment
g proportion of sales to be spent on general and administrative costs
/  total annual income
I] dose per patient per year
I2  target population size
/j market capture
I4  annual product demand
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C h a pt e r  3
S t o c h a st ic  Co m b in a t o r ia l  O p t im is a t io n  A p p r o a c h
TO BIOPHARMACEUTICAL PORTFOLIO MANAGEMENT
3.1. In t r o d u c t io n
In chapter 2 a framework for reconciling between strategic options for acquiring 
biomanufacturing capacity was presented. The work in this chapter takes this 
considerably further by exploring the options available to a biopharmaeeutieal 
manufacturer for the development of a portfolio of drugs and the development of a 
technique to optimise such strategies. Given the relevance and importance of 
contributions to large-scale portfolio and capacity optimisation problems in 
biopharmaeeutieal settings, especially in modem industry, this chapter addresses the 
development of a holistic framework for the simultaneous stochastic combinatorial 
and multi-objective optimisation of biopharmaeeutieal research and development 
portfolio management and manufacturing capacity planning decisions. More 
specifically, given a set of dmg candidates and their uncertain development, 
manufacturing, and commercial parameters, alongside an availability of external 
corporate bodies for development and manufacturing with their various uncertain 
technical characteristics this work presents a novel method for finding the optimal 
stmcture of the:
■ Optimal stmcture of the dmg development portfolio,
■ Development sequence for the selected dmg candidates,
■ Schedule of critical development activities, and
■ Itinerary of activities at specific stages that should be integrated in-house, 
outsourced, or partnered such as to maximise important multiple objectives.
The overall framework is a combination of the simulation-based evaluation 
framework based on the framework described in chapter 2 and a bespoke estimation 
of distribution algorithm (EDA) (Mühlenbein and Pass, 1996) to iteratively evolve a 
population of candidate strategies. All strategies are formulated according to a 
common superstmcture and the simulation model, which integrates a
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biopharmaeeutieal manufaeturing proeess model, is used to determine important 
stoehastie properties demonstrated in performanee objeetives. Due to the vast 
multidimensional deeision spaee and multimodal objeetive spaee presented by the 
addressed problem, this work features an EDA that harnesses the unsupervised 
maehine learning eapabilities of Bayesian networks to diseover the probabilistie 
nature and intereonneeted strueture of the deeisions that eomprise superior performing 
strategies within the model. To further support the capture of probabilistic data and 
hence the representational power of the EDA, superior strategies are algorithmically 
clustered according to their performance in the objective space so that a specific 
probabilistic model can be constructed for each clustered region. The EDA then uses 
these probabilistic models to formulate new strategies. Each iteration in the 
optimisation procedure consists of evaluating a population of candidate strategies, 
selection of superior candidate strategies, probabilistic modelling and generation of 
the subsequent population. The approach also features a range of uncertain 
parameters, product line and corporate affiliation dependency specifications. In 
addition to these structural elements this study pays attention to the practicalities of 
illustrative cases. It is the aim of this chapter to investigate how performance 
optimised strategies and the boundaries of optimal performance in the objective space 
will vary according to selected constraints. These constraints are the size of the 
portfolio and the magnitude of the constraint on cash flow.
The organisation of the remainder of this chapter is now described. Section 3.2 
details the complete model formulation for the stochastic evaluative framework and 
for the EDA. Section 3.3 presents a case specific to the production of monoclonal 
antibody drug candidates to exemplify the use of the framework. Section 3.4 
describes and discusses the results pertaining to the case presented. The final section 
discusses any final conclusions.
3.2. M odel  Fo r m u la tio n
The stochastic optimisation process makes use of an evaluative framework to capture 
the impact of decisions made by strategies in the modelled environment and to 
estimate their stochastic properties. This is coupled with an EDA that operates the 
optimisation procedure through the machine learning of instances of decision
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variables that are assoeiated with superior performance. Here, any interdependent 
relationships between decision variables and their instances are data mined and then 
used to build a probabilistic model on which the formulation of new strategies are 
based.
The model is designed using C++ and MS Excel. The entire simulated environment is 
assembled in C++ as this contains the most frequently utilised calculations and the 
C++ language offers significant savings in computational time. MS Excel is used as 
the main graphical user interface as it offers a convenient means for storing, 
extracting and manipulating data. The environment is interfaced with MS Excel via a 
dynamic link library where it is represented as a user-defined function. Decision 
variables are entered into the function and defined parameters are outputted. Modules 
for controlling the flow of data in the simulation and optimisation procedures are 
compiled in Visual Basic for Applications (VBA) which is readily executable in the 
MS Excel environment.
To illustrate to the reader how the salient sub-procedures of the framework link 
together, an example describing the flow of computational tasks is henceforth 
summarised. This should also provide the reader with an overall perspective of the 
methodology and an understanding of how the following subsections are linked. A 
batch of strategies is generated towards a simulated environment that characterises the 
portfolio problem that is to be investigated. Each strategy in this batch is sequentially 
selected and simulated where the deeisions for portfolio construction, scheduling, and 
the involvement of third parties are recognised by the framework. Simulation tasks 
include calculating the economics of development, manufacturing, and marketing 
which will lead to the determination of objective metrics. The simulation framework 
contains stochastic variables which require the simulation to be repeated for multiple 
trials for each strategy. This will subsequently provide statistics pertaining to the 
objective metrics that are useful for comparing the performance of different strategies. 
Once all strategies have been simulated an algorithmic selection process is used to 
identify superior strategies according to their performance against pre-determined 
objectives whilst discarding the remainder. These superior strategies are split into a 
specified number of clusters, again based on their performance against pre-determined 
objectives. For each of these clusters a Bayesian network is learned in order to
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identify and classify any probabilistic interdependencies between the decisions that 
comprise the member strategies. This provides an understanding, albeit complex and 
from a probabilistie perspective, as to how strategies in each cluster and hence 
superior strategies are structured. The learned Bayesian networks serve as 
probabilistic models which are sampled in order to generate new and improved 
strategies. Here the entire batch of strategies that was previously simulated is now 
replaced with a new batch that is modelled on its superior features. This simulation 
and regeneration procedure is repeated until a termination criterion is reached. 
Thorough details of the entire method are now described.
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Figure 3.1. Schematic of the framework used to evaluate populations of candidate solutions and 
iteratively evolve superior populations of strategies.
3 .2 .1 . Ev a l u a t iv e  Fr a m e w o r k
The framework for evaluating each candidate solution (Figure 3.1) models the 
performance of the strategy by mapping the consequences of decisions made within 
the simulated environment. Various facets of the drug development process and its 
wider commercial environment are captured within the modular structure of the 
evaluative framework. Each module is designed to carry out a set of related 
calculations and, as illustrated, these modules are networked and eventually result in
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the evaluation of a set of criteria. The following sub-sections will detail the contents 
of these modules.
3 .2 .1 1 .  S u p e r - s t r u c t u r e  o f  a  c a n d i d a t e  s o l u t io n
Consider generation G{t) as a population of candidate solutions at a given iteration of 
the optimisation procedure, /, within the total number of iterations, îmax, that can 
potentially maximise the objectives of the decision maker. Each candidate solution, 
g, in G{t) has a generalised structure for representing its decisions. Figure 3.2 
demonstrates this generalised structure for a portfolio of five drugs where the 
structure can be segregated into three sub-types: drug development sequence, 
scheduling, and third party usage.
The strategy for the drug development sequence, Dg, codes the drugs that are included 
in the portfolio and the order in which they are commercialised:
Dg = {Dg,i=u Dg,i=2 , Dgi=3 , . . Dg^M} Vg e G(t),i e /  (3.54)
where Dg i is the drug chosen as the i‘^  drug in the drug development sequence by the 
g‘^  candidate solution, and /  is the total number of drugs in the drug development 
portfolio. It is clear that / can be any drug not already chosen as part of Dg.
The scheduling strategy for the drug in the development sequence according to the 
candidate solution, Tgj, commences development of drug i according to when drug 
/-I reaches the beginning of a particular stage of development. These stages can be 
instantiated as: target identification { ‘ID ’), preelinical testing { ‘P C ’), phase I clinical 
trials { ‘P I’), phase II clinical trials { ‘P II’), phase III clinical trials { ‘PHI’), FDA 
review ( ‘FDA ’), and market approval ( ‘M KT’). Thus:
^  7^.,-3, •••, Tgj-i.\] Vg e G{t),i g /  (55)
Tg, =  { ‘ID ', ‘P C ’, ‘P I’, ‘PIT, ‘P lir , ‘FDA ’, ‘M KT’] Vg g G{t),i g /  (56)
where Tg is the set of timing strategies for all drugs in the portfolio.
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The third party strategy belonging to the solution for the i‘^  drug at the
development activity, Cgjj, has three possible instances for each stage: in-house or 
otherwise referred to as an integrated activity (7 '), outsourced activity ( ‘C ’), and 
partnered activity ( ‘P ’), hence:
C'g/=3, Cg,i-]}
Cg,i — {Cgij-\, Cgjj^2, Cg/ij^T,, • • •, Cgij^i]
Q , ,=  {7', 'C , T '}
V g E G ( 0 , f E /  ( 3 .5 7 )
Vg e G (0 ,/e  7,y e 7 (3.58)
y g  e G( t ) , i e  I , j  e J  (3.59)
where J  is the number of development activities. This format allows the framework 
to formulate a plan of critical activities to complete either by themselves or by another 
corporate body. The development activities, Cg^, are structured as: Cg,/,i -  target 
identification, Cg,/,2 -  preelinical testing, Cg / 3 -  phase I clinical testing, Cg,/,4 -  phase 
II clinical testing, Cg,, 5 -  phase III clinical testing, Cg,, 6 -  manufacturing for phase I 
clinical trials, Cgxi -  manufacturing for phase II clinical trials, Cg / g -  manufacturing 
for phase III clinical trials, and Cg,/.9 -  commercial manufacturing.
Candidate solution, g
Drug selection & order Corporate relationsTiming
;,i=3
Target PC Clinical development: M anufacturing:
ID Testing PI, PII, PHI PI, PII, Pill Market
1 3 ' = '  : 3 i = 1 - 4 3 ' = ' . 7 1 3  ' ^ 1 . 8  1
^ . ' ' 2 . 1 1 3 ' = 2 . 4 3 ' = 2 . 5  1 ^ X ' = 2 . 6 ^ . ' ' 2 . 7 1 3 ' = 2 . 8  1 3 ' = 2 , 9
1 q . 3 , 2 3 '  =  3 , 4 3 ' = 3 . 5  1 1 3 ' = 3 . 8  1 3 ' = 8 . 9
'=4,1 1 3 '= 4 .2 3 '= 4 .3 1 q . '= 4 .4 1 q ,= 4 .5 3 '= 4 ,6  1 1=4.7 ^X '=4.8 Q  '=4.9
^ X '=5.1 1 3 '  = 5,3 1 3 ' = m 1 3 '= 5 ,5 3 '= 5 .6  1 3 '= 5 .7 3 '= 5 .8 ^*.'=5.9
Figure 3.2. The super structure o f a candidate strategy for the commercialisation o f a portfolio o f five 
drugs.
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Structuring the strategies Dg and Tg is straightforward. Each instance within Dg can 
only refer to one drug whilst any combination of timing instances for each Tgj in Tg is 
permissible. Structuring the corporate strategy requires the application of some rules 
to avoid the formulation of nonsensical strategies. The first set of stipulations restricts 
the company from breaking and resuming contracts with partners:
If = ‘P ’ then Cgxj = ‘P ’ for y = {2, 3, 4, 5, 6, 7, 8, 9} (3.60)
IfQ ,,2  = ‘P ’then Cg,ij = ‘P ’ fbry = {3, 4, 5, 6, 7, 8, 9} (3.61)
IfQ,/,3 = ‘P ’then Cgxj = P ’ fbry= {4,5,6, 7, 8,9} (3.62)
If Q,/,4 = ‘P ’then Cgxj = P ' for; = {5, 7, 8, 9} (3.63)
IfQ .,5  = ‘P ’ then Cg,ij = P ’ fory = {8,9} (3.64)
If Q,/,6 = P ’thenCg,y = P ' fory = {3, 4, 5, 7, 8, 9} (3.65)
IfQ,,,7 = P ’thenCg,/,y= P ’ for y = {4, 5, 8, 9} (3.66)
ifQ,,,g = P ’then Cgxj = P ’ fory = {5, 9} (3.67)
This assumes that the partner is required for both clinical trial development and 
manufacturing. A second set of stipulations prevents the breaking of outsourcing 
contracts on clinical trial and clinical manufacturing activities:
If Q ,,,3 = 'C  then Cg,ij = 'C  for; = {4, 5} (3.68)
If Cg,,,4 = ‘C ’thenCg,ij= ‘C ’ for; = {5} (3.69)
If Q,,,6 = 'C  then Cg,ij = T ' for; = {7, 8} (3.70)
IfCg,,7 = ‘C ’thenCg,.j= ‘C ’ for; = {8} (3.71)
It is assumed that contracting for clinical trial testing and contracting for 
manufacturing will be completed by separate companies.
These stipulations have an added benefit of reducing the decision space and 
computational time. Without them each drug would have a total decision space for 
Cgj of 3^  solutions over its nine constituent decision variables, now this is reduced to 
207 solutions. To support computational efficiency Q ,  is programmed as a single 
variable having 207 instances, rather than as nine Cgjj variables each having three
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instances. This format means that Cgj can be instantiated from a database of 
permissible combinations of each Cgjj, as opposed to having an active procedure that 
validates and corrects the structure o f Cgj for each g  in G(t) over each t through to
tM A X -
3  2 .1 .2 . S t o c h a s t ic  v a r ia b l e s
To simulate the uncertain environment the model accounts for the stochastic nature of 
a range of uncertain variables (Table 3.1). In this study, each stochastic variable is 
characterised by a triangular probability distribution based on the specification of 
maximum, minimum, and most likely values. The types of variables included in the 
model formulation are costs, commercial factors, and manufacturing capabilities. 
Each variable bears relevance to a single element of Cgj and a separate distribution 
must be defined for each possible instance of the relevant element. Thus, for a 
portfolio of five drugs, individual distributions of 99 stochastic variables must be 
defined. Depending on the structure of g  the relevant stochastic variables will be 
selected for sampling.
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3 .2 .1 .3 . B i o m a n u f a c t u r i n g  m o d e l
The framework used to model the manufacture of biopharmaeeutieal products is 
based on work reported by George et al. (2007), Farid et al. (2000, 2005a, 2006), and 
Lim et al. (2005a and b). Included in the model are the main process and ancillary 
tasks involved in the manufacturing procedure. The main input parameters to the 
model are the annual demand to be met by the facility, the expected fermentation titre, 
the overall product yield, and the probability of achieving success for a single batch 
fermentation. Equations for calculating the utilisation of equipment, materials, 
utilities and labour are also included. Cost calculations are supported by a database of 
unit costs for equipment and materials used in the manufacturing process.
3 .2 .1 .4 . D e p e n d e n c ie s
Within a set of decisions it is possible that at least one of these decisions can have an 
impact on the performance of remaining decisions that are yet to be executed. In the 
real world, this can be a consequence of making decisions that affect the utilisation of 
the same tangible or intangible resource. The framework recognises three such 
contexts of dependency where this type of impact may occur: contractual, revenue, 
and manufacturing cost.
Contractual dependencies here refer to the utilisation of a third party for 
manufacturing or research activities. Here, the premise is that the longer the period 
for which a third party is used and the greater the number of activities that it is 
involved in, the more favourable the rates it charges becomes. Additionally, for each 
third party there is a minimum charge that it will not breach. This clearly affects how 
the corporate relation strategy performs in the model.
Revenue dependencies here refer to the impact that constituents of the company’s 
drug pipeline create when competing within the same market. When multiple drugs 
compete in the same market each drug can suffer from reduced returns in comparison 
to what it might have achieved if commercialised in absence of competing drugs, 
given the same commercial environment. It is also possible that multiple drugs can
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enhance the sales revenue of each other if they have eompiementary applications. In 
the model, the impact of this dependency is realised through Dg and Tg. The 
configuration of Tg is important here because, in the absence of other dependencies 
affected by these strategies, it may be more beneficial to stagger the development of 
competing drugs so that there are periods of reduced or no competition. Also, the 
performance of these strategies will depend on the revenue related penalties or 
benefits of having competing or complementary drugs in the market place.
Capital dependencies are modelled here as affecting the capital expense required for 
manufacturing a drug, due to the sharing of resources for structurally similar drugs. 
Where such drugs are being manufactured, it may be possible to use some part of the 
same manufacturing facilities hence reducing the overall capital requirements. The 
impact of this dependency is reliant on the capital savings than can be realised within 
a group of drugs. This dependency is affected by the strategies for the structure of the 
drug portfolio where the choice of structurally similar drugs supports reduced capital 
expense requirements. The strategy for the order in which drugs are commercialised 
is also important because drugs commercialised later in the pipeline may require less 
capital. Additionally, these strategies must reconcile the penalties and benefits of 
their impact on capital and revenue dependencies.
3 .2 .I .5 . P r o c e s s in g  s e l e c t io n  c r it e r ia  a n d  s t o c h a s t ic  p r o p e r t ie s
The simulation of any candidate strategy will lead to a distribution of outcomes in 
each performance criterion considered, providing a variety of information to the 
decision maker. As a basis for comparing the quality and superiority of strategic 
options the following approach was taken. The approach was based on two metrics, 
the mean positive NPV produced by the strategy and the probability of generating a 
NFV above zero, p(NPV>0). These allow for the decision maker to establish which 
strategics demonstrate optimal performance in generating profit and those that 
maximise the expectancy of generating profit of any magnitude. This was also used 
for the selection of superior strategies for which the procedure will be formalised in 
later sections.
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The rationale for bifurcating the distribution of NPV values is now discussed. The 
distribution of all NPV values produced by each strategy is expected to be bimodal. 
The leftmost mode will be correspondent to the expected level of loss or the expected 
impact of failure when the candidate strategy does not yield a positive NPV. 
Similarly, the rightmost mode will correspond to the expected level of financial gain 
when the strategy yields drug development projects that successfully reach the 
marketing stage. It should be borne in mind that the rightmost mode is expected to be 
positive for all strategies, and this may especially be true in scenarios where heavy 
development costs and particularly low probabilities of reaching the marketing stage 
are combined with imprudent third party strategies and projects that yield modest 
revenues. Additionally, as realistic expectancies of a monoclonal antibody drug 
progressing to the marketing phase are typically below 0.3 (Reichert, 2003) the left 
most mode is expected to be the most pronounced of the two. In the optimisation 
framework, if the NPV distribution is treated as a single attribute then the 
optimisation process is more likely to be driven towards minimising the impact of 
failure than it is towards maximising the rewards that come with successful drug 
development. Hence, the NPV distribution is treated as two separate attributes of the 
candidate strategy that are simply dichotomised at NPV = 0. If an alternative 
objective function was used then it may be appropriate to consider the entire 
distribution rather than any specific and separable constituents of it. Additionally, it 
should be considered that the probability of achieving a positive NPV is a single 
metric derived from the simulation data and clearly does not have a mean, minimum, 
maximum or semi standard deviation.
The objective function p(NPV>0) is a straight forward calculation that can also be 
extended to the more specific needs o f the decision maker. For example p(NPV>/) or 
p(NPV>/)>y could be used as suitable and more malleable alternatives, where i and j  
used in this context are defined by the needs of the decision maker. The objective 
function p(NPV>0) is used here so that the full landscape of the objective space can 
be viewed and analysed.
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3.2.2. E s t i m a t i o n  o f  D i s t r i b u t i o n  A l g o r i t h m
EDAs, otherwise known as estimation of distribution algorithms (EDAs) (Mühlenbein 
and PaaB, 1996), are comparable to a class of optimisation algorithms known as 
genetic algorithms (GAs) (Holland, 1975) and have been shown to be a class of 
promising approaches in solving combinatorial optimisation problems (Pelikan et al., 
2000). Like GAs, EDAs function by iteratively evolving a population of candidate 
solutions to the problem until a termination criterion is satisfied. A main driver by 
which GAs are thought to achieve this is through the manipulation of building blocks 
(Holland, 1975; Goldberg, 1989). Building blocks are a central concept in GA theory, 
where superior building blocks are expected to be key components of superior 
solutions. They can be any set of instantiations of decision variables present in any 
set of candidate solutions. Additionally, a superior building block can be considered 
as a set of instances of decision variables that work together to support the 
performance of any set of superior candidate solutions in the objective space 
considered. The instances of decision variables forming a building block may also 
exhibit a dependency relationship where added value in superiority is achieved by the 
holistic presence of a set of instances rather than necessarily through individual 
incremental increases in performance contributed by each constituent of the building 
block. EDAs are designed to recognise superior building blocks explicitly by 
constructing probabilistic models of the states of decision variables that are present in 
superior solutions. Examples of simple EDAs in literature include the univariate 
marginal distribution algorithm (UMDA) (Mühlenbein, 1997) and the compact 
genetic algorithm (cGA) (Harik et al., 1999). Examples of more complex EDAs 
include the Bayesian optimisation algorithm (BOA) (Pelikan et al., 2000) and the 
multi-objective hierarchical Bayesian optimisation algorithm (mohBOA) (Pelikan et 
al., 2005).
In this study, and like the BOA, the data structure used as the framework for the 
probabilistic model is a Bayesian network. A Bayesian network is an annotated 
directed graph that encodes probabilistic relationships and their use here derives from 
the fact that artificial intelligence researchers have used them to encode expert 
knowledge (Heckerman, Geiger and Chickering, 2005). The topology of the network 
is learned directly from the structure of top performing candidate solutions in S{t) and
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is then randomly sampled via the conditional probabilities that it encodes to generate 
G(/+l). The EDA used here (Figure 3.3) is largely based algorithmic concepts found 
in the mohBOA.
Estimation of Distribution Algorithm
Initial population:
Let the population o f candidate solutions be G(J).
/ -  1
Randomly generate the initial population o f candidate solutions, (7(1).
Let t ^  be the maximum number o f populations to be evolved.
Fort -  1 to t„ax'- 
Evaluation:
Simulate each g  in G(t) and record stochastic properties.
Selection:
Use the fast nondominated sorting and crowding distance algorithms to select the top 50% 
o f solutions, 5(0, from (7(0 
Clustering o f  the objective space:
Using the k-means clustering algorithm, separate 5(0  into z clusters.
For each cluster, K.\
Probabilistic model building:
Construct the Bayesian network, using a hill climbing procedure to optimise the 
Bayesian Dirichlet metric over 5,.
Sampling o f  the probabilistic model:
Generate a new set o f strategies (7,(/) by randomly sampling the joint probability 
distribution encoded by B.. The number o f strategies to be generated will be twice the 
original cluster size.
Population regeneration:
Generate the new population G (/+ l) by randomly by replacing all strategies in G{t) with all strategies 
in each O ft).
Figure 3.3. Pseudocode for the EDA.
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3 .2 .2 .I . Fa s t  n o n - d o m i n a t e d  s o r t i n g
Fast nondominated sorting (Deb et a i, 2002) is used to support the discovery of a 
wide spread and densely populated Pareto optimal front (Figure 3.4). This is of great 
value to the optimisation process where discovery of a wide spread Pareto front at 
each iteration can reduce the likelihood that the optimisation algorithm converges to a 
small and restricted region of the objective space and also increases the capacity for 
the algorithm to discover new areas of the objective space. Algorithmically steering 
the discovery towards candidate solutions along the Pareto front has its advantages. 
Firstly, the nature and severity of conflict between objectives can be better understood 
with wider coverage of the objective space. Secondly, a more efficient traversing of 
the objective space can be achieved through accelerated progress at individual 
iterations. Thirdly, improved probabilistic models are likely to be built as they are 
more representative of candidate solutions along the Pareto front. This also supports 
the likelihood that stronger performing candidate solutions will be sampled from these 
improved models. Nondominated sorting is designed to support achievement of these 
advantages by splitting the objective spaee into Pareto layers, and then identifying the 
members of each layer. Pareto layers are comprised of candidate solutions that are 
Pareto optimal in the absence of other dominating solutions. A candidate solution is 
Pareto optimal if there is no other solution that exists which yields an improvement in 
any objective without yielding degradation in any other objective. The first layer 
contains candidate solutions that are not dominated by any other candidate solution in 
G{t). In the absence of members belonging the first layer, members of the second 
layer will not be dominated by any of the remaining solutions. Accordingly, the layer 
to which each member belongs represents its rank so those in the first layer will be the 
most highly ranked in G{t).
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Fast Nondominated Sorting Algorithm
For each candidate solution p  in the current population G{t)\ 
Empty the set o f solutions that are dominated by g,
The number o f solutions that dominate g ,r ig - 0  
For each remaining solution q in G{t)\
If g  dominates q then:
{q}
Else if q dominates g  then:
Increment the domination count o f g ,d g ^ d g +  1 
If = 0 (g is a nondominated solution) then:
The domination rank o f g, grank = 1
Add g  to the set forming the first Pareto layer, F,
/ - I
While the set o f members for the f '  Pareto layer, F„ is not empty: 
Set Q  as having no members.
For each g  e  F/.
For each q e  Sg.
Decrement the domination count o f g, dg^ dg -  \
If (/, = 0 then:
The domination rank o f q, q^ ank = /  + 1
/ - / + !
Figure 3.4. Pseudocode for the nondominated sorting procedure. Adapted from Deb et al. (2002).
3 .2 .2 2 .  C r o w d i n g  d i s t a n c e
To support the function of the nondominated sorting procedure, crowding distance is 
used to determine how densely populated the current objective space around this 
solution is (Figure 3.5). (Deb et al., 2002). The principle is that candidate solutions 
situated in less densely populated areas of the objective space are of higher preference 
than those in more densely populated areas. The reason being is that a candidate 
solution in a less densely populated region is considered to be more unique. Also, the 
more unique candidate solutions that are included when building probabilistic models 
the more diverse the base of information will be when characterising the structure of 
superior candidates. Thus, a candidate solution with a relatively high crowding
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distance will be situated in a region of the objective space that is relatively less dense 
and will be considered to be relatively more unique. The measure of crowding 
distance for a candidate solution is the perimeter of the cuboid created by its two most 
proximal candidate solutions in the objective space.
Crowding Distance Algorithm
Let |C7(/)| be the number o f  candidate solutions in G(t).
For each candidate solution g  e  G(t):
Crowding distance for g, C(g) = 0 
For each objective, v:
Let O be the set o f candidate solutions in G(/) sorted in ascending order according to v. 
C ((D [l]) =  oo
C(0[1G(/)1]) -  00
Let n(g) be the value o f the v'* objective as a function o f g.
For g  = 2 to ( |G (/) |-  I):
C ( $ [ g |)  =  C ( % ] )  +  (p(<D [g+ l] ) -M (< I> [g -  1] ) ) ( m( O [ 1 ] ) - h(<I>[|C(0I1))'
Figure 3.5. Pseudocode for the allocation o f  crowding distances. Source: Adapted from Deb el al. 
(2002).
Both the fast nondominated sorting and crowding distance procedures form the basis 
for the selection of successful candidate solutions on which the generation of G(/+l) 
will be based. Figure 3.6 describes the procedure by which this is achieved. Fast 
nondominated sorting is used to select candidate solutions in nondominated layers and 
add them to the set of superior performing candidate solutions, S{t). If all the 
members of the next Pareto layer will not fit into S{t) then candidate solutions are 
chosen in order of having the greatest crowding distance.
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Selection of Superior Candidate Solutions
Let S(t) be the set o f successful candidate solutions to be selected from the current population, 
G(/).
Let |5'(/)| be the number o f successful candidate solutions to be selected.
Let ||5'(/)|| be the number o f  candidate solutions remaining to be selected.
115(011 -  |5(/)|
Sort all members o f  G(/) using the fast nondominated sorting procedure.
For each candidate solution, g, in G(t), determine its crowding distance, C(g).
Let F/be the set o f  candidate solutions belonging to the/* Pareto layer 
For each/
Let \F  ^ be the number o f candidate solutions in Ff.
If|F}j< 11^ (011 then:
115(011 - 115(011 -  n
Else:
Sort all members o f F }(0  according to crowding distance.
Let G{t)seiect be the set o f H5(/)l| candidate solutions belonging to G{t) with the greatest 
crowding distance values.
5 ( 0  5 (0  U  { G { t ) s e l e c l )
Figure 3.6. Pseudocode for the selection o f superior candidate solutions.
3.1.23. K-MEANS CLUSTERING
Once S{t) has been populated, it is algorithmically clustered so that the properties of 
superior candidate solutions can be analysed for region-specific properties in the 
objective space (Figure 3.7). The k-means clustering algorithm (MacQueen, 1967) 
was selected for this purpose beeause its ease of implementation. The advantage of 
elustering the objective space is that it supports the avoidance of identifying traits of 
candidate solutions in one region of the objective space that may not support the 
performance of traits present in other regions. This algorithm requires the number of 
clusters and an initial set of eoordinates that represent the centres of these clusters in 
the objective space to be speeified by the decision maker. The initial coordinates can 
be set randomly. Members of S{t) are each assigned to a eluster based on the 
corresponding cluster centre of the closest Euclidean distance. The coordinates for 
each cluster centre is sequentially updated until the set of members for each cluster 
eentre is unchanged when compared to the previous iteration.
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k-means Clustering Algorithm
Input the number o f clusters, z.
Initialise a coordinate for each cluster centre, k^ , where each dimension in k^ , k^  y, is a value for 
each performance objective, v.
Let K^  h be the set o f candidate solutions in the z'^  cluster at the h'^  iteration.
/j = 0
Do until K\ h = 1^ 1,h ~ K.2 .h-h ■■■■> f^ z.h -
/? = + 1
For each candidate solution, g, in the current population, G{t):
Initialise each K^  h as having no members.
Let i^y{g) be the value o f  the v'* objective as a function o f g.
For each z:
Determine the Euclidean distance o f p  from k^ , Cpy.
For the k^  that produces the smallest egy.
f^z .h   ^f^z.h {g}
For each z:
For each v:
Let \K^  h\ be the number o f candidate solutions in K^  h-
Figure 3.7. Pseudocode o f the k-means clustering algorithm.
3 .2 .2 .4 . C o n s t r u c t i n g  t h e  B a y e s i a n  n e t w o r k
Bayesian networks (Neapolitan, 2003) are used here to characterise the probabilistic 
nature of relationships between decision variables and their instances occurring in the 
set of candidate solutions of the cluster, via machine learning. This data 
structure is subsequently used for generation of G(r+1). As the objective space is 
partitioned into z clusters a Bayesian network, is constructed for each z. Each 
decision variable, is represented by a node, 4,z, in the network B .^ Any 
relationships between each Sn,z are represented by a directed edge drawn between 
them (see Figure 3.8 as an example). The node from where the edge is directed is a 
parent node, while the node to which the edge is directed is its child node. That is, 
within each B: the instance of each child node is conditional upon the set of instances 
of its parents. It is important to note that all B^ are acyclic so a node cannot be
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directed to itself nor can it be part of a structure within Bz that eventually ends up 
being directed to itself (Figure 3.9).
Figure 3.8. An example o f  a Bayesian network with three nodes. 0,,% has no parents and is the parent 
of 02,1 and 03,j. has one parent, 0 ],%, and is the parent o f  63,;. 63,% has two parents, and 02,j, and 
no children.
Figure 3.9. Two Bayesian network structures that are disallowed in the model: a. 0,^ has a node that is 
directed to itself; b. 0 ,  ^ is part o f  a network structure that is later directed back to itself.
In order to avoid this, this study takes advantage of the nature of the problem for 
which this framework is developed and puts all ôn,z into ascending order according to 
the time in the development schedule that each 4».z occurs. Hence, this sequence will 
be:
d 2 ^ - = C / = i ,  0 3 ^ = 7 ’/ = ! ,  § 4 ^ =  A = 2 ,  d 5 , z = C = 2 ,  d 6 ^ = 7 ' / = 2 , - • •
- -, 03/.2^=Aw, 03/.!^ —Ci=i
where Z), is the decision variable representing the choice of the drug, C, is the 
decision variable for the choice of corporate relations strategy for the drug, and Ti 
is the decision choice for the length of time to wait before development of drug /-I is 
commenced. The stipulation is imposed that no edge can be directed from any Si to 
any other Si which occurs before it in this specified time order.
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The procedure for constructing Bz from Kz is described in Figure 3.10. A score based 
approach is used where the Bayesian Dirichlet (BD) metric and the network is 
constructed with the intent to maximise this score. The BD metric is a measure of 
how closely Bz models the data in Kz. The construction procedure begins with an 
empty network and each possibility for adding the next directed edge in Bz is scored. 
The next directed edge to be added will be the one that maximises the value of the BD 
metric. This process continues until no improvement in score can be achieved. 
Additionally, no restrictions are imposed on the complexity of the network that can be 
built so that no important topological details are lost.
Bayesian network construction
Each decision variable Ô represents a node in the network to be built for the z'* cluster, 
Set B. as having no directed edges.
Repeat until no improvement in p(K^ 5-|^) can be made:
For all possibilities o f adding the next directed edge:
Add the next directed edge.
Calculate p(K., B-\Q.
Remove the previously added directed edge from the network.
Add the directed edge that results in the greatest value o f p (K , B^ \l^ ).
Figure 3.10. Pseudocode for Bayesian network construction.
The BD metric for Bz given Kz and background information is denoted by p{Kz 
Bz\^) and is defined as:
p(k„ba )^ = p(b m )Y[{y \
(3.72)
where p(Bi\Ç) is the prior probability of B ,^ . ^ is the n'* node instantiated to the m'*
value in K/, the product over runs over all instances of all parents of , ; the 
product over runs over all instances of 6{7t^  ) is the number of instances 
in/iz where the parent nodes of , are instantiated to ;r  ^ ; ) is
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the number of instanees in that have  ^ equal to and set to ; and 
r(x ) is the Gamma function where r(jc) = (%-1)!. When the set is empty there 
is one instance of that is equal to 0, and the number of instances is set to the 
number of members of K ,^ |Æz|. Additionally:
J  (3.73)
where is an instance of the parents of  ^ that is summed over all instances of 
0^^.  The numbers ) and represent prior information about
the problem that can be incorporated into the metric.
The extent to which the network being measured represents another network relevant 
to the problem is measured by p{B^ | . There are a number of methods available for
calculating p{B^ | ^ ) . In this study all networks are treated equally thus p{B^ | is 
set to 1. There are also a variety of methods for setting the numbers )
(Buntine, 1991; Heckerman, Geiger, and Chickering, 1995; Yang and Chang, 2002). 
In particular, research by Yang and Chang (2002) has demonstrated that for a range of 
integer values of ) between 1 and 10, and also for other methods
considered for scoring Bayesian network topology, the BD metric with 
s'{0„ ) = 10 ranked as one of the best for discovering the true structure of the
Bayesian network. Accordingly, £'{S„^^,7Tg ) = 10 is used here. Additionally,
because the factorials in Equation (3.72) can grow to unmanageably large numbers, 
especially within large sizes of K^, its logarithmic equivalent is used.
3 .2 .2 .S . R e g e n e r a t in g  t h e  p o p u l a t io n
In generating G(/+l) each is treated as a random variable that can be instantiated
to any of its possible instances subject to probabilities encoded by B .^ For each 
decision variable all probabilities for each possible conditional upon each
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possible Ttg given Kz are computationally determined and referenced when needed. 
The process for generating one candidate solution for G(^+l) is shown in Figure 3.11.
Generation of one candidate solution in G(M-l)
For all n:
Mark all  ^as unprocessed.
Select an unprocessed  ^with all parents processed already, if  any.
Randomly instantiate  ^ to with probability p{S ^   ^ ~  I  )
Mark , as processed.
Figure 3.11. Pseudocode for generating one candidate solution, g, for the new population G(/+1 ) from 
B..
The joint distribution encoded by Bz can be written as:
p(S ,) = Y [p (S ,., I (3.74)
n=\
where S, = is a vector of random variables representing the entire
set of decision variables; and p{S^ , | ) is the conditional probability of given
its set of parent variables . Intuitively, this conditional probability is defined as:
(3.75)
Each Kz is proportionally represented in the generation of G(/+l). As S{t) contains 
half the solutions present in G{f), the number of solutions generated using each Bz is 
2-\KX
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3.3. C ase  St u d y  D esc r iptio n
A hypothetical case was formulated to illustrate and examine ability of the framework 
to discover optimal strategies for performance against multiple objectives in an 
uncertain environment. In this case a biopharmaceutical company has 10 monoclonal 
antibody drug candidates available for development but can only choose 5. It needs 
to know which drug candidates should be chosen, their order of their development, 
the timing schedule of development activities, and which corporate bodies should be 
assigned to each development activity. The optimisation model is considerate of the 
commercial characteristics of drug candidates (Table 3.2), technical probabilities of 
success for each drug group (Table 3.3), durations and costs associated with various 
stages of the drug development (Table 3.4). As seen in Table 3.2 there are three 
groups of indication that these candidates belong to. Annual demand figures and 
compound annual growth rates (CAGR) are based on levels on realistic figures. The 
dependencies for revenue and capital expense are detailed in Table 3.5. 
Specifications for contractual dependencies and technical probabilities of success are 
displayed in Table 3.6.
An example of the complexity of the decision space concerning the 5 drug portfolio is 
discussed. Overall, each strategy consists of 54 decision variables: 5 for the selection 
of drugs for the portfolio, 4 for timing the commencement of development activities 
for the next drug in the pipeline, and 9 assignments of corporate bodies to critical 
activities for each of the five drugs. Hence, the choice of portfolio structure has 
10x9x8x7x6 possibilities that are combined with ^Ps possibilities for the order of 
development. There are 1  ^possibilities for the overall timing strategy. Additionally, 
there are 207^ possibilities for assigning corporate bodies to critical activities during 
the developmental phases and commercial life of each drug. Overall the entire 
decision space has a total of -3.31x10^* individual strategies. If each strategy took 1 
second to evaluate it would take 1.05x10’'^  years to enumerate all possibilities. 
Hence, the combinatorial optimisation algorithm has been specifically developed to 
efficiently search this vast decision space.
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The settings used for the mechanics of the optimisation procedure are now stated and 
are true for all generations. The maximum number of generations tmax = 17. The size 
of a given generation, |G(OI = 1000. The number of superior strategies selected from 
a given generation, |5'(/)| = 500. The number of clusters used in the objective space, z 
= 3.
A few comments to consider. The number of generations over which the populations 
are improved was tested through multiple evaluations and was indicated by the lack of 
progression in subsequent generations and the consistency of results across multiple 
tests. Because of the hierarchical super-structure of a candidate solution the total 
number of decisions is 14 instead of 54, which would have been the case if decisions 
on internalising or externalising critical activities were not grouped into a single 
decision. Using 250 Monte Carlo trials per candidate strategy was found to be 
adequate for purposes of making comparisons of quality between candidate strategies. 
To assure that performance metrics are entirely dependent on the strategy as opposed 
to being assisted by the generation of an opportunistic set of random numbers, the 
same set of random numbers is used across strategies. The pseudo-random number 
generator used here is the Mersenne Twister algorithm (Matsumoto and Nishimura, 
1998). To enhance the efficiency in estimating stochastic output properties stratified 
sampling was used for each stochastic variable where boundaries of significance were 
set individually. Also, a discount rate of 20% was used for calculating the NPV 
values.
Table 3.2. Commercial characteristics o f  available drug candidates.
Drug Candidate Drug Group Annual Demand (kg/year) CAGR (%)
A 1 Tr( 120,250,380) Tr( 1.00,1.01,1.02)
B 1 Tr( 100,200,300) Tr( 1.00,1.01,1.02)
C 1 Tr(80,150,230) Tr( 1.00,1.01,1.02)
D 2 Tr(50,100,150) Tr( 1.00,1.01,1.02)
E 2 Tit 100,200,300) Tr( 1.01,1.03,1.04)
F 2 Tr(80,l 50,230) Tr( 1.01,1.03,1.04)
G 2 Tr(50,100,150) Tr( 1.01,1.03,1.04)
H 3 Tr(80,150,230) Tr( 1.02,1.05,1.06)
I 3 Tr(50,100,150) Tr( 1.02,1.05,1.06)
J 3 Tr( 100,200,300) Tit 1.02,1.05,1.06)
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Table 3.3. Duration and cost information for various phases o f the drug development process.
Phase o f  Development Duration (years) Cost ($MM)
Target Identification 1 Tr(3,5,8)
PreClinical 2 Tr(20,35,50)
Phase 1 clinical trials 1 Tr(5,15,20)
Phase 11 clinical trials 2 Tr(I5,25,35)
Phase 111 clinical trials 3 Tr(45,85,125)
Scale-up synthesis 1 Tr(3,5,8)
Formulation 1 Tr(5,10,15)
Commercial Preparation 1 Tr(l,2,3)
Marketing 1 Tr(2,4,6)
FDA Review 1 Tr(2,4,6)
Market Lifetime 10 -
Ramp time to peak market: 7 ’ Tr(3,4,5) -
Ramp time to peak market: ‘C ’ Tr(3,4,5) -
Ramp time to peak market: P  ’ Tr(2,l,3) -
Decay time after market expiry: / ' Tr(2,I,3) -
Decay time after market expiry: ‘C ’ Tr(2,l,3) -
Decay time after market expiry: ‘P ’ Tr(3,4,5) -
Note: The cost o f  producing a drug for the marketing phase is determined by the biomanufacturing cost
model. means that particular combination o f  referencing items is irrelevant.
Table 3.4. Technical information for manufacture o f drug candidates according to clinical phase and
corporate body.
Corporate Developmental Whole Process Fermentation Titre Batch Success
Body Phase Yield (%) (g/L) Probability
7 ' Phase I Tr(0.25,0.35,0.50) Tr(0.20,0.30,0.50) Tr(0.8,0.6,1.00)
C ’ Phase 1 Tr(0.45,0.55,0.85) Tr(0.8,1.00,1.50) Tr(0.7,0.9,1.00)
P  ’ Phase 1 Tr(0.40,0.50,0.75) Tr(0.60,0.75,1.20) Tr(0.65,0.85,1.00)
7 ’ Phase II Tr(0.40,0.50,0.75) Tr(0.30,0.40,0.60) Tr(0.65,0.85,1.00)
‘C ’ Phase 11 Tr(0.45,0.60,0.90) Tr( 1.20,1.50,2.30) Tr(0.75,0.95,1.00)
P ’ Phase 11 Tr(0.40,0.50,0.75) Tr(0.80,1.00,1.50) Tr(0.70,0.90,1.00)
7 ’ Phase 111 Tr(0.40,0.50,0.75) Tr(0.80,1.00,1.50) Tr(0.70,0.90,1.00)
'C  Phase 111 Tr(0.55,0.75,1.00) Tr( 1.50,2.00,3.00) Tr(0.75,1.00,1.00)
P ' Phase 111 Tr(0.45,0.60,0.90) Tr( 1.20,1.50,2.30) Tr(0.75,0.95,1.00)
7 ’ Market Tr(0.40,0.50,0.75) Tr(0.80,1.00,1.50) Tr(0.70,0.90,1.00)
C ’ Market Tr(0.55,0.70,1.00) Tr( 1.50,2.00,3.00) Tr(0.75,1.00,1.00)
P  ’ Market Tr(0.45,0.60,0.90) Tr( 1.20,1.50,2.30) Tr(0.75,0.95,1.00)
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Table 3.5. Specification o f  dependencies as related to the number o f drugs from the same group within
the chosen drug development portfolio.
Number o f drugs % o f full revenue % of full capital % o f full COGS
1 100% 100% 100%
2 85% 93% 95%
3 75% 85% 90%
4 65% 78% 85%
Note; COGS -  cost o f goods sold.
Table 3.6. Specification o f contractual dependencies and stage-wise probabilities o f success.
Royalty rate (% o f  revenue) Probability o f  success
Development Stage CRO CMO Partner Group 1 Group 2 Group 3
Target identification 6% - 60% 0.90 0.80 0.85
Pre-clinical trials 7% - 58% 0.90 0.90 0.95
Phase I clinical trials 8% 10% 56% 0.75 0.85 0.75
Phase II clinical trials 9% 12% 54% 0.50 0.40 0.55
Phase III clinical trials 10% 14% 52% 0.70 0.60 0.80
Market - 16% 50% 0.95 0.95 0.95
Note: A decrease in royalty rate applies per additional drug and is measured in percentage points. 
Royalty rates decrease by 1% with the CRO, and 2% with the CMC or partner for each additional drug 
development project for which they are involved. A minimum royalty rate applies o f  3% with the 
CRO, 5% with the CMC, and 40% with the partner. Groups 1, 2, and 3 refer to drug groups 1, 2, and 
3. means that particular combination o f referencing items is irrelevant.
3.4. Results
The case study results are discussed in the following sections focusing on analysing 
competing strategies along the Pareto front generated and identifying trends along the 
frontier using cluster analysis.
3 .4 .1 . P a r e t o  F r o n t  P r o g r e s s i o n
In this section the performance of strategies in the final population is examined in 
terms of their ability to generate profits, satisfy multiple objectives, and provide an 
acceptable risk profile. The analysis highlights the challenges that exist when 
pursuing multiple objectives in the context considered.
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Figure 3.12. Progressive discovery o f  the objective space: a. 1st generation, b. 3rd generation, c. 7th 
generation, d. 10th generation, e. 14th generation, f. 17th generation.
The progression of the EDA in discovering the Pareto front is demonstrated in Figure 
3.12. As might be expected, random initialisation of the population of strategies has 
resulted in a generally even dispersion of the mean positive NPV and p(NPV>0) 
performance attributes over the objective space. Interestingly, what can immediately 
be seen is that it is possible to construct a portfolio of drugs with a significantly higher 
probability of attaining a profit than any of its individual comprising drugs. Here 
drugs with a probability of reaching market that is less than 0.25 have been pooled in 
such a way that offers the decision maker a p(NPV>0) value in excess of 0.70. 
Progression of the algorithm in the objective space appears to be considerably more 
constrained in the p(NPV>0) dimension than it is in the mean positive NPV 
dimension. Progression of the evolutionary process has been accompanied by some 
degree of succession at each generation. It is apparent that the strategies available in 
the objective space have generally converged towards a clearly defined non-
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dominated frontier, the Pareto front. The Pareto front is wide enough to be inclusive 
of p(NPV>0) values that might be realistically sought after by a decision maker in this 
setting. It is also apparent that for this problem the machine learning mechanisms 
have greatly reduced the variability encoded in the conditional and probabilistic 
models of superior strategies. It should be noted that the ability of the algorithm to do 
this is dependent on whether a new set of building blocks is able to clearly distinguish 
itself as superior to any existing alternatives in the evolutionary process. At some 
stages, succession in some regions of the objective space is accompanied by 
deterioration in other regions. This deterioration refers specifically to the non­
population of certain regions that were previously populated. In this particular case, it 
was considered appropriate that the convergence of the algorithm was tracked 
visually, principally because the objective space has only two dimensions. The 
optimisation procedure was considered to be converged when general progression of 
the Pareto front was insignificant, leading to an unfavourable loss of regions along the 
Pareto front. Some deterioration was tolerated in regions where rational decision 
makers were unlikely to seek strategies. An example of such a region would be where 
p(NPV>0) is less that 0.20 or where the mean positive NPV is less than S200M. 
Further analysis indicated that progression beyond 17 generations for this case study 
leads to a severe deterioration of the Pareto front.
The superior strategies selected from the seventeenth generation (Figure 3.13) show 
that a non-dominated frontier exists in the approximate region 0.18<p(NPV>0)<0.75. 
The frontier indicates that a definite trade-off exists here between maximizing the 
mean positive NPV to be generated by a particular strategy and maximizing the 
probability of attaining a positively valued profit, p(NPV>0). At no point along the 
frontier can the maximisation of mean positive NPV and p(NPV>0) be aligned. 
Hence, improving p(NPV>0) means accepting a degradation in mean positive NPV. 
Also, this forces the decision maker into the process of selecting strategies that begins 
with deciding upon minimum acceptable levels of profit and probability of 
profitability. The region 0.50<p(NPV>0)<0.65 offers the least trade-off along the 
frontier when searching for strategies that improve p(NPV>0). In practical terms, not 
all of the frontier will be appealing to the decision maker as there will be strategies
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that either offer probabilities of success or mean positive NPV values that are too low 
to be considered for further action.
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Figure 3.13. Mean positive NPV versus p(NPV>0). Note: ( - )  represents an estimate o f the non­
dominated frontier. Strategies chosen for further analysis are annotated as SI, S2, S3, and S4.
To assess the effectiveness of the EDA, the Pareto front discovered is compared with 
that of a simple random search (Figure 3.14). For the random search seventeen 
thousand unique strategies were randomly generated and then evaluated. The 
rationale for generating this number of strategies for the random search in this case is 
based on the EDA evaluating seventeen thousand strategies before termination. It 
can be seen that the EDA offers a marginal improvement above the performance 
obtained from random search. It is also observed that at the extremities of the 
objective space there is negligible difference in the performance offered by either 
algorithm. This indicates that either a performance limit has been reached or that the 
EDA is simply ineffective for these regions. Without an algorithm that guarantees 
discovery of the true Pareto front it is impossible to identify which postulation is 
correct. Certainly the fact that these extremities were discovered by random search 
suggests that they were relatively easy to find. Where the EDA performs more 
convincingly above random search is in the intermediary region between the 
extremities. Across the Pareto front the average improvement afforded by the EDA is 
approximately 10% in mean positive NPV for a given p(NPV>0). The improvement 
seen can be up to 20%.
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Figure 3.14. Pareto fronts for Mean positive NPV versus p(NPV>0). Note: ( - )  is the Pareto front 
discovered by the EDA, and (—  ) is the Pareto front discovered by random search.
3 .4 .2 . A n a l y s i s  o f  C q m f e t i n g  S t r a t e g i e s
A close examination of competing strategies along the frontier indicates that they can 
have similar reward-risk characteristics whilst demonstrating marked differences in 
key decisions relating either to the portfolio structure (drug selection), timing or third 
party strategies (Table 3.7). Four strategies along the non-dominated frontier have 
been selected to illustrate this and demonstrate how a decision maker might 
rationalise the choice between two strategies of similar risk and reward as visualised 
in Figure 3.13.
Table 3.7. Attributes o f strategies chosen for comparison.
Positive NPV ($MM) Negative NPV ($MM)
Strategy p(NPV>0) Mean Min. Max. SSD Mean Min. Max. SSD
SI 0.184 $1421 $17 $3505 $271 -$14 -$28 -$5 $7
S2 0.192 $1420 $10 $3271 $255 -$31 -$66 -$11 $15
S3 0.368 $1126 $12 $6198 $357 -$29 -$313 -$7 $141
S4 0.376 $1082 $18 $4412 $224 $29 $290 -$8 $133
Note: Min Minimum, Max Maximum, SSD semi-standard deviation.
SJ and S2 are strategies that generate the greatest mean positive financial reward but 
also the greatest risk. Although these competing strategies have very similar third
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party strategies and portfolio struetures, they differ greatly in their timing strategies as 
illustrated in Table 3.8 and Table 3.9. Both strategies share the approaeh of 
partnering for the majority of activities for the first drug and then preferring to use a 
combination of in-house and outsourced development and manufacturing for the 
remaining drugs. The only exception to this is for drug 3 with SJ where partnering is 
used for commercial manufacturing. The first two drugs are either developed within 
three years of each other, as in SI, or simultaneously, as in S2, and developing the 
remaining drugs once these drugs are close to the marketplace. This approach has the 
advantage of dividing the risk and impact of failure between two drug development 
projects and it is clear that the expected profits from either of the first two drugs are 
used to fund the development of future projects. SI staggers the development of its 
drugs with lengthy development intervals between each drug. Resultantly the time it 
takes to complete development of the portfolio is 35 years. S2 has a shorter 
development time of 26 years because of the shorter intervals between the 
developments of its final three drugs. Each strategy develops almost the same 
portfolio of drugs with the difference being that for the fourth drug SI develops Drug 
G and S2 develops Drug B. Much like the strategy with the first two drugs, SI 
develops its third and fourth drugs together and S2 develops its fourth and fifth drugs 
within three years of each other. For SI these two drugs are taken from the same 
group whereas with S2 this is not the case. SI and S2 generate similar performances 
in mean positive NPV but a strong reason for selecting S2 exists. S2 has the 
additional advantage of being executed over a significantly shorter period.
Table 3.8. Structure o f  the SI portfolio development strategy.
/ D, Cm Q,2 C„3 C,4 C„5 C,6 C„7 C,,8 C„9 T.
1 F T 'P' 'P' ,p, 'P' 'P' 'P' T ' 'P' ‘P I’
2 I T 'C 'C 'C 'C T T T 'C ‘FD A’
3 J 'C 'C T T 'C T T T 'P' ‘FD A’
4 G T T T 'C 'C 'C 'C 'C T ‘P i r
5 H 'C T T 'C 'C T T 'C 'C -
Note: 7 ’ in-house activity, ‘C ’ outsourced activity, ‘P ’ partnered aetivity, C„i -  target
identification; C„2 preclinical studies; C„3 Phase I clinical development; C„4 Phase 11 clinical
development; C,,^  Phase 111 clinical development; C„6 Phase I manufacturing; C,,? Phase II
manufacturing; C,,» Phase 111 manufacturing; C„9 Market, that particular combination o f
referencing items is irrelevant.
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Table 3.9. Structure o f  the S2 portfolio development strategy.
/ D, Q , C,2 C„3 C„4 C,s C„6 C,i C„8 C„9 Ti
1 F T T T 'P' P ' T P ' P ' p , P C ’
2 I T ’C 'C 'C 'C T T T • c ‘M KT’
3 J T 'C T T • c T T 'C T P I ’
4 B T 7' T 'C 'C 'C 'C 'C T P I ’
5 H 'C T T T 'C T T 'C • c -
Note: 7 ’ in-house activity, C ’ outsourced activity, ‘P ’ -  partnered activity, C„, -  target 
identification; C,,2 -  preclinical studies; C„3 Phase 1 clinical development; C„4 -  Phase 11 clinical 
development; C„5 Phase 111 clinical development; C„6 -  Phase 1 manufacturing; C„? -  Phase 11 
manufacturing; C„g -  Phase 111 manufacturing; C„9 -  Market, that particular combination o f  
referencing items is irrelevant.
Examining the differences between another pair of competing strategies illustrates 
how marked differences in third party strategies can also results in similar reward-risk 
characteristics. In contrast to SI and 82, strategies S3 (Table 3.10) and S4 (Table 
3.11) possess similar timing strategies but very different third party strategies as well 
as portfolio structures. S3 utilises a mixture of in-house, outsourced, and partnered 
activities whereas S4 develops the entire portfolio in-house. The portfolio constructed 
by S3 consists of one low demand drug, two medium demand drugs, and two high 
demand drugs that are sourced from all three groups. The first three drugs are 
developed first and simultaneously with the remaining two drugs developed with 
lengthy intervals of nine years in between. For the second and third drugs contractors 
are only used for clinical development, clinical manufacturing is kept in-house, and 
commercial manufacturing is conducted with a partner. The fourth and fifth drugs use 
contracting more intensively for clinical development but contractors are also used for 
clinical manufacturing where they are used during phase III trials. The total portfolio 
development time plus time taken during the marketing phase for S3 is 28 years. S4 
develops drugs from all three groups and its portfolio consists of two low demand 
drugs, two medium demand drugs, and one high demand drug. Similar to S3, the first 
three drugs are developed in close succession and also staggers the development of its 
final two drugs in a similar fashion. The total time for development and marketing 
completion of S4 is 30 years, which is similar to that taken for S3. Comparing their 
performances, S3 generates a marginally superior mean positive NPV than S4 and is
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executed over a slightly shorter period. Although marginal, the performance results 
suggest S3 as being the superior strategy.
Table 3.10. Structure o f  the S3 portfolio development strategy.
/ D, Cm C„2 C,3 C,4 C„5 C,-,6 C/,7 C„8 C/,9 Ti
1 F T P ' P ' P ' p , >p< 'P' p , p . P C ’
2 D 'C T T 'C 'C T  T T P ' P C ’
3 B 'C 'C T T 'C T  T T P ' F D A ’
4 H T T 'C 'C 'C T  T 'C T F D A ’
5 J 'C T T 'C 'C T  T • c 'C -
Note: 7 ’ in-house activity, ‘C  - outsourced activity, ‘P ’ partnered activity, C„, -  target
identification; C„2 preclinical studies; C„3 Phase 1 clinical development; C„4 Phase II clinical 
development; C„5 - Phase III clinical development; C„6 Phase 1 manufacturing; C„7 -  Phase II 
manufacturing; C„8 -  Phase 111 manufacturing; C„g - Market, that particular combination o f
referencing items is irrelevant.
Table 3.11. Structure o f  the S4 portfolio development strategy.
i Di Cm C/.2 C„3 C/,4 C,5 C„6 C,7 C„8 C/,9 Ti
1 F T T T T T T T T T P C ’
2 C T T T T T T T T T ‘ID ’
3 G T T T T T T T T T ‘F D A ’
4 J T T T T T T T T T ‘F D A ’
5 I T T T T T T T T T -
Note: 7 ’ -  in-house activity, ‘C  outsourced activity, P ’ partnered activity, C„, target 
identification; C„2 -  preclinical studies; C„3 Phase 1 clinical development; C„4 -  Phase II clinical 
development; C„5 -  Phase 111 clinical development; C„6 Phase I manufacturing; C,,? -  Phase II 
manufacturing; C„g -  Phase III manufacturing; C„9 -  Market, -  that particular combination o f  
referencing items is irrelevant.
From sampling the strategies along the Pareto front it is observable that their 
positioning in the objective space and even their occurrence within the optimised 
population of strategies is not intuitive. It is taken that this is due to the complexity 
that is inherent in the model of the biopharmaceutical drug development pathway and 
the complexity that governs the formulation of superior strategies. This is an 
important underscore because it highlights to the decision maker the value of 
accounting for the concept of building blocks, which is considerably difficult to 
achieve without the use of advanced computational tools. Another important
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observation is that strategies with clear differences in either drug selection, timing, or 
third party strategies can compete with similar reward versus risk profiles. Hence it is 
useful for the decision-maker to identify a desirable region along the frontier and 
closely examine the different options that can yield the desired return and acceptable 
risk.
3 .4 .3 . C l u s t e r  A n a l y s i s
In order to investigate if any discernable trends in strategy formulation exist amongst 
the population of superior strategies, the objective space was decomposed into three 
clusters. It was anticipated that an analysis of these clusters might add useful insight 
when considering if any particular regions of the Pareto front give rise to the 
prevalence of certain building blocks. As building blocks effectively compete with 
each other for selection it would be useful to discover if and why any particular 
building blocks are emphasised.
Table 3.12. Characteristics o f drug selection and timing strategies in each cluster.
Cluster Characteristic Drug 1 Drug 2 Drug 3 Drug 4 Drug 5
Demand M H L H H
1 Drug Group 2 1 2 3 3
Timing ‘ID ’ ‘F D A ’ ‘PIIF ‘F D A ’ -
Demand M L H H L
2 Drug Group 2 2 1 2 2
Timing ‘P C ’ PC ‘M KT’ ‘FD A’ -
Demand M M H H M
3 Drug Group 2 1 3 1 3
Timing ‘ID ’ ‘F D A ’ PI I ’ ‘P II’ -
Portfolio structure
Table 3.12 displays the most probable constituents of strategy for each cluster. This 
includes the annual level of demand for the selected drug, the group that the drug 
belonged to, and the time after which development of the next drug would commence. 
The reader is reminded that group 1 drugs have a low annual growth rate, while 
groups 2 and 3 respectively have medium and high annual growth rates. Also, group
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3 drugs have the greatest probability of achieving marketing approval whilst group 2 
drugs have the least. Cluster 1 consists of strategies that perform highly in mean 
positive NPV, such as SI and S2, and cluster 3 consists of strategies that have high 
values of p(NPV>0). Cluster 2 represents strategies that balance both of these 
performance metrics more evenly, such as S3 and S4. The clusters and their member 
strategies are derived by application of the k-means clustering algorithm. For cluster 
1, the most probable portfolio consists of one low demand drug, one medium demand 
drug and three high demand drugs from all three drug groups. Strategies in this 
cluster tend to utilise the largest number of high demand drugs which assists in 
explaining the larger mean positive NPV values generated by these strategies. Also, a 
larger portion of selected drugs belong to drugs with high and medium probabilities of 
success. For cluster 3 at the opposite end of the Pareto front, the most probable 
portfolio is three medium demand drugs and two high demand drugs drawn from all 
three drug groups, which perhaps surprisingly highlights that cluster 3 strategies aim 
to meet a similar level of market demand as cluster 1 drugs. As cluster 3 strategies 
have significantly lower mean positive NPV values than cluster 1 strategies this 
indicates that there are other decisions outside of portfolio structure which lower this 
profitability measure but maybe contribute to a greater p(NPV>0) value. With the 
exception of one drug the portfolio opts for drugs with high and medium probabilities 
of success thereby using more drugs of this type than the other clusters. This is 
intuitive because this cluster exhibits the greatest p(NPV>0) values. Overall, there 
appear to be no clear trends in portfolio structuring strategies. The presence of certain 
portfolio structuring decisions within certain clusters appears to align with the 
position in the objective space relative to other clusters, while there are others which 
do not. The remaining constituents of the portfolio development strategy will be 
investigated to discover if more overarching drivers of performance exist.
Timing strategies
Decisions on timing are an important constituent of the portfolio development 
strategy as they are used to favourably organise cash flows. This is particularly 
important when having to consider the probability that a project will succeed, the 
financial impact of failed projects, and the impact of the discount factor when 
determining the mean positive NPV. In cluster 1, Table 3.12 shows that the 
prevailing strategy is to develop the first two drugs together coupled with long
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intervals of either eight or nine years between the development of the remaining 
drugs. Because of the probabilities of success of available drugs it would be rational 
to expect only one successful drug within a portfolio of five projects. Also, it is 
observable that when considering the growth and impact of the discount factor over 
time, cluster 1 strategies must rely considerably on the production of a successful drug 
from the first two projects. This assists in reasoning the low p(NPV>0) values seen in 
this cluster. Remaining drugs have comparatively little impact on cash flows because 
of the extent to which their respective cash flows are discounted. This also provides 
an explanation for the superior mean positive NPV values as when one successful 
drug emerges from within the first two projects its profits are not greatly discounted. 
Also and importantly, profits from this drug will mainly need to absorb the expense of 
its own development and that of the other concurrent project. The cost of developing 
the remaining drugs is less restrictive as these are heavily discounted. Albeit this 
occurs with a relatively modest probability. The time for development until the end 
of marketing for this strategy is 34 years. For cluster 2 it is shown that the first three 
drugs are most likely to be developed with short intervals of one year between them 
and that the time for development and marketing completion for this approach is 31 
years. This strategy is a driver of the higher p(NPV>0) values and the lower mean 
positive NPV values observed when making comparison to cluster 1. Like cluster 1, 
remaining drugs are likely to be developed with the longest intervals between them 
and are anticipated to have modest impacts on cash flow because of the magnitude of 
the discount factor at these stages in portfolio development. Considering this, such 
strategies are reliant on at least one successful drug emerging from the first three 
projects. Developing the first three drugs in close succession in cluster 2 bears a 
greater likelihood that at least one successful project will emerge from this group than 
from within the remaining two drugs. When a successful drug emerges from this 
group, because of a more favourable discount factor there is also a greater likelihood 
that it can also cover the expense of other failed projects than when developing two 
drugs in close succession. Having to effectively absorb the cost of an increased 
number of projects whose development costs are less discounted contributes to lower 
mean positive NPV values. Strategies in cluster 3 exhibit a tendency to develop the 
first two drugs together followed by a period of at least nine years then later drugs are 
developed with medium length intervals of four years in between them. The time for 
development and marketing completion most likely in cluster 3 is 27 years. This
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Strategy relies on at least one successful drug being found in two distinct groups, that 
is a group of two drugs developed together at the outset and a group of three drugs 
developed in close succession later in the timeline. It has already been mentioned that 
the impact of developing two drugs together whilst positioning the remaining projects 
to subject them to far more significant discounting results in relatively high mean 
positive NPV values with relatively low probabilities of success. It follows that some 
aspects of the development of the remaining three drugs contribute significantly to the 
high p(NPV>0) values but low mean positive NPV values ultimately exhibited by 
strategies in this cluster. The shorter portfolio development time means that profits 
for each year are discounted by a significantly smaller extent than seen with clusters 1 
and 2. Strategies in this cluster also take advantage of the high annual market growth 
rate and high probability of success of group 3 drugs and position them late in the 
pipeline of products to maximise their potential for generating revenues that 
overcome the magnitude of the discounting. This is important as if each drug is to 
contribute significantly to the revenue generated by the portfolio then any successful 
drugs must support up to four failed projects, which helps to explain the smaller mean 
positive NPV values. Also it is more likely to see at least one successful drug emerge 
from within the second group of three projects than from the first group of two. 
When this occurs, profits arising from these drugs which are heavily discounted and 
must also be enough to cover the expenses of failed projects which are less heavily 
discounted. This further erodes the potential magnitude for mean positive NPV. 
Overall, the trend with timing strategies is that portfolio development times tend to 
become progressively shorter towards the right hand side of the frontier and that 
strategies make use of grouping projects more closely together. Interestingly, the 
presence of the discount factor appears to have a significant influence on strategy 
formulation. Hence it is anticipated that alternative settings for the discount rate may 
result in a noticeably different set of superior strategies.
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Third party strategies
Table 3.13. Selected probabilities o f third party strategies.
D, Cm Co2 C , 3 C ,.4 C ,.5 C „ 6 C „ 7 C „ 8 C,9 P
7 ’ 7 ’ 7' 7' 7' 7 ’ 7' 7 ’ 7' 0.64
Drug 1
T T 7' 7' P ' 7' 7' P ' P ' 0.18
7' 7' 7' 7 ’ 7' 7 ’ 7 ’ 7 ’ 7' 0.64
Drug 2
T 'C' 'C' 'C' 'C 7' 7' T 'C' 0.12
7 ’ 7' 7 ’ 7' 7' 7" 7 ’ 7' 7 ’ 0.64
Drug 3
'C T 'C' 'C 'C' 'C 'C 'C' P ' 0.12
7' 7' 7' 7' 7' 7 ’ 7 ’ 7 ’ 7' 0.64
Drug 4
T T 7' 'C 'C' 'C' 'C' 'C 7' 0.10
7 ’ 7' 7 ' T 7' 7 ’ 7" 7' 7' 0.63
Drug 5
T T 7' 'C 'C' 7' T 7' 'C' 0.09
7 ’ 7 ’ 7' 7 ’ 7 ’ 7 ’ 7' 7 ’ 7 ’ 0.38
Drug 1
T 'P' 'P' P ' P ' P ' P ' P ' P ' 0.15
7' 7 ’ 7 ’ 7 ’ 7' 7 ’ 7' 7' 7' 0.38
Drug 2
'C T T 7' 7' 7' 7' 'C P ' 0.15
7 ’ 7 ’ 7 ' 7 ’ 7" 7 ’ 7' 7' 7 ' 0.38
Drug 3
'C 'C 7' 7' 'C' T 7' 7' p r 0.13
7 ’ 7' 7 ’ 7 ’ 7 ’ 7 ’ 7' 7 ’ 7 ’ 0.38
Drug 4
T 'C' 7' 'C 'C 'C 'C' 'C' 'C 0.15
7 ’ 7' 7 ’ 7' 7' 7' 7 ’ 7 ’ 7 ’ 0.38
Drug 5
T 'C 'C 'C 'C' 'C' 'C 'C' P ' 0.15
7 ’ 7 ’ 7 ’ 7 ’ 7 ’ T 7 ’ 7 ’ 7 ’ 0.54
Drug 1
T 7' 7' 7' P ' T 7' P ' P ' 0.26
7' 7' 7' 7 ' 7' 7' 7 ’ 7' 7 ’ 0.53
Drug 2
T 'C' 'C 'C' 'C 7' 7' T 'C 0.16
7' 7 ’ 7 ' 7 ’ 7' 7 ’ 7' 7 ’ 7" 0.53
Drug 3
'C 7' 'C' 'C' 'C' T 7' 7' 'C 0.14
7' 7 ’ 7 ' 7 ’ 7 ’ 7' 7' 7 ’ 7' 0.53
Drug 4
T 7' 7' 'C 'C 'C' 'C' 'C' 7' 0.15
7 ’ 7' 7 ' 7 ' 7' 7 ’ 7 ’ 7' 7' 0.53
Drug 5




Note: For each D, in each cluster the two most probable strategies have been displayed.
The probability of selecting a particular strategy for a particular drug position in a 
particular cluster of the objective space is addressed and the top two strategies in each
119
STOCHASTIC COMBINATORIAL OPTIMISATION APPROACH TO
BIOPHARMACEUTICAL PORTFOLIO MANAGEMENT
circumstance are shown in Table 3.13. In all cases the most probable third party 
strategy for each drug is to integrate all activities in-house. This is intuitive from the 
viewpoint of minimizing contracting fees and premiums as well as avoiding the 
sharing of sales revenues and royalty charges. As seen in Table 3.13 and with 
strategies SI through S4, alternative third party strategies are present in significant 
proportion within the population. This demonstrates that when supported by 
appropriate strategic decisions in other areas these are viable constituents of superior 
strategies. It is postulated that one possible reason for complete in-house strategies to 
be present with significant likelihoods is that such strategies may serve as a more 
flexible building block than others for creating superior portfolio development 
strategies. With the aim of managing the impact of failure it may seem counter­
intuitive for a eompany to go the entire drug development process without third party 
assistance. Because no budgetary constraint exists, in such scenarios there is no direct 
requirement to limit the impact of failure. However, to some degree maximizing 
mean positive NPV is likely to involve some mitigation of the impact of failure. As 
might be expected, it can be seen that strategies in eluster 1 are most likely to choose 
to develop drugs entirely in-house as these offer the greatest potential for achieving 
the greatest mean positive NPV values if the drug passes all stages of testing and 
review. For the first drug an alternative strategy, albeit much less likely in this case, 
is to partner from the commencement of phase III clinical trials or from pre-clinical 
testing. Partnering from phase III clinical trials allows for some savings on the 
proportion of revenue that must be paid to the partner. Partnering from preclinical 
testing onwards allows for the impact o f failure to be shared but a substantial share of 
any sales revenues must be paid to the partner. Across all clusters strategies tend to 
utilise partners much less intensively from drug 1 onwards, where partners are used 
almost exclusively for commereial manufacturing and contractors are preferred. The 
use of contractors does not appear to be limited to a particular set or series of 
activities and in most cases the use o f contractors is used as a supplement to 
integrated activities. Finally, although the model shows that in-house activities are 
the most probable for optimised strategies, the presence of budgetary constraints is 
expected to impact such a decision. This is explored further in chapter 4.
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3.5. Co n c l u sio n s
The development of a stochastic multi-objective combinatorial optimisation 
framework has been presented that addresses three key decisions simultaneously: 
portfolio management, scheduling of drug development and manufacturing, and the 
involvement of third parties for specific activities has been presented. Demonstrated 
within this work is the value carried by considering these critical strategic 
considerations within a unified framework that simulates and optimises all such 
decisions across the entire product portfolio. A case study was used to illustrate the 
capabilities of the framework and also highlighted that the scope of decisions that a 
drug developer may be confronted with can be vast and complex. Due to the 
complexity of this problem, a principle contribution of this work is in demonstrating a 
formulation based on techniques from artificial intelligence, in particular evolutionary 
computation and machine learning, employed for an efficient search of the decision 
space and for effective traversing of the objective space.
It is proposed that biopharmaceutical product development strategies in the real world 
may be better analysed when considering the impact of decisions holistically rather 
than only individually. One reason for this is the presence of dependencies between 
decisions that may impact economic relationships. Another is that it has been 
demonstrated that an effective strategy for portfolio development can result in a 
p(NPV>0) value that is significantly greater than the probability of successful 
development for any singular drug in the portfolio. Hence, by considering a portfolio 
of multiple drugs it is possible to control its risk to some extent through careful 
strategic formulation, whilst this is not possible with a singular drug. Use of the 
model has highlighted that pursuit of mean positive NPV can conflict with pursuit of 
high p(NPV>0) values, although this may change under different case study settings. 
The results of the case study lean towards suggesting the integration of all activities 
in-house. This can conflict with common perspectives in industry that accept such 
strategies with reluctance because of the uncertainty of the drug development process 
and the consequential impact of failure. The added presence of budgetary constraints 
and a range of sizes for the portfolio would serve as factors that can further capture 
limitations in the real world and are also capable of significantly influencing results
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seen here; this is explored in chapter 4. Furthermore the optimal set of solutions is 
expected to be sensitive to the relative difference in manufacturing efficiencies 
assumed between in-house and external manufacturing.
Finally, the learning of Bayesian networks from superior solutions presented here has 
been shown to be effective and efficient in improving the population, and in 
discovering a dense and widespread Pareto front when compared to random search in 
the regions that are not at the extreme of either dimension of the objective space. 
Their effectiveness in these regions is presumed to be due to their ability to iteratively 
learn and exploit the structure of the problem as noted by contributions in artificial 
intelligence literature. At the extremity of each objective it is observed that any 
comparative improvement to random search here is negligible. It is not known 
whether this is due to a limit inherent to the problem itself or to the algorithm itself. 
This should be investigated in future work. A noteworthy insight from using the 
framework is that use of machine learning has potential for future development in 
solving portfolio development and capacity planning problems simultaneously.
3.6 N o m enclature
Bayesian network pertaining to cluster 
Cg third party strategy of the g'* strategy in G{t) whose instances are
combinations of: 7 ’ (in-house aetivity), ‘C ’ (outsourced activity), 
and ‘P  ’(partnered activity).
Dg drug development sequence of the strategy in G(t)
G(t) a generation of candidate strategies at iteration t
|G(/)| number of candidates in G{t)
g  candidate solution in G(/), also a subscript.
K: cluster of candidate strategies in S{t)
\K^ \ size of Kz
NPV net present value
Oz{t) set of strategies generated from
S{t) set of superior candidate strategies in G(t) at iteration t
|S(/)| number of candidates in S{t)
I m a x  maximum number of iterations in the optimisation procedure
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Tg scheduling strategy of the strategy in G{t) whose instances are
combinations of: ‘ID ’ (target identification phase), ‘P C ’ (pre-clinical 
development phase), ‘P I’ (phase I clinical trials), ‘P II’ (phase II 
clinical trials), ‘P ///'(phase  III clinical trials), ‘FDA’ (FDA review 
phase), and ‘MKT’ (marketing phase).
Greek Symbols:
node in Bz of the cluster instantiated to the m‘^  value
CD the set of Monte Carlo trials
<t> result of a single Monte Carlo trial
parent set of ^
7t .  instance of
number of instances in Kz where ^„^is set and set to
7T,
Subscripts:
i e l drugs in the drug development sequence
y e J development activities
u e U Monte Carlo trials
V  s  V objectives
Z  G  Z clusters
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C h a p t e r  4
S t r a t e g ic  B io p h a r m a c e u t ic a l  Po r t f o l io  
D e v e l o p m e n t : A n  A n a l y s is  o f  C o n s t r a in t  In d u c e d  
Im p l ic a t io n s  o n  S t r a t e g ie s
4.1. In t r o d u c t io n
The framework introdueed in chapter 3 is now used for further exploration of the 
decision making landscape. Some of the challenges of formulating appropriate 
biopharmaceutical research and development strategies include deciding how many 
drugs should comprise the portfolio given a group of candidates, and finding a 
suitable strategic approach that satisfies any constraints on cash flow whilst 
maintaining an optimal balance between risk and reward. Accordingly, these issues 
are addressed here. The objective of finding optimal drug development portfolios has 
been covered in literature (for example see Blau et a i, 2004; Rogers et a i, 2002) 
where the most common approaeh is to optimise the content of the portfolio given a 
particular problem formulation whilst bound by some form of monetary constraint. 
Also, the assumption that is often taken in illustrative cases is that the eompany under 
analysis wishes to develop all drugs by themselves and usually all at once. To extend 
this concept, this chapter relaxes these assumptions by investigating the discovery of 
optimal strategies that include possibilities for assigning critical development 
activities to third parties in as well as an optimal yearly schedule by which these 
activities should occur. Optimal strategies will maximise a level of reward for a 
particular measure of risk which are namely the mean positive NPV and the 
probability of obtaining a profit, p(NPV>0), respectively. When optimised, strategies 
in the objective space comprised of mean positive NPV returns and p(NPV>0) will 
form a non-dominated frontier that is expected to present a trade-off to the decision 
maker. Explicitly this trade-off is likely to mean that opting to achieve greater 
expected profits will also entail accepting a lesser p(NPV>0). It is the aim of this 
paper to investigate how the construction of performance optimised strategies and the
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position of this frontier in the objeetive space will vary according to selected 
constraints. These constraints are the size of the portfolio and the magnitude of the 
constraint on cash flow.
4.2. M e t h o d
The optimisation procedure, settings, and case study assumptions are the same as 
those described in chapter 3, with any additions mentioned here. The technique 
measures two objectives: mean positive NPV and p(NPV>0).
Additionally, the effect of constraints on portfolio size and cash flow were 
investigated to highlight insights from the illustrative cases, these are the only two 
constraints considered. The first portfolio consisted of 5 drugs and the cash flow 
constraints applied to this portfolio were unconstrained, -$200MM, -$100MM, and - 
S75MM. The second portfolio consisted of 3 drugs and the cash flow constraints 
applied are unconstrained, -SIOOMM, and -S75MM. Specifically, each cash flow 
constraint, z\^ comh represented the maximum negative net present value (NPV) that the 
company’s cash flow was allowed to reach. For both sizes of portfolio, each could be 
constructed from the same set of available drug candidates, which are also identical to 
those seen in chapter 3. The optimisation model is considerate of the commercial 
characteristics of drug candidates, technical probabilities of success for each drug 
group, durations and costs associated with various stages of the drug development. 
As previously seen there are three groups of indication that these candidates belong 
to. Annual demand figures and compound annual growth rates (CAGR) are based on 
levels on realistic figures. The dependencies for revenue, capital expense and royalty 
dependencies are identical to those displayed in chapter 3. For simplicity, no outside 
competition from other drug developers is assumed. The stochastic variables included 
in this work are exclusively characterised by way of triangular probability 
distributions because of their convenience when limited sample data are available. 
For instance, if a Gaussian distribution was used a mean and standard deviation value 
would also have to be specified, and such values can be very difficult to obtain. It is 
clear that other distributions can be used if the appropriate data is available.
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During the simulation, the maximum negative NPV, NPVmin, during the timeline of 
the project is recorded. Because no initial inflow of cash is assumed the NPV must 
initially decline into negative territory and then increase if and when a minimum of 
one drug is approved for marketing. As shown in Figure 4.1 this cash flow will have 
a maximum negative value during the simulated lifetime of the project. In reality, a 
company will have limited cash resources available to devote to the development of a 
portfolio of drugs at any one time. The cash flow values imposed here are meant to 
represent the possible cash limitations of a company when funding portfolio 
development. If this negative cash flow is breached then clearly the company is 
stretched beyond the limit of finance it had intended to use.
I
>
T im e  (Y e a rs )
Figure 4.1. Example o f NPV over time for the development o f a portfolio o f  biopharmaceutical drugs.
In order to locate strategies which either do not breach this limit or have low 
probabilities of doing so, a straight forward penalty method is applied to the set of 
simulation results produced from the Monte Carlo simulation for each strategy. For 
each Monte Carlo trial on a strategy, if any value in the projected cash flow over the 
lifetime of the portfolio’s development is less than NPVmin then, if positive, the 
terminal NPV indicated by that particular Monte Carlo trial is set to 0. This has the 
impact of reducing p(NPV>0). Ultimately for strategies that are unable to meet a 
given cash flow restriction for any particular Monte Carlo trial p(NPV>0) will equal 0 
with use of this penalty method.
4.3. R e s u l t s  a n d  D i s c u s s i o n
The results are now presented and discussed.
126
STRATEGIC BIOPHARMACEUTICAL PORTFOLIO DEVELOPMENT:
AN ANALYSIS OF CONSTRAINT INDUCED IMPLICATIONS
4 .3 .1 . Fiv e  d r u g  p o r t f o l io
Figure 4.2 shows the final results for a five drug portfolio subject to the various 
constraints considered. It can immediately be seen that a negative relationship 
between mean positive NPV and p(NPV>0) exists for all constraints. It is also 
noticeable that although individually each drug has a probability of reaching the 
marketing phase of between 0.14 and 0.25, depending on the development strategy, 
the entire portfolio has a p(NPV>0) of up to 0.76, over 5 times the lower bound of this 
range. This relationship highlights a challenge to the drug developer that here appears 
to be a problem of making decisions when the objectives that must be optimised are 
also conflicting. It can also be seen in each case that for a given p(NPV>0) value the 
more restrictive the cash flow constraint the lower the mean positive NPV. Similarly, 
for a given target in mean positive NPV these constraints reduce the probability of 
achieving this profit. As might be expected, this is indicative that the decision maker 
in this case needs to consider that by having more financial resources available for the 
drug development process it is possible to enhance the profitability of the venture. 
This also suggests that resources critical to the generation of profit are compromised 
upon the introduction of such constraints. It is also observed in Figure 4.2 that the 
decline in profitability for a given value of p(NPV>0) is most pronounced between 
the cash flow constraints of -SIOOMM and -S75MM. The large drop between such a 
relatively small margin suggests the loss of availability of a key profit-generating 
resource. Interestingly, the maximum value of p(NPV>0) is not reduced by the 
presence of even the most severe constraints on cash flow investigated. The analysis 
will proceed by analysing the most probable constituents of strategies for the 
unconstrained example alongside the -$200MM and the -SIOOMM constraints. 
Analysis of the -S75MM constraint is not taken further here as it is unrealistic to 
develop a portfolio of five drugs on such a low level of financing.
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Figure 4.2. Mean positive NPV versus p(NPV>0) for a five-drug portfolio under the following 
constraint levels: unconstrained (-), -$200MM (^ ) ,  -$100M M (^), -S75MM (■).
4  3 .1 .1 . T h i r d  P a r t y  S t r a t e g ie s
When analysing the third party strategies in the final generation for each constraint 
(Table 4.1, Table 4.2 , and Table 4.3) it is clear that the general trend in third party 
strategy is to develop and manufacture all drugs in-house under the presence of no 
constraints and then move towards the increased involvement of partners as 
constraints become more severe. This is understandable from the viewpoint that 
increasing the severity of cash flow constraints makes it imperative that more cost- 
effective strategies be formulated and in the problem formulation used here partners 
offer the most cost-effective route for drug development. With an unlimited cash 
flow the dominant strategy is a complete in-house approach however it is not the only 
possibility amongst the optimised strategies, demonstrating that for the problem 
considered there are alternative approaches that involve third parties in some way to 
obtain equivalent and nondominated results. If the complete in-house approach is 
supported by appropriate strategies for portfolio structure and scheduling strategies 
that are parsimonious with spending so as to manage the impact of risk during drug 
development phases then the revenue stream does not have to be compromised. For 
the -S200MM constraint it can be seen that partners are chosen to be included for the 
development of either the first drug only or for both the first and second drug. The 
involvement of the partner is then kept to commercial manufacturing for successive 
drugs while contractors are used to assist with clinical development and 
manufacturing. In general, in-house activities appear to be initially constrained to
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clinical development for early drugs and then become involved in clinical 
manufacturing for successive drugs. Also for this constraint it is observed that for the 
vast majority of strategies presented a third party is seleeted for commercial 
manufacturing, indicating that this level of eonstraint makes in-house commercial 
manufacturing to be economically unattractive. Finally, the use of partners appears 
to be the most extensive for the -$ 1OOMM eonstraint. Here partners are used for the 
majority of activities in clusters 1 and 2. In cluster 3 partners are used more 
sparingly, with contractors mostly being used for clinieal and commercial 
manufacturing. Consistent with the -$200MM example, commercial manufacturing is 
also mostly completed by a third party. The above examples clearly show that third 
parties are an important resource in managing the risk and impact of failure.
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Table 4.1. Most probable strategies for a five drug portfolio with no constraints.


































Note: 7 ’ -  in-house activity, ‘C  ~ outsourced activity, f  partnered activity, p  -  the probability o f  
the corresponding strategy being present. C, i through C, s refer to preclinical and clinical trials. C, 6 
through C, 9 refer to manufacturing for clinical phases and market.
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Table 4.2. Most probable strategies for a five drug portfolio with a constraint o f $400MM.
A A , C,2 Q 3 C,-,4 C -,5 C„6 C ,i C . 8 C „ 9 P
Drug 1 'C T T •P’ 'P' T p , p , p , 0.51
Drug 2 'C T T T T T 'C 'C p , 0.39
Cluster 1 Drug 3 T 'C T T T T 'C 'C p , 0.39
Drug 4 T 'C 'C 'C 'C 'C 'C 'C 'C 0.29
Drug 5 'C 'C 'C 'C 'C T T T p , 0.36
Drug 1 T 'P' , p , 'P' P ' p , p , P ' P ' 0.99
Drug 2 'C T T T ' , p , T p , P ' p , 0.66
Cluster 2 Drug 3 T 'C T T T T 'C 'C P ' 0.60
Drug 4 T 'C 'C 'C 'C 'C 'C 'C 'C 0.28
Drug 5 'C 'C T T T T 'C 'C 'C 0.27
Drug 1 T 'P' , p , r p , , p , p , p . p , P ' 0.99
Drug 2 'C T T , p , P ' T p , p , P ' 0.69
Cluster 3 Drug 3 T 'C T T T T 'C 'C p , 0.56
Drug 4 T 'C 'C 'C 'C 'C 'C • c 'C 0.43
Drug 5 'C 'C 'C 'C 'C T T 'C T 0.29
Note: 7 ’ -  in-house activity, ‘C ’ -  outsourced activity, f  partnered activity, -  the probability o f  
the corresponding strategy being present. C, i through Q 5 refer to preclinical and clinical trials. Qg 
through C, 9 refer to manufacturing for clinical phases and market.
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Table 4.3. Most probable strategies for a five drug portfolio with a constraint o f S250M.
A Cm C,2 C o C , 4 C ,,5 C„6 C,2 Qg C „ 9 P
Drug 1 , p , p , p , p , p , P ' p , P ' p , 0.98
Drug 2 T T T T 'C T T 'C T 0.55
Cluster 1 Drug 3 T ' p , p , P ’ p , p , P ' p . P ' 0.91
Drug 4 , p , p , p , P ' p , p , P ' P ' p , 0.72
Drug 5 P ' p , p , P ’ p . P ' p , p , p , 0.98
Drug 1 'P' P ' p . p , p , P ’ p . p , p , 1.00
Drug 2 T T T T 'C T T 'C P 0.55
Cluster 2 Drug 3 P ' p , p , p , p , p , P ' p , P ' 0.96
Drug 4 P ' p , p , p , p , p , p , p , p , 0.81
Drug 5 p . p , p , p , p , p , P' P ' p , 1.00
Drug 1 T p , P ' p , P' P ' p , p , P ' 0.99
Drug 2 'C T T T T 'C 'C 'C P ' 0.99
Cluster 3 Drug 3 'C T T T T T T T 'C 0.99
Drug 4 'C T T T T 'C 'C 'C 'C 0.99
Drug 5 'C 'C 'C 'C 'C T T T P ' 0.99
Note: 7 ’ -  in-house activity, ‘C ’ -  outsourced activity, ‘P ’ partnered activity,/? -  the probability o f  
the corresponding strategy being present. C, i through C, 5 refer to preclinical and clinical trials. Qg  
through C, 9 refer to manufacturing for clinical phases and market.
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4 .3 .I .2 . D r u g  S e l e c t io n  S t r a t e g ie s
The probable portfolios that are selected in accordance with the constraints can be 
seen in Table 4.4, with more detailed results shown in Table A.l in Appendix A. The 
performance in the objective space has been spilt into three clusters in order to 
facilitate the analysis of any trends or patterns that may exist amongst optimised 
solutions. The first cluster contains strategies that generate high mean positive NPV 
values and low p(NPV>0) values. The second cluster consists of strategies that 
exhibit intermediate values of these metrics. The third cluster contains strategies that 
perform highly in p(NPV>0) but have low mean positive NPV values. For the 
unconstrained case, the most probable portfolios for clusters 1 and 3 develop two 
medium demand drugs and three high demand drugs, and for cluster 2 this portfolio is 
one low demand drug, one medium demand drug and three high demand drugs. Even 
given the unlimited cash flow resources the dominant drug development strategy is 
not to develop all four high demand drugs, indicating that such an approach in this 
ease offers a relatively unfavourable balancing of the impact of failure with attainable 
financial rewards. It should be noted that all three portfolios in the unconstrained case 
develop three high demand drugs. Under the -$200MM cash flow eonstraint, as may 
be expected, the total demand sought to be developed by the most probable portfolio 
in each cluster under this level of constraint is less than that sought for development 
in each corresponding cluster in the unconstrained example. The most probable 
portfolio in cluster 1 develops one low demand drug, two medium demand drugs, and 
two high demand drugs. In cluster 2 this is one low demand drug, three medium 
demand drugs and one high demand drug. For cluster 3 this portfolio consists of three 
medium demand drugs and two high demand drugs. Under the -SIOOMM constraint 
the observed portfolios develop for an even smaller demand than under the -S200MM 
cash flow constraint. For cluster 1 this portfolio is comprised of two low demand 
drugs, one medium demand drug, and two high demand drugs. In cluster 2 this is two 
low demand drugs, two medium demand drugs, and one high demand drug. In cluster 
3 this portfolio is one low demand drug, three medium demand drugs, and one high 
demand drug. More generally, the constraints force successful strategies to form 
portfolios that cater for a lower demand for all clusters. This is one contributor to why 
the mean expected NPV decreases with increasing magnitudes of cash flow
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constraint. The level of reduction is generally equal across clusters 1, 2, and cluster 3. 
Aeross all clusters it can be seen that in most cases a mixture of drugs from all groups 
are chosen. As might be expected, drugs from group 3 are most commonly seen in 
cluster 3 for each level of constraint, as group 3 drugs have the highest probability of 
success. Additionally, group 3 drugs are seareely seen in clusters 1 and 2.
Table 4.4. Characteristics o f  the most probable drug selection and timing strategies for a 5 drug 
portfolio subject to cash flow constraints.
Unconstrained -$200MM -SIOOMM
Characteristic 1 2 3 4 5  1 2 3 4 5  1 2 3 4 5
Demand M M H H H M M H H L L H M H l "
Cluster AGR M M L L H  M L L H M  M M M L M
1 Drug group 2 1 2 3 3  2 1 1 2 2  2 1 1 2 2
Timing ID F III M - F III II F - III I II F -
Demand M L H H H  M M H L M  M L M H L
Cluster AGR M L M M M  M L M M H  H M M L M
2 Drug group 2 2 1 2 2  2 1 2 2 3  2 2 1 2 1
Timing P P M F - F III II F - III I II F -
Demand M H H H M  M M H H M  L H M M M
Cluster AGR M L H L H  M L L H H  M M L H M
3 Drug group 2 1 3 1 3  2 1 2 3 3  2 3 3 1 3
Timing ID F II II - F III F III - III F III III -
Note: Demand relative level o f  annual demand, AGR annual growth rate, Drug group -  the 
indication groups most likely to be selected, and Timing timing strategy for the portfolio. M, L, and 
H refer to low, medium, and high respectively. 1 through 5 in the header refer to the first through fifth 
drugs to be developed. 1,2,  and 3 in the drug group rows refer to drug groups 1 , 2,  and 3. In the 
timing rows: ID -  target identification, P -  preclinical trials, I -  phase I clinical trials, II -  phase II 
clinical trials. III -  phase III clinical trials, F -  FDA review, and M -  marketing stage. means that 
the datum is irrelevant for that particular combination o f referencing items.
4 .3 .I .3 . T i m i n g  S t r a t e g ie s
The most probable timing strategies ean be viewed aeeording to eash flow eonstraint 
level and cluster is as shown in Table 4.4. The popular theme exhibited by strategies 
generated under no cash flow constraints appears to be to develop an initial collection 
of drugs in close succession or even together and then to develop the remaining drugs 
with longer intervals between them. As seen in cluster 2 with this level of constraint.
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this initial collection can be as many as three drugs. With an unconstrained cash flow 
the most probable timing strategies for clusters 1, 2, and 3 take 35 years, 31 years, and 
28 years for completion of portfolio development and marketing activities, 
respectively. Specifically, research and development activities on the portfolio are 
expected to be completed 10 years prior to eaeh of these completion times, which is 
true for all figures of this type reported in the results section unless otherwise stated. 
This indicates a trend of shorter completion times with increasing probability of 
success. In cluster 1 two drugs are developed together with the remaining drugs being 
developed almost one at a time due to the lengthy intervals imposed by the strategy. 
In cluster 2 three drugs are developed within a year of each other, while the remaining 
drugs are developed with at least a nine year interval between them. In cluster 3, the 
first two drugs are developed together, the third drug is developed after a nine year 
interval, and then the two remaining drugs are developed with medium length 
intervals of four years in between them. Under the -S200MM cash flow constraint, in 
all clusters the portfolio development times become longer. Clusters 1,2, and 3 take 
38 years, 38 years, and 40 years for the completion of portfolio development and 
marketing activities, respectively. The trend exhibited with the unconstrained 
example no longer exists here and the development times across the clusters have 
become almost equal. If any trend exists then it is that the development times are 
longer towards the higher values of p(NPV>0). The theme of developing at least two 
drugs in close succession is also not maintained. As shown in Table 4.4 in all clusters 
the most probable strategy is to wait until drug 1 is expected to begin the FDA review 
before developing drug 2. Interestingly, the development times for drugs 2, 3, and 4 
are brought into closer succession for clusters 1 and 2. For cluster 3 this is not the 
case and instead an alternation of waiting times is seen between waiting until the FDA 
review and then until phase III clinical trials for the next drug. Under the -SIOOMM 
cash flow constraint the total completion time for development and commercialisation 
is 32, 32, and 37 years, respectively. It is possible that the intensive involvement of a 
partner, as shown earlier, allows for this to happen by serving as an effective scheme 
for managing the impact of failure. The intervals after drugs 2 and 3 are shorter for 
clusters 1 and 2 when compared to the same clusters for the -S200MM constraint. It 
is thought that in clusters 1 and 2 any cash flow arising from revenue of the first drug 
will fuel the development of some subsequent drugs allowing for shorter intervals to 
be applied up to a point. In cluster 3, the intervals have stayed identical to those
135
STRATEGIC BIOPHARMACEUTICAL PORTFOLIO DEVELOPMENT;
AN ANALYSIS OF CONSTRAINT INDUCED IMPLICATIONS
correspondent with the less restrictive constraint considered and this is thought to be 
the case because this cluster takes on portfolios that cater for a much larger demand 
than the other two clusters. The most observable trend across the constraints is that 
the development time between drugs 2, 3, and 4 becomes consistently shorter in 
clusters 1 and 2. One way of mitigating the impact of failure is to lengthen the time 
interval between the developments of subsequent drugs such as to allow for the 
possibility of previous drugs to reach market and provide a cash flow to fund future 
projects.
4 .3 .2 . T h r e e  d r u g  p o r t f o l io
The final results for a three drug portfolio can be seen in Figure 4.3 where the effect 
of constraints on the final population is clear. Again as with the five drug portfolio 
the impact of constraints reduces the mean positive profit for a given p(NPV>0) 
value. It is immediately noticeable that the probability of the portfolio yielding a 
positive NPV is significantly reduced when compared to five drug portfolio. It is also 
noticeable that the range of mean positive NPV values for the three drug portfolio is 
effectively the same as for the five drug portfolio suggesting that both portfolios are 
relying on the same number of drugs reaching market, which is most probably one 
drug. This is because drug development is uncertain and drugs are more likely to fail 
than not during this process. Thus with portfolios of decreasing size there is a 
decreased likelihood that at least one candidate will reach the market place. It can be 
seen that the fi’ontier of the -SIOOMM constraint is of closer proximity to the frontier 
of the unconstrained scenario than to that of the -S75MM constraint. This signifies 
the loss of some set of critical strategies with the -S75MM constraint that would 
otherwise contribute significantly to profit generation and the mitigation of unwanted 
risk in this region. Figure 4.3 also shows that the topology of the frontier for the - 
SIOOMM constraint lies similar to that for the unconstrained problem above a mean 
positive NPV of S1,000MM. There is even a point along the frontier for the - 
SIOOMM constraint at approximately p(NPV>0) = 0.3 where it is equal to the 
unconstrained problem. Below this measure of profit the profile of the frontier 
produced by the -SIOOMM constraint inverts demonstrating the largest loss of value 
and strategies as imposed by the constraint is in this region.
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Figure 4.3. Mean positive NPV versus p(NPV>0) for a three-drug portfolio under the following 
constraint levels: unconstrained (-), -SIOOMM (A) ,  -$75M M (^).
4.3 .2 .I. T h i r d  P a r t y  S t r a t e g i e s
As seen in Table 4.5, Table 4.6, and Table 4.7 all strategies take a completely 
different approach to the strategic involvement of third parties as with those 
formulated for the five drug portfolio. The most popular strategy amongst these is to 
assign the majority of development activities for the first drug to a partner and then to 
develop successive drugs with the involvement of a contractor. In the unconstrained 
problem, the approach to include partners in this way is phased out towards cluster 3 
where in-house and outsourcing strategies dominate. When cash flow constraints do 
not apply it can be seen that the involvement of third parties is minimal when 
compared to third party strategies seen when such constraints are applied. With the - 
SIOOMM constraint, more partners are included towards the third cluster where a 
complete partnered approach is the most probable third party strategy. The -S75MM 
constraint yields strategies that use partners more in clusters 1 and 3 than in cluster 2. 
The probable approach of intensive use of partners and contractors in this manner 
highlights the necessity for parsimonious cash flow management with the three drug 
portfolio when compared to the five drug portfolio. The use of partners during early 
stages is understandable as in this case they allow for the most economically efficient 
route to market. The clear trade-off is that a large proportion of the revenue must be 
shared and it is economically inefficient to continue with this strategy unless forced to 
do so by cash constraints. Limiting subsequent use of a partner to commercial
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manufacturing minimises the proportion of revenue that will have to be paid and it 
also allows the company to overcome the significant cost of acquiring commercial 
manufacturing facilities. As this facility is scheduled to be built at the beginning of 
phase III cUnical trials for the drug that it will be manufacturing there is a reasonable 
likelihood that the drug will fail leaving the company with a sunk capital expense. 
Clearly, partnering reduces this impact of failure.
Table 4.5. Most probable strategies for a three drug portfolio with no constraints.
A Ci,\ C/,2 C o C /,4 C „ 5 C „ 6 C , 7 Q s C /,9 P
Drug 1 T T ,p, P ' P ' p , P ' P ' p , 0.48
Cluster 1 Drug 2 T T T 'C ’C 'C 'C 'C 'C 0.48
Drug 3 'C T T T T T T 'C P ' 0.48
Drug 1 T T ,p, ,p, p , p , P ' P ' P ' 0.85
Cluster 2 Drug 2 T T T 'C 'C 'C 'C 'C 'C 0.85
Drug 3 'C T T T T T T 'C p> 0.85
Drug 1 T T T T T 'C 'C 'C T 0.52
Cluster 3 Drug 2 'C 'C T T 'C T T 'C p , 0.52
Drug 3 'C T T T 'C T T T 'C 0.52
Note'. 7 ’ -  in-house activity, ‘C ’ -  outsourced activity, ‘P ’ -  partnered activity, p  -  the probability o f  
the corresponding strategy being present. C, i through C, s refer to preclinical and clinical trials. C, 6 
through C, 9 refer to manufacturing for clinical phases and market.
Table 4.6. Most probable strategies for a three drug portfolio with a -SIOOMM constraint.
A C o C/,2 C o C /,4 C o C,6 C o C,8 C /,9 P
Drug 1 T p , p , P ' P ' P ' p , P ' p , 1.00
Cluster 1 Drug 2 'C T T 'C 'C T T T p , 0.92
Drug 3 'C 'C 'C 'C 'C T T 'C T 0.55
Drug 1 T p , p , p , P ' P ' P ' p , p , 1.00
Cluster 2 Drug 2 'C T T 'C 'C T T T P ' 0.81
Drug 3 'C 'C 'C 'C 'C T T 'C T 0.52
Drug 1 p . p , P ' P ' P ' P ' P ' p , P ' 1.00
Cluster 3 Drug 2 p , P ' P ' p , P ' P ' P ' P ' P> 1.00
Drug 3 P ' p , P ' p , p , P ' p , P ' P ' 1.00
Note'. / '  in-house activity, C ’ outsourced activity, ‘P ’ -  partnered activity,/? the probability o f  
the corresponding strategy being present. C,j through C, 5 refer to preclinical and clinical trials. C, 6 
through C/ 9 refer to manufacturing for clinical phases and market.
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Table 4.7. Most probable strategies for a three drug portfolio with a -$75MM constraint.
A Cu2 C o C„4 C o C o C,i C o C o P
Drug 1 T 'P' , p , P ' p , p , p , p . p . 0.422
Cluster 1 Drug 2 'C T , p , p . p , p , p , p , p , 0.281
Drug 3 T T T P T T T T p , 0.281
Drug 1 T T 'C • c 'C T T 'C p , 0.198
Cluster 2 Drug 2 T 'C P ’ P ' p , p , P ' P ' p . 0.228
Drug 3 'C T T T T T T T T 0.216
Drug 1 T 'P' 'P' p , p , p , p , p , P ' 0.409
Cluster 3 Drug 2 'C T P ' P ' P ' p , p , P ' P ' 0.309
Drug 3 T T T T T T T T P ' 0.271
Note: 7 ’ - in-house activity, ‘C ’ outsourced activity, f  partnered activity,/? - the probability o f  
the corresponding strategy being present. C,j through Q 5 refer to preclinical and clinical trials. C, 6 
through C, 9 refer to manufacturing for clinical phases and market.
4.3.2.2. D r u g  S e l e c t i o n  S t r a t e g i e s
The drug selection strategies for the most probable portfolio for each cluster in the 
optimised population of strategies ean be viewed in Table 4.8. More detailed results 
can be viewed in Table A.2 in Appendix A. Across the entire range of constraints and 
clusters there are no discernable trends with the demand of drugs that are consistent 
over all constraints. All portfolios select drug candidates that have a mixture of 
demands, rather than what might be thought to be an aggressive profit-focussed 
strategy such as selecting all high demand drugs. All portfolios contain at least one 
high demand drug and no portfolio opts to develop more than one low demand drug. 
High demand drugs are developed second or third by the majority of strategies in 
Table 4.8. Additionally, relatively few strategies in Table 4.8 choose drugs with high 
annual growth rates.
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Table 4.8. Probabilities o f drug selection for a three drug portfolio.
Unconstrained -SIOOMM -S75MM
Characteristic 1 2 3 1 2 3 1 2 3
Demand M H L M M H M H L
AGR M F H M L L M M M
Cluster 1
Drug group 2 1 3 2 1 1 1 2 1
Timing M M - M M - M M -
Demand M H H M M H M H H
AGR M L L M L L M L H
Cluster 2
Drug group 2 2 1 2 2 3 1 2 1
Timing M M - M M - M M -
Demand M H H M L H H L M
AGR L M H L M L L H L
Cluster 3
Drug group 2 2 2 2 1 3 1 3 1
Timing M M - M M - F M -
Note: Demand -  relative level o f annual demand, AGR -  annual growth rate, Drug group -  the 
indication groups most likely to be selected, and Timing -  timing strategy for the portfolio. M, L, and 
H refer to low, medium, and high respectively. 1 through 5 in the header refer to the first through fifth 
drugs to be developed. 1, 2, and 3 in the drug group rows refer to drug groups 1, 2, and 3. In the 
timing rows: ID -  target identification, P - preclinical trials, I -  phase I clinical trials, II -  phase II 
clinical trials. III phase III clinical trials, F FDA review, and M marketing stage.
4 .3 .2 3 . T i m i n g  S t r a t e g i e s
Under almost all constraints for all clusters the optimised strategies opt to extend the 
development of the portfolio to as long as possible (Table 4.8). In clusters 1 and 2 
there is an increase in the probability by which these timing strategies are selected. It 
is clear that the constraints on the portfolio limit the number of projects that ean be 
undertaken simultaneously. What might be unintuitive is that even with unlimited 
cash flow constraints this remains the most probable strategy and alternative timing 
strategies to this follow a probability distribution that becomes less probable for 
selecting more time prudent alternatives. This is very much different to the approach 
on timing seen for the five drug portfolio where usually two or three drugs are often 
either developed together or in close succession with the remaining drugs staggered 
into longer phases. Because there is a significantly greater probability that the entire 
three drug portfolio will fail to reach market and produce a profit, it becomes less
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appropriate to develop multiple drugs together. In this case it is most appropriate to 
completely disaggregate the cash flows of drug development projects.
4.4. Co n c l u s io n s
The technique presented has been used to explore the difficult task of identifying 
optimal strategic approaches to the development of a portfolio of drugs. Analyses 
using a five drug portfolio and a three drug portfolio have been presented. 
Additionally, cash flow constraints on these portfolios have been applied. It has been 
seen in the cases investigated here that mean positive NPV and p(NPV>0) are 
conflicting measures however both are desirable to the decision maker. The 
introduction of cash flow constraints can lead to a reduction in the expected rewards 
or probability of success of strategy. Cash flow constraints also directly influence 
third party strategies. The reduction in portfolio size from five drugs to three drugs 
produces the same mean positive NPV range but results in a significant reduction in 
the probability that the portfolio returns a profit. The timing and third party strategies 
for each size of portfolio are very different showing that the size of the portfolio has a 
specific impact on how it should be developed and commercialised regardless of how 
much capital is available. This signals to the decision maker that it may not be 
appropriate to apply similar development strategies to portfolios of different sizes. It 
is important to remember that the results are dependent on the nature of the scenario 
that is to be investigated. In this case, if drugs that were already partially through the 
clinical trial process had been considered then it is possible that a very different set of 
results may have been generated by the framework. On the issue of comparability, it 
is difficult to compare the results here to that of other works because of the individual 
properties of the case study. Also, because each strategy within the set of optimised 
strategies is comprised of decisions that can add value collectively rather than just 
individually it is difficult to compare the elements that are common with similar 
works. Finally, the reader should be aware that this is a computationally intensive 
procedure which through the use of a Pentium IV processor can take approximately 
15 hours to execute without the use of parallel processing techniques. Hence 
depending on available computational resources extending model variables such as 
the number of Monte Carlo trials or the size of the portfolio can come at the 
significant expense of time. Specifically, it is important to note that the
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computational limits of this framework are dependent on a few factors: the processing 
capacity of the computational system under use, the programming language that it is 
executed in, multi-threaded design of the program, and the allowable execution time.
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C h a p t e r  5
Economic Correlations for Whole Monoclonal Antibody 
Manufacture and Antibody Fragments Manufacture
5.1. In t r o d u c t io n
In chapters 2-4 methods for rationalising between strategic options, optimising 
superstructures of strategies, and analyses for determining the impact of factors 
affecting these processes have been investigated. These studies have all required the 
development of mathematical models for simulating the capital expenditure and the 
operating cost incurred in constructing biopharmaceutical manufacturing facilities. 
Such models require computationally expensive evaluation procedures for 
determining the required économie metrics. The level of modelling employed permits 
a rich level of detail to be provided and is particularly useful in the event that a 
discerning detail-orientated decision maker wishes to access such information. It is 
intuitive that there are situations where computational efficiency is also of great 
interest. Such situations might include when using the optimisation framework 
presented in chapter 3 which must perform numerous Monte Carlo samples for 
several thousand strategies. Also from a more practical perspective, decision makers 
in the biopharmaceutical industry could benefit from access to simplified formulae for 
calculating key economic metrics of interest, such as fixed capital investment and the 
cost of goods sold per gram (COGS/g). In either of these cases, it is obvious that a 
less computationally intensive estimation method that is able to provide an acceptable 
level of accuracy would be of considerable use. This is the focus of this chapter.
Specifically, the scope of investigation here is focused on the development of 
formulae that approximate the economic outputs of detailed mathematical 
biopharmaceutical manufacturing models. A common straightforward approach has 
previously been used in industry to estimate the cost of individual items of 
bioprocessing equipment, with the following relationship between size and cost 
employed otherwise known as the R factor method Remer and Idrovo (1991):
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This technique inherently assumes a geometric relationship between variables. The 
exponent R for this correlation ean be found through linear regression of size and cost 
data on log-log axes, where R is the gradient of the line of best fit. Such methods 
commonly set this value to 0 .6  although this is not ubiquitous for all equipment. This 
method was first applied by Williams (Williams, 1 9 4 7 ) for equipment costing and 
later by Chilton (1 9 5 0 )  for plant costing. As the biopharmaceutical industry has 
grown, the value of the exponent R has been investigated for commonly used 
equipment often used in this industry (Remer and Idrovo, 19 9 1 ; Remer and Chai, 
1 9 9 0 ). Remer and Idrovo (1 9 9 1) have conducted empirical evaluations of R for a 
large range of upstream and downstream bioprocessing equipment. Their results 
indicating that R varies between 0 .3 7  and 1 .16 and that the average value of ^  for the 
dataset used in their investigation was 0 .6 3 . More recently R = 0 .6  has been used in 
literature for cost models in the optimisation of the design of biopharmaceutical plants 
(for example see Dietz et a / . ,  2 0 0 7 ; Dietz, et a / . ,  2 0 0 6 ) . The above indicates that 
geometric expression of the relationship between the size and cost of bioprocessing 
equipment has been accepted in literature. Also the above highlights that this 
technique has been useful for approximating the cost of individual items of 
equipment, as seen in Remer and Idrovo (1991), as well as for building more intricate 
cost models of biopharmaceutical processes, as seen in Dietz et ûr/.(2006  and 2 0 0 7 ) . 
Some limitations of this technique have been noted by Remer and Idrovo (1991). 
Some types of bioprocess equipment such as high performance liquid chromatography 
are difficult to scale up using the R factor method. As there must be a referencing 
value for size and cost to use the technique Remer and Idrovo (1 9 9 1 )  note that there is 
a range of validity beyond which use of this method becomes inappropriate.
The approach taken by this work is to extend the concept of geometric relationships 
used to approximate the cost of individual items of equipment, and also to investigate 
if a straightforward geometric expression can be used to estimate the key economics 
of an entire facility. When determining cost estimating equations for equipment, the
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R factor technique will not be used in place of regression analysis techniques where 
appropriate. This is because regression analysis techniques can characterise an entire 
dataset without the need for base values to be used in the equation itself, thus potential 
issues such as ranges of validity are avoided. This requires the development of a 
detailed mathematieal model of specific biopharmaceutical manufacturing processes 
so that costs are accurately determined. The next step draws computationally 
straightforward relationships between key input factors and the broad economic 
metrics of interest to a decision maker in a biopharmaceutical setting. Such metrics 
are typically the fixed capital investment required to build a biomanufacturing facility 
as well as its operating cost. The approximation method used to achieve this here is 
multiple regression analysis (Kitchens, 1998) which is used to leam nonlinear 
relationships between the inputs and outputs of the model. Two types of 
manufacturing process will be considered, that is, the manufacture of whole 
monoclonal antibodies using mammalian cells, and the manufacture of antibody 
fragments using E.coli. The following sections will entail:
■ Description of each manufacturing process with regard to the unit operations that 
comprise them.
■ Mathematical modelling of the relevant unit operations
■ Analysis of model outputs over a range of industrially relevant inputs.
■ Development of the approximation formulae.
■ Analysis on the error when predicting the outputs of the fully detailed 
mathematical models.
5.2. M e t h o d
The method for the modelling, simulation, and approximation of the economics of 
whole monoclonal antibodies and antibody fragments manufacture is now presented.
5.2.1 P r o c e s s  O v e r v i e w s
The production process for the manufacture of whole monoclonal antibodies is 
exhibited in Figure 5.1. The choice of process operations for this product was largely 
influenced by similar processes of mammalian cell culture-derived monoclonal 
antibody drugs such as Herceptin^^, Zenapax™, Rituxan™, Synagis™, and
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Remicade™ (Farid, 2001). Also, in Figure 5.2 the process for manufacturing 
antibody fragments is presented which is based on the manufacturing procedure for 
Celltech’s E.coli based production of PEG-conjugated antibody fragments, CDP870 
(Farid, 2001). Accordingly, the mathematical models constructed to replicate these 
processes include the unit operations required for production and processing, as well 
as the ancillary tasks, raw materials, utilities and labour. There are four inputs to this 
model: the annual level of market demand that must be met by the facility, the 
fermentation titre that will be achieved, the product yield after downstream 
processing, and the probability of achieving successful batch fermentation. These 
inputs were used to calculate the masses and volumes of products and wastes that will 
be generated during the manufacturing process. These were subsequently used to 
calculate the appropriate number and size of equipment, alongside the raw materials 
and utilities utilised. The data used for equipment prices was collected from a variety 
of commercial sources. Correlations between the price and size of each item of 
equipment or raw material were derived and the model uses the correlation-based 
equations to evaluate the economics of the required manufacturing process. In cases 
where only fixed denominations of size were available the model references the cost 
for the appropriate size. These models are implemented as spreadsheet architectures 
in MS Excel.
5.2.2 U n i t  O p e r a t i o n s
Key inputs and outputs to the mathematical models for calculation of equipment costs 
and sizing are hereon described. Equipment and mass balance equations are based on 
work by Farid (2001), with full details provided in Appendix B.
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Figure 5.1. The whole monocloncal antibody biopharmaceutical manufacturing process model. 
Abbreviations: DSP - downstream processing, QC/QA -  quality control / quality assurance, PCI -  
fixed capital investment, COGS -  cost o f  goods sold. Demand is the annual product demand 
determined from the market analysis and depends on market size, market capture and the drug dosage 
per patient per year. Titre refers to the titre o f  crude product (g/L) that is expected to be achieved in the 
fermenter, DSP yield is the overall yield after all downstream processing steps have been completed. 
Batch success rate refers to the likelihood o f  batch success given the chances o f  contamination or 
equipment failure. The manufacturing operations and the ancillary tasks have been modelled to 
determine estimates o f utilisation o f major cost components. Utilisation estimates are combined with 
an extensive cost database to determine the PCI and COGS values.
147












^  ■ • Cost Databases ■ •
Seed Ptowmlation■ ■ ^
ProdiKlicm Fermentadffii















[ Eiq^qjpna^ Sizes # 
[ Materiala Usage
[ UdliHes Coo$w»ptloftl
[ Libonr R e^tdr^ ^
Figure 5.2. The antibody fragments biopharmaceutical manufacturing process model. Abbreviations: 
DSP - downstream processing, QC/QA -  quality control / quality assurance, PCI -  fixed capital 
investment, COGS -  cost o f goods sold. Demand is the annual product demand determined from the 
market analysis and depends on market size, market capture and the drug dosage per patient per year. 
Titre refers to the titre o f crude product (g/L) that is expected to be achieved in the fermenter. DSP 
yield is the overall yield after all downstream processing steps have been completed. Batch success 
rate refers to the likelihood o f  batch success given the chances o f contamination or equipment failure. 
The manufacturing operations and the ancillary tasks have been modelled to determine estimates o f  
utilisation o f major cost components. Utilisation estimates are combined with an extensive cost 
database to determine the PCI and COGS values.
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Table 5.1. Key inputs and outputs for key operations.
Input Type Inputs Outputs
Main Annual demand 
Titre (g/L)
Whole process yield 
Batch success probability 
Batches per year
Fixed capital investment 
COGS/g
Inoculum Process cycle time 
Inoculum volume required
Outflow volume
Fermentation Process cycle time 
Production volume required 
Stoichiometry coefficients 
Inflow stream composition 
Media required
Outflow stream composition
Filtration Inflow stream composition 
Average flux (L/m^/h) 
Concentration factor 
Rejection coefficient
Outflow stream composition 
Retentate tank size
Chromatography Inflow stream composition
Chromatography steps




Outflow stream composition 
Buffer holding tank sizes
Centrifugation Inflow stream composition 
Flow rate
Solid carry-over level 
Cycle time
Outflow stream composition 
Supernatant holding tank size
Note: Equipment numbers, equipment costs, raw materials costs, and operating costs are outputs for all 
operations. All operations require details o f the inflow stream composition as an input.
149
ECONOMIC CORRELATIONS FOR WHOLE MONOCLONAL ANTIBODY MANUFACTURE AND
______________________________________________________ ANTIBODY FRAGMENTS MANUFACTURE
Table 5.1 displays the principle inputs and outputs to the simulation models as well as 
to individual unit operations. The overarching inputs to the models are the annual 
demand for the facility, titre of product to be achieved at fermentation, whole process 
yield, batch success probability, and the number of batches to be run annually. It is 
important to note that the number of batches to be run annually is more dependent on 
the nature of the manufacturing process rather than on decisions made for design of 
the manufacturing facility. This is mainly because of the time required for the host 
expression system to achieve the desired titre of crude product. In the mammalian- 
derived whole monoclonal antibody process it is assumed that 20 batches per year are 
produced, whereas for the bacterial production of antibody fragments this number is 
50. These numbers are based on the time taken to produce the crude product and 
cascaded scheduling of the manufacturing process such that fermentation can be 
recommenced immediately after the bioreactor has been sterilised. Because no 
operations in the downstream process for either manufacturing procedure are longer 
than the fermentation stage no bottlenecks in the downstream operations are created in 
the model by use of this design. Inputs to unit operations beyond the four main inputs 
are derived from within each model and do not have to be provided by the user once 
the model has been programmed. For example, inputs such as the inflow stream 
composition for a particular unit operation are taken from the outflow stream of its 
preceding operation. This data can be subsequently used to determine the number of 
equipment units required as well as their sizes using mathematical relationships. 
Raw materials and operating costs can also be determined by calculating their usage 
and referencing a database containing relevant costs. Ultimately all equipment 
numbers, equipment costs, raw material costs, and operating costs are calculated from 
mathematically relating the mass composition of the input stream to the requisite 
operational protocols of individual equipment units.
150
ECONOMIC CORRELATIONS FOR WHOLE MONOCLONAL ANTIBODY MANUFACTURE AND
ANTIBODY FRAGMENTS MANUFACTURE
Table 5.2. Rules for adding additional equipment units.
Equipment Rule for adding new equipment units
Inoculum flask Processing volume > 0.5L
Fermentation Processing volume > 20,000L
Ultrafiltration unit Processing time > 24h
Affinity chromatography column Column diameter > 0.45m
Virus inactivation tank Processing volume > 20,000L
Cation exchange chromatography column Column diameter > 0.45m
Virus nanofiltration unit Processing time > 24h
Diafiltration unit Processing time > 24h
Anion exchange chromatography column Column diameter > 0.45m
Dead-end filtration Column diameter > 0.45m
Periplasmic extraction tank Processing volume > 20,000L
Tank for pH and conductivity adjustment Processing volume > 20,000L
Dilution tank Processing volume > 20,000L
PEGylation tank Processing volume > 20,000L
Centrifugation Processing time > 24h
Note: Above equipment dimensions represent maximum dimensions available at the time o f study.
Table 5.2 displays the protocols for adding new equipment units across both 
manufacturing processes. These are based on maximum sizes of commercially 
available equipment and processing times that would not create bottlenecks in the 
manufacturing process. Realistic denominations of equipment sizes were used, which 
included sizes of marketed equipment where available. By ensuring that processing 
time did not introduce bottlenecks scalability of the model was supported in 
determining appropriately equipped facilities that could operate in line with given 
time constraints. It should be noted that when a new fermenter is added its outflow 
stream is merged with that of other fermenters, rather than creating a new downstream 
processing train. This is true of any other equipment unit. Also, equipment sizes are 
calculated such that multiple units of the same equipment are all sized equally.
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5.2.3 C o s t  o u t p u t s
The output costs of the models are now presented. The fixed investment cost is 
calculated by linear correlation to the total equipment cost using the Lang Factor 
method (Lang, 1948):
~ ^Eop ^  f.i (5-2)
i
Where FCI is the fixed capital investment required to build the facility, E e q p  is the 
total equipment cost of the facility, and L/i is the value of the factor of the relevant 
Lang factors . The breakdown of the Lang factors (Lang, 1948; Novais, Titchener- 
Hooker, and Hoare, 2001) are shown in Table 5.3. The model used for the cost of 
goods is seen in Table 5.4.
Table 5.3. Lang factor constituents and values.
Description fi
Equipment and utilities 1.00











Source: Novais et al. (2001).
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Table 5.4. COGS model breakdown.
Cost Category Description
Direct raw materials ^utilisation) ( 5 j )
Miscellaneous materials 0.5 X direct raw materials (5.4)
Direct Direct utilities ((utilisation) ( 5 j )
Cost Operating labour ((utilisation) (5.6)
o f  Goods Supervisors 0.2 X operating labour (5.7)
Quality control and quality 1 X operating labour (5.8)
assurance
General management 1 X operating labour (5.9)
Maintenance 0.1F7 (5.10)
Indirect Local taxes 0.02FY (5.11)
Cost o f Insurance O.OIFY (5.12)
Goods Capital charge F  (1 + rate o f interest) ^ C ' (5.13)
General utilities Cost per unit area per year x Facility size x Y (5.14)
Total Cost o f  Goods Direct Cost o f Goods + Indirect Cost o f Goods (5.15)
Total Cost o f  Goods p er  Gram (COGS) Total Cost o f  Goods / Annual Production Output (5.16)
Note: Where F  is the fixed capital investment, Y is the project duration in years, and C is the capital 
charge period. Source: Mustafa et al. (2004).
In the model, the facility size was estimated through a correlation determined from 
data presented in Pavlotsky (2004) and Farid (2007). Pavlotsky (2004) takes a 
detailed approach to approximating facilities cost and includes more than 100 
pharmaceutical projects. The facilities in the study were categorised into three size 
ranges: 25,000 sq.fr, 50,000 sq.fr and 100,000 sq.fr with the encompassing cost data 
being adjusted to fit these categories. Farid (2007) includes data on recently built 
antibody manufacturing facilities that use mammalian cell culture. The size to cost 
data from these studies are plotted in Figure 5.3 with a geometric relationship being 
strongly supported.
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Figure 5.3. Facility size versus cost relationship based on data from Pavlotsky (2004) and Farid 
(2007). The solid line represents the line o f best fit as determined by geometric regression. The 
equation o f this line is f(x) I730jc°^’^^ , with = 0.9539.
5.2.4 S i m u l a t i o n  M e t h o d  f o r  D a t a  A c q u i s i t i o n
Estimation of key process economic metrics was investigated by determining 
relationships via multiple regression analysis to the four main inputs: annual demand 
(D), fermentation titre (7), whole process yield (7), and batch success probability (ps). 
In order to acquire the data necessary for investigating relationships, different 
combinations of instances of these inputs were inputted to the model with the outputs 
recorded. Table 5.5 summarises the range of instances for these inputs. The number 
of batches produced by the facility per year, ng, was kept constant at 20 batches/year 
for mammalian-derived monoclonal antibody production and 50 batches per year for 
bacterial derived antibody fragment production.
Table 5.5. Input value ranges.
Input Range Number o f instances
D 10kg, 25-500kg at 25kg intervals 21
Y 0.4, 0.5, 0.6, 0.7 4
T 0.25,0.5, 1.0, 1.5, 2 .0g/L 5
P b 0.7, 0.8, .0.9, 1.0 4
The ranges in Table 5.5 were based on what is currently achieved in industry plus 
some reasonable extension that might represent future developments at the time of
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Study (2004). In terms of titre, the typical maximum value observed in the industry in 
2004 was about Ig/L although higher titres of 3-5g/L are now seen in 2008. At the 
time of study it was sensible to choose values ranging from 0.25g/L to 2g/L 
(Sommerfeld & Strube, 2005). Resultantly, a set of 1680 input combinations was 
used to build correlations to the outputs. The outputs measured from the simulation 
were:
■ Fixed capital investment
■ Upstream process (USP) equipment cost
■ Downstream process (DSP) equipment cost
■ COGS/g
■ Contribution (%) of material, labour, and indirect costs comprising COGS/g 
The reasons for selecting these outputs are now explained. Capital investment and 
cost of goods related metrics are of clear importance to decision makers in the 
industry. Determination of the USP and DSP costs as well as the ratio between them 
can assist in identifying the most influential driver of capital expense. COGS/g 
indicates the profitability of the manufacturing process and implies its efficiency. The 
contribution of key components to COGS/g will identify its most influential driver.
5.2.5 M ultiple Re g r e ssio n  T ec h n iq u e
Multiple regression aims to establish the nature of relationships between a set of 
independent variables, and a dependent variable (Kitchens, 1998). In this 
circumstance the independent variables are D, T, Y, and pb . The dependent variable 
can be any one of the outputs previously mentioned. The technique is able to 
determine the extent to which a set of independent variables explains the variance in a 
dependent variable through a significance test. The measure of significance used here 
is the coefficient of determination, 1^. The independent variables are the input 
variables, which are assumed to have no correlation with each other. The dependent 
variable is the output metric of interest that is determined by some computation on the 
independent variables. The multiple regression technique can be used to learn a range 
of relationships including linear, hyperbolic, geometric, and polynomial relationships. 
This study focuses on exploring the derivation of geometric relationships between the 
model inputs and outputs. This is partly because, as previously stated, geometric 
relationships for estimating economic metrics in relevant settings have received
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acceptance in published literature. Geometrie relationships as used here will also lead 
to straightforward formulae. Also, they were generally found here to have the least 
error in explaining model outputs when compared to linear and hyperbolic 
relationships. Deriving polynomial relationships is more involved and relies on 
specifying the maximum exponent value in the polynomial equation. As the order of 
the polynomial equation increases, more reliability in the estimation of outputs is 
expected but the trade-off is relationships that are more expansive and less 
convenient. For this reason polynomial relationships were not considered here. 
Geometric relationships between the independent variables and the dependent 
variable in the multiple regression model take the following form:
ln ( X )  =  /?o +  A  ) +  A  hi(% 2 )4- A  ln ( x 3 ) +  ... +  A  ) 4 - g  (5 .1 7 )
Where X  -  a variable dependent on the values of x\ through x„, fi  -  regression 
coefficient, and e -  constant. It should be noted that here e is taken as equal to 0. 
Specifically, for the model developed here the multiple regression model is:
\n{X) = A + A  H D ) + A H Y ) + A H T )  + A H P b ) (5.18)
Or more conveniently:
X  = p / "  (5 .1 9 )
The multiple regression analysis used in this study was carried out with MS Excel 
using its Data Analysis add-in. To acquire the requisite data for this analysis, every 
output value of interest, that is FCI and COGS, from the model was recorded for 
every possible combination of instances of independent variables, that is D, Y, T, and 
P b , within the desired range of values (Table 5.5). In total this constituted 1680 
combinations of instances of independent variables each requiring an output value. 
This process was automated using VBA macros in MS Excel. All input and output 
values were subsequently converted to their natural logarithm equivalent and 
processed using linear regression, which allows determination of the geometric 
relationship.
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In addition to the model, the coefficient of determination, was recorded to measure 
the significance of the independent variables in determining the dependent variable.
is bound between 0 and 1. A high ^  value means that a large proportion of the 
variance can be actually attributed to the independent variables as established and 
explained by the learned model. A low value means that the correlation is 
relatively weak, and suggests a poor ability of the independent variables to explain the 
dependent variable. Therefore, ^  represents the percentage of the variance in the 
dependent value that can be solely attributed to the effects of the independent 
variables within the dataset analysed. By comparing different values one it can be 
determined where the model produces acceptable accuracy within the ranges of input 
values considered.
5.3. R e s u l t s
The results are now presented and discussed.
5.3.1. F ix e d  c a p i t a l  i n v e s t m e n t
Figure 5.4a and Figure 5.4b both show that total fixed capital investment (FCI) 
increases with increasing annual output. This is expected because with increasing 
annual output, processing equipment with greater capacities and greater numbers are 
clearly required. Figure 5.5a and Figure 5.5b complement these figures by 
demonstrating how behaviour in FCI is influenced by behaviour in equipment costs 
from the upstream processing (USP) and downstream processing (DSP) streams. This 
is because FCI is calculated as a linear function of equipment cost via the Lang factor 
method. Figure 5.4a shows that there are regions where the relationship between FCI 
and annual demand shows gradual progression with intermittent accelerated increases. 
These intermittent accelerated increases are seen at annual demand ranges of 100- 
125kg, 150-175kg, 225-250kg, 300-325kg, 350-375kg, and 475-500kg. Analysis 
shows that these increases are due to requirements for additional equipment. The 
need for additional equipment occurs at the upper bound of each of these ranges 
because annual demand is sampled at every 25kg. Increases in FCI outside of these 
ranges are attributable to increasing equipment sizes within commercially available
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dimensions where there is no need for increased equipment numbers. Such regions 
are seen to be 175-225kg and 375-475kg. At 175kg, 325kg, and 500kg an additional 
fermenter is added to the facility whose magnitude of expense causes an accelerated 
increase in FCI at each of these demand levels. These increases simply indicate that it 
is more expensive to increase the number of fermenter units in the production process 
than it is to host the entire volume of multiple fermenters in a single larger fermenter 
when possible. Other additional USP equipment are not required in the demand range 
considered because of the smaller process volumes that they handle. In Figure 5.5a it 
can be immediately seen that the range for DSP equipment cost is larger than that for 
USP equipment cost, and the behaviour of DSP equipment cost against demand is 
generally more abrupt than with USP equipment cost. This is due to the greater 
number of DSP operations than USP operations combined with the significant cost of 
DSP equipment units. Resultantly, potentially more equipment will have to be scaled 
in appropriate numbers to meet demand levels. Table 5.6 details which additional 
equipment is required with increasing annual demand. Additions to DSP equipment 
numbers occur at a faster rate than with USP equipment numbers because of the 
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Figure 5.4, Fixed capital investment (£MM) against annual demand for production of: (a) mammalian 
cell-culture derived monoclonal antibodies, (b) E.coli derived antibody fragments. Titre = Ig/L, yield 
= 0.6, andPb= 0.9.
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Figure 5.5. Fixed USP (----- ) and DSP (-----) equipment costs (£MM) against annual demand for: (a)
mammalian cell-culture derived monoclonal antibodies, (b) E.coli derived antibody fragments. Titre = 
Ig/L, yield = 0.6, and pb = 0.9. Equipment cost figures include all equipment required for unit 
operations and their ancillary equipment such as holding tanks.
Figure 5.4b has a very different profile to that seen in Figure 5.4a. For annual 
demands below 150kg the eapital expense for the baeterial derived manufaeture of 
antibody fragments is greater than that for the mammalian derived manufaeture of 
whole monoclonal antibodies. Figure 5.5b shows that this is due to the greater DSP 
equipment cost for the bacterial derived manufacture of antibody fragments. This is 
intuitive as the process for producing antibody fragments has a downstream process 
that is 5 operations longer than for the manufacture of whole antibodies. Thus the 
fixed capital expense will be greater at lower demands where only one equipment unit 
is required for each unit operation. At demands greater than 150kg the eapital 
expense required for the manufacture of antibody fragments is consistently lower than 
that for whole monoclonal antibodies. This crossover is explained by the 
comparatively low processing volumes seen in the baeterial derived manufacture of 
antibody fragments and how this influences the rate at which equipment additions are 
made, and hence the rate of increase of FCI. Specifically, the manufacturing process 
for antibody fragments produces 50 batches per year which is 2.5 times more than for 
the mammalian cell-based process. Hence for the same annual output, the antibody 
fragments facility has a lower output per batch and smaller process volumes per batch 
when compared to the mammalian derived whole monoclonal antibody manufacturing 
facility. Overall for bacterial derived antibody fragments manufaeture, FCI is higher 
at annual demands below 150kg because of the greater equipment numbers utilised 
when only one equipment unit is required for each unit operation in either 
manufacturing process; whilst FCI is lower above annual demands of 150kg because
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of the significantly lower rate at which equipment numbers are increased to meet the 
annual demand relative to mammalian derived whole monoclonal antibody 
manufacture. Like Figure 5.4a, regions of gradual increase are seen with regions of 
intermittent accelerated increases. Figure 5.4b has a significantly more prolonged 
initial period of gradual increase, which is the region 0-375kg. This is because within 
this range equipment sizes can be increased without exceeding commercially 
available equipment dimensions. At 400kg an ultrafiltration unit is added to the 
facility, and at 425kg an additional fermenter is added.
For the mammalian derived monoclonal antibody manufacturing process, FCI values 
bear similarity to published figures in Farid (2007), but appear to lean towards 
underestimation. Farid (2007) includes a survey of recently completed 
biopharmaceutical manufacturing facilities where FCI figures fall within the range of 
$50MM-$600MM. Understandably it is difficult to achieve a complete analysis as 
the manufacturing procedures, technical manufacturing performance metrics, and 
exact facility design are all unknown for these facilities. FCI values specifically for 
bacteria derived antibody fragments have not been found in literature.




whole monoclonal antibody manufacture
Bacteria derived
antibody fragments manufacture
125 Ultrafiltration unit -
175 Fermenter -




375 Ultrafiltration unit -




Note-. Equipment required for a level demand builds upon those required at previous levels, 
indicates that no equipment additions were made at the referenced annual demand level.
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5.3.2. Fer m e n t a t io n  a n d  c h r o m a t o g r a ph y  capacity
Figure 5.6a and Figure 5.6b demonstrate how the total fermentation and 
ehromatography capaeities scales with annual demand when all other factors are 
constant. It is observed that for mammalian derived whole monoclonal antibody 
manufacture both fermentation and ehromatography capacities are consistently 
approximately 2.5 times greater. This reflects the greater processing volumes 
required by this manufacturing process as it runs 2.5 times less batches per year when 
compared to the manufacture of bacteria derived antibody fragments. It is also seen 
that chromatography capacity scales at an increased rate for annual demands above 
200kg because of the additional chromatography units required by the facility. For 
bacteria derived antibody fragments manufaeture this relationship scales more linearly 
as there are no additions to chromatography equipment made within the range of 
annual demand values considered. In both cases fermentation capacity scales almost 
linearly with annual demand. This is expected as fermentation capacity is calculated 
as a linear fimetion of annual demand which is then rounded to match commercially 
available denominations of equipment dimensions.
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Figure 5.6. Fermentation capacity (----- ) and chromatography capacity (----- ) requirements against
annual demand for: (a) mammalian cell-culture derived monoclonal antibodies, (b) E.coli derived 
antibody fragments. Fermentation capacity is the total fermentation capacity required across all 
fermenters. Chromatography capacity is the volume o f all resins used across all chromatography unit 
operations. Titre = 1 g/L, yield = 0.6, and Pb = 0.9.
5.3.3. Fixed  in v e st m e n t  c o st  per litre
Figure 5.7a and Figure 5.7b both show that FCI/L decreases with increasing 
fermentation capacity demonstrating that there are economies of seale with FCI/L. It
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is observed that FCI with the whole monoclonal antibody manufacturing process 
building fermentation capacity is more efficient with regard to FCl/L. This is 
understandable as the output of the antibody fi-agment facility per batch is 
significantly lower than that for the whole monoclonal antibody process, and requires 
more DSP operations. For the mammalian-derived monoclonal antibody 
manufacturing process model, estimated FCI/L figures for fermentation capacities 
above 10,000L align with published values for mammalian derived whole monoclonal 
antibody manufacturing facilities. For example, work by Farid (2007) suggests that 
benchmark FCI/L values for antibody manufacturing facilities are in the range 
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Figure 5.7. Fixed capital investment per litre o f  fermentation capacity against fermentation capacity 
for: (a) mammalian derived whole monoclonal antibodies manufacture, and (b) bacteria derived 
antibody fragments manufacture. Titre = Ig/L, yield == 0.6, andPb^ 0.9.
5.3.4. C o st  of g o o d s  so l d  per g r a m
Figure 5.8a and Figure 5.8b show how COGS/g values vary with demand for both 
manufacturing processes. It is expected for COGS/g to decrease with increasing 
annual demand because relevant fixed costs are spread over a larger annual output. 
Thus, each gram becomes less expensive to produce. Additionally, if the annual 
demand is large enough then the COGS/g should converge towards a value as the 
composition of COGS/g becomes increasingly based on variable costs, such as the 
cost of raw materials, and decreasingly based on fixed costs. Some fluctuations in 
COGS/g will occur with the requirement for additional equipment items. This is 
because equipment additions can give rise to step increases in both raw materials
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costs, due to step increases in the use of consumable materials, and indirect costs, due 
to step increases in FCI and facility size. As observed in both cases COGS/g 
decreases rapidly at first, then gradually increases, and then gradually decreases. 
With the manufacture of antibody fragments this is far more marginal. Increases 
occur at annual demands of 225kg in Figure 5.8a and 425kg in Figure 5.8b which 
both accompany the addition of a fermenter which causes a step increase in FCI and 
adds significantly to indirect costs. This is because indirect costs increase with 
increasing capital expense and also with the increasing facility size required for 
accommodating additional equipment. In the manufacture of whole monoclonal 
antibodies a cation exchange chromatography column is also added at an annual 
demand of 225kg which assists in explaining why the increase in COGS/g is more 
dramatic in Figure 5.8a than in Figure 5.8b. The addition of any new equipment can 
introduce a significant step-wise increase in the use of materials, consumables, and 
utilities. This is particularly the case with chromatography columns because of the 
ancillary holding tanks and the use of expensive buffers that accompany additional 
columns.
Cost of goods figures for specific processes with specified technical details on 
manufacturing are difficult to locate in literature. Werner (2004) calculates that for a 
mammalian whole monoclonal antibody production facility where D = 250kg/yr, T = 
Ig/L, and Y = 0.7, COGS/g is $260/g or approximately £130/g. Assuming that 
Werner (2004) uses pg = 1, the model in this work estimates COGS/g = £150/g using 
these figures. Young et al. (1997) estimate that for a mammalian production process 
with an annual demand of lOOkg/yr the COGS/g range will be $300<COGS/g<$3000, 
or approximately £ 150<COGS/g<£ 1500. Even using assumptions that would have 
been optimistic at the time of that study, that is T = Ig/L, Y = 0.7, and = 1, the 
model used here estimates that COGS/g = £190/g. Model assumptions in those 
studies are likely to have different details than those found here but it has been 
demonstrated that the model estimates are within the range of those seen in Young et 
al. (1997) and Werner (2004). Comparable figures for bacteria derived production of 
antibody fragments have not been found in literature.
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Figure 5.8. COGS/g against annual demand for; (a) mammalian derived whole monoclonal antibody 
manufacture, and (b) bacteria derived antibody fragments manufacture. Titre = Ig/L, yield = 0.6, and 
Pb= 0.9.
From observing Figure 5.9a and Figure 5.9b it is elear that the cost of direct raw 
materials is by far the main driver of COGS/g, except at low levels of annual demand 
where indirect costs prevail. For both processes, the percentage comprising direct raw 
materials increases significantly from low levels of demand upwards where the rate of 
increase consistently decreases. This is because raw material costs are variable costs 
which must increase with the increased production requirements. These costs 
increase at a faster rate than indirect costs because the use of raw materials is more 
positively correlated to annual demand than FCI. Labour costs comprise the most 
modest percentage of COGS/g because amongst the type of costs considered it is the 
least correlated to annual demand. Also, the need for staffing is most correlated to the 
number of equipment units in the facility. The sharp increase in the direct raw 
materials percentage in Figure 5.9a at 225kg is primarily associated with the addition 
of a cation exchange chromatography column which uses expensive buffers. The 
accelerated increases in indirect cost percentage observed in Figure 5.9a at 125kg, 
250kg, 375kg, and 500kg are primarily associated with the addition of ultrafiltration 
units which adds to indirect costs because of considerable increases in FCI and 
facility size. The increase in the indirect costs percentage seen in Figure 5.9b at 
400kg is associated with the addition of an ultrafiltration unit.
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Figure 5.9. The percentage that direct raw materials( ), indirect costs (---- ), and labour (------)
comprise COGS/g against annual demand for: (a) mammalian derived whole monoclonal antibody 
manufacture, and (b) bacteria derived antibody fragments manufacture. Titre = Ig/L, yield = 0.6, and 
P s=0.9 .
5.4. R e s u l t s : E c o n o m i c  A p p r o x i m a t i o n s
The approximations derived from multiple regression analysis are now presented. 
The reader is reminded that these approximations take the form:
\n(X) = A + A  ln(D) + ln(T) + \n(T) + p , \n{p, ) (20)
(21)
Where units are: D -  kg, Y -  percentage, T -g /L , pb -  percentage, FCI -  £, and COGS 
-  £/g. Tables 5.7 through 5.10 give the regression coefficient, coefficients of 
determination, t-statistics, and p-values for specified ranges of annual demand. 
Region specific coefficients have been investigated so as to improve accuracy of the 
multiple regression approximation. The specified ranges have been chosen according 
to the behaviour of FCI and COGS/g against annual demand. It can be observed that 
for each region a different set of values for regression coefficients has been derived 
showing that, as expected, a ubiquitous model would be less accurate than a region 
specific model. Coefficients of determination increase with increasing annual output 
due to the less abrupt changes in the output values. Generally, high coefficients of 
determination are observed for most regions considered. The coefficients of 
determination show considerably less accuracy in the region 0kg/yr<ZK100kg/yr 
when compared to regions of higher demand for which more accurate approximations 
are derived. This is intuitive as this region is the most sensitive to changes in the
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factors considered. It is also possible that because of this, step changes in output 
values are seen towards the upper bound for the annual demand and the lower bounds 
for the remaining factors. As the level of demand increases the behaviour of FCI 
becomes increasingly less abrupt within the ranges considered. It can be seen that for 
both FCI and COGS/g, coefficients of determination are generally above 0.9 for the 
range 100kg/yr<Z)<500kg/yr. The t-statistics are generally high for all ranges of 
demand suggesting that the regression coefficients observed are statistically different 
from a coefficient value of zero. Additionally, the p-values generally indicate that the 
t-statistics are significant to at least the 0.1% level. This shows that there is at most a 
probability of 0.001 that the relevant t-statistic could be the value observed if the true 
coefficient is actually zero. These observations strongly suggest that the coefficients 
are valid for the range of demand values considered. The only exception is Pi for the 
estimation of COGS/g for antibody fragments manufacture in the range 
100kg/yr<D<500kg/yr. For this particular coefficient the p-value is only significant 
to the 10% level. While this itself does not invalidate the coefficient it does show 
that, for this range of demand values, demand has less of a statistically significant 
impact on estimating COGS/g for antibody fragments manufacture than the other 
variables considered. For FCI concerning the manufacture of mammalian cell culture 
derived whole monoclonal antibodies, the derived correlation is in the range 
100kg/yr<D<500kg/yr:
= (22)
Interestingly, as the variable exponents are all close to 1 it indicates that the FCI for 
whole monoclonal antibody manufacture is almost directly proportional to D  and 
almost inversely proportional to Y, T, and ps- For FCI concerning the bacteria derived 
antibody fragments manufacturing process, the derived correlation is in the range 
100kg/yr<D<5 OOkg/yr :
FC/ = g'3 912)0 58y-O.60^ -0.63^ -^0.69 (23)
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Table 5.7. Region specific regression coefficients, coefficients o f determination, t-statistics, and p- 
values for the approximation o f  FCI for whole monoclonal antibody manufacture.
Aimual Demand Region Po Pi P2 P3 P4 R"
coefficient 16.225 0.185 -0.253 -0.244 -0.249 0.659
Okg/yr<D< 100 kg/yr t-statistic 327.5 17.2 -5.9 -20.7 -3.7 -
p-value <0.001 <0.001 <0.001 <0.001 <0.001 -
coefficient 12.098 0.937 -0.881 -0.853 -0.922 0.933
100kg/yr<ZK350 kg/yr t-statistic 100.2 42.9 -26.0 -91.1 -17.3 -
p-value <0.001 <0.001 <0.001 <0.001 <0.001 -
coefficient 10.950 1.095 -1.101 -1.177 -1.103 0.965
3 5 Okg/yr<D<5 OOkg/yr t-statistic 21.8 13.2 -28.3 -109.5 -18.1 -
p-value <0.001 <0.001 <0.001 <0.001 <0.001 -
coefficient 11.778 0.981 -0.964 -0.974 -0.990 0.937
100kg/yr<D<5 OOkg/yr t-statistic 130.9 63.6 -31.6 -115.8 -20.7 -
p-value <0.001 <0.001 <0.001 <0.001 <0.001 -
Table 5.8. Region specific regression coefficients, coefficients o f determination, t-statistics, and p- 
values for the approximation o f  FCI for antibody fi-agment manufacture.
Annual Demand Region Po Pi P2 P3 P4
coefficient 16.975 0.061 -0.082 -0.078 -0.091 0.596
0kg/yr<TK100 kg/yr t-statistic 913.6 15.1 -5.1 -17.8 -3.6 -
p-value <0.001 <0.001 <0.001 <0.001 <0.001 -
coefficient 14.801 0.440 -0.432 -0.489 -0.485 0.799
100kg/yr<ZK3 50 kg/yr t-statistic 118.4 19.5 -12.3 -50.4 -8.8 -
p-value <0.001 <0.001 <0.001 <0.001 <0.001 -
coefficient 11.111 0.997 -0.876 -0.867 -1.032 0.921
3 5 Okg/yr<D<5 OOkg/yr t-statistic 19.1 10.4 -19.4 -69.6 -14.6 -
p-value <0.001 <0.001 <0.001 <0.001 <0.001 -
coefficient 13.905 0.578 -0.598 -0.631 -0.690 0.821
100kg/ yr<D<5 OOkg/yr t-statistic 135.3 32.8 -17.2 -65.6 -12.6 -
p-value <0.001 <0.001 <0.001 <0.001 <0.001 -
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Table 5.9. Region specific regression coefficients, coefficients o f determination, t-statistics, and p- 
values for the approximation o f COGS/g for whole monoclonal antibody manufacture.









































Table 5.10. Region specific regression coefficients, coefficients o f determination, t-statistics, and p- 
values for the approximation o f COGS/g for antibody fragment manufacture.









































The error analyses for the multiple regression approximations for mammalian-derived 
whole monoclonal antibody manufacture are seen in Figure 5.10 and Figure 5.11. It 
can be seen that the error does not exceed 0.40 for the fixed capital expenditure 
correlation. The majority of the error values are equal to or below 0.20. The 
approximation for COGS/g generally shows a more favourable margin of error, which 
does not exceed 0.20 for the vast majority of input variables considered. In Figure 
5.11 a band of increased error is seen for the range 100kg/yr<D<250 kg/yr. This is 
attributed to the step changes that accompany the need for additional process 
equipment.
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Figure 5.10. Error analysis for FCI approximation for mammalian-derived whole antibody 
manufacture. Where T =  Ig/L and /?g=0.90.
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Figure 5.11. Error analysis for COGS/g approximation for mammalian-derived whole antibody 
manufacture. Where T = Ig/L and Pb=0.90.
Analyses of the scope of error values seen for FCI approximations of bacteria-derived 
antibody fragment are demonstrated in Figure 5.12 and Figure 5.13. For the majority 
of input values for FCI approximation it can be seen that the magnitude of error is 
within 0.20. A similar behaviour in the margin of error as it varies against annual 
demand and yield is exhibited between Figure 5.10 and Figure 5.12, where there is a 
central diagonal band of relatively high error. These are attributed to the step changes 
that accompany the need for additional process equipment. The COGS/g 
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Figure 5.12. Error analysis for FCI approximation for bacteria-derived antibody fragments 
manufacture. Where T ^  Ig/L and /?b=0.90.
169






T 5 1/ 1 II
/ LZ1 § à g#J 7 X # =3i n(F&
Yield
10 25 50 75 100 125 150 175 200 225 250 275 300 325 350 375 400 425 450 475 500
Annual Demand (kg)
00%-10% E110%-20% ■20%-30%!
Figure 5.13. Error analysis for COGS/g approximation for bacteria-derived antibody fragments 
manufacture. Where Ig/L and/?s=0.90.
5.5. C o n c l u s i o n s
Approximations for the capital expense and COGS/g have been developed for 
construction of facilities for whole monoclonal antibody manufacture and antibody 
fragment manufacture. A mathematical model was developed specific to each 
manufacturing process so that the inputs of annual demand, yield, titre, and batch 
success probability could be used to generate output metrics that would be of interest 
to decision makers in the corresponding industry. It has further been shown that the 
model outputs can successfully be approximated using multiple regression analysis. 
In this study a geometric regression model was used and has been shown to produce 
acceptable levels of accuracy when compared to actual model outputs.
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C h a p t e r  6
C o m m e r c ia l  C o n s id e r a t io n s
6.1. I n t r o d u c t i o n
In previous sections the theoretical development of a computational framework for 
the stochastic, combinatorial, and multi-objective optimisation of biopharmaceutical 
portfolio management and capacity acquisition strategies has been described in full 
detail. As a reminder the framework has been set up into two broad areas: one which 
uses Monte Carlo simulation to evaluate the stochastic performance of strategies, and 
another that optimises the strategies according to pre-defined objective criteria. Here 
the focus has been on acquiring a set of computational tools that together form a 
process that is fit for the purpose described. For the framework to be transformed into 
a software tool of commercial standards and expectations the focus of development 
must be shifted towards catering for the needs of the end user. The details that need 
to be considered for such software development aims are:
■ An intuitive and aesthetically pleasing graphical user interface (GUI).
■ Definable biopharmaceutical development environment so that the user can
present an accurate computational description of the current corporate and 
technological situation to the software tool.
■ Objective criteria that can be selected by the user.
■ Fully adjustable settings for the simulation and optimisation routines such that
the robustness of the solution and the timescale for the routine can be
controlled by the user.
■ Professionally formatted output reports and datasets that are exportable for use 
with popular data analysis software packages.
■ Multi-threading options so that routines can be performed with multiple 
processors for increased efficiency.
■ An adequately descriptive help file that includes troubleshooting advice and 
aligns with the expectations of the most stringent regulatory bodies.
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The following section explores these features in further detail alongside how they are 
connected within the software architecture.










Figure 6.1. Schematic o f software architecture.
Figure 6.1 demonstrates the principal elements and interconnectivity of the software 
architecture. It is recommended that in the interests of time efficiency that the model 
is built within a single fast execution programming language such as C++, or a 
programmable environment such as Matlab™. Because of the intense computational 
requirements it is imperative that the programming language or environment provides 
fast execution speeds and multi-threading capabilities for the use of multiple 
processors. Additionally, some form of visual output for intermittent and final results 
is seen as a desirable feature for user convenience. The end users are considered to be 
but not restricted to:
■ Technical support staff and consultants of the firm issuing this software.
■ Decision-making specialists in industry.
■ Management consultants that have a biopharmaceutical focus.





■ University and business school research teams.
In each case it is expected that the user will be familiar with:
■ Biopharmaceutical manufacturing and economics.
■ Monte Carlo sampling.
■ Evolutionary computation.
■ Probabilistic modelling using Bayesian networks.
■ Data analysis techniques.
The benefit to such clients is clear. Those aiming to use the software for commercial 
insight can benefit from the data produced as well as the strategies discovered by the 
framework. Significant cost savings or profit generation can result from having an 
improved set of strategic decisions. At present, because such frameworks do not 
appear to be used in the industry it provides an opportunity for business creation by 
software developers who can also act as full service providers with employed 
consultants. Those involved in academic research can use the tool for economic 
analysis of commercial scenarios. The following sections detail the principal 
elements of the model architecture and how the software may be used in a client and 
consultant commercial relationship.
6 .2 .1 . G r a p h ic a l  U se r  I n t e r f a c e
The GUI design should be intuitive enough to facilitate rapid learning of the software 
environment as well as principal functions and settings. The GUI design features 
should include:
■ Drop-down menus that are categorised and sub categorised for ease of use.
■ Menu bars that can be docked and floated.
■ Access to all settings of the modelling environment, simulation protocols, 
optimisation protocols, and database.
■ Convenient visualisation of numerical and graphical data.
■ Data input from previous sessions.
■ Add-on functionalities which are easy to locate and use.
Drop-down menus should provide convenient access to the functionality of the 
software and assist in facilitating the speed at which users can meaningfully use the 
software as an advanced analytical tool. Additionally, sensible design of right-click 
accessible features from the mouse should be applied alongside sensible functional
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design for use of the left mouse button. An added convenience is when menu bars that 
are important to the user can be accessed by floating them temporarily or docking 
them in the standard menu bar. Access to all settings would allow for the design of a 
computational process that is fully definable by the user. This feature allows the user 
only make visual the tools that they are likely to require. The ability to conveniently 
access and visualise data inputted to the model and data produced by the model is 
very important as the model is expected to produce very large datasets. It should be 
highlighted that the software should still be able to do this while simulation and 
optimisation procedures are under execution so sufficient computational and memory 
related resources should be dynamically allocated for this. Data input from previous 
sessions would allow for a session to be stopped and restarted at some future point. 
Finally, ftirther features will undoubtedly be produced as a result of individualistic 
creation via the software design firm and may be in the form of updates, patches, and 
add-ons that provide extended specialist functionalities. All such software items must 
be straightforward to incorporate. In the case where extended functionalities are 
provided then these features need to be easily found and applied by the user once the 
installation procedure has been completed.
6.2.2. M o d e l l i n g  E n v i r o n m e n t
The modelling environment should be a flexible environment that can define any 
process pertinent to pharmaceuticals or biopharmaceuticals to include:
■ Manufacturing processes.
■ Cost databases for raw material, utilities, and staffing.
■ Commercial characteristics of drugs.
■ Dependency relationships between options made within a portfolio of drugs’.
■ Cost information on third parties.
■ Costs and transition probability data related to the drug development process.
A visual tool should be used for defining the manufacturing processes within the 
modelling environment. This procedure should use icons that represent unit 
operations and their relation within the manufacturing environment. A considerable 
range of manufacturing processes should already be provided for access within the
' See chapter 3 for more information on dependencies.
174
COMMERCIAL CONSIDERATIONS
software database. The user should be able to change any settings within the provided 
manufacturing process. Adjustable settings would include mass balancing, costing, 
and staffing information. Importantly, there should be a design feature where the user 
can define new unit operations and create bespoke manufacturing processes. All cost 
databases should be amenable for extension according to the user’s databases.
6.2.3. Simulation Protocols
The simulation protocols control what is simulated and how it is simulated. This 
should be featured as an accessible list that shows:
■ Whether an input variable is deterministic or stochastic.
■ Distribution types and numerical settings of stochastic variables.
■ The Monte Carlo sampling protocol.
The variable type and stochastic features should be easy to represent within a single 
page. The distribution types can include triangular, Gaussian, and log-Gaussian 
types. The Monte Carlo sampling protocol should include a range of advanced 
features such as stratified sampling, quasi-random Monte Carlo sampling, and 
Markov Chain Monte Carlo, for example. Simulation protocols should be executable 
independent of the optimisation protocols. This would allow for use of the software 
as a calculation tool for determining important characteristics of manufacturing 
processes and company cashflows.
6.2.4. Optimisation Protocols
User definable features of the optimisation protocols include:
Decision variables that comprise a strategic superstructure.
Instances of each decision variable.
Number of Monte Carlo samples that should be used for each strategy. 
Population size.
Objectives.
Number of top performing strategies that will be selected for probabilistic 
modelling.
Bayesian network modelling settings.
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Decision variables should be restricted to predefined types which are the drugs 
available for selection, the eorporate body that completes the activity, and the 
scheduling strategy. The remainder of the above list ean be made adjustable by 
presenting these variables as a combination of lists fi"om which options can be 
seleeted and input boxes where required numerical data can be entered. A list of pre­
defined objectives should be included with the software. Bayesian network modelling 
settings will inelude restrictions, if any, on the number of parents that a node ean have 
or if a partieular decision variable can never be modelled as being probabilistically 
influenced by another decision variable.
6.2.5. D a t a b a s e
The database will include reference items such as cost items but will also include 
information on results. Results databases will have to be segregated into the 
generation of the evolutionary eomputation proeedure by which they are generated. 
Also, the user should be able to define what is reeorded with minimal or no 
restrictions.
6.2.6. A n a l y t i c s
A reasonable range of data analyties should be included in the software package 
alongside a range of graphing options. The data should be exportable such that it can 
be used in other data analysis and graphing paekages. One important function to 
consider would be the type of analytics seen in chapter 5 where the outputs of a 
particular manufacturing process ean be modelled according to relationships derived 
by regression analysis. Provided that the use of regression relationships would fall 
within acceptable margins of error then these relationships could be used to replaee 
the need for using the computationally expensive models. Significant savings on 




6.3. Project Im plem entatio n
It would be unlikely that the software eould be sold without the need for heavy 
technical support and consultation fi’om the developer. Furthermore, it would be 
imprudent not to take advantage of opportunities to charge consultation fees for 
bespoke use of the software. This section details the process by which the software is 
intended to be used within a commercial project planning environment.
6.3.1. P h a s e  I: A n a l y s i s  o f  U s e r  R e q u ir e m e n t s
■ Consultants visit client site in order to gain an understanding of the user 
requirements and goals.
■ Elements of the tool that require bespoke modelling will be identified for 
further attention.
■ Computer hardware available at the client site will be assessed for 
compatibility with the software to be delivered.
■ A realistic timeline for project completion to include all relevant tasks will be 
proposed, negotiated, and agreed upon.
■ A contract will be agreed upon to address issues that include payment, work to 
be completed, specified users, the software license, and expiry date.
6.3.2 P h a s e  II: S y s t e m  D e s i g n  a n d  D e v e l o p m e n t
■ Consultants visit client site to determine a full bespoke list of modelling and 
simulation requirements.
■ Fully functional software designed for specific use by the client is developed 
at the developer’s site.
■ Any data that is likely to change with time is validated using the relevant 
sources.
■ All documentation is validated for accuracy.
■ The optimal hardware configuration for use with the software should be 
developed on site for expedient processing of client settings. The hardware is 
most likely to be a grid with several high-end processors to take full advantage 
of the multi-threading functionality of the software. This presents an 
opportunity for the company to charge a fee for its use.
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6.3.3. P h a s e  III: O p e r a t i o n  a n d  M a i n t e n a n c e
■ Installation of software and additional modules at client site with the relevant 
license applied.
■ Specified users will be trained.
■ Maintenance will be maintained via online means primarily and then through 
visits to the client site when necessary.
6.3.4 P r o j e c t  C o s t  A n a l y s i s
An example cost analysis is provided to give some approximate means of the 
considerations and costs to run such a project within a commercial environment. The 
assumptions apply:
■ Consultants command a rate of £1000 per day.
■ Contractually specified duties will be completed by the agreed timeline.
■ Additional services are charged on a per use basis.
■ No legal fees for the construction of the contract are applied.
■ No mark up is included for services rendered.
Phase Task Resource Cost
Phase I Client visit I consultant for I week £5,000
Phase II Client visit
Development o f bespoke features
Validation
Documentation
1 consultant for 1 week
2 consultants for 8 weeks 
1 consultant for 2 weeks





Phase III Client visit for software installation 1 consultant for 1 week £5,000
Training
Unrestricted software license
I consultant for 1 week £5,000
£10,000
Total Cost £66,000
Total Duration 16 weeks
Figure 6.2. Cost and time breakdown for an example project.
A cost analysis of an example project is shown in Figure 6.2. Additional services to 
be charged for include:
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Additional client visits for follow-on consultation in the interpretation of 
results and assessment of new or modified faeilities.
Modification of licensed software modules.
Additional software modules.
Use of developer’s hardware for expedient results.
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Ch a p t e r  7
V a l id a t io n
7.1. In t r o d u c t io n
In the biopharmaceutical industry any process that impacts the manufacture of final 
product must be validated by law according to the guidelines of the respective 
regulatory body where it will be licensed and used. The FDA provides full 
information on the validation of products and processes. Most applicable for the 
future uses of any software items based on this work are the FDA regulations for 
validation and validation protocol (Food and Drug Administration, 2007a) as well as 
software verification and validation (Food and Drug Administration, 2007b). 
Validation is defined by the FDA as establishing documented evidence which 
provides a high degree of assurance that a specific process will consistently produce a 
product meeting its pre-determined specifications and quality attributes. Validation 
protocol is defined by the FDA as a written plan stating how validation will be 
conducted, including test parameters, product characteristics, production equipment, 
and decision points on what constitutes acceptable test results. Such validation 
processes should be catered for by the software developer so that ease of validation by 
the client is facilitated. For instance, the software developer should ensure that 
documentation aligns with the most stringent expectations of all regulatory bodies and 
that no part of the software violates any regulations drafted by any regulatory body. 
Such considerations by the software developer may also have the added benefit of 
encouraging uptake of the software and associated services. Alongside being a legal 
requirement the process of validating software in the context of this work can have the 
following benefits:
■ Increased usability and reliability of the software, resulting in decreased 
failure rates, fewer recalls and corrective actions, less risk to patients and 
users, and reduced liability.
■ Protection of commercial reputation.
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■ A sensible long term approach to validation can reduce long term costs by
making it easier and less costly to reliably modify software and revalidate
software changes.
■ Increased understanding of all associated systems and processes, both virtual 
and physical.
■ Improved accuracy of modelling and optimisation procedures.
■ Ensuring the safety of manufactured therapeutics.
■ Ensuring commercially sensible decisions.
■ Encouraging the development of appropriate and demonstrable quality control 
protocols and error handling mechanisms within the software tool.
■ Galvanising the integrity o f any data produced by the software.
The remainder of this section explores the principal aspects of software validation in 
further detail.
7.2. S oftw are V er ific a tio n  a n d  V a l id a t io n
This section is based on regulations presented on software verification and validation 
by the FDA (Food and Drug Administration (2007b) where it makes specific 
references to software verification and software validation. Software verification is 
the provision of objective evidence that the design outputs of a particular phase of the 
software development life cycle will meet all of the specified requirements for that 
phase. Software verification looks for consistency, completeness, and correctness of 
the software and its supporting documentation, as it is being developed. These and 
suchlike activities will aim to provide support for the conclusion that software is 
indeed validated. Software testing is one of many verification activities intended to 
confirm that the software development output meets its input requirements. Other 
verification activities include static and dynamic analyses, inspections of codes and 
documents, and walkthroughs of the ftill function of the software. Software validation 
activities may occur both during, as well as at the end of software development to 
ensure that all requirements have been fulfilled. Since software is usually part of a 
larger hardware system, software validation will include evidence that all software 
requirements have been implemented correctly and completely, and aligns with 
hardware requirements. The conclusion that software is fully validated is highly
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dependent upon an appropriate plan, execution of software testing, inspections, and 
analyses performed at each stage of software development.
Software verification and validation in the context set out by this work can be difficult 
because model assumptions must be deemed acceptable for commercial use. In the 
worst case complex modelling of variables in the software may be required where 
more straightforward techniques were originally used. The FDA says that software 
validation is a matter of developing a level of confidence that the software meets all 
requirements and user expectations for its functions and features. The level of 
confidence, and hence the level of software validation, verification, and testing efforts 
required will also vary depending upon the safety risks imposed by the intended use 
of the software. In this case it must be assured that strategic suggestions discovered 
by the model do not lead a biopharmaceutical developer to configuring a strategy that 
is hazardous to its workers, third party associates, and ultimately the patients for 
which the biopharmaceutical therapeutics will be made.
The FDA recommends that the period over which a software product is developed, the 
software life cycle, include the following activities:
■ Quality Planning which identifies necessary tasks, procedures for anomaly 
reporting and resolution, necessary resources, and management review 
requirements, including formal design reviews.
■ System Requirements Definition which includes a rigorous definition of its 
intended use.
■ Detailed Software Requirements Specification which details the identification, 
analysis, and documentation of information about the software.
■ Software Design Specification where the software requirements specification 
is translated into a comprehensive physical representation of the software to be 
implemented.
■ Construction where the detailed design specification is implemented as source 
code.
■ Testing which entails running the software under known conditions with 




■ Installation where the software is tested for integrity during the installation 
process.
■ Operation and Support which will also include testing at the site of the user.
■ Maintenance includes corrective, perfective, and adaptive maintenance..
■ Retirement where issue of the software is ceased.
Additionally, software security should be considered so that the integrity of the 
software is immune from the impact of software viruses.
The guidelines set out by the FDA are not exhaustive and require for additional 
awareness to be applied so that software products operate as intended and do not 
generate non-obvious and significantly adverse outputs.
7.3. Reg u la tio n  of D ecisio n  Su ppo r t  System s
The FDA guidelines appear only to require strict adherence for software products that 
directly impact the operation of manufacturing systems and medical devices. The 
work presented in this thesis might be categorised as a decision support system and 
does not appear to be of current regulatory concern to the FDA. The reader is 
reminded that the scope of use of the tool is in the generation of plans for the selection 
of biopharmaceutical drug candidates, scheduling of critical activities in the 
development of drugs, and the scheduling of third party involvement. Hence, the 
translation of this work into a software tool for commercial use, with original 
intentions intact, would not affect the way in which a manufacturing process is 
operated.
Despite this, the decision support software will be expected to undergo a quality of 
software development that has an equivalent rigour to that demanded by the FDA for 
regulated software products. This is certainly understandable as corporate decisions 
of the nature covered within the scope of this work can call for the allocation of 
capital that amounts to the order of billions of US dollars. Thus, the reference data 
and the quality of routines built into the software are far from trivial. Applying the 
software development cycle and related regulations underscored by the FDA will 
facilitate the development of a software product which clients can trust. Such a
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software development eycle will also provide a solid operational foundation and 
commercial reputation upon which the developer can build further.
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C h a p t e r  8
Co n c l u s io n s  a n d  Fu t u r e  D ir e c t io n s
8.1. I n t r o d u c t i o n
Developing a cogent portfolio development strategy for biopharmaceutical 
therapeutics far in advance of execution forces the biopharmaceutical developer to 
consider:
■ The superstructure of decision variables that defines the scope of a strategy 
and its inherent decisions.
■ Strategic options that exist for the development, manufacture, and marketing 
of therapeutics with the added consideration of strategic scheduling and third 
party involvement policies.
■ Strategic objectives that indicate the theoretical success of strategic 
approaches when conducting ealeulative investigations.
■ Physical, financial, and operational requirements of developing and 
manufacturing a specific therapeutic.
■ Stochastic variables inherent in the development process, manufacture, and 
revenue expectations of specific and individual therapeutics.
■ The dependency relationships that exist between the activities for 
development, manufacture, and marketing for a group of therapeutics.
■ Control of the cost, cashflow, profitability, and probability of success for an 
entire biopharmaceutical drug development portfolio.
■ Optimisation of the strategy superstructure given specific objectives and a 
model of the drug development and marketing environment.
This thesis has addressed all of these features of strategy development and their 
associated issues in detail. It has been shown that whilst the mathematical definitions 
of decision variables ean be straightforward the result ean be that decision spaces that 
are far too large to be handled manually, or even by complete enumeration 
computationally. Strategic objectives can be numerous but understandably in 
literature NPV is the metric most widely used to assess the profitability of a project or
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strategy. As previously underscored, an extension to this approach will include 
additional objectives that cater more closely to the decision-maker’s objectives. 
Significant computational effort may be expended in assessing the probability 
distributions of objective criteria for a particular strategy especially when models are 
accurately detailed with numerous stochastic variables. Numerous strategic 
objectives will create a high dimensional objective space which cannot be easily 
visualised and where several nondominated strategic options can result. To avoid this 
situation it has been shown that a practical solution can be to take advantage of 
MCDM to combine strategic objectives into a single metric. Another demonstrated 
approach is via Pareto optimality which considers multiple objectives without 
combining them and identifies strategies that are nondominated. Whatever the set of 
strategic objectives used it is observed that optimal strategies still require the 
allocation of significant capital and operating costs. Across the strategies 
demonstrated in previous chapters it is anticipated that for a portfolio of therapeutics 
these costs can amount to the order of billions of US dollars. Finally, optimising the 
strategic options to generate optimal objective criteria values is a non-trivial process 
that in the case of non-linear criteria and a high dimensional, multi-modal objective 
space may require an intelligent search procedure, as demonstrated here.
8.2. Co n t r ib u t io n s  of t h is  T h esis
The reader is reminded that the principal aim of this work is the creation of a 
computational, intelligent, stochastic, combinatorial, and multi-objective décision- 
support framework that can optimise a strategic map fo r the year-by-year planning o f 
critical development, manufacturing, and marketing activities for an entire portfolio 
o f biopharmaceutical therapeutics, where key related findings in the development o f  
this framework will also be distilled. The development of such a framework has been 
described alongside illustrations of its intended use and the key findings of related 
investigations. The salient contributions of research chapters 2 through 7 will now be 
presented.
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8 .2 .1 . A  M u l t i-C r it e r ia  D e c is io n -M a k in g  Fr a m e w o r k  f o r  t h e  S e l e c t io n  
OF S t r a t e g ie s  f o r  A c q u i r i n g  B io p h a r m a c e u t ic a l  M a n u f a c t u r in g  
C a p a c it y
Chapter 2 takes the approach of investigating an extended set of objective criteria to 
those commonly used. The intention of this chapter was to investigate if this provided 
additional information that could be used to formulate strategies for the manufacture 
of monoclonal antibody based therapeutics. Several financial and operational criteria 
were considered to provide a broad and detailed analysis from financial and 
operational perspectives. A principal outcome of this chapter was the development of 
a décision-support framework to assist in the selection strategies for the acquisition of 
biopharmaceutical manufacturing capacity. The framework provided a structured and 
transparent method of analysing such scenarios through the utilisation of MCDM and 
Monte Carlo simulation. A hypothetical case study was formulated to demonstrate 
the usefulness and limitations of the framework.
In analysing the case study the weighted sum method proved to be highly suitable for 
data handling and for the analysis of results. The Monte Carlo simulation was 
valuable in highlighting the probability distributions and variance of base case values. 
Use of the model has highlighted that the employment of a single criterion in making 
strategic manufacturing decisions of this nature may not allow the decision maker to 
be aware of other important financial and operational criteria. However, use of 
multiple criteria analysed under uncertainty provided an approach for identifying and 
confirming the optimal strategy under consideration. The approach highlights the 
complexity that can be involved in making decisions similar to the one analysed. 
Ultimately, a thorough and accurate analysis of financial and operational data is 
essential to make confident distinctions between feasible and attractive strategic 
options.
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8 .2 .2 . A  P r o b a b i l i s t i c  M o d e l  B u i l d i n g  A p p r o a c h  f o r  t h e  S t o c h a s t i c  
O p t i m i s a t i o n  o f  B i o p h a r m a c e u t i c a l  D r u g  D e v e l o p m e n t  a n d  
C o m m e r c i a l i s a t i o n  S t r a t e g i e s
Chapter 3 takes a significant step forward from chapter 2. Chapter 2 featured a 
décision-support framework based on MCDM illustrated through a scenario analysis 
case study. Intuitively a scenario analysis based approach does not usually consider 
all possible options but can be useful for gaining detailed information about the 
fiinctionality and scope of use for a décision-support technique. The overarching 
result is the development of a computational, intelligent, stochastic, multi-objective, 
and combinatorial optimisation fi'amework to assist decision-making in strategies for 
portfolio management, clinical development, and the acquisition manufacturing 
capacity for biopharmaceutical therapeutics has been presented. Due to the 
complexity of the intended problem, techniques from artificial intelligence, in 
particular evolutionary computation and machine learning, were employed for an 
efficient search of the decision space and an effective traversing of the objective 
space. Multiple objectives were included and assessed through an extensive 
evaluative fi'amework that was considerate of principles featured in chapter 2. The 
stochastic properties of candidate strategies were evaluated by Monte Carlo 
simulation. A hypothetical case study was formulated to demonstrate the capabilities 
of the framework. This case study showed that the deeision-space presented consisted 
of 3x10'"^ possible solutions and would take in the order of 1x10 '^  ^ to evaluate the 
objective space in its entirety. This immediately highlighted the complexity of 
decisions that a drug developer may be confronted with and that optimisation 
approaches offer invaluable advantages in discovering optimal strategies over those 
that are based on scenario analysis. Also observed is that in the presence of 
dependencies biopharmaceutical product development strategies in the real world may 
be best analysed when considering entire sets of decisions holistically rather than as a 
collection of individual decisions. It was seen that, as might be expected, that the two 
objective criteria applied, mean positive NPV and p(NPV>0), are conflicting 
measures in the case study which created a nondominated fi*ont in the objective space. 
At all points along this nondominated frontier a gain in one criterion is coupled with a 
compromise in the other criterion. Additional observations included that it has been
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demonstrated that an effective strategy for portfolio development can result in a 
p(NPV>0) value that is significantly greater than the probability of successftil 
development for any singular drug in the portfolio. Hence, by considering a portfolio 
of multiple drugs it is possible to control its risk to some extent through careful 
strategic formulation, whilst this is not possible with a singular drug. Another is that 
while the use of NPV as an objective criterion is valuable many strategic approaches 
can generate similar NPV values. These strategies will often differ in the value they 
offer in other criteria giving additional opportunities for the comparison of strategic 
approaches. The learning of Bayesian networks from superior solutions presented 
here has been used for the deep datamining of the conditional and probabilistic nature 
of interactions between decision variables. This element of the optimisation 
framework has been shown to be effective and efficient in consistently improving the 
quality of strategies available in each population in regions that are not at the extreme 
of either objective. Their effectiveness in these regions is presumed to be due to 
their ability to iteratively learn and exploit the structure of the problem as noted by 
contributions in artificial intelligence literature. At the extreme of either objective the 
performance above random search needs to be further investigated to establish 
whether the negligible performance improvement is due to limitations inherent to the 
problem or to the algorithm. A noteworthy insight from using the framework is that 
use of machine learning has potential for future development in solving portfolio 
development and manufacturing capacity planning problems simultaneously.
8 .2 .3  S t r a t e g i c  B i o p h a r m a c e u t i c a l  P o r t f o l i o  D e v e lo p m e n t :  A n
A n a l y s is  o f  C o n s t r a i n t  In d u c e d  Im p l ic a t io n s  o n  S t r a t e g ie s
Chapter 4 extended the use of the framework presented in chapter 3 by using it to 
analyse the impact of the size of the drug development portfolio and cashflow 
constraints on the discovery nondominated strategies. Analyses included a five drug 
portfolio and a three drug portfolio, as well as the application of a range of cash flow 
constraints. Again, mean positive NPV and p(NPV>0) were selected as the objective 
criteria. It was seen that the introduction of cash flow constraints can lead to a 
reduction in the expected rewards or probability of success of a strategy. The 
reduction in portfolio size from five drugs to three drugs produces the same mean 
positive NPV range but results in a significant reduction in p(NPV>0). Finally, the
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timing and third party strategies for each size of portfolio are very different showing 
that the size of the portfolio can have a specific impact on how the entire portfolio 
should be developed and commercialised regardless of how much capital is available. 
This signals to the decision maker that it may not be appropriate to apply the same 
development strategies to portfolios of different sizes.
8 .2 .4  Ec o n o m ic  C o r r e l a t io n s  f o r  W h o l e  M o n o c l o n a l  A n t i b o d y  
M a n u f a c t u r e  a n d  A n t ib o d y  Fr a g m e n t s  M a n u f a c t u r e
Chapter 5 extends the use of the manufacturing models seen in chapters 2, 3, and 4 by 
investigating whether reliable approximations to the computationally intense 
manufacturing models can be derived. The principal benefits of this include building 
computationally efficient modelling procedures and straightforward formulas that 
accurately estimate the economics of manufacture for biopharmaceutical developers 
requiring preliminary figures. In addition to the mathematical model for the 
mammalian manufacture of whole monoclonal antibodies, a mathematical model for 
the bacterial manufacture of antibody fragments was also developed. Multiple 
geometric regression was the chosen procedure for learning approximations. 
Approximations for fixed capital investment and COGS/g were developed for the 
construction of facilities for mammalian derived whole monoclonal antibody 
manufacture and bacteria derived antibody fragment manufacture. The inputs to each 
model were annual demand, yield, titre, and batch success probability. These could 
be used to generate output metrics that would be of interest to decision makers in the 
corresponding industry. It has further been shown that the model outputs can 
successfully be approximated using regression analysis techniques. In this study 
approximations were shown to produce acceptable levels of accuracy when compared 
to actual model outputs with results falling mostly within a 30% margin of error.
8 .2 .5 . C o m m e r c ia l  C o n s i d e r a t i o n s  f o r  t h e  D e v e l o p m e n t  o f  a  
S t o c h a s t ic  C o m b in a t o r ia l  M u l t i-O b je c t iv e  O p t im is a t io n  Fr a m e w o r k  
FOR B io p h a r m a c e u t ic a l  P o r t f o l io  M a n a g e m e n t  s t r a t e g ie s
Chapter 6 demonstrated that the fi-ameworks presented in this thesis can be translated 
into a commercial software tool as part of a viable consultancy business. The
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software architecture was detailed alongside examples of end users that may have a 
reasonable propensity for using it. An example of how a business eould be 
constructed for use of the software was described alongside cost breakdown and 
project duration details.
8 .2 .6 . V a l i d a t i o n
Software validation protocols were discussed in chapter 7. It was seen that 
regulations concerning software validation were not applicable for the type of 
software that would be developed as a direct translation of this work into a 
commercial software tool. Despite this it is certainly within the interests of the 
service provider of such software to follow equivalent validation protocols to software 
products regulated by stringent authorities such as the FDA. Engaging in activities 
like these is likely to galvanise client confidence and improve the quality of outcomes 
following decisions.
8.3 R e c o m m e n d a t i o n s  f o r  F u t u r e  W o r k
Within the context of the strategic development and manufacture of a portfolio of 
biopharmaceutical drugs, the recommendations for future work presented here will 
aim to extend the use of:
■ Probabilistic model-building genetic algorithms.
■ Computing resources.
■ Problem features.
This section addresses immediate opportunities for fixture investigations that possess 
the capacity to greatly enhance the breadth and calibre of the methods and insights 
provided by this thesis. With principal regard to commercial considerations, these 
improvements can lead to improvements in the:
■ Range of addressed problems.
■ Efficiency by which solutions to problems are acquired.
■ Functionality and performance of the commercial software.
■ Scope and quality of the business proposition.
■ Reputation of the service provider as held by regulatory bodies and clients.
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These improvements may also require lengthier development and validation periods, 
and may necessitate expensive hardware specifications for enhanced performance.
8.3 .1 . Ex t e n d in g  t h e  P r o b a b il is t ic  M o d e l -B u i l d i n g  G e n e t ic  A l g o r it h m
Improvements in the features provided by the algorithms used in this work can 
enhance their capabilities and efficiency concerning the type of problems approached 
in this work. Such improvements may also enhance the quality of results obtained in 
more difficult problems.
In the EDA used in chapters 3 and 4 it was taken that mutation operators seen in 
conventional genetic algorithms were not required because the random sampling of 
learned Bayesian networks based on superior performing strategies was taken to 
provide an equivalent function. Although it has been shown that the EDA used here 
works on the example cases seen, opportunities for increasing the rate at which 
nondominated solutions are discovered have been considered. One approach is to 
induce a random point mutation on a given strategy after its evaluation and then re­
evaluate the mutated strategy. If the mutant strategy yields an improvement in at least 
one criterion and no degradation in any other criterion then it will replace its original 
in the population. This approach assumes that is possible for an improvement to be 
yielded from a mutation in a single decision variable. Mutations may also be applied 
to in a similar manner to multiple decision variables. Sastry et al. (2004) take an 
alternative approach. As described earlier building blocks can be considered as a set 
of instances of decision variables that work together to support the performance of 
candidate solutions in the objective space. Their approach is to explicitly identify 
building blocks within a population using marginal product models. Marginal product 
models are partitions of the decision making superstructure that group together highly 
correlated decision variables. An enumerative greedy search procedure is run on each 
marginal product model with the original configuration being the top performing 
candidate in a population. Once this process is complete, the most beneficial 
instances of each marginal product model are used for the induction of point 
mutations. The first approach is obviously simpler than that taken by Sastry et al. 
(2004). Their approach assumes that mutations are more effective when considered
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as the mutation of a building block rather than of an individual decision variable. It 
should be noted that it is possible for a single decision variable to constitute an 
individual though simplistic building block. The advantage of this approach over 
blind random mutations is that it further decomposes and exploits the structure of the 
problem to enhance the efficiency of the optimisation procedure.
The EDA used earlier in this work dynamically clustered the objective space into 
three partitions from which separate Bayesian network models could be learned. A 
method of automating the number of clusters that are identified has not been found in 
literature. Increasing the number of clusters will increase the specificity by which 
superior performing solutions are modelled. In so doing, the nondominated front in 
the objective space can be maintained more effectively and more confidence can be 
held in the quality of the nondominated front produced at the final generation. 
Investigating the impact of the number of clusters on the quality of the nondominated 
front at the final generation will require a supervised approach where increased 
partitioning is used until no improvement in the quality of the nondominated front can 
be observed.
The size of the population is important in allowing for the opportunity for superior 
strategies to be discovered. In larger populations it can be considered that a greater 
probability exists for the discovery of superior strategies. But for sufficiently large 
population sizes this opportunity does not inevitably increase with every larger 
population. Thus choosing a population size that is too large can expend time and 
computational resources unnecessarily. A procedure for automating the population 
size has been reported by Pelikan and Lin (2004). Here, two population sizes are 
maintained with one being twice the size of the other. Because increased 
opportunities for discovering superior solutions are provided by the larger population 
they propose that it is expected for the average performance of the larger population 
to be greater than that of the smaller population. If this holds true when executing the 
procedure then in the next generation the larger population becomes the smaller 
population and the new larger population is again twice the size of this smaller 
population. This continues until the average performance of each populations become 
equivalent. From here onwards the smaller population is maintained. One variant of 
this technique proposed here is to compare the average performance of only the set of
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top performing strategies identified for selection, as this specifically targets the 
quality of superior strategies.
Improvements to the way Bayesian networks are constructed can also be investigated. 
In chapter 3 it was described that decision variables were time ordered so that earlier 
decisions could not be conditionally and probabilistically dependent on decisions to 
be executed later in the development schedule. It is recognised that it may be possible 
for a strategic decision that must be executed earlier to be made in preparation for a 
sufficiently important strategic decision that must be exercised later. The impact of 
relaxing this original topological constraint can be investigated. Another 
improvement that can be made to the procedure for constructing Bayesian networks is 
the added learning of local structure as reported by Pelikan (2005). Here highly 
correlated decision variables are algorithmically discovered and grouped together then 
treated as singular decision variables, which can improve the time in which Bayesian 
networks are learned as the nodes in the network are effectively reduced. For further 
information on the construction and evaluation of Bayesian networks with local 
structure see Chickering et al. (1997), Friedman and Goldszmidt (1999), and Pelikan 
and Goldberg (2001).
Performance evaluation of each strategic option can be computationally expensive 
and is the rate limiting factor in the running of the EDA used here. By applying 
acceptable performance estimation techniques there can be significant time savings in 
the execution of the algorithm. The first recommendation will require the estimation 
of the manufacturing model outputs, as seen in chapter 5. Such an approach will 
involve regression based modelling of the relationships between inputs and outputs of 
the mathematical model. The first step would be to decide the range of values upon 
which the regression technique will be performed and the boundary of error that all 
estimates must fall within. The inputs would have to be split into multi-dimensional 
regions for region specific regression modelling until all model coefficients yielded 
regression models that yield acceptable error margins. Depending on the complexity 
of the model this can be time consuming. It is also possible that user defined error 
margins will never be met in all instances. The end result would be a database of 
region specific coefficients that can be used within the same form of regression model 
which can be used as long as the original mathematical model is not updated. When
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referenced, the calculation procedure would need to search for the correct coefficients 
and then use then in the estimation formula. This is more efficient than the vast 
number of calculations required for deriving a singular performance output in the full 
mathematical model. This search and then calculate approach must be repeated for 
each Monte Carlo iteration. An alternative approach ean be seen in Pelikan and 
Sastry (2004) and Sastry et al. (2004). Both use Bayesian networks as a tool for 
estimating the key performance metrics of a strategy. As performance evaluations are 
conducted they are added to a permanent database. When Bayesian network models 
are built fi’om each population a model of how a performance metric varies according 
to the conditional relationships described by the Bayesian network is also built using 
this permanent database as a reference for the required performance data. These 
models are analogous to the conditional probability tables associated with Bayesian 
networks except that a performance metric is used instead. These models also use a 
linear estimation scheme. It can be seen that with this approach it may be possible to 
estimate the required data about an entire probability distribution of the performance 
of a strategy without the need for Monte Carlo sampling and is likely to be one of the 
most promising techniques for this purpose. Non-linear estimation schemes may 
certainly be applicable but none applied to this specific purpose have been seen in 
literature. Classification methods in machine learning literature such as neural 
networks may provide a suitable non-linear estimation technique for this purpose.
Alternatives to the EDA approach can be explored as viable core applications to the 
large-scale multi-objective combinatorial optimisation problems seen here and there 
are a vast number of methods to be considered. Such examples include GRASP 
(Pitsoulis and Resende, 2002), local search methods (Aarts and Lenstra, 2003) such as 
reactive search (Battiti, 1996) and tabu search (Glover and Laguna, 1997), annealing 
methods such as simulated annealing (Kirkpatrick et al. 1983) or quantum annealing 
(Das and Chakrabarti, 2005), and swarm intelligence methods such as ant colony 
optimisation (Dorigo et a l, 1992) and particle swarm optimisation (Eberhart and 
Kennedy, 1995). It is important to note that there is no single optimal optimisation 
method and that different methods may be better suited some types of problem than to 
others. For this reason it may be most useful to view an optimisation method in terms 
of the features it possesses and comparing those to features that would be necessary 
and desirable for approaching a particular problem. Of course, it is always
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worthwhile exploring whether the unique strengths of some of these methods may be 
combined to create enhanced combinatorial optimisation algorithms. For example 
local search methods or annealing methods could be coupled with the EDA as a fine- 
tuning secondary search process to find non-dominated solutions within clusters of 
the objective space. GRASP operates on a similar principle. Reactive search 
methods also have the advantage of automatically fine-tuning algorithm parameters 
during the optimisation process, which could be a worthwhile feature to incorporate 
into the EDA. Another example is methods that utilise memory of the search process 
so far. Tabu search memorises which candidate solutions have already been visited so 
that they cannot be revisited and can include rules that the restrict formulation of 
candidate solutions with undesirable features. Swarm intelligence methods retain 
knowledge of current optimal solutions and use that information to influence the 
formulation of candidate solutions. Whilst the EDA uses probabilistic models to 
model superior candidate solutions it does not retain a specific memory of current 
optimal solutions so as to have a direct impact on the formulation of other solutions, 
so incorporating memory retainment features could prove advantageous. Also from 
the reverse perspective, many other relevant methods do not have the facility for 
acquiring detailed knowledge of the broad structure of the problem or specific 
advantageous building blocks of decisions as featured by the EDA approach. Overall, 
it is important to remember that there is typically a trade-off to be made when making 
enhancements of these natures, which may be in the form of programming 
complexity, computational requirements, or execution time. More importantly 
because these methods incorporate some set of heuristics it is usefiil to know which 
features are significantly advantageous to the problem. This may itself necessitate a 
process of trial-and-error.
8 .3 .2 . C o m p u t i n g  R e s o u r c e s
Computing resources offer significant opportunity for increasing the time efficiency 
by which results are obtained. The recommendations offered here cover the use of 
fast programming languages and parallel computing.
It is fully recommended that the model be exported in its entirety to a single, fast 
execution programming language, such as C++. Parts of the model presented in this
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thesis have been implemented in MS Exeel and VBA which is convenient for the 
visualisation and manipulation of data but is widely known to be much slower than
C + + .
Multi-threaded computing offers one of the greatest opportunities for increases in 
time efficiency depending on the number of computer processors that are available. 
Here each processor is assigned a task that can be completed in parallel with other 
tasks. An example of such a task is the performance evaluation of a population of 
strategies. If enough processors exist then the performance evaluation of each 
strategy can be individually assigned to a processor. In the model formulated 
previously the population size was 1000 strategies so if 1000 processors can be 
utilised then an improvement in time efficiency by a factor close to 1000 should be 
observed.
8 .3 .3 . P r o b l e m  Fe a t u r e s
The types of problems that can be considered for further exploration will now be 
addressed.
In chapter 4 two portfolio sizes were considered: a three drug portfolio and a five drug 
portfolio. Wider ranges of portfolio sizes and cash flow constraints can be 
investigated to study further their impact on the types of strategies produced by the 
framework.
Flexible portfolio sizing was not included as a possible feature of the decision making 
process because the impact of portfolio size was of specific concern. However, this 
feature is relevant to the types of problems investigated. For a given decision making 
scenario in the model future investigations should include the possibility for the 
decision maker to find the optimal size of drug development portfolio within the 
boundaries of resource constraints. In addition to the constraints seen, time 
constraints should be added so that solutions found by the optimisation algorithm fall 
within a specified time of completion for development and marketing.
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Additional drug types and their respective manufacturing routes should be considered. 
For example, antibody fragment therapeutics should be considered in the list of 
candidates. Also, disposable manufacturing routes could also be featured.
Variable initial scenarios of drugs in the model can give novel insight into the best 
strategic options when therapeutics are already undergoing the clinical trial process. 
Also, a model that determines the impact of competitor activity on the size of markets 
can be an additional feature.
Adding market competition as an additional consideration may influence portfolio 
construction towards markets that are less populated and increase pressure to 
complete drug development expediently.
Assumptions about manufacturing capabilities can be investigated. Based on 
historical developments and specific knowledge about the limitations of 
manufacturing technologies, the expected rate of improvements in titres and yields 
may be included as fiinctions rather than point values. This would effectively provide 
some incentive to developing drugs later rather than sooner because of the economic 
benefits of more favourable titres and yield.
The objectives seen in chapters 3 and 4 can be extended. For example for purposes of 
investigating the scope of the objective space p(NPV>0) was used as an objective 
criterion. This could be modified to p(NPV>jc) where the decision-maker is seeking a 
minimum acceptable level of NPV. This can also be further extended to p(NPV>x)>j 
where the decision-maker is seeking minimum acceptable levels of both profit and 
probability of success. For reasons of simplicity and transparency of results most of 
the objectives featured in chapter 2 were not used in the optimisation method featured 
in chapters 3 and 4. Further work should seek for a way to incorporate these.
Finally, the correlations developed in chapter 5 can be extended to include 
prospective titre and yield values in industry.
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Table A.I. Probabilities o f drug selection for a five drug portfolio.
Unconstrained -$200MM -SIOOMM
Drug 1 F(0.82,M,M) F(0.59,M,M) G(0.61,L,M)
Drug 2 C(0.32,M,M) C(0.35,M,L) ^(0.37,H,M)
Cluster 1 Drug 3 5(0.28,H,L) ^(0.36,H,L) F(0.45,M,M)
Drug 4 ^(0.25,H,L) J(0.34,H,H) 5(0.34,H,L)
Drug 5 J(0.36,H,H) (7(0.35,L,M) D(0.28,L,M)
Drug 1 F(0.44,M,M) F(1.00,M,M) //(0.47,M ,H)
Drug 2 D(0.29,L,M) C(0.31,M,L) D(0.32,L,M)
Cluster 2 Drug 3 5(0.47,H,L) E(0.29,H,M) F(0.48,M,M)
Drug 4 ^(0.22,H,L) D(0.30,L,M) 5(0.46,H,L)
Drug 5 E(0.24,H,M) //(0.34,M ,H) G(0.34,L,M)
Drug 1 F(0.86,M,M) F(1.00,M,M) D(0.63,L,M)
Drug 2 ^(0.25,H,L) G(0.28,M,L) E(0.48,H,M)
Cluster 3 Drug 3 J(0.74,H,H) D(0.24,H,L) C(0.55,M,L)
Drug 4 5(0.25,H,L) J(0.43,H,H) //(0.40,M ,H)
Drug 5 H(0.56,M,H) //(0.50,M ,H) F(0.48,M,M)
Note: The letter preceding the bracket indicates the most probable drug. The first term within the 
bracket is the probability by which the selection o f  the corresponding drug is observed within its 
cluster. The second inside the bracket is the demand level o f the drug where: L -  low demand, M -  
medium demand, and H -  high demand. The third term is the compound annual growth rate o f  the 
drug where: L -  low demand, M -  medium demand, and H -  high demand.
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Table A.2. Probabilities o f drug selection for a three drug portfolio.
Unconstrained -SIOOMM -S75MM
Drug 1 F(0.70,M,M) F(0.99,M,M) F(0.71,M,M)
Cluster 1 Drug 2 5(0.28,H,L) C(0.19,M,L) £(0.19,H,M)
Drug 3 7(0.34,L,H) W(0.19,H,L) D(0.23,L,M)
Drug 1 F(0.65,M,M) F(1.00,M,M) F(0.30,M,M)
Cluster 2 Drug 2 5(0.30,H,L) 77(0.26,M,L) ^(0.30,H,L)
Drug 3 ^(0.53,H,L) 7(0.34,H,L) J(0.32,H,H)
Drug 1 C(0.63,M,L) C(0.28,M,L) v4(0.65,H,L)
Cluster 3 Drug 2 E(0.32,H,M) G(0.25,L,M) 7(0.26,L,H)
Drug 3 ^(0.86,H,H) ^(0.24,H,L) C(0.42,M,L)
Note: The letter preceding the bracket indicates the most probable drug. The first term within the 
bracket is the probability by which the selection o f the corresponding drug is observed within its 
cluster. The second inside the bracket is the demand level o f the drug where; L -  low demand, M -  
medium demand, and H -  high demand. The third term is the compound annual growth rate o f  the 
drug where: L -  low demand, M medium demand, and H -  high demand.
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B . l  I n o c u l u m
The inoculum step is the first stage in upstream processing to cultivate product 
producing cells to the required cell concentration so that the product can be produced 
in its required quantity. This cell culture step is achieved in flasks. The equipment 
sizing equations for this step are as follows:
lOOOTTw^ pg
(B.2)^  f la s k i k _V
f la s k
where the subscript inc specifies reference to the inoculum step, Vine ~ processing 
volume (L), D -  annual output of the facility (kg), T -  product titre in the fermentation 
broth (kg/L), Y -  product yield achieved after downstream processing, riB -  number of 
batch cycles that take place in one year, ps  - probability that a fermentation batch is 
run successfully, njjask ~ number of flasks required, Vjiask -  flask volume taken as 0.5L, 
The function seen above, [x], is the ceiling function that is the nearest integer greater 
than %. riB is taken as 20 batches/year for the whole monoclonal antibody 
manufacture, and 50 batches/year for antibody fragment manufacture.
Cost relationships:
^ E Q P ,in c  -  ^ f la s k  ^ f l a s k  (B.3)
^ D R M M c  ~  ^  m ed ia  I L ^ f l a s k ^ f l a s k  ^ i n c ^ i n d ^ ^  C IP  / L  (B.4)
P,W.inc = (B.5)
^  L B R ,in c  ^  s ta f f  ! hr  ^s ta f f  , in c ^  inc  (B.6)
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^ O P R J n c  ~ ^ D R M , i n c  ^ D U , i n c  ^ L B R , i n c  ( B - 8 )
where Einc -  total equipment cost, Edrmmc ~ direct raw materials cost, Eoujnc ~ direct 
utilities cost, E c i p / l  -  clean-in-place buffer cost per litre, E w f i / l  -  water for injection 
cost per litre, Esteam/i -  steam cost per litre, Ecw/l ~ cooling water cost per litre, EiBR.mc 
- total labour cost, Estaff/hr -  cost of technical staff assumed to be, ristaff -  number of 
technical staff assigned, -  number of inoculum operations required, and -  total 
processing time is taken as 346 hours for mammalian processes and 30 hours for 
bacterial processes to include operation and necessary cleaning cycles. The constants 
in equations (B.4 and (B.5 represent the volume of component required relative to the 
volume of inoculum used for CIP and SIP operations. The value of expense items that 
are constant are listed in Table B.l.








Sources: a -  personal communication with researchers at the ACBE, UCL (2004); b -  Farid (2001)
B.2 S eed  ferm entatio n
The seed fermentation steps ramp up cell concentration in small fermenters before 
being transferred to the commercial scale fermenter where the product is produced in 
crude form. This procedure is modeled as two steps in series thus at least two seed 
fermenters are required for this process. The first seed fermenter processes one- 
hundredth of the volume processed by the commercial scale fermenter, whilst the 
second hosts one tenth of this volume. Thus, the volume is scaled up by a factor of 10 
for each operation when progressing from seed fermentation to commercial scale 
fermentation.
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Equipment sizing equations:
K/II,  io o tT h jjP j




where the subseript sf, sf\, and sfl, respectively denote reference to any seed 
fermentation step, the first seed fermentation step, and the second seed fermentation 
step. Additionally, Vsf,b -  processing volume for seed fermentation (L), -  smallest
denomination of seed fermenter volume available. Vs/ -  commercial size of fermenter 
volume required, and q -  space efficiency factor taken as 0.75 which is used 
ubiquitously across the mathematical model. Vsf,max and Vsf,d are respectively taken as 
20,000L and 1,000L.
Mass balance equations:
= Z  (B. 12)
where mi sf,media -  mass of media inflow to be added to the seed fermentation operation 
(kg), Vsfx,b -  volume of stream component jc in the process volume of the seed 
fermenter, -  density of stream component x, and rrio,sf -  total mass outflow to 
fermenter (kg). At this stage, the densities of stream components are all assumed to 
be Ikg/L.
Cost relationships:
^EQP,sf -  ^sf^sf (B. 1 3)
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^ D R M , s f  “  ^ m e d i a l L ^ s f ^ s f  ^ s f ^ s f i ^ ^ C I P / L  (B.14)
^ D U , s f  ~ 0 - ^ ^ s t e a m / L  c w ! i W s f ^ s f  (B.15)
^ L B R , s f  ~ ^ s ta f f/hr s^ t a f f , s f ^ s f  (B .l6)
"* "^ "“ " { 3  otherwise
O^PRJnc ~ L^BR,inc '^ ^DRMJnc (B.l 8)
where EEQp,sf- total equipment eost, E d r m . s / -  direet raw materials cost, Eou.sf- direct 
utilities cost, E c i p / l , s f -  clean-in-plaee buffer eost per litre, ^p^y/Æ.^-water for injection 
eost per litre, Esteam/i -  steam eost per litre, Ecw/i -  cooling water cost per litre, E l b r , s / -  
total labour eost, Estaff/hr -  cost of technical staff per hour, ristaff -  number of technical 
staff assigned, and tsf -  total processing time. For whole monoclonal antibody 
manufacture 4/ is taken as 346 hours and for antibody fragment manufacture 4/ is 
taken as 144, which includes the time taken for the necessary cleaning cycles.
B.3 F e r m e n t a t i o n
In fermentation substrates such as media undergo biochemical reactions, resulting in 
cell growth and product formation, which in the cases considered are whole 
monoclonal antibodies and monoclonal antibody fragments. The whole manufacture 
of monoclonal antibodies usually relies on a mammalian eulture expression system 
such as Chinese hamster ovary (CHO) cells. The manufacture of antibody fragments 
is achieved by bacterial fermentation in organisms such as E. coli.
The equipment sizing equations are;
T Y n.p ,
rif =
^ f =
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where the subscript/ denotes reference to fermentation, Vf^ b -  volume of fermentation
broth used (L), D -  annual output of the facility (kg), T -  product titre in the
fermentation broth (kg/L), Y -  product yield achieved after downstream processing, tib 
-  number of batch cycles that take place in one year, ps - probability that a batch is 
run successfully, rif -  number of fermentation units required, Vf^ max -  maximum 
volume of fermenter available, Vfj ~ smallest denomination of fermenter volume 
available, and Vf commercial size of fermenter volume required.
The mass inflow equations are as follows:
%
A  -  m ,j (B.22)
« (./.c*  = (B.23)
(B.24)
where mi_f media -  media mass inflow to fermenter (kg), rrioj -  mass outflow from 
fermenter, mif -  mass inflow to fermenter, niij^ ceiis -  cell mass inflow to fermenter 
(kg), Vf^ x.b -  volume of stream component jc in the process volume of the fermenter, 
-  product mass inflow to fermenter, p f -  density of fermentation broth.
The mass outflow equations are:




^  i , f ,m e d ia  ^  p r o d
where moj,media -  media mass outflow to fermenter (kg), moj,ceiis -  cell mass outflow to 
fermenter (kg), j  is the stoichiometric ratio of the corresponding substance in the 
fermentation reaction and r is the reaction extent. It is assumed here that Sceiis ^  0.5, 
Smedia = -15, and Sprod = 0.5. Here, mass stoichiometry and the extent of reaction were
2 2 2
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used to describe the relationship between substrate consumption and product 
formation. Intuitively, the stoichiometric coefficients used in the model were 
negative for the media, which contains the substrate, and positive for product and 
cells.
The cost relationships are:
E e q p j  =  (83011n(K;) - 14889)»/ (B.28)
^ D R M J  ~ ^  m e d ia l  L ^ i J , m e d i a  ^ CIP IL  '^'^^WFUl) (B.29)
^ D U J  ~ 0 s te a m !L  l W f  (B.30)
^LBRJ -  ^  s ta f f  I hr^ s ta f f  f  (B.31)
F2 » . < 3
"'"•^•^"13 otherwise
^OPRJ ~ ^EQPJ "*■ ^ DRMJ ^LBRJ (B.33)
where Ef -  total equipment cost, E d r m j  -  direct raw materials cost, Eou,f ~  direct 
utilities cost, E c i p / l / -  clean-in-place buffer cost per litre, EfVFi/L/-wsdQT for injection 
cost per litre, E s te a m / i  -  steam cost per litre, E c w / l  ~  cooling water cost per litre, E l b r j -  
total labour cost, Estaff/hr -  cost of technical staff per hour, ristaff -  number of technical 
staff assigned, and // -  total processing time for fermentation. For whole monoclonal 
antibody manufacture t/ is taken as 346 hours and for antibody fragment manufacture 
tf is taken as 144, which includes the time taken for the necessary cleaning cycles. 
The cost relationship E/ is derived from a logarithmic regression fit for the price of 
fermenters over a range of volumes (Figure B.l). It was found that this type of 
regression was able to explain the fermenter size and price data most accurately. 
Using the geometric capital size and cost relationship seen in Equation 5.1 may very 
well be inappropriate in this ease. This is because selecting an appropriate reference 
fermenter to make an estimate from is difficult. This is illustrated in Table B.2. It can 
be observed that using the 300L or lOOOL fermenter as a reference results in gross 
overestimation of the 15000L fermenter. Also, use of the 15,000L fermenter as a 
reference results in significant underestimation of the 300L and lOOOL fermenters. It 
can also be seen that using the logarithmic relationship derived fi-om Figure B.l
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Figure B .l. Cost versus volume for a fermenter. A logarithmic regression fit to the data is also shown 
where J(x) = 732541n(jc) -  64605, and correlation coefficient is 0.9002. Data source; Personal 
discussion with C.Osborn at the ACBE, UCL (2004), and Jacobs (2006).
Table B.2. Comparison o f predictors for fermenter costs.
Fermenter Size (L) Actual 300L lOOOL 1500L 732541n(x) -  64605
lOOL £301282 £144839 £123082 £31166 £272742
300L £280000 £280000 £237941 £60250 £353220
lOOOL £490000 £576614 £490000 £124075 £441416
2000L £498066 £873984 £742701 £188063 £492192
15000L £630000 £2927791 £2488003 £630000 £639791
Note: The column labelled ‘Actual’ denotes the actual price o f each specified fermenter. Columns 
labelled ‘300L’, ‘lOOOL’, and ‘1500L’ refer to the estimated fermenter costs when these fermenter 
sizes are used as the base reference, or Size; and Cost;, in equation 5.1. The column labelled 
‘732541n(x) -  64605’denotes to the estimated fermenter costs when this relationship is used. Data 
source: Personal discussion with C.Osbom at the ACBE, UCL (2004).
B.4 U ltr a filtratio n
It is assumed that for the intended range of inputs that the use of one ultrafiltration 
unit is sufficient.
Relationships for the mass balance are:
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^ p e r m , x , u f  ~  ^ i , x , u f  ^ r e t , x , u f (B.36)
y  _ y^ I"dsp 
^ u f  -  ^ (B J7)
where the subseript u f  denotes belonging to the ultrafiltration unit, mret,x -  mass of 
stream component x  in the retentate, mi^x.uf- the mass inflow of stream component x, 
Fc -  the concentration factor, Cr,x -  rejection coefficient for stream component x, and 
Yuf -  yield of the ultrafiltration unit, udsp -  number of downstream processing units 
have non-negligible effects on the mass of product in the stream. The values for 
Cr,media, Qce/k, aud Cr,buffer arc respcctivcly taken as 0,1, and 0.
Relationships for processing time are:
i^,uf
^  c y c le ,u f
' l _ l l
F c ) (B.38)
K f  ~ ( . ^ C I P , u f  ^ c y c l e , u f ) ^ c y c l e , u f  (B.39)
where tcycle - cycle time, V^uf- volume inflow to the ultrafiltration unit, average 
flux taken to be lOOL/m^/hr, ^ « /-  total membrane area, «„ /- number of ultrafiltration 
units, tcip.uf- CIP completion time, and ricyde.uf- number of cycles.
Table B.3. Relevant equipment priee data for the ultrafiltration process.
Item Cost
Ultrafiltration rig £37,500
Filter cartridge, Auf= 0.93m^ £883
Filter cartridge, Auf= 1.9m^ £1763
Filter cartridge, Auf^ 3.7m^ £3228
Source: Millipore.
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T h e  p r ic e s  o f  r e q u ir e d  h o ld in g  ta n k s  w e re  b a s e d  o n  a  l in e a r  re g re s s io n  f i t  to  p r ic e s  o f  
a v a ila b le  d a ta  (T a b le  B .3 ) , w h ic h  p r o d u c e d  th e  re la tio n s h ip :
= 7 2 5 4 9
y
r e t ,u f
h t ,d
+ 1 1 3 7 .3  (B .4 0 )
w h e re  th e  s u b s c r ip t  ht d e n o te s  re fe re n c e  to  th e  h o ld in g  ta n k , Vret.uf- v o lu m e  o f  th e  
r e te n ta te , a n d  Vht,d -  s m a lle s t  d e n o m in a t io n  o f  h o ld in g  ta n k  s iz e  a v a ila b le . T h e  
r e la te d  c o s t  re la t io n s h ip s  a re :
^EQP,uf ~  ^ ht,ret,uf '^^rig,uf (B .4 1 )
^DRM,uf -^ht,ret,u f^ht,ret,uf(^C IP/L  (B .4 2 )
y, ^
^DU,uf ~  ^filter,uf^filter,uf ~~ ^filter,tf (B .4 3 )
^filter,uf
^  LBR,uf ~  ^  staff ! hr^ staff ,uf^ uf (B .4 4 )
^staff,uf =  2  (B .4 5 )
^OPR,uf ~  ^DU,uf +  ^DRM,uf +  ^LBR,uf (B .4 6 )
w h e re  E e q p . u / -  to ta l  e q u ip m e n t  c o s t  fo r  u ltr a f i l tra t io n ,  E h t , r e t ,u f ~  h o ld in g  ta n k  c o s t  fo r  
re te n ta te ,  E r ig ,u f -  c o s t  o f  o n e  u l t r a f i l t r a t io n  r ig , Vht,ret,uf~ v o lu m e  o f  r e te n ta te  h o ld in g  
ta n k , a n d  rfiuer,uf ~  r a te  a t  w h ic h  th e  u lt r a f i l t r a t io n  f i l te r  c a r tr id g e  is  re p la c e d . T h e  
s u b s c r ip t  f i l t e r  d e n o te s  r e f e r e n c e  to  th e  u ltr a f i l tr a t io n  f i l te r  c a r tr id g e . T h e  m o d e l 
s e le c ts  th e  a p p r o p r ia te  s iz e  o f  f i l te r  b a s e d  o n  th e  v o lu m e  th ro u g h p u t re q u ir e m e n ts  fo r  
th e  u l t r a f i l t r a t io n  p ro c e s s  w h ic h  a re  r e f e r e n c e d  to  th e  c o s ts  e x h ib ite d  in  T a b le  B .3 .
B.5 Ch r o m a t o g r a p h y
C h r o m a to g r a p h y  is  u s e d  n o t  o n ly  to  e l im in a te  c o n ta m in a n ts  b u t  to  a ls o  c a p tu re  
p ro d u c ts .  C h r o m a to g r a p h y  te c h n iq u e s  a l lo w  fo r  th e  b in d in g  s p e c if ic i ty  o f  th e  
c h r o m a to g r a p h y  m a tr ix  to  th e  p r o d u c t  to  s e p a ra te  it f ro m  th e  c ru d e  p ro d u c t s tre a m . 
B ro a d ly , th e  o p e r a t io n  in v o lv e s  th e  lo a d in g  o f  th e  in le t s tre a m  to  th e  c h ro m a to g ra p h y  
c o lu m n , th e  w a s h in g  o f  th e  m a tr ix  to  re m o v e  u n b o u n d  m a te r ia ls ,  u s u a lly
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contaminants, followed by an elution step to recover the bound product. The matrix is 
then re-equilibrated in preparation for the next cycle. The types of chromatography 
considered between the two manufacturing processes are affinity and ion-exchange 
chromatography.
The equipment sizing relationships for the chromatography column are as follows:
^ b ^ c y c l e ,c h r
c^hr -
c^hr —
^ c h r , d  V ^ c h r ^ c h r
^chr




K h r  —  K h r  ^ c h r  (B. 5 1 )
n
(B.5 2 )
^ c h r  j
where the subscript chr denotes reference to the chromatographic operation, Cb -  
binding capacity of the chromatography matrix (kg/L), dchr ~ chromatography column 
diameter, dchr.d -  smallest denomination of column diameter, hchr -  chromatography 
column height, dchr.max -  maximum available column diameter, richr ~ number of 
chromatography columns, Achr -  cross-sectional area of column, Vchr -  column 
volume, and vy -  number of column volumes of buffer required for each step in the 
operation, as shown in Table B.4.
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Table B.4. Column volumes, v„ required for affinity chromatography operations used.
Step
1. Equilibriation A 5
2. Equilibriation B 5
3. Post load wash 5
4. Elution 2
5. Regeneration A 5




Table B.5. Column volumes, v„ required for anion and cation exchange chromatography operations.
Step
1. Equilibriation 5
2. Post load wash 1 3









p r o d ,c h r  ~  p r o d ,c h r  ^
^ o ,m e d i a ,c h r  ^
^ o , c e l l s , c h r  ~  ^





where the subscript bfr refers to storage buffer.
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Cost relationships:
= 72549 ^ c h r , j  ^ j  ^  cycle, chr r . , +1137.3 (B.57)
h t ,d
J
q V h .
^ E Q P ,c h r  -  ^ c h r  ( ^ r i g , c h r  + ^ c h r  ) + % ]  ^ h t , c h r , j  (B.5 8)
j
V n n ^_  chr chr  cyc le ,ch r  p  p  ^
D R M  ,chr m tx  ! L  /  j  bu ffer I L . i ^ c h r ^  cycle .chr  ^ 0 . 3 7  j
^m tx  y
£'d« ,.* = 0  (B.60)
^ L B R .c h r  s ta f f  ! h r ^ s i q j f  . c h d c h r  (B.61)
f2 < 3
-  j j  otherwise
^ O P R ,ch r  “  ^ L B R ,c h r  + ^ D R M ,chr  (B.63)
where Eht,chr,j - holding tank expense for the buffer of the chromatography step, 
Erig.chr -  cost the chromatography rig, Echr -  cost of the chromatography column, Vmtx -  
reusability of the chromatography matrix represented as the number of wash cycles it 
can be used for before it must be discarded, Emtx/i -  cost chromatography matrix per 
litre, and Etuffer ~ cost of buffer per litre. It should be noted that when the same 
buffers are being used for different chromatography step then a single holding tank 
can house the corresponding buffer. The values of r^tx used for Protein-A and ion- 
exchange media are respectively 300 and 250. The costs for matrices, equipment, and 
buffers used are given in Table B.6 and Table B.7.
Table B.6. Chromatography matrix costs.
Protein-A Matrix £7178/L Source: Millipore
Ion Exchange Matrix £9000/L Source: GE Healthcare
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Table B.7. Chromatography equipment costs.
Item Cost
Chromatography column, diameter^ 0.7 dm £4,947
Chromatography column, diameter^ 1.0 dm £5,686
Chromatography column, diameter^ 1.4 dm £7,740
Chromatography column, diametei^ 2.0 dm £8,529
Chromatography column, diameter= 2.5 dm £14,065
Chromatography column, diameter= 3.0 dm £18,591
Chromatography column, diameter^ 3.5 dm £25,372
Chromatography column, diameter^ 4.5 dm £46,332
Chromatography Rig £140,000
tography columns represented have a bed height o f 1.1dm.




IM Glycine/NaOH + 0.30 NaCl, pH8.6 £2.1390/L
IM Glycine/NaOH + 0.15 NaCl, pH8.6 £2.0972/L
O.IM Borate/0.15 NaCl, pH8.5 £0.5691/L
Phosphate Buffered Saline £0.6570/L
O.IM Citrate, pH6.0-3.0 £0.7358/L
O.IM Glycine/HCl, pH3.5-3.0 £0.6556/L
HCl pH 1.5 £0.5243/L
H3PO4 pH 1.5 £0.6301/L
6M Guanidine HCl £9.3105/L
20% Ethanol £0.6408/L
O.OlMTris/HCl, pH 7.0 £0.5505/L
0.00IM Glycine/6M Urea, pH 4.55 £3.4375/L
0 .0 IM Tris/HCl with 0 .0IM NaCl £0.5532/L
0.02M Sodium Citrate/0.1M NaCl, pH 7.0 £0.6075/L
Source: Adapted from Fisher Scientific. Note: The above substances are normally sold in powdered 
form for which the original prices are obtained. The costs reflect the resultant cost when converted to 
the liquid formulation required for processing operations. These can be conveniently used in the model 
as usage is based on the volume o f  the respective vessel.
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Holding Tank Volume (L)
35000 40000 45000
Figure B.2. Cost versus volume relationship for holding tanks. The solid line represents the line o f  
best fit as determined by geometric regression. The equation o f this line is f(x) = 244.33jc‘^ ®^*^ , with 
= 0.9988. Data source: Personal discussion with C.Osbom at the ACBE, UCL (2004), and Jacobs 
(2006).
The cost relationship of the holding tank relative to volume is displayed in Figure B.2. 
The value is very high demonstrating that a large proportion of the variance in cost 
can be explained by the derived equation.
B .6  V i r a l  I n a c t i v a t i o n
Viral inactivation is the first viral clearance step in the process. The incoming crude 
product stream is added to a formulation of acid designed to inactivate viral 
molecules. As this is not a separation process it is assumed that the product loss is 
negligible and that the yield for the process is equal to 1.
The mass balance relationships are straight forward:
^o,vi.x -




where the subscript vi indicates reference to the viral inactivation unit operation, moyi,x 
-  mass outflow of stream component x  (kg), and rriiy x -  mass inflow of stream
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component x  (kg). The outflow stream also includes the aeid added during the 
procedure. It should be noted that it is taken that the volume of acid added is at a ratio 
of 1:100 with the incoming process stream volume.
The processing time is represented as:
^vi ^ ^ C IP ,v i  ^S IP ,v i  ^ c y c le ,v i ^ ^ c y c l e ,v i (B.66)
where /v/ -  total processing time, tcip.vi -  time taken for elean-in-place, and tsjp.vi -  
time taken for steam-in-plaee. The values tciPM, tsip.vh tcyde.vh and ricydeM are taken as 
2 hours, 6 hours, 4 hours, and 1 hour respectively.
The cost relationships are:
72549
V  ni,v i  cycle ,v i
QV,
K m =




F , , , +1137.3
^ E Q P , v i  -  ^ h t , v i
^ D R M , v i  ^ a c i d / L  ^ i ,v i ,a c i d  ^ c y c le ,v i
^ D U , v i  ~  - ^ ^ s t e a m / L  ' ^ ' ^ • ^ ^ C I P / L  ^  W FI ! h t ,v
^ L B R , v i  ~  ^  s ta f f  I h r ^  s ta f f , v iK i
^ s t a f f , c h r  ^









where Eadd/L -  cost of viral inactivation acid per litre.
B.7 F i l t r a t i o n  o p e r a t i o n s
This section covers the diafiltration, viral nanofiltration, and dead-end filtration 
operations. Such filtration operations are characterised by exploiting the differences
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in particle sizes to separate particles found in the crude product stream by passing the 
stream through a filtration membrane. The portion of the stream retained by the filter 
membrane is defined as the retentate and the particles that passes through the 
membrane are defined as the permeate. Filtration operations are often used to recover 
products and to concentrate the product stream. Viral nanofiltration has the added 
function of assisting in the sterilisation of the product stream through design of the 
membrane filter which removes viral particles. Cross-flow filtration employs 
tangential flow across the membrane surface to reduce fouling of the membrane.




'«p.™,.,,/ = '«i.,,,/ -  (B.77)
X/1 0 = 7 ' '”“ '  (B.78)
where the subscript x f  denotes referral to diafiltration, virus nanofiltration, and dead­
end filtration processes, u -  number of filtration volumes used which is taken as 6. 
The values of Cr,x used are exhibited in Table B.9.
Table B.9. Rejection coefficients for components in filtration operations.
Component Viral Nanofiltration Diafiltration Dead-End Filtration
Product 1.00 0.99 1.00
Media 0.99 0.00 0.00
Cells 1.00 1.00 1.00
Buffer 0.90 0.00 0.00
Acid 0.90 0.00 0.00
Source; Farid (2001).
Process time relationships are as follows:
V  - ( ^ C I P , x f  ~ ^ h i p , x f  c y c l e , x f ) ^ c y c l e , x f  (B.79)
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where tcyde.xf- cycle time, F,>/- volume inflow to the filtration unit, Jxf-  average flux 
taken to be lOOL/m^/hr, A -  total membrane area, rixf- number of ultrafiltration units, 
tcip.xf -  CLP completion time, tsip,xf ~ SIP completion time, and ricycie.xf -  number of 
processing cycles.
Table B.IO. Relevant equipment price data for the ultrafiltration process.
Item Cost Source
Filtration rig £192,373 Jacobs
Filter cartridge, viral inactivation, Auj= 0.48m^ £2,142 Millipore
Filter cartridge, viral inactivation, Au/= 0.70 m^ £5,091 Millipore
Filter cartridge, viral inactivation, 1.4m^ £10,182 Millipore
Filtration buffer £1.50/L Millipore
Cost relationships are as follows:
=72549 r e t , x f
h t ,d
+1137.3
^ E Q P , x f  ^ h t , r e t , x f  ^ r i g , x f
^ D R M , x f  ~ ^ h t , r e t , x f ^ h t , r e t , x / i ^ C I P t L  ' ^ ^ S I P / L  ^  W FI /  l )  ^ b u f f  , x f  ^ .b u ff  I L
V  — V





^ D U , x f ^ f i l t e r , x f  ^  f i l t e r , x f  ^ f i l t e r , x f
K x f (B.86)
^ f i l t e r , x f
f
^ L B R , x f ~~ ^  s ta f f  ! h r ^  s ta f f  , x f ^  x f (B.87)
= 1 (B.88)
F^
O P R , x f ~  ^ L B R , x f  +  ^ D R M , x f (B.89)
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where E e q p ,x/  -  total equipment cost for filtration, E h t ,r e t .x f  ~  holding tank cost for 
retentate, Erig,xf- cost of one filtration rig, Vht,ret,xf~ volume of retentate holding tank, 
Vbuff.xf- volume of filtration buffer required, Ebuff/i -  cost of filtration buffer per litre, 
Vperm.xf ~ volumc of pcrmcatc stream, and rfiiter,xf ~ rate at which the filtration filter 
cartridge is replaced. The model selects the appropriate size of filter based on the 
volume throughput requirements for the ultrafiltration process which are referenced to 
the costs exhibited in Table B.IO. It should be noted that in the model the viral 
nanofiltration and dead-end filters utilise the same model of filter cartridge, and that 
diafiltration uses no filter cartridges.
B.8 C e n t r i f u g a t i o n
Centrifugation is used to separate out the solids firom the liquids from a mixture, 
based on the components’ size and density. As seen in Equation 5.1, it is used in as a 
primary separation operation to remove cells and cell debris via the application of 
centrifugal forces to produce the sediment and the supernatant. The output stream 
was calculated using the dewatering level that can be achieved and the solid carry­
over level. The model assumes that there was a single component in the solid phase, 
cells. The sediment stream and the supernatant stream were calculated separately.
Mass balance relationships:
^  c tr  , s p  , c e lls  ~ ^  I, c e ll  , c t r  ^  s  (B.90)
, J = ffl; W,c tr ,sd ,c e lls  i ,c e lls ,c tr  ‘'ce lls ,sp
mc tr  ,s d  .m ed ia
^  c tr  , s d ,cells ^ c t r , s d , c e l b
P cells ^ d  P cellsV




( 1 - 7  + ^ c t r , s d , c e l l s
^  c tr ,sp ,m e d ia  ^ i , m e d i a  ^  c tr ,sd ,m e d ia  (B.94)
^ i ,  p r o d u c t ^  c tr ,sp ,m e d ia
^ c t r , s p ,p r o d u c t  ~ (B.95)
i^,media
mc tr ,sp ,m e d ia  ^ i , m e d i a  ^  c tr  , s d ,m ed ia  (B.96)
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Where the subseript ctr specifies reference to the centrifugation process, mctr.sp.ceii -  
cell mass in the supernatant stream, rui^ ceii.ctr -  inflowing mass of the cells to the 
centrifuge, Q  -  solid carry over level which is taken here as 0.02, nictrMceii ~ cell mass 
in the sediment stream, nictrMmedia -  media mass in the sediment stream, Ld -  
dewatering level, and m sd ,m e d ia  ~  media mass in the sediment stream.
Processing time relationships:
 ^c tr  ^ c y c le ,c tr  c y c le ,c tr  ~ ^ ^ C I P ,c t r ^  (B.97)
(B.98)
^ctr
where tctr -  total processing time taken for the centrifugation process, ricyde.ctr -  
number of cycles for which the operation is run which is taken as 1, tcyde.ctr -  
throughput time for the process stream, tcip,ctr ~ CIP time taken as 6 hours, F,,crr -  
inflow volume of process stream to the centrifuge, and Qctr -  operating fiowrate of 
centrifuge.
The prices of required holding tanks were based on a linear regression fit to prices of 
available data (Table B.3), which produced the relationship:
= 72549
V
h t ,c tr ,s p +1137.3 (B.99)
^ E Q P , c t r  = c^trUctr + (B.lOO)
^  c y c le ,c tr (B.lOl)
6
^  D R M ,c tr  ~  Q c t r ^ c y c l e , c t r i ^ C I P I  L S IP  ! l )  (B.102)
^  D U  ,c tr  ' ^ Q c t r ^  c y c le ,c tr  stea m  ! L ^ c w l L ^  (B.103)
^  L B R ,c tr  ~  ^  s ta f f  i h r ^  s ta f f  , c t r ^  c tr  (B. 104)
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1 <3
"*'■^■"'“ { 2  Otherwise
^ O P R , c t r  ~ ^ L B R , c t r  D R M ,c tr  (B.106)
where Eht,ctr.sp - cost o f the holding tank for the supernatant,, EsQp.ctr -  total equipment 
cost for centrifugation, Ectr -  cost of one centrifuge, and rictr -  number of centrifuges 
required. The centrifuge used for the process is assumed to have a fiowrate of 
1500L/hr and costs £474,995 (Source: Jacobs).
B.9 P e r ip l a s m ic  e x t r a c t io n
The monoclonal antibody fragments produced by the E.coli cells are exported to the 
periplasmic space. Periplasmic extraction enables gentle and efficient solubilisation 
of the outer membrane of E.coli cells, permitting rapid extraction of the fragments 
from the periplasmic space. This can result in an increase in product yield compared 
to other extraction methods such as homogenisation and lysis of the entire cell 
(Cossins et al. 2007). The yield for this unit operation was assumed to be 100%, as 
the unit operation does not involve any types of separation of the input stream.
Equipment sizing and process time relationships:
^ h t , p p e
V
h t ,p p e
Vi ,p p e
qy,ht.màx
(B.107)
V.i ,p p e (B.108)
^ p p e  ^ c y c l e ,p p e ^ ^ c y c l e ,p p e  ~ ^ ^ C I P ,p p e  ~ ^ ^ S I P , p p e ^  (B.109)
where the subscript ppe denotes reference to the periplasmic extraction operation. 
The values r icyc ie .p p e , tc y d e .p p e , tc iF ,p p e ,  uud ts ip ,p p e  arc taken as 1, 8, 6, and 4 respectively.
The mass balances are straightforward as this process is assumed to negligible loss in 
product.
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h t , p p e '
h t ,d
+1137.3 (B.llO)
^ E Q P , p p e  ^  h l , p p e ^ h t , p p e (B .lll)
^ D R M ,p p e  ~  ^ h t , p p e ^ h t , p p e i ^ ' ^ ^ ^ T E X / L  ^ C IP  1L  ^ W F I / l ) (B.112)
^ D U ,c p p e  ^ h t , p p e ^ h t , p p e ^ ^ s t e a m ! L  ~ ^ ^ c w ! L ^ (B.113)
^ L B R ,p p e  ^ s ta f f  ! h r ^ s t a f f  , p p e ^ p p e (B.114)
_  B ^ h t , p p e  -  3
s ta f f ,p p e  | 2  Otherwise (B .ll 5)
^ O P R ,p p e  ~ ^ L B R , p p e  ^ D R M ,p p e (B.116)
where E tex/l  -  cost of TEX buffer used taken as £1.50/L.
B.IO  p H  a n d  c o n d u c t iv it y  a d j u s t m e n t
A pH and conductivity adjustment is carried out after the periplasmic extraction so as 
to precipitate the product. The equipment sizing, mass balances and costs are almost 
identical to periplasmic extraction. The only exception is that tcycie.pc =2 hours, with 
pc denoting reference to this operation. Also no TEX buffer is used in this operation; 
instead an acid is used in a volumetric ratio of 1:200 to the process volume at a cost 
£0.50/L.
B . l l  D i l u t io n
In the dilution step, the product stream was diluted to a predefined concentration as a 
preparation for the following chromatography operation. Chromatography operations 
are sensitive and expensive thus such precautionary steps are required. As with pH 
adjustment and conductivity, the equipment sizing, mass balances and costs are 
almost identical to periplasmic extraction. The only exception is that no TEX buffer
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is used in this operation; instead another buffer used in a volumetric ratio of 1:10 to 
the process volume at the same cost of £1.50/L.
B.12 PEG y l a t io n
PEGylation is applied to intravenously administered therapeutic proteins, in 
particular, to improve their stability, biological half-life, water solubility, and 
immunologic characteristics (Harris, 2003). The equipment sizing, mass balances 
and costs are almost identical to periplasmic extraction. The only exception is that 
hycie.PEG=^ 2 hours, with PEG denoting reference to this operation. Also no TEX 
buffer is used in this operation; instead another buffer used in a volumetric ratio of 1:5 
to the process volume at the same cost of £1.50/L.
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Abstract
Selecting an appropriate path for acquiring commercial-scale biopharmaceutical manufacturing capacity often requires the rationalisation of 
multiple conflicting criteria and the reconciling of financial and non-financial issues. Multi-criteria decision-making (MCDM) can provide a holistic 
framework for evaluating such scenarios. This paper presents the development o f a décision-support framework for decision-making scenarios 
involving the acquisition o f comm ercial-scale biopharm aceutical manufacturing capacity that utilises MCDM. To illustrate the functionality of 
the framework, a hypothetical scenario was constructed based on a biopharmaceutical company faced with a number of options for acquiring 
commercial manufacturing capacity. A deterministic analysis showed that building manufacturing capacity was the highest ranking option for the 
scenario considered. Stochastic analyses demonstrated that this option was also the highest ranking overall.
© 2006 Elsevier Ltd. All rights reserved.
Keywords: Biopharmaceutical manufacture; Strategy selection; Décision-support; Multi-criteria decision-making; Uncertainty; Process economics
1. Introduction
Biopharmaceutical manufacture is a highly expensive and 
technology-intensive activity. Biopharmaceutical products are 
among the most technically complex to manufacture o f any 
industry (Ransohoff, 2004). Biopharmaceuticals also take longer 
to manufacture than chemical entities and require produc­
tion operations that are more difficult to control (Mcgurk, 
2004). In recent years, it has been reported that the biophar­
maceutical industry has been faced with potential shortages 
in manufacturing capacity with decreasing revenue potential. 
This is exacerbated by higher pressures from regulatory bodies 
(Molowa, Shenouda, & Meyers, 2001; Pisano, 1997). Although 
anticipated shortages may not have been realised (Ginsberg, 
Bhatia, & McMinn, 2002) the importance of this issue to the 
biopharmaceutical industry was clearly displayed in the general 
level of concern generated at the time. Consequently and criti­
cally, this demonstrates a link between a firm’s manufacturing 
operations and its long-term business strategy.
’ Corresponding author.
E-mail address: s.farid@ucl.ac.uk (S.S. Farid).
Several studies have indicated a strong link between pro­
duction and business strategies (Brown, 1998; Demeter, 2003). 
For the biopharmaceutical industry in particular, aligning deci­
sions with a business strategy forms a major factor in the 
decision of whether to make products in-house or to outsource 
their manufacture to a contractor (Ransohoff, 2004; Seymour & 
Galliher, 2002). Because of the significant costs and resources 
required, the manufacturing strategy undertaken is influenced 
by the approach to portfolio management and drug development 
issues. The size of the portfolio, success rates through clinical 
trials, doses and expected market demand for each drug dictate 
the potential production requirements. The budget, cost of drug 
development, and speed to market required constrain the amount 
of capital that can be allocated to manufacturing within a specific 
time-period and how long the company has to acquire manufac­
turing capacity. All of these factors increase the difficulty facing 
biopharmaceutical firms, especially smaller ones, in achieving 
success in the industry. Given the multitude, significance, and 
complexity of decisions to be made for acquiring biopharma­
ceutical manufacturing capacity there are a surprisingly small 
number of published studies in the area.
There are a number of options to consider when acquiring 
commercial manufacturing capacity. These would be to build
0098- 1354/s -  see front matter © 2006 Elsevier Ltd. All rights reserved, 
doi: 10 1016/j. compchemeng.2006.12.009







E total annual expense
E\ capital investment
£2 cost o f goods sold
£2 general and administrative
£3 royalties
£4 total plant expenses to be paid
£3 profits owed to partner
£  fixed capital investment
g proportion of sales to be spent on general and
administrative costs 
total annual income
1 dose per patient per year
2 target population size
3  market capture
4  annual product demand 
estimated sales price 
other income
L  par value o f issued convertible debt
m proportion o f profit payable as tax
M peak market capture
N total number o f drugs
p proportion of profits owed to partner
Pe proportion o f expenses that the company is obli­
gated to pay 
P profit after interest and tax
^KNPV expected net present value
Pnpv net present value
£pv annual present value
£i profit before interest and tax
£ 2  depreciation
£ 3  taxable profit
£4 tax
q  number of manufacturing personnel required
r proportion of sales that will used to pay royalty
fees
decay period after peak market capture 
tn ramp period from commercialisation to peak mar­
ket capture 
w normalised weight value
X normalised attribute value
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7t transition probability
Xp,k kth qualitative component of the flexibility cate­
gory
XL,k kth qualitative component of the location category
XM,it A^ h qualitative component of the manufacturing
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one’s own capacity, partner with a company that can provide 
the required capacity, or outsource the production to a contract 
manufacturing organisation (CMO). Each of these options has 
its merits and trade-offs that need to be considered by the deci­
sion maker. Opting to build full manufacturing capacity gives 
the highest level o f control over managerial issues and intellec­
tual property acquisition but it also requires the largest outlay 
of capital and carries the highest penalty in the event o f fail­
ure. Additionally, this option must be considered quite early 
as commercial-scale biopharmaceutical manufacturing facili­
ties can take at least 3 years to build (Ginsberg et al., 2002). In 
light of this, the remaining options can be particularly attractive. 
Partnering with a company capable of providing manufactur­
ing capacity allows expenses, operational and financial risk, 
and knowledge to be shared (George, Zahra, Wheatly, & Khan,
2001). On the downside, profits must also be shared and such 
alliances can be difficult to manage (Koza & Lewin, 2000). Out­
sourcing manufacturing responsibilities to a CMO reduces the 
upfront costs associated with building a facility compliant with 
current good manufacturing practice regulations (cGMP) (Nahri 
& Nordstrom, 2005). The cost per gram of manufacturing a 
biopharmaceutical with a CMO will be more expensive than 
building a facility and control over manufacturing activities will 
be compromised to some extent (Rajapakse, Titchener-Hooker, 
& Farid, 2005). Typically, a company will have multiple products 
in their pipeline and here there will be the need to consider more 
than one commercial manufacturing option for each product so 
as to arrive at the most preferable solution overall.
There are numerous contributions in literature that address 
the problem of expanding capacity in the chemical process 
industries. Internal planning decisions of a company and the 
recognition of market opportunities have been considered 
by Gupta and Maranas (2004). Cheng, Subrahmanian, and 
Westerberg (2005) provide an approach to capacity planning 
and inventory control. Oh and Karimi (2004) approach capacity 
expansion through a focus on regulatory factors. A mathe­
matical programming approach to capacity planning for the 
pharmaceutical industry was presented by Gatica, Papageorgiou,
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and Shah (2003). Levis and Papageorgiou (2004) provide a 
mathematical programming method for long-term, multi-site 
capacity planning under uncertainty for the pharmaceutical 
industry. Additionally, Maravelias and Grossman (2001) present 
a framework for the simultaneous optimization of capacity 
planning and new product development. Literature in this area 
largely focuses on mathematical programming formulations of 
optimization-based frameworks. In contrast, this paper employs 
a simulation-based approach as a means for assessing specific 
capacity expansion strategies.
Literature on decision-making specific to biopharmaceutical 
manufacture has typically focused on strategic process decisions 
faced by companies that are planning to build pilot-scale or 
commercial-scale manufacturing facihties (Farid, Novais, Karri, 
Washbrook, & Titchener-Hooker, 2(KX); Farid S., Washbrook, & 
Titchener-Hooker, 2005; Lim, Washbrook, Titchener-Hooker, & 
Farid, 2005; Lim, Zhou, et al., 2005; Mustafa et al., 2004). In 
reality, there are a significant number of biopharmaceutical com­
panies that manufacture at least some of their drugs externally 
(Langer, 2004; Rogers, Maranas, & Ding, 2(X)5) and an exten­
sion of such frameworks is required to capture this aspect of the 
business. Such work was investigated by Rajapakse et al. (2005) 
who modelled the decision to build manufacturing capacity or 
to outsource this activity. Additionally, these tools tend to use 
one or two criteria to capture the value of making a particular 
decision and this by definition excludes other useful evaluative 
criteria. The usefulness of extending the criteria considered was 
demonstrated by Farid, S. S., Washbrook, and Titchener-Hooker 
(2005) who used multiple quantitative and qualitative criteria to 
assess the use of disposable components when building a bio­
pharmaceutical manufacturing facility. This was supported by a 
framework that used multi-criteria decision-making (MCDM).
In problems involving capacity expansion there may be many 
conflicting criteria to be considered for decision-making. Gen­
erally, the available types of methods for reconciling between 
multiple objectives include: transforming the multi-objective 
problem into a single objective problem, the lexicographic 
approach, and the Pareto approach. The field o f MCDM offers 
numerous techniques that transform multi-objective problems 
into single-objective ones. This often involves assigning a weight 
to each objective so that relatively more important objectives 
contribute more to the output score of each alternative. In cases 
where a score is derived and in its simplest application, the 
most preferred candidate solution will yield the optimal score. 
The lexicographic approach involves assignment of a prefer­
ence order to each objective and then optimizing each objective 
in order o f preference until a non-dominated solution is found 
(e.g. Sawik, 1997; Volgenant, 2002). The Pareto approach (e.g. 
Cheng, Subrahmanian, & Westerberg, 2003) compares each 
solution against each criterion and results in a set of Pareto opti­
mal solutions that are said to be non-dominated. A solution is 
considered Pareto optimal if there is no other existing solution 
that can improve the value of one criterion without degradation in 
any other criteria. A key advantage of using lexicographic and 
Pareto approaches over transforming multiple objectives into 
a single objective is that they compare solutions according to 
each criterion. However, for numerous criteria it can be difficult
for the decision maker to prioritise each individual objective, 
as in the lexicographic approach, without having a reasonable 
understanding of each one. Additionally, having a set o f Pareto 
optimal solutions means that the decision maker still has the task 
of selecting a solution from this set. This can be especially diffi­
cult if there are more than two criteria as multiple trade-offs may 
exist between individual objectives. For these reasons the sim­
pler technique of transforming multiple objectives into a single 
objective has been chosen for this paper.
The use of multiple criteria as a basis for analysing decisions 
can be supported effectively through MCDM which is one o f the 
most well known branches o f decision-making (Triantaphyllou, 
2(X)0). Its potential ability to support the selection of strategies 
in biopharmaceutical manufacturing lies in the flexibility it pro­
vides to reconcile both the financial and operational concerns of 
the decision maker. There are many methods available in MCDM 
which have been used to process financial and non-financial 
data. For example, Platts, Probert, and Canez (2002) used the 
weighted sum method (WSM) to analyse the decision to invest 
in internal manufacturing capabilities or to outsource these 
activities. Additionally, Steuer and Na (2(X)3) have published 
a review of 265 publications that focus on utilising MCDM to 
aid decision-making in financial contexts.
This paper investigates the design of a décision-support 
framework for the stochastic analysis of options for acquiring 
commercial-scale manufacturing capacity using multiple crite­
ria and MCDM. The remainder of this paper will discuss the 
architecture of the décision-support framework, demonstrate 
this framework by application to a case study, and draw con­
clusions from the results obtained.
2. Décision-support framework
The décision-support framework was designed to model the 
financial and operational perspectives of strategies for acquiring 
commercial manufacturing capacity. Microsoft Excel was used 
for its implementation and an overview is presented in Fig. 1. 
A hierarchical approach was applied to facilitate a clear and 
detailed representation of the business and manufacturing pro­
cesses involved. This approach also offers the abihty to rapidly 
change assumptions so that a wider variety o f scenarios can 
be captured and analysed. The framework has four elements: 
a biomanufacturing process model, a profit and loss model, 
an MCDM technique, and a set o f criteria used to distinguish 
between the strategic options.
A decision-making scenario is comprised o f a set o f alterna­
tive options with each one representing a capacity acquisition 
strategy. Each option is defined as a collection of probabil­
ity distributions to be inputted to the model. These inputs can 
be split into technical, commercial, business and qualitative 
categories. Technical inputs describing the manufacturing capa­
bilities, such as the fermentation titre and the overall process 
yield, are directed to a biomanufacturing cost model. These tech­
nical inputs are used to generate data such as the cost o f goods 
sold per gram (COGS) and the capital investment required. Com­
mercial inputs include the market capture and the market lifetime 
of each drug. These inputs are used to define the production
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Fig. 1. An overview of the MCDM framework.
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Fig. 2. The biomanufacturing process model. Abbreviations: DSP, downstream processing; QC/QA, quality control/quality assurance; PCI, fixed capital investment; 
COGS, cost of goods sold. Demand is the armual product demand determined from the market analysis and depends on market size, market capture and the drug 
dosage per patient per year. Titre refers to the titre of crude product (g/L) that is expected to be achieved in the fermenter. The DSP yield is the overall yield after all 
downstream processing steps have been completed. The batch success rate refers to the likelihood of batch success given the chances of contamination or equipment 
failure. The manufacturing operations and the ancillary tasks have been modelled to determine estimates of utilisation of major cost components. Utilisation estimates 
are combined with an extensive cost database to determine the PCI and COGS values.




Direct cost of goods Direct raw materials /(utilisation) (4)
Miscellaneous materials 0.5 X direct raw materials (5)
Direct utilities /(utilisation) (6 )
Operating labour /(utilisation) (7)
Supervisors 0 .2  X operating labour (8)
Quality control and quality assurance 1 X operating labour (9)
General management 1 X operating labour ( 10)
Indirect cost of goods Maintenance O.IFT (11)
Local taxes 0.02 FT (12)
Insurance 0.01 FT (13)
Capital charge F(1 +  rate of interest) (14)
General utilities Cost per unit area per year x facility size x T (15)
Total cost of goods Direct cost of goods/indirect cost of goods (16)
Total cost of goods per gram (COGS) Total cost of goods/annual production output (17)
Note: Where F  is the fixed capital investment, Y the project duration in years, and C is the capital charge period. Source: Mustafa et al. (2004).
capacity required and expected sales revenue. Inputs from the 
business category define the structure of any contractual agree­
ments such as royalty payments and the terms of any partnerships 
formed. Qualitative aspects o f each option include the suitability 
of the location, control and flexibility over the projects consid­
ered, and the expected acquisition of manufacturing knowledge. 
Qualitative scoring is used to describe most o f the operational 
aspects. The outputs o f the biomanufacturing cost model are 
directed to the profit and loss model. The outputs of the profit 
and loss model determine the values of the financial criteria used 
to discriminate between the alterative options. Subjective oper­
ational inputs are fed directly to their corresponding criteria. 
Details of the biomanufacturing model and the profit and loss 
model will be discussed in further detail in Sections 2.1 and 2.2, 
respectively.
2 .1. Biomanufacturing process model
The framework used to model the manufacture of biophar­
maceutical products (Fig. 2) is based on work reported by Farid 
et al. (2(XK)), Farid, S., et al., 2(X)5 and Lim, Washbrook, et 
al. (2005), Lim, Zhou, et al. (2005). Fig. 2 represents a typi­
cal manufacturing route for monoclonal antibodies. Included in 
the model are the main process and ancillary tasks involved in 
the manufacturing process as well as equations for calculating 
the utilisation of equipment, materials, utilities and labour. The 
cost calculations are supported by a database of unit costs for 
equipment and materials used in the manufacturing process.
The overall input parameters to the model are the annual 
demand, the expected fermentation titre, the overall product 
yield and the anticipated success rate of each batch. Each unit 
operation has a process model comprising of design equations 
and mass balances. These are used to size equipment, determine 
the composition of the output streams and the amount of mate­
rials required (e.g. chromatography buffers). More details on 
these models can be found in Farid et al. (in press). Equipment 
sizes are determined by matching processing requirements such 
as volume to a database of equipment dimensions available at the
time of writing. If the processing requirements require an equip­
ment size that is in excess of available equipment dimensions 
then the sizes o f equipment allocated will be such that all units 
will be of equal size with their number clearly being sufficient 
to handle process requirements. The outputs from this model are 
the fixed capital investment for the manufacturing plant as well 
as the COGS. The fixed capital investment was estimated by the 
Lang Factor method (Lang, 1948) which correlates this figure 
to the equipment cost. The COGS model employed is shown in 
Table 1.
2.2. Profit and loss model
A profit and loss model was built to process income and 
expense data (Table 2) and to generate values for the decision­
making criteria. In addition to the business revenues achieved 
from the sale of therapeutics other sources o f finance are also 
modelled. These additional sources of finance include an initial 
public offering (IPO) and the issuance of convertible debt. It is 
assumed that this will be in the form of convertible bonds which 
are issued in the same year as the IPO. The holder of any convert­
ible bonds can convert them to common stock o f the issuing firm 
according to conditions specified by the firm prior to issuing the 
bonds (Kimura & Shinohara, 2006). The static conditions are the 
term of the bond, its coupon, the probability of conversion and 
the conversion premium which is the amount the bond holder 
must pay the firm in order to convert. The only variable condi­
tion is the year of conversion, providing this happens, which is 
modelled as a triangular distribution. Additionally, the year of 
conversion is expected to coincide with the successful commer­
cialisation of the first drug which is reflected in the probability 
distribution. The amount of finance required to be raised through 
the issue of this instrument is calculated. The model assumes that 
there are no possibilities of negative cashflows. If the cashflow 
in any year for any scenario falls below $5 million then enough 
is raised to correct this with an upper limit o f $ 10 million for the 
same year. It is assumed that there are no restrictions to issuing 
convertible debt at the time of need.
894 E. George et al. /  Computers and Chemical Engineering 31 (2007) 889-901
Table 2
Profit and loss model
Year Year t
Income
Dose per patient per year h ,t
Target population size h,i
Market capture, t f ( t \ ,  M, to) (18)
Annual product demand, U j h .th . th . t (19)
Hstimated sales price®, 5 9 .8 3 2 /^ '^ ^ (2 0 )
Total sales, h, (2 1 )
Other income h .
Total annual income, 1, bt +  If,,t (2 2 )
Txpenses
Capital investment E u
COGS Vt
General and administrative, E2,i gh .t (23)
Royalties, £ 3,, rl6,i (24)
Total plant expenses to be paid, £4,, P t ( E \ j  +  £ 2,/ 4- £ 3/  +  Vt) (25)
Profits owed to partner, £ 5,, P i h  — £ 4 , f ) (26)
Convertible debt repayments cL (27)
Total annual expense, £, Es.t +  £ 5,/ (28)
Profit
Profit before interest and tax, £ 1,, I t  — E t (29)
Depreciation P u
Taxable profit, £ 3,, P u  -  P u (30)
Tax. £4,, m Pj.t (31)
Profit after interest and tax, P, Et — (Pi.t 4- £4,/) (32)
Net present value
Annual present value, £py,, P i at (33)
Net present value, £N PV .r ^ £ p v , r (34)
Expected net present value
Transition probability tt t
Cumulative transition probability, jtc n * ' (35)
Expected net present value, £ e n p v . /
r = l
A iPV ./ttc (36)
Wote: tR is the ramp period from commercialisation to peak market capture, M  
the peak market capture, to the decay period after peak market capture, g the 
proportion of sales that are expected to be spent on general and administrative 
costs, r the proportion of sales that will be used to pay royalty fees, pe the 
proportion of expenses that the company is obligated to pay, p  the proportion of 
profits it owes to any partners, c the coupon rate payable on the par value of the 
issued convertible debt T, m the tax payable as a percentage of profit, and a is 
the discount factor.
" Derived by correlating sales price vs. demand for therapeutic monoclonal 
antibodies.
category four categories were considered: productivity, the 
suitability of the location, control and flexibility over the 
projects considered, and the expected acquisition of manufactur­
ing knowledge. The qualitative component of the productivity 
category includes the ease of training manufacturing person­
nel. The location category includes the abihty of the local 
infrastructure to support operations and logistics, and the 
access to qualified manufacturing personnel. The flexibility 
category includes the abihty to control its drug manufacture 
projects, the ease of expanding operations, and the ease of 
consolidating manufacturing operations. The manufacturing 
knowledge category includes the readily available manufactur­
ing expertise, the number of company personnel assigned to 
manufacturing, the potential to acquire manufacturing knowl­
edge, and the control over any manufacturing knowledge 
acquired.
When applying these criteria to a decision-making scenario 
a higher criterion value represents a stronger position. Some of 
these criteria, such as those based on costs had to be inverted to 
reflect stronger positions as higher values rather than as lower 
values.
2.4. The weighted sum method
The weighted sum method (WSM) was chosen to evaluate 
the criteria shown in Table 3. These criteria are not all measured 
in the same dimensions and thus result in a multi dimensional 
decision-making scenario. For comparisons between options to 
be drawn meaningfully and usefully the criteria values must 
be converted into an equivalent set of dimensionless numbers 
(e.g. Triantaphyllou, 2000). Normalisation can convert the cri­
teria values as described and a normalised criterion value can be 
represented as:
ea
X i i  — (1)
where eij is the value of the ith criterion of the yth alternative 
option and Xÿ is the normalised rating of attribute I for the 
alternative option j .
Each criterion is given a weighting that can be configured by 
the decision maker to reflect how important each criterion is in 
the decision-making process. These weight values must also be 
converted to an equivalent set o f dimensionless numbers. The 
normalised weight value, Wi, is:
2.3. Criteria
The criteria used in the framework (Table 3) were cho­
sen to represent a broad spectrum of values that may be 
important when considering detailed financial and operational 
perspectives. Also, each criterion is intended to capture a cer­
tain aspect of each option over its lifetime from an overall 
perspective. In the financial category five categories o f cri­
teria are considered: profitability, asset utilisation, liquidity, 
long-term solvency and capital structure. In the operational
W i  =
Zi
(2)
where Zi is the weight value of the ith criterion.
The score, 5), generated by the WSM method can be repre­
sented as:
Sj  — y ^ W j X j j (3)
i= l
The preferred alternative option has the highest score.
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Table 3
Criteria used in the MCDM framework
Group Category Criteria Definition
N r ^
Financial Profitability ENPV c , = E
n = l









Total profits to total sales
Total profits to total assets
Total profits to total equity
Total sales to total fixed assets
Total profit to total current assets
Total current assets to total current liabilities
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Manufacturing knowledge Qualitative manufacturing knowledge score
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.\’(>rc: For symbol definitions refer to the Nomenclature section.
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2.5. Uncertainty
To determine the stochastic ranking configuration, input val­
ues were specified as triangular distributions characterized by 
minimum, maximum and expected values. These inputs were 
subjected to a Monte Carlo simulation and the options were 
ranked according to their mean WSM score. Subsequent anal­
yses were conducted to identify any trade-offs linked to these 
mean scores.
3. Case to be studied
A hypothetical case study was formulated to illustrate and 
examine the use of the framework in capturing the financial 
and operational perspectives of decision-making scenarios in the 
acquisition of commercial-scale biomanufacturing capacity. The 
example is based on a biopharmaceutical company that needs to 
acquire commercial manufacturing capacity and has three mon­
oclonal antibody drug candidates in its product pipeline. One 
has just recently entered late stage clinical trials, whereas the 
others are still in the early stages of clinical testing. The first, 
second and third drugs are required in different levels o f demand. 
Given the progress of the drug portfolio toward commercialisa­
tion the necessity to acquire commercial manufacturing space 
is urgent. The company’s initial pubhc offering (IPO) has 
raised $100 million. The following possible options have been 
identified;
Table 4
Market and development characteristics of drugs in the case study
Characteristic Drug 1 Drug 2 Drug 3
Dose (grams per patient per year) 6 3 1
Annual market size (patients) 100,000 2 00 ,000 25,000
Clinical trial stage Phase 111 Phase I Phase 1
Expected time to market entry (years) 5 8 8
Expected market lifetime (years) 10 10 10
•  'Partner' option; Partner with a large pharmaceutical com­
pany and split the expenses and profits.
•  'CMO' option; Outsource all manufacturing requirements to 
a contract manufacturing organisation (CMO).
•  'Build' option; Build a new facility and undertake all o f the 
manufacturing by in-house.
•  'PartnerlBuild' option; A hybrid option involving following 
through with the partnership but only for the first drug. The 
remaining drugs will be manufactured by the construction of 
a new facility.
•  'CMO!Build' option; A hybrid option involving a contract 
manufacturer but only for the first drug. The remaining drugs 
will be manufactured by the construction o f a new facility.
3.1. Method
The commercial and development characteristics o f the drug
candidates are outlined in Table 4. The input values for the 'Part-
Table 5
Input values used for the case study
Input Partner CMO Build
Expected market capture. Drug 1 (%) Tr(5.5, 11, 16.5) Tr(5, 10, 15) Tr(5, 10, 15)
Expected market capture. Drug 2 (%) Tr(16.5,33,49.5) Tr(15,30,45) Tr(15,30,45)
Expected market capture. Drug 3 (%) Tr(ll,22 , 33) Tr(10, 20, 30) Tr(10, 20, 30)
Ramp time to peak market capture (years) Tr(3, 2, 1) Tr(4,3,2) Tr(4,3,2)
Decay time from peak market capture (years) Tr(3, 2, 1) Tr(4,3,2) Tr(4,3,2)
Transition probability. Phase 1 to 11 0.7 0.7 0.7
Transition probability. Phase 11 to 111 0.5 0.5 0.5
Transition probability. Phase III to FDA review 0.8 0.8 0 .8
Transition probability, FDA review to approval 1 1 1
Discount rate 0.12 0.12 0 .12
Fermentation titre (g/L) Tr(0.6, 0.8, 1.2) Tr(0.8, 1.0, 2.0) Tr(0.4,0.6, 1.0)
DSP yield (%) Tr(55, 60,65) 65 Tr(50, 55,60)
CMO’s mark-up on COGS (%) - 80 -
CMO's royalty charge on sales (%) - 15 -
Profit paid to partner (%) 60 - -
Expenses paid by patiner (%) 50 - -
Ease of training staff Tr(5, 7, 9) Tr(l, 1,3) Tr(3, 5, 7)
Ability of the local infrastructure to support operations and logistics Tr(6 , 8 , 10) Tr(6 , 8 , 10) Tr(8 , 10, 10)
Ability to acquire manufacturing personnel Tr(6 , 7, 9) Tr(8 , 10, 10) Tr(3, 5, 7)
Ability to control and manage drug manufacture Tr(3, 5, 7) Tr(8 , 10, 10) Tr(8 , 10, 10)
base of manufacturing expansion Tr(4, 5, 7) Tr(5, 7, 9) Tr(3, 5, 7)
Ease of manufacturing consolidation T r(l,3 ,5 ) Tr(l, 1,3) Tr(8 , 10, 10)
Readily available manufacturing expertise Tr(5, 7, 9) Tr(8 , 10, 10) Tr(l, 1,3)
Potential to acquire manufacturing knowledge Tr(5, 7, 9) Tr(l, 1,3) Tr(3, 5, 7)
Control over manufacturing knowledge Tr(2, 4, 6 ) Tr(l, 1,3) Tr(8 , 10, 10)
Note: hot each input the first, second and third numbers represent the worst case, base case and best case scenarios, respectively. Where only one number is present, 
that value remains constant through all scenarios.
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Table 6
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n e r \  "CMO" and 'BuilcT options are detailed in Table 5. These 
values were determined based on assumed differences in capa­
bilities between the options. For example, the CMO option was 
assumed to offer the highest titres due to their specialised exper­
tise in the manufacture o f biopharmaceuticals. Advice from 
industrial experts was solicited to ensure sensible assumptions 
were made. For the "Partner!Build’ option, manufacture of the 
first drug is modelled on the input values for the "Partner’ option 
and manufacture of the remaining drugs are modelled on the 
B uild’ option. Similarly, for the "CMOIBuild’ option, manu­
facture o f  the first drug is modelled on the input values for the 
"CMO’ option and manufacture o f the remaining drugs are mod­
elled on the "Build’ option. The convertible debt instrument is 
the same across all scenarios and the input values can be found 
in Table 6. The expected values were used to generate a deter­
ministic ranking configuration. By default the financial criteria 
and operational criteria were assigned equal aggregate weight­
ings. The weighting o f each group of financial criteria is equal. 
Likewise, the weighting o f  each group of operational criteria is 
equal.
The base case input values were processed through the 
décision-support framework to generate deterministic scores. 
A sensitivity analysis, based on the best and worst case values, 
was used to identify the most influential factors. A stochastic 
analysis was conducted using triangular distributions based on 
worst, base case, and best values of manufacturing, commer­
cial, and operational variables. Here, 1000 iterations of a Monte 
Carlo simulation were found to be sufficient to represent the 
stochastic behaviour o f each option considered for the purposes 
o f  comparability.
4. Results and discussion
4.1. Base case
The deterministic results are presented in Table 7, which for 




Option ENPV ($ MM) WSM Score Rank
Build $855 0.2157 1st
Partner $641 0.2062 2nd
Partner/Build $683 0.2026 3rd
CMO/Build $829 0.1960 4th
CMO $764 0.1795 5th
The Build, Partner and PartnerlBuild options scored higher 
than the average WSM score. The Build option scores highest 
indicating that is the most preferred option. This option generates 
the greatest ENPV value as well as the highest total value of 
assets which contribute highly in the capital stmcture category. 
Additionally, the highest degree of flexibility and the greatest 
expected gain in manufacturing knowledge are associated with 
this option.
The Partner option ranks second place. The sharing of 
expenses results in its total liabilities being the lowest of all 
the options and contributes to a high score in the long-term sol­
vency category. The Partner option also involves sharing profits 
making it the least profitable option. The smaller profits result in 
a smaller equity value when compared with other options con­
tributing to a low score in the capital structure category. This 
option also scored low in the flexibility category because the 
partnering company has been granted some control over the 
manufacturing projects.
The PartnerlBuild option scores lower than the Partner and 
Build options even though it is a combination of both. The ben­
efits that the PartnerlBuild option gains from the Build option 
are counteracted because these benefits happen halfway into the 
lifetime of the project. This is relevant because the discount fac­
tor and the transition probabilities used to calculate the ENPV 
cashflows have the resultant effect of giving events occurring 
soonest the highest degree of impact on this figure. This will 
consequently impact the WSM score. Similarly, the fixed assets 
that are gained from building manufacturing capacity are used 
to generate highly discounted profits and hence lower equity. 
This results in a low score in the asset utilisation category and 
the capital structure category. Additionally, the PartnerlBuild 
option scores lowest in the productivity category as the labour 
force is not used as efficiently as with the Partner or Build 
options.
The CMO and CMOIBuild options score the lowest overall. 
Contributors to these scores include the higher COGS and roy­
alty charges associated with both of these options. This results 
in significantly higher current liabilities and lower equity val­
ues than any of the other options and gives rise to low scores 
in the liquidity and long-term solvency categories. Contracting 
out manufacturing obligations means that these options compro­
mise some of the potential to build manufacturing knowledge so 
these options achieve lower scores in manufacturing knowledge. 
The CMOIBuild option scores low in the productivity category 
as the labour force is not used as efficiently as with either the 
CMO or the Build options.
4.2. Sensitivity analysis
This analysis displays the maximal sensitivities across all 
options. For individual options these values will change as may 
the order of these factors. The analysis revealed that the most 
significant factor affecting the deterministic WSM score was the 
market capture achieved by the company (Fig. 3). It was found 
that the most critical drivers were associated with commercial 
factors. These are similar to results from research conducted by 
Rajapakse et al. (2(X)5) and Stonebraker (2002).
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Fig. 3. Tornado diagram illustrating the overall maximal effects of best (#  ) and 
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Fig. 4. Distribution of the expected net present value for the Partner (■), CMO 
(♦), Build (A ), Partner-Buüd (■) and CMO/Build (♦) options under uncertainty.
4.3. Expected net present value (ENPV)
Use of the WSM proved to be highly useful in its abil­
ity to aggregate many aspects of the financial analysis and 
the operational evaluation. Furthermore, analysing the options 
under uncertainty via a Monte Carlo analysis also proved to 
be highly informative in revealing the expected performance of 
each option. Fig. 4 demonstrates that the CMOIBuild option is 
the most profitable and has a marginally greater upside potential 
in generating profit. The reason why the Build option does not 
generate the most profit in all circumstances is mainly due to its 
less developed technical manufacturing capabilities. In this case 
study, the option to build has significantly less efficient technical 
manufacturing capabilities than with outsourcing to a contrac­
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Fig. 5. WSM score of the for the Parmer (■), CMO (♦), Build (A ), Partner-Build 
(■) and CMO/Build (♦) options under uncertainty.
Build option than the COGS premium and royalties charged will 
do in the CMO/Build option. When considering the Build and 
CMO options alone it can be seen that the Build option demon­
strates a better performance in ENPV which is consistent with 
research by Ginsberg et al. (2002). Additionally, it is shown that 
in this scenario increasing mean ENPV is coupled with greater 
uncertainty of this value being achieved.
4.4. Stochastic WSM scores
The stochastic WSM score highlights the holistic value of the 
option to the decision maker as defined by the décision-support 
methodology. Fig. 5 reveals the difference in this case between 
an analysis-based entirely on ENPV and one based on multiple 
criteria. In particular, the CMO/Build option which came first 
in the ENPV analysis is one of the lowest scoring options in 
the WSM analysis. Another notable difference is that none of 
the ranking positions achieved with the ENPV analysis are the 
same with the WSM analysis. In contrast, the stochastic WSM 
ranking positions are the same as the deterministic WSM ranking 
positions (Tables 7 and 8).
Fig. 5 also highlights a distinction between the top three 
options. Build., Partner, and Partner/Build and the remaining 
alternatives. By regarding the peaks of each distribution alone, 
the Build option can be considered to be most preferential 
and more certain, but not entirely distinct from the Partner 
option. The Partner/Build ranks closely behind the Partner 
and Build options but not close enough to be preferred over 
either. To draw further distinction between the Partner and
Table 8
Deterministic rankings of the options considered within each decision-making category
Group Category Parmer CMO Build Partner/Build CMO/Build
Financial Profitability 5 3 2 4 1
Asset utilisation 3 1 5 4 2
Liquidity 2 5 3 1 4
Long-term solvency 1 5 3 2 4
Capital structure 5 3 1 4 2
Operational Productivity 2 1 3 5 4
Location 5 1 3 4 2
Flexibility 4 5 1 2 3
Manufacturing knowledge 3 5 1 2 4
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Fig. 6 . Ri.sk vs. reward of considered options. The vertical dotted line and the 
horizontal dotted line are representative of the mean reward and risk values, 
respectively, across all options. The size of each bubble is proportional to the 
initial expenditure required to exercise each option.
Build options a two-sample two-tailed f-test assuming equal 
variances demonstrated full confidence that both samples 
are completely dissimilar. What needs to be determined 
from this point is the extent to which the WSM valuation 
can be relied upon to distinguish the Build and Partner 
options.
4.4.1. Risks and rewards
It is useful to quantify the impact o f uncertain variables for 
each option on the WSM score. Here, the risk refers to the semi­
standard deviation and the reward refers to the stochastic WSM 
score. Further, deviations above the mean value are not con­
sidered to be undesirable risk so the standard deviation which 
includes values both above and below the mean value, is not 
an appropriate metric. Fig. 6 plots the semi-standard deviation 
versus the reward of each option and also displays the initial 
expenditure for each option. It is ideal to have options in the 
lower rightmost quadrant. The Partner/Build option is shown to 
perform within this quadrant. The Build option performs approx­
imately at the average semi-standard deviation value across the 
group with an above average reward.
The Build option is also shown to require the highest ini­
tial expenditure. If the company could not afford this option 
then it would have to reconcile between the trade-offs seen 
with the other options that perform above the average reward. 
As demonstrated in Fig. 6, these options would be the Partner 
and PartnerlBuild options. The Partner option offers a higher 
reward than the PartnerlBuild option but is also coupled with 
significantly higher risk.
This risk and reward analysis allows the decision maker to 
draw clearer distinctions between the Build and Partner options 
than was possible with Fig. 4 or Fig. 5 exclusively. Fig. 6 
makes clear that although the rewards are above average for 
the Build and Partner options, the Build option incurs a sig­
nificantly lower risk. The Build option has the advantage of 
offering over 14% lower risk with nearly a 4% greater reward 
than the Partner option. It is intuitive to attach little advantage 
to this gain in reward, however, this is not necessarily an accu­
rate association to make. As seen in this case, a gain o f nearly 
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Fig. 7. Operational vs. financial aggregate scores of the Partner (■), CMO (♦), 
Build ( A) ,  Partner-Build (□) and CMO/Build (0). Each data point is represen­
tative of its deterministic value. The x  and y error bars each signify one standard 
deviation either way of the data point. The vertical line intercepting the financial 
aggregate score axis is the mean financial aggregate score. The horizontal line 
intercepting the operational aggregate score axis is the mean operational score. 
The diagonal line shows the profile of financial and operational scores that are 
equally balanced.
4.4.2. Financial and operational aggregate scores
While analysing the hoUstic value of the WSM score reveals 
the overall worth of the option to the decision maker it is impor­
tant to discern the factors that have been most influential in 
score’s determination. This is especially significant in confirm­
ing whether or not the characteristics attributable to the highest 
ranking option are aligned with the business strategy. Due to the 
structure of the MCDM-based model it is possible to breakdown 
the WSM value of each option into scores that relate specifi­
cally to financial and to operational criteria. Fig. 7 demonstrates 
the balance of operational to financial scores for each option in 
this scenario. A high financial score suggests a highly sustain­
able investment and likewise a high operational score suggests 
a high level of practicality and manageability. Hence, the most 
desirable option is the one that lies most to the upper rightmost 
quadrant. The Build option performs fully above the group aver­
age for both scores. Comparison between the Build and Partner 
options demonstrate that the Build option is most valuable both 
financially and operationally.
Under uncertainty it is also highlighted that there is greater 
variance with the financial aggregate scores than with the oper­
ational scores. Because of the subjective nature of scoring for 
many of the operational attributes it would not be accurate to 
say that this would necessarily translate to a lower operational 
risk.
4.4.3. Operational to financial ratio
The relative weighting of the operational aggregate score to 
financial aggregate score, R, is the final analysis considered in 
this paper and is demonstrated in Fig. 8. The previous analyses 
were under the presumption that operational and financial char­
acteristics were of equal value to the decision maker. In Fig. 8, 
values of R ranging from 0 to 2 were used to investigate the stabil­
ity of the ranking configuration. Within this range, it was found 
R did not have an effect on the top ranking option demonstrating 
that this option dominates the other options when considering 
both the financial and operational aspects. It can be seen from
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Fig. 8 . The impact of the ratio, R, of operational to financial aggregate weight­
ings on the mean overall aggregate score for the Partner (■), CMO (♦), Build 
( A) ,  Partner-Build (□) and CMO/Build (0).
Fig. 7 that the CMO' option stochastically dominates all other 
options in operational scoring so as the value of R increases this 
option becomes increasingly preferred and is most preferential 
at values of R above 6.02.
4.4.4. Summary o f stochastic results
The results indicate that all options are financially and opera­
tionally viable but according to all analyses the Build option 
is most preferential. Although there were many conflicting 
attributes associated with the selection of any option, it is impor­
tant to be aware that the Build option is the option most aligned 
with the company’s business strategy. Overall, the factors defin­
ing the decision proved to be its ability to exercise the option 
along with its willingness to accept the inherent trade-offs. It 
is important to remember that the results are specific to the 
assumptions made in the case study; for example, if  tighter bud­
get constraints were assumed, this could influence the ranking of 
the option to build capacity and might even rule it out completely 
as infeasible.
Comparing the results presented, an investigation by 
Rajapakse et al. (2005) contained similar investigations with 
regard to risk and ENPV analysis. The paper involved the 
comparison of the construction of a biopharmaceutical manu­
facturing facility and the utilisation of a CMO. Similar to the 
results shown here was that the CMO displayed a significantly 
lower performance in ENPV when compared with building a 
new facility. Contrary to the results demonstrated here, was that 
the CMO was found to be less risky than the option to build. It is 
difficult to compare results accurately as there are many differ­
ences between the case studies, assumptions and architectures 
of the models. For example, the drugs used in this case study 
are at later stages of development so the portfolio risk will be 
lower than a portfolio of drugs all entering early stage clinical 
trials as in Rajapakse et al. (2005). This reinforces the fact that 
the results are case study specific.
One issue still to be resolved is that of the weightings o f the 
criteria and their respective categories. In the case study equal 
weighting was assigned to all criteria and their categories but 
this configuration will conflict with the preferences of a deci­
sion maker that is more aggressive on generating profits. The 
line of inquiry following this is then in determining a suitable 
w eighting configuration between the group, their categories, and
their individual criteria to best represent the preferences of the 
decision maker. This consideration is outside the scope of this 
paper.
Finally, the decision maker needs to be aware that, by defini­
tion, the normalisation of criteria values distorts or removes any 
meanings associated with their original magnitudes. Addition­
ally, further distortion of the original magnitudes is exacerbated 
by the amalgamation of criteria values into a score and thus cau­
tion is required when interpreting the value of that score. As 
demonstrated earlier, the Build option outperformed the Partner 
option by a modest percentage in its WSM score but a significant 
gain in ENPV was a contributor in this performance.
5. Conclusions
The development of a décision-support framework to assist 
decision-making in strategies for the acquisition of biophar­
maceutical manufacturing capacity has been presented. The 
framework provides a structured and transparent method of 
analysing such scenarios through the utilisation of MCDM and 
Monte Carlo simulation. Additionally, several financial and 
operational criteria were considered to provide a broad and 
detailed analysis from both perspectives. A hypothetical case 
study was formulated to demonstrate the usefulness and limita­
tions of the framework.
The WSM proved to be highly suitable for data handling 
and for the analysis of results. The Monte Carlo simulation was 
valuable in highlighting the probability distributions and vari­
ance of base case values. Use of the model has highlighted that 
the employment of a single criterion in making strategic man­
ufacturing decisions of this nature may not allow the decision 
maker to be aware of other important criteria. However, use 
of multiple criteria analysed under uncertainty provided a suc­
cessful approach in identifying and confirming the best option. 
The analytical approach required highlights the complexity that 
can be involved in making decisions similar to the one anal­
ysed. Ultimately, a thorough and accurate analysis o f financial 
and operational data is essential to make confident distinctions 
between feasible and attractive options.
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Stochastic Combinatorial Optimization Approach to Biopharmaceutical Portfolio 
Management
Edmund D. George and Suzanne S. Farid*
The Advanced Centre for Biochemical Engineering, Department of Biochemical Engineering,
University College London, Torrington Place, London WCIE 7JE, U.K.
Key strategic decisions in biopharmaceutical portfolio management include drug selection, activity scheduling, 
and third party involvement. Optimizing strategies is complicated by uncertainty, dependency relationships 
between decisions, and multiple objectives that may conflict. This paper presents the development of a stochastic 
combinatorial multiobjective optimization framework designed to address these issues. The framework simulates 
portfolio management strategies while harnessing Bayesian networks and evolutionary computation conceitedly 
to characterize the probabilistic structure of superior decisions and evolve strategies to multiobjective optimality. 
This formulation is applied to a case study entailing a portfolio of five therapeutic antibody projects. 
Optimization was driven by two objectives that conflicted here; maximizing profitability and maximizing the 
probability of being profitable. Initial analysis o f competing strategies along the Pareto optimal front indicated 
that strategies with clear differences in comprising decisions can compete with similar reward—risk profiles. 
Hence optimization yielded results that were not intuitive but instead suggested that flexibility between strategies 
can exist in such large-scale problems. A cluster analysis was used to identify the prevalence of broad and 
superior building blocks along the Pareto front. In-house development of drugs generally emerged as a preferred 
constituent o f superior strategies which suggested a drive toward minimizing contracting fees, premiums, 
royalty charges, and losses in sales revenue to third parties; no budgetary constraints were imposed in this 
case study. It appeared that strategies for scheduling activities had the most overarching impact on performance. 
Strategies for portfolio structure appeared to have the greatest degree of flexibility relative to other strategic 
components.
1. Introduction
Biopharmaceutical drug development is expensive, lengthy, 
risky, and complex. The literature has seen published figures 
in excess of $800 million for developing a single drug,*’^  with 
6—10 years as a typical development tirne.^”  ^ Developmental 
uncertainties complicate the development process by introducing 
the possibility that it may be necessary to terminate development 
of a drug before a return can ever be realized. Market-related 
uncertainties introduce the risk that a marketed product may 
not meet the revenue expectations of the developer. Hence, a 
major and ubiquitous problem confronting biopharmaceutical 
drug developers is how and when to best make and implement 
critical business decisions so that important rewards such as 
profitability are optimized. Yet more expensive, risky, and 
complex is the development of a portfolio of drug candidates. 
Within a company’s pipeline, valuing one drug at a time is not 
sufficient and drug developers must consider the entire portfolio 
under technological and market uncertainties and resource 
constraints.^ Here the developer must also make decisions to 
best construct the portfolio to optimize the management of 
resources and reward related trade-offs that each drug develop­
ment project may introduce.
Decisions made on the portfolio will include deciding the 
number of comprising projects subject to those that are most 
promising given resource constraints. Also included is the 
scheduling of critical development activities subject to a 
prioritized order of development based on considerations such 
as the identification of the most promising projects and 
accounting for strategic windows of opportunity in targeted drug 
markets. Portfolio selection problems pertaining to drug devel­
* To whom correspondence should be addressed. Tel.: + 44  (0)20 
767d 4415. Fax: + 44  (0)20 7916 3943. E-mail: s.farid@ucl.ac.uk.
opment have been addressed in the literature and cover a variety 
of methodological features, technical problems, and scenarios. 
For example, see Subramanian et al.,*’^  Blau et al.,‘®’" Rogers 
et al.,*  ^ and Jain and Grossmann.*^
In addition to decisions made on portfolio structure, drug 
developers must also address acquisition of or access to 
infrastructure for capacity-related decisions in drug development 
and manufacturing endeavors. These will include important 
strategic decisions such as whether to integrate activities within 
the company, to outsource them to a contract researcher (CRO) 
or manufacturer (CMO), or to partner with a company that has 
complementary developmental, manufacturing, and marketing 
resources. For example, strategic outsourcing to a contractor 
has become a vital component of the research and development 
process'’^ and plays an increasingly important role in the 
operations of established and emerging pharmaceutical com­
panies.’  ^ There are contributions that address the issue of 
capacity planning in the pharmaceutical industry using optimi­
zation-based approaches of which the majority pertains to drug 
developers who have or plan to have integrated in-house 
development and manufacturing infrastructures. There are some 
who develop frameworks for wider settings which consider third 
party developers and manufacturers. These include Rogers and 
Maranas,’  ^ Oh and Karimi,’*^ and Rajapakse et al.'^” ’ 
Approaches have been reported for the development of 
frameworks that incorporate both the problems of portfolio 
management and manufacturing capacity planning simulta­
neously, representing an important advancement. These present 
more challenging and realistic large-scale optimization problems 
that offer vast extensions to the lines of inquiry for either of 
the two problems in isolation. Such approaches include those 
by Levis and Papageorgiou,’  ^Maravelias and Grossman,^” and 
Papageorgiou et al.^’
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Figure 1. Schematic of the framework used to evaluate populations of candidate solutions and iteratively evolve superior populations of strategies.
Given the relevance and importance of contributions to large- 
scale portfolio and capacity optimization problems in biophar­
maceutical settings, especially in modem industry, this paper 
addresses the development of a holistic framework for the 
simultaneous stochastic, combinatorial, and multiobjective 
optimization of biopharmaceutical research and development 
portfolio management alongside manufacturing capacity plan­
ning decisions. More specifically, given a set of drug candidates 
and their uncertain development, manufacturing, and commercial 
parameters, alongside an availability of external corporate bodies 
for development and manufacturing with their various uncertain 
technical characteristics, this work presents a novel method for 
finding the optimal structure of the drug development portfolio, 
the development sequence for the selected drug candidates, the 
schedule of critical development activities, and the itinerary of 
activities at specific stages that should be integrated in-house, 
outsourced, or partnered to maximize important multiple objec­
tives. The overall framework is a combination of a simulation- 
based evaluation framework based on work by George et al.^  ^
and a bespoke estimation of distribution algorithm^^ (EDA) to 
iteratively evolve a population of candidate strategies. It is the 
aim of this paper to investigate the performance of strategies 
optimized via the proposed framework and to ascertain any 
important implications.
The organization of the remainder of this paper is now 
described. Section 2 details the complete model formulation for 
the stochastic evaluative framework and for the EDA. Section 
1 presents a case specific to the production of monoclonal 
antibody drug candidates to exemplify the use of the framework. 
Section 4 describes and discusses the results pertaining to the 
case presented. The final section discusses any final conclusions.
2. Model Formulation
The stochastic optimization process makes use of an evalu­
ative framework to capture the impact of decisions made by
strategies in the modeled environment and to estimate their 
stochastic properties (Figure 1). This is coupled with an EDA 
that operates the optimization procedure through the machine 
learning of instances of decision variables that are associated 
with superior strategy performance. Any interdependent rela­
tionships between decision variables and their instances are data 
mined and are used to build a probabilistic model on which the 
formulation of new strategies is based. The quality of strategies 
is thereby iteratively improved.
The model is designed using C + +  and MS Excel. The entire 
simulated environment is assembled in C + +  as this contains 
the most frequently utilized calculations and the C + +  language 
offers significant savings in computational time. MS Excel is 
used as the main graphical user interface as it offers a convenient 
means for storing, extracting, and manipulating data. The 
environment is interfaced with MS Excel via a dynamic link 
library where it is represented as a user-defined function. 
Decision variables are entered into the function and defined 
parameters are outputted. Modules for controlling the flow of 
data in the simulation and optimization procedures are compiled 
in Visual Basic for Applications (VBA), which is readily 
executable in the MS Excel environment.
2.1. Evaluative Framework. The framework for evaluating 
each candidate solution (Figure 1) models the performance of 
the strategy by mapping the consequences of decisions made 
within the simulated environment. Various facets of the drug 
development process and its wider commercial environment are 
captured within the modular structure of the evaluative frame­
work. Each module is designed to carry out a set of related 
calculations, and as illustrated, these modules are networked 
and eventually result in the evaluation of a set of criteria. The 
following subsections will detail the contents of these modules.
2.1.1. Superstructure of a Candidate Solution. Consider 
generation G{t) as a population of candidate solutions at a given 
iteration of the optimization procedure, t, within the total number
Ind. Eng. Chem. Res., Vol. xxx, No. xx, XXXX C
Candidate solution, g
____ A____
T im in g  V, C o rp o ra te  re la tio n s
1 ^g.i-2  1 ^Vi-3 1 1 S . '- l  1 1 1 ^
T ,irg o t P C  C lin ic a l  d e v e lo p m e n t:  
ID  T e s tin g  PI, PII, PHI
M a n u fa c tu r in g :
PI, P II, PHI M a rk e t
3 } '
Figure 2. Superstructure of a candidate strategy for the commercialization of a portfolio of five drugs.
of iterations, fmax, that can potentially maximize the objectives 
of the decision maker. Each candidate solution, g, in G(l) has 
a generalized structure for representing its decisions. Figure 2 
demonstrates this generalized structure for a portfolio of five 
drugs, where the structure can be segregated into three subtypes; 
sequence, timing, and third party usage.
The strategy for the drug development sequence, Dg,  codes 
the drugs that are included in the portfolio and the order in which 
they are commercialized:
Dg =  D^,^3, ..., V g e  G(t), i e l  (1)
where D g j  is the drug chosen as the /th drug in the drug 
development sequence by the gth candidate solution, and I is 
the total number of drugs in the drug development portfolio. It 
is clear that i must be any drug not already chosen as part of 
Dg.
The timing strategy for the zth drug in the development 
sequence according to the gth candidate solution, Tgj, com­
mences development of drug / according to when drug / — 1 
reaches the beginning of a particular stage of development. 
These stages can be instantiated as the following: target 
identification (ID), preclinical testing (PC), phase 1 clinical trials 
(FI), phase II clinical trials (Pll), phase 111 clinical trials (Pill), 
FDA review (FDA), and market approval (MKT). Thus
VgeG(f) ,  z E / ( 2 )
T^,= {ID, PC, PI, Pll, Pill, FDA, MKT} V g e G (/) , i e l
(3)
where Tg is the set of timing strategies for all drugs in the 
portfolio.
The corporate strategy belonging to the gth solution for the 
zth drug at the yth development activity, C g j j ,  has three possible 
instances for each stage: in-house or otherwise referred to as 
an integrated activity (/), outsourced activity (C), and partnered 
activity (P). Hence
c , =  C ,„ ,}  V g e  G(/), i e  I (4)
~
V g e  G(t), i e  I, j e  J (5) 
c , „  =  {/, C, P] Vg e G{t), i e  I, j e  J (6)
where J is the number of development activities. This format 
allows the framework to formulate a plan of critical activities 
to complete either by themselves or by another corporate body. 
1 he development activities, Cgjj, are structured as follows: Cgj,\, 
target identification; C^ ,,,2, preclinical testing; Gg.,,3, phase 1 
clinical testing; C^ ,,,4, phase 11 clinical testing; Cgj,s, phase 111
clinical testing; Q,,.6, manufacturing for phase 1 clinical trials; 
Cgjj, manufacturing for phase 11 clinical trials; Q,,,8, manufac­
turing for phase 111 clinical trials; and Q,/,9, commercial 
manufacturing.
Structuring the strategies Dg and Tg is straightforward. Each 
instance within Dg can only refer to one drug, while any 
combination of timing instances for each Tgj in Tg is permissible. 
Structuring the corporate strategy requires the application of 
some rules to avoid the formulation of nonsensical strategies. 
The first set of stipulations restricts the company from breaking 
and resuming contracts with partners:
If Cg,i =  PthenCg,^ =  P fory= (2 ,3 ,4 ,5 ,6 ,7 ,8 ,9 }  (7) 
If q ,.  2 =  P then =  P for y = {  3 ,4 ,5 ,6, 7 ,8,9  ) (8) 
If C^ ,,. 3 =  P then =  P for y = {  4 ,5 ,6, 7 ,8,9} (9)
If =  P then .. =  P fory = { 5 ,7 ,8 ,9 )  (10)
If q .,5 =  P then =  P fory = { 8 ,9 }  (11)
If =  P then Cgjj =  P fory =  {3 ,4 ,5 ,7 ,8,9} (12)
If C^ ,,. 2 =  P then .. =  P for y =  {4 ,5 ,8,9} (13)
If q ,,8 =  Pthen C ,,, =  P fory= {5,9} (14)
This assumes that the partner is required for both clinical 
trial development and manufacturing. A second set of 
stipulations prevents the breaking of outsourcing contracts 
on clinical trial and clinical manufacturing activities:
C fory ={4 ,5} (15)
If 4 =  C then =  C for y =  {5} (16)
(17)
(18)
If Cg,i,6 =  C then =  C fory = { 7 ,8 }
If Cgij =  C then =  C for y =  {8}
It is assumed that contracting for clinical trial testing and 
contracting for manufacturing will be completed by separate 
companies.
These stipulations have an added benefit of reducing the 
decision space and computational time. Without them each drug 
would have a total decision space for Q,, of 3^  solutions over 
its nine constituent decision variables; now this is reduced to 
207 solutions. To support computational efficiency, Q,, is 
programmed as a single variable having 207 instances, rather 
than as nine Q,,j variables with each having three instances. 
This format means that Cgj can be instantiated from a database 
of permissible combinations of each Cgjj, as opposed to having 
an active procedure that validates and corrects the structure of 
Cgj for each g in G(t) over each t in T.
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2.1.2. Stochastic Variables. To simulate the uncertain 
environment, the model accounts for the stochastic nature of a 
range of uncertain variables. In this paper, each stochastic 
variable is characterized by a triangular probability distribution 
based on the specification of maximum, minimum, and most 
likely values. The types of variables included in the model 
formulation are costs, commercial factors, and manufacturing 
capabilities. Each variable bears relevance to a single element 
of Cgj, and a separate distribution must be defined for each 
possible instance of the relevant element. Thus, for a portfolio 
of five drugs, individual distributions of 99 stochastic variables 
must be defined. Depending on the structure of g, the relevant 
stochastic variables will be selected for sampling. Cost variables 
directly influence decisions made within Cgj. Commercial factor 
variables impact the structure of D, and the instantiation of Cg,,,9, 
and hence the choice of drugs as well as third party involvement 
for commercial manufacture. Manufacturing capability variables 
will influence decisions made on the instances of Cgjj for 6 < 
j  < 9, and thus the involvement of third parties in clinical and 
commercial manufacturing.
2.13. Biomanufacturing Model. The framework used to 
model the manufacture of biopharmaceutical products is based 
on work reported by George et al.,^  ^Farid et al.,^ '^ ~^  ^and Lim 
et al.^ -^^ * Included in the model are the main process and 
ancillary tasks involved in the manufacturing procedure. The 
main input parameters to the model are the annual demand to 
be met by the facility, the expected fermentation titer, the overall 
product yield, and the probability of achieving success for a 
single batch fermentation. Equations for calculating the utiliza­
tion of equipment, materials, utilities, and labor are also 
included. Cost calculations are supported by a database of unit 
costs for equipment and materials used in the manufacturing 
process.
2.1.4. Dependencies. Within a set of decisions it is possible 
that at least one of these decisions can have an impact on the 
performance of remaining decisions that are yet to be executed. 
In the real world, this can be a consequence of making decisions 
that affect the utilization of the same tangible or intangible 
resource. The framework recognizes three such contexts of 
dependency where this type of impact may occur; contractual, 
revenue, and manufacturing cost.
Contractual dependencies refer to the utilization of a third 
party for manufacturing or research activities. Here, the premise 
is that the longer the period for which a third party is used and 
the greater the number of activities that it is involved in, the 
more favorable the rates it charges become. Additionally, for 
each third party there is a minimum charge that it will not 
breach. This clearly affects how the corporate relation strategy 
performs in the model.
Revenue dependencies refer to the impact that constituents 
of the company’s drug portfolio create when competing within 
the same market. When multiple drugs comp>ete in the same 
market, each drug can suffer from reduced returns in comparison 
to what it might have achieved if commercialized in the absence 
of competing drugs, given the same commercial environment. 
It is also possible that multiple drugs can enhance the sales 
revenue of each other if they have complementary applications. 
In the model, the impact of this dependency is realized through 
Dg and Tg. The configuration of Tg is important here because, 
in the absence of other dependencies affected by these strategies, 
it may be more beneficial to stagger the development of 
competing drugs so that there are periods of reduced or no 
competition. Also, the performance of these strategies will
depend on the revenue-related penalties or benefits of having 
competing or complementary drugs in the marketplace.
Capital dependencies are modeled here as affecting the capital 
expense required for manufacturing a drug, due to the sharing 
of resources for structurally similar drugs. Where such drugs 
are being manufactured, it may be possible to use some part of 
the same manufacturing facilities, hence reducing the overall 
capital requirements. The impact of this dependency is reliant 
on the capital savings that can be realized within a group of 
drugs. This dependency is affected by the strategies for the 
structure of the drug portfolio, where the choice of structurally 
similar drugs supports reduced capital expense requirements. 
The strategy for the order in which drugs are commercialized 
is also important because drugs commercialized later in the 
pipeline may require less capital. Additionally, these strategies 
must reconcile the penalties and benefits of their impact on 
capital and revenue dependencies.
2.1.5. Timeline. The timeline module contains calculations 
for producing the entire schedule of activities for the portfolio. 
The inputs for the calculations are Dg, Tg, and the time it takes 
to perform each activity in the proeess of drug development 
and commercialization. The timeline is used to instruct the profit 
and loss module when to account for the various elements on 
income and expense.
Estimation of Distribution Algorithm. Estimation of dis­
tribution algorithms'^ (EDAs), are similar to a class of 
optimization algorithms known as genetic algorithms'^’ (GAs) 
and have been shown to be a class of promising approaches in 
solving combinatorial optimization problems.^’ Like GAs, EDAs 
function by iteratively evolving a population of candidate 
solutions to the problem until a termination criterion is satisfied. 
A main driver by which GAs are thought to achieve this is 
through the manipulation of building b lo c k s .B u ild in g  blocks 
are a central concept in GA theory, where superior building 
blocks are expected to be key components of superior solutions. 
They can be any set of instantiations of decision variables 
present in any set of candidate solutions. Additionally, a superior 
building block can be considered as a set of instances of decision 
variables that work together to support the performance of any 
set of superior candidate solutions in the objective space 
considered. The instances of decision variables forming a 
building block may also exhibit a dependency relationship where 
added value in superiority is achieved by the holistic presence 
of a set of instances rather than necessarily through individual 
incremental increases in performance contributed by each 
constituent of the building block. EDAs are designed to 
recognize superior building blocks explicitly by constructing 
probabilistic models of the states of decision variables that are 
present in superior solutions. Examples of simple EDAs in 
literature include the univariate marginal distribution algorithm^  ^
(UMDA) and the compact genetic algorithm^"’ (cGA). Examples 
of more complex EDAs include the Bayesian optimization 
algorithm^  ^(BOA) and the multiobjective hierarchical Bayesian 
optimization algorithm^  ^ (mohBOA).
In this paper, and like the BOA, the data structure used as 
the framework for the probabilistic model is a Bayesian network. 
A Bayesian network is an annotated directed graph that encodes 
probabilistic relationships, and their use here derives from the 
fact that artificial intelligence researchers have used them to 
encode expert know ledge.T h e topology of the network is 
learned directly from the strueture of top-performing candidate 
solutions in S{t) and is then randomly sampled via the 
eonditional probabilities that it encodes to generate G(t+1). The
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Initial population:
Let the population o f  candidate solutions be G'(/). 
t -  I
Randomly generate the initial population o f  candidate solutions, G(I).
Let be the maximum number o f populations to be evolved.
For t - 1 to t„^,:
Evaluation:
hvaluate the stochastic properties of each g in Git).
Selection:
I sc the fast nondominalcd sorting and crowding distance algorithms to select the top 50% of 
solutions, from 0 \t)
('lu.\tenng o f the objective space:
I sing the k-nieatis clustering algoiithin, separate 5(1) into / clusters.
For each cluster, A(/, t):
Erohahilistic inoite! hiiilJini;:
Construct the Rayesian network. t). using a hill climbing procedure to optimize the 
Rayesian Dirichlet metric o \e r  H(i, t).
Sam;iluiii o f  the probabilistic model:
Cienerate a new set o f strings l)(i. t) by randomly sampling the joint probability distribution 
encoded by H(i, t). The number o f  strings to be generated will be twice the original cluster
Population reftcneration
Generate the new population G (t' 1 ) by randomly by replacing all strings in G(t) with all strings in 
each Oil, t).
Figure 3. Pseudocode for the EDA.
Table 1. Commercial Characteristics of Available Drug Candidates
drug candidate drug group
annual demand 
(kg/year) CAGR (%)
A 1 Tr( 120,250,380) Tr(1.00,1.01,1.02)
B 1 Tr( 100,200,300) Tr( 1.00,1.01,1.02)
C 1 Tr(80,150,230) Tr( 1.00,1.01,1.02)
D 2 Tr(50,100,150) Tr( 1.00,1.01,1.02)
E 2 Tr(l 00,200,300) Tr( 1.01,1.03,1.04)
F 2 Tr(80,150,230) Tr( 1.01.1.03,1.04)
G 2 Tr(50,100,150) T r(l.01,1.03,1.04)
H 3 Tr(80,150,230) Tr( 1.02,1.05,1.06)
I 3 Tr(50,100,150) Tr( 1.02,1.05,1.06)
J 3 Tr( 100,200,300) T r(l.02,1.05,1.06)
Table 2. Duration and Cost Information for Various Phases of the 
Drug Development Process"
phase of development duration (years) cost ($MM)
EDA used here (Figure 3) is largely based algorithmic concepts 
found in the mohBOA.
More detailed information regarding the selection of superior 
strategies using fast nondominated sorting and crowding dis­
tance, clustering of the objective space using A:-means clustering, 
and issues concerning practicalities of constructing Bayesian 
networks can be found in the Appendix A, Appendix B, and 
Appendix C, respectively.
3. Case Study Description
A hypothetical case was formulated to illustrate and examine 
the ability of the framework to discover optimal strategies for 
performance against multiple objectives in an uncertain environ­
ment. In this case a biopharmaceutical company has 10 
monoclonal antibody drug candidates available for development 
but can only choose five. It needs to know which drug candidates 
should be chosen, their order of their development, the timing 
schedule of development activities, and which corporate bodies 
should be assigned to each development activity. The optimiza­
tion model is considerate of the commercial characteristics of 
drug candidates (Table 1 ), durations and costs associated with 
various stages of the drug development (Table 2), and technical
target identification 1 Tr(3,5,8)
preclinical 2 Tr(20,35,50)
phase 1 cliitical trials 1 Tr(5,15,20)
phase II clinical trials 2 Tr( 15,25,35)
phase III clinical trials 3 Tr(45,85,125)
scale-up synthesis 1 Tr(3,5,8)
formulation 1 Tr(5,10,15)
commercial preparation 1 Tr( 1,2,3)
marketing 1 Tr(2,4,6)
FDA review 1 Tr(2,4,6)
market lifetime 10
ramp time to peak market: I  Tr(3,4,5) -
ramp time to peak market: C Tr(3,4,5) —
ramp time to peak market: P Tr(2,l,3) —
decay time after market expiry: I  Tr(2,l,3) -
decay time after market expiry: C Tr(2,l,3) -
decay time after market expiry: P Tr(3,4,5) -
"The cost of producing a drug for market is determined by the
biomanufacturing cost model.
manufacturing characteristics for each corporate body (Table 
3). As seen in Table 1, there are three groups of indication that 
these candidates belong to. Annual demand figures and com­
pound annual growth rates (CAGRs) are based on realistic 
figures. The dependencies for revenue and capital expense are 
detailed in Table 4. Specifications for contractual dependencies 
and technical probabilities of success are displayed in Table 5.
An example of the complexity of the decision space concern­
ing the five-drug portfolio is discussed. Overall, each strategy 
consists of 54 decision variables: five for the selection of drugs 
for the portfolio, four for timing the commencement of 
development activities for the next drug in the pipeline, and 
nine assignments of corporate bodies to critical activities for 
each of the five drugs. Hence, the choice of portfolio structure 
has 1 0 x 9 x 8 x 7  x 6  possibilities that are combined with
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Table 3. Technical Information for Manufacture of Drug Candidates According to Clinical Phase and Corporate Body
corporate body development phase whole process yield (%) fermentation titer (g/L) batch success probability
/ phase I Tr(0.25,0.35,0.50) Tr(0.20,0.30,0.50) Tr(0.80,0.60,1.00)
C phase I Tr(0.45,0.55,0.85) Tr(0.80,1.00,1.50) Tr(0.70,0.90,1.00)
P phase I Tr(0.40,0.50,0.75) Tr(0.60,0.75,1.20) Tr(0.65,0.85,1.00)
I phase II Tr(0.40,0.50,0.75) Tr(0.30,0.40,0.60) Tr(0.65,0.85,1.00)
C phase 11 Tr(0.45,0.60,0.90) Tr( 1.20,1.50,2.30) Tr(0.75,0.95,1.00)
P phase II Tr(0.40,0.50,0.75) Tr(0.80,1.00,1.50) Tr(0.70,0.90,1.00)
I phase III Tr(0.40,0.50,0.75) Tr(0.80,1.00,1.50) Tr(0.70,0.90,1.00)
C phase III Tr(0.55,0.75,1.00) Tr(l.50,2.00,3.00) Tr(0.75,1.00,1.00)
P phase III Tr(0.45,0.60,0.90) Tr( 1.20,1.50,2.30) Tr(0.75,0.95,1.00)
I market Tr(0.40,0.50,0.75) Tr(0.80,1.00,1.50) Tr(0.70,0.90,1.00)
C market Tr(0.55,0.70,1.00) Tr( 1.50,2.00,3.00) Tr(0.75,1.00,1.00)
P market Tr(0.45,0.60,0.90) Tr( 1.20,1.50,2.30) TdO.75,0.95,1.00)
Table 4. Specification of Dependencies As Related to the Number of 
Drugs from the Same Group within the Chosen Drug Development 
Portfolio"













COGS, cost of goods sold.
Table 5. Specification of Contractual Dependencies and Stage wise 
Probabilities of Success"
royalty rate 
(% of revenue) probability of success
development stage CRO CMO partner group 1 group 2 group
target identification 6 - 60 0.90 0.80 0.85
preclinical trials 7 - 58 0.90 0.90 0.95
phase I clinical trials 8 10 56 0.75 0.85 0.75
phase 11 clinical trials 9 12 54 0.50 0.40 0.55
phase 111 clinical trials 10 14 52 0.70 0.60 0.80
market - 16 50 0.95 0.95 0.95
“ A decrease in royalty rate applies per additional drug and is 
measured in percentage points. Royalty rates decrease by 1% with the 
CRO, and by 2% with the CMO or partner for each additional drug 
development project for which they are involved. A minimum royalty 
rate applies of 3% with the CRO, 5%  with the CMO, and 40% with the 
partner. Groups 1, 2, and 3 refer to drug groups 1, 2, and 3.
possibilities for the order of development. There are 7^ * 
possibilities for the overall timing strategy. Additionally, there 
are 207^ possibilities for assigning corporate bodies to critical 
activities during the developmental phases and commercial life 
of each drug. Overall the entire decision space has a total of 
~3.31 X 10^‘ individual strategies. If each strategy took 1 s to 
evaluate, it would take 1.05 x 10'“* years to enumerate all 
possibilities. Hence, the combinatorial optimization algorithm 
has been specifically developed to efficiently search this vast 
decision space.
The settings used for the mechanics of the optimization 
procedure are now stated and are true for all generations. The 
maximum number of generations /max =  17. The size of a given 
generation IG(/)I =  1000. The number of superior strategies 
selected from a given generation I5(/)I =  500. The number of 
clusters used in the objective space z =  3.
A few comments should be considered. The number of 
generations over which the populations are improved was tested 
through multiple evaluations and was indicated by the lack of 
progression in subsequent generations and the consistency of 
results across multiple tests. Because of the hierarchical 
superstructure of a candidate solution, the total number of 
decisions is 14 instead of 54, which would have been the case 
if decisions on internalizing or externalizing critical activities 
were not grouped into a single deicsion. Using 250 Monte Carlo
trials per candidate strategy was found to be adequate for 
purposes of making comparisons of quality between candidate 
strategies. To ensure that performance metrics are entirely 
dependent on the strategy as opposed to being assisted by the 
generation of an opportunistic set of random numbers, the same 
set of random numbers is used across strategies. The pseudo­
random number generator used here is the Mersenne Twister 
algorithm .T o enhance the efficiency in estimating stochastic 
output properties, stratified sampling was used for each sto­
chastic variable where boundaries of significance were set 
individually. Also, a discount rate of 20% was used for 
calculating values of the profitability indicator, net present value 
(NPV).
4. Results
The case study results are discussed in the following sections, 
focusing on analyzing competing strategies along the Pareto 
front generated and identifying trends along the frontier using 
cluster analysis.
4.1. Pareto Front Progression. In this section the perfor­
mance of strategies in the final population is examined in terms 
of their ability to generate profits, satisfy multiple objectives, 
and provide an acceptable risk profile. The analysis highlights 
the challenges that exist when pursuing multiple objectives in 
the context considered.
The progression of the EDA in discovering the Pareto front 
is demonstrated in Figure 4, where the mean positive NPV (net 
present value) is a measure of reward and p(NPV > 0) is a 
measure of risk. As might be expected, random initialization 
of the population of strategies has resulted in a generally even 
dispersion of the mean positive NPV and p(NPV > 0) 
performance attributes over the objective space. Interestingly, 
what can immediately be seen is that it is possible to construct 
a portfolio of drugs with a significantly higher probability of 
attaining a profit than any of its individual comprising drugs. 
Here drugs with a probability of reaching market that is less 
than 0.25 have been pooled in such a way that offers the decision 
maker a ;?(NPV > 0) value in excess of 0.70. Progression of 
the algorithm in the objective space appears to be considerably 
more constrained in the p(NPV > 0) dimension than it is in the 
mean positive NPV dimension. Progression of the evolutionary 
process has been accompanied by some degree of succession 
at each generation. It is apparent that the strategies available in 
the objective space have generally converged toward a clearly 
defined nondominated frontier, the Pareto front. The Pareto front 
is wide enough to be inclusive of p(NPV > 0) values that might 
be realistically sought after by a decision maker in this setting. 
It is also apparent that for this problem the machine learning 
mechanisms have greatly reduced the variability encoded in the 
conditional and probabilistic models of superior strategies. It 
should be noted that the ability of the algorithm to do this is
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Figure 4. Progressive discovery of the Pareto front; (a) 1st generation, (b) 3rd generation, (c) 7th generation, (d) 10th generation, (e) 14th generation, and 
(f) 17th generation.
dependent on whether a new set of building blocks is able to 
clearly distinguish itself as superior to any existing alternatives 
in the evolutionary process. At some stages, succession in some 
regions of the objective space is accompanied by deterioration 
in other regions. This deterioration refers specifically to the 
nonpopulation of certain regions that were previously populated. 
In this particular case, it was considered appropriate that the 
convergence of the algorithm was tracked visually, principally 
because the objective space has only two dimensions. The 
optimization procedure was considered to be converged when 
general progression of the Pareto front was insignificant, leading 
to an unfavorable loss of regions along the Pareto front. Some 
deterioration was tolerated in regions where rational decision 
makers were unlikely to seek strategies. An example of such a 
region would be where p(NPV > 0) is less than 0.20 or where 
the mean positive NPV is less than $200 million. Further 
analysis indicated that progression beyond 17 generations for 
this case study leads to a severe deterioration of the Pareto front.
The superior strategies selected from the 17th generation 
(Figure 5) show that a nondominated frontier exists in the 
approximate region 0.18 < p(NPV > 0) < 0.75. The frontier 
indicates that a definite trade-off exists here between maximizing 
the mean positive NPV to be generated by a particular strategy 
and maximizing the probability of attaining a positively valued 
profit, p(NPV > 0). At no point along the frontier can the
maximization of mean positive NPV and p(NPV > 0) be 
aligned. Hence, improving p(NPV > 0) means accepting a 
degradation in mean positive NPV. Also, this forces the decision 
maker into the process of selecting strategies that begins with 
deciding upon minimum acceptable levels of profit and prob­
ability of profitability. The region 0.50 < p(NPV > 0) < 0.65 
offers the least trade-off along the frontier when searching for 
strategies that improve p(NPV > 0). In practical terms, not all 
of the frontier will be appealing to the decision maker as there 
will be strategies that either offer probabilities of success or 
mean positive NPV values that are too low to be considered 
for further action.
4.2. Analysis of Competing Strategies. A close examination 
of competing strategies along the frontier indicates that they 
can have similar reward—risk characteristics while demonstrat­
ing marked differences in key decisions relating either to the 
portfolio structure (drug selection), timing, or third party 
strategies. Four strategies along the nondominated firontier have 
been selected to illustrate this and demonstrate how a decision 
maker might rationalize the choice between two strategies of 
similar risk and reward as visualized in Figure 5.
SI and 82 are strategies that generate the greatest mean 
positive financial reward but also the greatest risk of being 
unprofitable. Although these competing strategies have very 
similar third party strategies and portfolio structures, they differ
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Table 6. Structure of the 81 Portfolio Development Strategy" Table 8. Structure of the S3 Portfolio Development Strategy"
i Di Cm c ,.2 Cy C,4 Cii C,6 Ci.1 Ci,8 C.9 Ti i Di Q.1 Ca Co Co Co Co Co Co Co Ti
I F / p P P p p p p p PI I F / P p P p p p p p PC
2 I I c C c c / I I c FDA 2 D c / I c c I I I p PC
3 J C c / I c / I / p FDA 3 B c c I I c I I I p FDA
4 G I I I c c c c c I PH 4 H / I c c c I I c I FDA
5 H c I I c c I / c c — 5 J c I I c c I I c c -
"/, in-house activity; C, outsourced activity; P, partnered activity; 
Q i, target identification; preclirtical studies; C,-,3 , phase I clinick 
development; C,,4 , phase II clinical development; Q^, phase III clinical 
development; C,.6, phase I manufacturing; C,j, phase II manufacturing; 
Ca, phase III manufacturing; C,,9 , market. ID, target identification; PC, 
preclinical testing, PI/PII/PIII, phase I/II/III clinical trials; FDA, FDA 
review; MKT, market approval.
Table 7. Structure of the S2 Portfolio Development Strategy"
i Di Cm C/,2 Co C/.4 Co Co Co Co Co Ti
I F I I I p p I p p p PC
2 I / c c c c I I I c MKT
3 J / c I I c I I c I PI
4 B I I I c c c c c I PI
5 H C / / I c I I c c -
“ /, in-house activity; C, outsourced activity; P, partnered activity; 
C,.i, target identification; C^, preclinical studies; Cy, phase I clinical 
development; C,,4 . phase II clinical development; phase III clinical 
development; C,.6, phase I manufacturing; Q j,  phase II manufacturing; 
C,.8, phase 111 manufacturing; C<,9 , maricet. ID, target identification; PC, 
preclinical testing, PI/PII/PIII, phase I/II/III clinical trials; FDA, FDA 
review; MKT, market approval.
greatly in their timing strategies as illustrated in Tables 6 and 
7. Both strategies share the approach of partnering for the 
majority of activities for the first drug and then preferring to 
use a combination of in-house and outsourced development and 
manufacturing for the remaining drugs. The only exception to 
this is for drug 3 with SI, where partnering is used for 
commercial manufacturing. The first two drugs are either 
developed within 3 years of each other, as in SI, or simulta­
neously, as in S2, and developing the remaining drugs once 
these drugs are close to the marketplace. This approach has the 
advantage of dividing the risk and impact of failure between 
two drug development projects, and it is clear that the expected 
profits from either of the first two drugs are used to fund the 
development of future projects. SI staggers the development 
of its drugs with lengthy development intervals between each 
drug. Resultantly, the time it takes to complete development of 
the portfolio and subsequent market production is 35 years. S2 
has a shorter development time of 26 years because of the 
shorter intervals between the developments of its final three 
drugs. Each strategy develops almost the same portfolio of drugs, 
with the difference being that for the fourth drug SI develops
"/, in-house activity; C, outsourced activity; P, partnered activity; 
C,,i, target identification; preclinical studies; Cy, phase I clinical 
development; C,.4 , phase II clinical development; C,,s, phase 111 clinical 
development; C,,6, phase I manufacturing; Q j,  phase II manufacturing; 
Qg, phase III manufacturing; Q,9, market. ID, target identification; PC, 
preclinical testing, PI/PII/PIII, phase l/II/III clinical trials; FDA, FDA 
review; MKT, market approval.
drug G and S2 develops drug B. Much like the strategy with 
the first two drugs, SI develops its third and fourth drugs 
together and S2 develops its fourth and fifth drugs within 3 
years of each other. For S 1 these two drugs are taken from the 
same group, whereas with S2 this is not the case. SI and S2 
generate similar performances in mean positive NPV, but a 
strong reason for selecting S2 exists. S2 has the additional 
advantage of being executed over a significantly shorter period.
Examining the differences between another pair of competing 
strategies illusfrates how marked differences in third party 
strategies can also result in similar reward—risk characteristics. 
In contrast to SI and S2, strategies S3 (Table 8) and S4 (Table 
9) have similar timing strategies but very different third party 
strategies as well as portfolio structures. S3 utilizes a mixture 
of in-house, outsourced, and partnered activities, whereas S4 
develops the entire portfolio in-house. The portfolio constructed 
by S3 consists of one low-demand drug, two medium-demand 
drugs, and two high-demand drugs that are sourced from all 
three groups. The first three drugs are developed first and 
simultaneously with the remaining two drugs developed with 
lengthy intervals of 9 years in between. For the second and third 
drugs contractors are only used for clinical development, clinical 
manufacturing is kept in-house, and commercial manufacturing 
is conducted with a partner. The fourth and fifth drugs use 
contracting more intensively for clinical development, but 
contractors are also used for clinical manufacturing where they 
are used during phase III trials. The total portfolio development 
time plus time taken during the marketing phase for S3 is 28 
years. S4 develops drugs from all three groups, and its portfolio 
consists of two low-demand drugs, two medium-demand drugs, 
and one high-demand drug. Similar to S3, the first three drugs 
are developed in close succession and S4 also staggers the 
development of its final two drugs in a similar fashion. The 
total time for development and marketing completion of S4 is
30 years, which is similar to that taken for S3. Comparing their 
performances, S3 generates a marginally superior mean positive 
NPV than S4 and is executed over a slightly shorter period. 
Although marginal, the performance results suggest S3 is the 
superior strategy.
From sampling the strategies along the Pareto front, it is 
observable that their positioning in the objective space and even 
their occurrence within the optimized population of strategies 
is not intuitive. It is taken that this is due to the complexity 
that is inherent in the model of the biopharmaceutical drug 
development pathway and the complexity that governs the 
formulation of superior strategies. This is an important under­
score because it highlights to the decision maker the value of 
accounting for the concept of building blocks, which is 
considerably difficult to achieve without the use of advanced 
computational tools. Another important observation is that 
strategies with clear differences in either drug selection, timing, 
or third party strategies can compete with similar reward versus 
risk profiles. Hence it is useful for the decision maker to identify 
a desirable region along the frontier and closely examine the 
different options that can yield the desired return and acceptable 
risk.
4 3 . Cluster Analysis. In order to investigate if any discern­
ible trends in strategy formulation exist among the population 
of superior strategies, the objective space was decomposed into 
three clusters. It was anticipated that an analysis of these clusters 
might add useful insight when considering if any particular 
regions of the Pareto front give rise to the prevalence of certain 
building blocks. As building blocks effectively compete with 
each other for selection, it would be useful to discover if and 
why any particular building blocks are emphasized.
43.1. Portfolio Structure. Table 10 displays the most 
probable constituents of strategy for each cluster. This includes 
the annual level of demand for the selected drug, the group that 
the drug belonged to, and the time after which development 
of the next drug would commence. The reader is reminded that 
group 1 drugs have a low annual growth rate, while groups 2 
and 3 respectively have medium and high annual growth rates. 
Also, group 3 drugs have the greatest probability of achieving 
marketing approval while group 2 drugs have the least. Cluster 
1 consists of strategies that perform highly in mean positive 
NPV, such as SI and 52, and cluster 3 consists of strategies 
that have high values of p(NPV > 0). Cluster 2 represents 
strategies that balance both of these performance metrics more 
evenly, such as S3 and S4. The clusters and their member 
strategies are derived by application of the k-means clustering 
algorithm. For cluster 1, the most probable portfolio consists 
of one low-demand drug, one medium-demand drug, and three 
high-demand drugs from all three drug groups. Strategies in 
this cluster tend to utilize the largest number of high-demand 
drugs, which assists in explaining the larger mean positive NPV 
values generated by these strategies. Also, a larger portion of 
selected drugs belong to drugs with high and medium prob­
abilities of success. For cluster 3 at the opposite end of the Pareto 
front, the most probable portfolio is three medium-demand drugs 
and two high-demand drugs drawn from all three drug groups, 
which perhaps surprisingly highlights that cluster 3 strategies 
aim to meet a similar level of market demand as cluster 1 drugs. 
As cluster 3 strategies have significantly lower mean positive 
NPV values than cluster 1 strategies, this indicates that there 
are other decisions outside of portfolio structure which lower 
this profitability measure but may contribute to a greater p(NPV 
> 0) value. With the exception of one drug, the portfolio opts 
(or drugs with high and medium probabilities of success, thereby
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Table 9. Structure of the S4 Portfolio Development Strategy"
i D i c , l  Ci,2 C,,3 c,,4 C,,5 C,,6 Ci,7 Ci,g Ci,9 Ti
1 F I




I  I  PC
I  I  ID
/  I  FDA
I  I  FDA
/  I
° I, in-house activity; C, outsourced activity; P, partnered activity; 
Ci,i, target identification; Cm, preclinical studies; Ci,3 , phase 1 clinical 
development; Ci,4 , phase II clinical development; Q,;, phase 111 clinical 
development; C,6, phase 1 manufacturing; C p, phase II manufacturing; 
Ci,8, phase III manufacturing; Ci,9 , market. ID, target identification; PC, 
preclinical testing, PI/PII/PIII, phase I/II/III clinical trials; FDA, FDA 
review; MKT, market approval.
Table 10. Characteristics of Drug Selection and Timing Strategies 
in Each Cluster
cluster characteristic drug 1 drug 2 drug 3 drug 4 drug
1 demand M H L H H
drug group 2 1 2 3 3
timing ID FDA PHI FDA -
2 demand M L H H L
drug group 2 2 1 2 2
timing PC PC MKT FDA -
3 demand M M H H M
drug group 2 1 3 1 3
timing ID FDA PH PH —
ID, target identification; PC, preclinical testing, PI/PII/PIII, phase 1/11/ 
III clinical trials; FDA, FDA review; MKT, market approval; H, high; 
M, medium; L, low.
using more drugs of this type than the other clusters. This is 
intuitive because this cluster exhibits the greatest p(NPV > 0) 
values. Overall, there appear to be no clear trends in portfolio 
structuring strategies. The presence of certain portfolio structur­
ing decisions within certain clusters appears to align with the 
position in the objective space relative to other clusters, while 
there are others which do not. The remaining constituents of 
the portfolio development strategy will be investigated to 
discover if more overarching drivers of performance exist.
43.2. Timing Strategies. Decisions on timing are an im­
portant constituent of the portfolio development strategy as they 
are used to favorably organize cash flows. This is particularly 
important when having to consider the probability that a project 
will succeed, the financial impact of failed projects, and the 
impact of the discount factor when determining the mean 
positive NPV. In cluster 1, Table 10 shows that the prevailing 
strategy is to develop the first two drugs together coupled with 
long intervals of either 8 or 9 years between the development 
of the remaining drugs. Because of the probabilities of success 
of available drugs, it would be rational to expect only one 
successful drug within a portfolio of five projects. Also, it is 
observable that, when considering the growth and impact of 
the discount factor over time, cluster 1 strategies must rely 
considerably on the production of a successful drug from the 
first two projects. This assists in reasoning the low /?(NPV > 
0) values seen in this cluster. Remaining drugs have compara­
tively little impact on cash flows because of the extent to which 
their respective cash flows are discounted. This also provides 
an explanation for the superior mean positive NPV values, as 
when one successful drug emerges from within the first two 
projects its profits are not greatly discounted. Also, and 
importantly, profits from this drug will mainly need to absorb 
the expense of its own development and that of the other 
concurrent project. The cost of developing the remaining drugs 
is less restrictive as these are heavily discounted, although this 
occurs with a relatively modest probability. The time for
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development until the end of marketing for this strategy is 34 
years.
For cluster 2 it is shown that the first three drugs are most 
likely to be developed with short intervals of 1 year between 
them and that the time for development and marketing comple­
tion for this approach is 31 years. This strategy is a driver of 
the higher p(NPV > 0) values and the lower mean positive NPV 
values observed when making comparisons to cluster 1. Like 
cluster 1, the remaining drugs are likely to be developed with 
the longest intervals between them and are anticipated to have 
modest impacts on cash flow because of the magnitude of the 
discount factor at these stages in portfolio development. 
Considering this, such strategies are reliant on at least one 
successful drug emerging from the first three projects. Develop­
ing the first three drugs in close succession in cluster 2 bears a 
greater likelihood that at least one successful project will emerge 
from this group than from within the remaining two drugs. When 
a successful drug emerges from this group, because of a more 
favorable discount factor there is also a greater likelihood that 
it can also cover the expense of other failed projects than when 
developing two drugs in close succession. Having to effectively 
absorb the cost of an increased number of projects whose 
development costs are less discounted contributes to lower mean 
positive NPV values.
Strategies in cluster 3 exhibit a tendency to develop the first 
two drugs together followed by a period of at least 9 years; 
then later drugs are developed with medium-length intervals of 
4 years in between them. The time for development and 
marketing completion most likely in cluster 3 is 27 years. This 
strategy relies on at least one successful drug being found in 
two distinct groups, that is, a group of two drugs developed 
together at the outset and a group of three drugs developed in 
close succession later in the timeline. It has already been 
mentioned that the impact of developing two drugs together 
while positioning the remaining projects to subject them to far 
more significant discounting results in relatively high mean 
positive NPV values with relatively low probabilities o f success. 
It follows that some aspects of the development of the remaining 
three drugs contribute significantly to the high p(NPV > 0) 
values but low mean positive NPV values ultimately exhibited 
by strategies in this cluster. The shorter portfolio development 
time means that profits for each year are discounted by a 
significantly smaller extent than seen with clusters 1 and 2. 
Strategies in this cluster also take advantage of the high annual 
market growth rate and high probability of success of group 3 
drugs and position them late in the pipeline of products to 
maximize their potential for generating revenues that overcome 
the magnitude of the discounting. This is important because if 
each drug is to contribute significantly to the revenue generated 
by the portfolio, then any successful drugs must support up to 
four failed projects, which helps to explain the smaller mean 
positive NPV values. Also, it is more likely to see at least one 
successful drug emerge from within the second group of three 
projects than from the first group of two. When this occurs, 
profits arise from these drugs which are heavily discounted and 
must also be enough to cover the expenses of failed projects 
which are less heavily discounted. This further erodes the 
potential magnitude for mean positive NPV. Overall, the trend 
with timing strategies is that portfolio development times tend 
to become progressively shorter towîird the right-hand side of 
the frontier and that strategies make use of grouping projects 
nuire closely together. Interestingly, the presence of the discount 
factor appears to have a significant influence on strategy 
tormulation. Hence it is anticipated that alternative settings for
Table 11. Selected Probabilities of Third Party Strategies"
Di Cu C.-.2 Ci.2 C,4 Ci,5 Cify Cij Q.S C,9 P
drugl I I I
Cluster 1 
7 7 I I 7 7 0.64
I / I 7 P I I p P 0.18
drug2 / I I 7 I I I I I 0.64
I c c C C I I I C 0.12
dnigS I I I 7 I I I I I 0.64
C I c C C c c c P 0.12
drug4 I I I 7 I I I I I 0.64
I I I C C c c c I 0.10
drugs I I I 7 I I I I 7 0.63
/ / I C C I I I C 0.09




7 I I I 7 0.38
I p p P P p p p P O.IS
drug2 / I I I I I I I I 0.38
c I I I I I 7 c P O.IS
drug3 I / I I I I 7 I I 0.38
c c I I C I 7 I P 0.13
drug4 I / I I I I 7 I I 0.38
I c I C C c C c C O.IS
drugS I I I I I I 7 I I 0.38
I c c C C c C c P O.IS
drugl I I I I
Cluster 3 
7 I 7 I 7 0.54
I I I I P I 7 p P 0.26
drug2 I I / 7 I I 7 I I 0.S3
/ c c C C I 7 I C 0.16
drug3 1 1 7 7 I I 7 7 I 0.S3
c I c C C I 7 7 C 0.14
drug4 I I 7 7 I I 7 7 I 0.S3
I I 7 C C c C C I O.IS
drugs I I 7 7 I I 7 7 I 0.S3
I I 7 7 C c C C C 0.10
" For each D, in each cluster, the two most probable strategies have 
been displayed; I, in-house activity; C ,  outsourced activity; P, partnered 
activity; C ,, i ,  target identification; C ,.2 , preclinical studies; Q 3 ,  phase I 
cliniczd development; Cj,4, phase II clinical development; C, ;, phase III 
clinical development; C ,,6 , phase I manufacturing; C /,7 , phase II 
manufacturing; C ,,8 , phase III manufacturing; C,.g, market.
the discount rate may result in a noticeably different set of 
superior strategies.
4.3.3. Third Party Strategies. The probability of selecting 
a particular strategy for a particular drug position in a particular 
cluster of the objective space is addressed, and the top two 
strategies in each circumstance are shown in Table 11. In all 
cases the most probable third party strategy for each drug is to 
integrate all activities in-house. This is intuitive from the 
viewpoint of minimizing contracting fees and premiums as well 
as avoiding the sharing of sales revenues and royalty charges. 
As seen in Table 11 and with strategies SI through 84, 
alternative third party strategies are present in significant 
proportion within the population. This demonstrates that when 
supported by appropriate strategic decisions in other areas these 
are viable constituents of superior strategies. It is postulated 
that one possible reason for complete in-house strategies to be 
present with significant likelihoods is that such strategies may 
serve as a more flexible building block than others for creating 
superior portfolio development strategies. With the aim of 
managing the impact of failure, it may seem counterintuitive 
for a company to go the entire drug development process without 
third party assistance. Because no budgetary constraint exists, 
in such scenarios there is no direct requirement to limit the 
impact of failure. However, to some degree maximizing mean 
positive NPV is likely to involve some mitigation of the impact 
of failure. As might be expected, it can be seen that strategies 
in cluster 1 are most likely to choose to develop drugs entirely
in-house as these offer the greatest potential for achieving the 
greatest mean positive NPV values if the drug passes all stages 
of testing and review. For the first drug an alternative strategy, 
albeit much less likely in this case, is to partner from the 
commencement of phase III clinical trials or from preclinical 
testing. Partnering from phase III clinical trials allows for some 
savings on the proportion of revenue that must be paid to the 
partner. Partnering from preclinical testing onward allows for 
the impact of failure to be shared, but a substantial share of 
any sales revenues must be paid to the partner. Across all 
clusters strategies tend to utilize partners much less intensively 
from drug 1 onward, where partners are used almost exclusively 
for commercial manufacturing and contractors are preferred. The 
use of contractors does not appear to be limited to a particular 
set or series of activities, and in most cases the use of contractors 
is a supplement to integrated activities. Finally, although the 
model shows that in-house activities are the most probable for 
optimized strategies, the presence of budgetary constraints is 
expected to impact such a decision. This will be explained in a 
later paper.^*
5. Conclusions
The development of a stochastic multiobjective combinatorial 
optimization framework has been presented that addresses three 
key decisions simultaneously: portfolio management, scheduling 
of drug development and manufacturing, and the involvement 
of third parties for specific activities. Demonstrated within this 
work is the value carried by considering these critical strategic 
considerations within a unified framework that simulates and 
optimizes all such decisions across the entire product portfolio. 
A case study was used to illustrate the capabilities of the 
framework and also highlighted that the scope of decisions that 
a drug developer may be confronted with can be vast and 
complex. Due to the complexity of this problem, a principle 
contribution of this work is in demonstrating a formulation based 
on techniques from artificial intelligence, in particular evolution­
ary computation and machine learning, employed for an efficient 
search of the decision space and for effective traversing of the 
objective space.
It is proposed that biopharmaceutical product development 
strategies in the real world may be better analyzed when 
considering the impact of decisions holistically rather than only 
individually. One reason for this is the presence of dependencies 
between decisions that may impact economic relationships. 
Another is that it has been demonstrated that an effective 
strategy for portfolio development can result in a p(NPV > 0) 
value that is significantly greater than the probability of 
successful development for any singular drug in the portfolio. 
Hence, by considering a portfolio of multiple drugs it is possible 
to control its risk to some extent through careful strategic 
formulation, while this is not possible with a singular drug. Use 
of the model has highlighted that pursuit of mean positive NPV 
can conflict with pursuit of high p(NPV > 0) values, although 
this may change under different case study settings. The results 
of the case study lean toward suggesting the integration of all 
activities in-house. This can conflict with common perspectives 
in industry that accept such strategies with reluctance because 
of the uncertainty of the drug development process and the 
consequential impact of failure. The added presence of budgetary 
constraints and a range of sizes for the portfolio would serve 
as factors that can further capture limitations in the real world 
and arc also capable of significantly influencing results seen 
hero; this is explored in a further paper.^* Furthermore, the 
optimal set of solutions is expected to be sensitive to the relative
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difference in manufacturing efficiencies assumed between in- 
house and external manufacturing.
Finally, the learning of Bayesian networks from superior 
solutions presented here has been shown to be effective and 
efficient in improving the population, and in discovering a dense 
and widespread Pareto front. Their effectiveness is presumed 
to be due to their ability to iteratively learn and exploit the 
structure of the problem as noted by contributions in artificial 
intelligence literature. A noteworthy insight from using the 
framework is that use of machine learning has potential for 
future development in solving portfolio development and 
capacity planning problems simultaneously.
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Appendix A. Selection of Superior Candidate Solutions
To facilitate the selection of superior candidate solutions, fast 
dominated sorting and crowding distance algorithms'^ are used 
together. Both procedures are used to support the discovery of 
a widespread and densely populated Pareto optimal front. Fast 
dominated sorting ranks each strategy according to its degree 
of Pareto optimality in the objective space. A candidate solution 
is Pareto optimal if there is no other solution that exists which 
yields an improvement in any objective without yielding 
degradation in any other objective. To support the function of 
this sorting procedure, crowding distance is used to determine 
the proximity of a candidate solution to others in the objective 
space. The crowding distance measure for a candidate solution 
is the perimeter of the cuboid created by its two most proximal 
candidate solutions in the objective space. The premise is that 
candidate solutions situated in less densely populated areas of 
the objective space are considered to be more unique and thus 
can contain information not already discovered. Probabilistic 
models that are more inclusive of unique candidate solutions 
facilitate the use of a diverse base of information for the 
formulation of new superior candidates. Fast nondominated 
sorting is used first to select candidate solutions in order of rank 
and add them to the set of superior performing candidate 
solutions, S{t). If all the members sharing the same rank will 
not fit into S(t), then candidate solutions are chosen in order of 
those having the greatest crowding distance. Algorithmically 
steering the optimization procedure toward greater inclusion of 
candidate solutions along the Pareto front has its advantages 
here. First, the nature and severity of conflict between objectives 
can be better understood with wider coverage of the objective 
space. Second, a more efficient traversing of the objective space 
can be achieved through accelerated progress at individual 
iterations due to probabilistic models that model nondominated 
solutions more closely.
Appendix B. t-Means Clustering
Once S(t) has been populated, it is clustered so that the properties 
of superior candidate solutions can be analyzed for region- 
specific properties in the objective space. The A:-means clustering 
algorithm'^ ® was selected for this purpose because its ease of
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Figure 6 . Allowable and disallowable Bayesian network structures, (a) An 
example of an allowed Bayesian network structure consisting of three nodes.
has no parents and is the parent of 62^  and 63 .^ 62^  has one parent, 
61^, and is the parent of 63 .^ 63^ has two parents, and 62^ , and no 
children. Two Bayesian network structures that are disallowed in the model: 
(b) has a node that is directed to itself; (c) 6 ,^ is part of a network 
structure that is later directed back to itself.
implementation. The advantage of clustering the objective space 
is that a probabilistic model can be built for each cluster, thereby 
supporting the generation of a widespread Pareto front. This 
algorithm requires the number of clusters to be specified by 
the decision maker.
Appendix C. Constructing the Bayesian Network
Bayesian networks" '^ are used here to characterize the proba­
bilistic nature of relationships between decision variables and 
their instances occurring in the set of candidate solutions of 
the zth cluster, K^ , via machine learning. This data structure is 
subsequently sampled for the generation of G(t +  1). As the 
objective space is partitioned into z clusters a Bayesian network, 
B;, is constructed for each z. Each decision variable, (5„, is 
represented by a node, ô„^, in the network Any relationships 
between each are represented by a directed edge drawn 
between them (Figure 6). The node from where the edge is 
directed is a parent node, while the node to which the edge is 
directed is its child node. That is, within each the instance 
of each child node is conditional upon the set of instances of 
its parents. It is important to note that all B ,’s are acyclic, 
so a node cannot be directed to itself nor can it be part of a 
structure within Bj that eventually ends up being directed to 
itself (Figure 6).
In order to avoid this, this paper takes advantage of the nature 
of the problem for which this framework is developed and puts 
all into ascending order according to the time in the 
development schedule that each ô„,z. occurs. Hence, this sequence 
will be
=  <^ 2.z =  C ,=  „  ^ 3 .2 = 7 ’,= ,,  <54, =  D ,= 2 , ^5 ,z =
^ 1 = 2 ’ -  ^ / = 2 ......... ^ 3 , . ;  —  T 'i= l - V  <^3<-2.z ~  A = / ’ ^ 3 , - l . z  =  ^ i = I
where D, is the decision variable representing the choice of the 
iih drug, C, is the decision variable for the choice of corporate 
relations strategy for the /th drug, and T, is the decision choice 
for the length of time to wait before development of drug / —
1 is commenced. The stipulation is imposed that no edge can 
be directed from any (3, to any other 6, which occurs before it 
in this specified time order.
The procedure for constructing B; from is now described. 
A score-based approach is used with the Bayesian Dirichlet (BD) 
metric and the network is constructed with the intent to 
maximize this score. The BD metric is a measure of how closely 
B mcxlels the data in K~. The construction procedure begins 
with an empty network and each possibility for adding the next 
directed edge in B^  is scored. The next directed edge to be added 
will be the one that maximizes the value of the BD metric. This 
process continues until no improvement in score can be 
achieved. Additionally, no restrictions are imposed on the 
complexity of the network that can be built so that no important 
topological details are lost.
The BD metric for B% given and background information, 
is denoted by p(K^, B^ l^ ) and is defined as
t4  t t  r(e'(jr^ ))
l i  ' )
where p(BJi^) is the prior probability of B^ ; 0n^ ,m is the nth node 
instantiated to the /nth value in K{, the product over Jid„^  runs 
over all instances of all parents of the product over 0n,z,m 
runs over all instances of <5„^ ; e(jid^) is the number of instances 
in where the parent nodes of ô„ ,^ are instantiated to 
E{ôn ,^m,^d„J is the number of instances in that have 
0„  ^ equal to and set to and T(z) is the Gamma 
function where F(x) =  (jc — 1)! When the set Il(5„^  is empty, 
there is one instance of that is equal to 0, and the number 
of instances is set to the number of members of IX^ I. 
Additionally
(20)
where is an instance of the parents of (5„,z that is summed 
over all instances of <5„^ . The numbers and piB^\^)
represent prior information about the problem that can be 
incorporated into the metric.
The extent to which the network being measured represents 
another network relevant to the problem is measured by p(B^\^). 
There are a number of methods available for calculating p(B^\^). 
In this paper all networks are treated equally; thus //(B I^Ç) is set 
to 1. There are also a variety of methods for setting the numbers 
for example, see Buntine,'^  ^ Heckerman et al.,^  ^
and Yang and Chang.'*  ^ In particular, research by Yang and 
Chang”^  ^has demonstrated that, for a range of integer values of 
e'(<5n,z,m,.Tô„^ ) between 1 and 10, and also for other methods 
considered for scoring Bayesian network topology, the BD 
metric with =  10 ranked as one of the best for
discovering the true structure of the Bayesian network. Accord­
ingly, =  10 is used here. Additionally, because
the factorials in eq 20 can grow to unmanageably large numbers, 
especially within large sizes of K^ , its logarithmic equivalent is 
used.
Appendix D. Regenerating the Population
In generating G(t +  1 ) each 0n,z is treated as a random variable 
that can be instantiated to any of its possible instances subject 
to probabilities encoded by B^ . For each decision variable all 
probabilities for each possible conditional upon each
possible given are computationally determined and 
referenced when needed. The process for generating one 
candidate solution for G(t+1) requires itarative sampling of B^ .
The joint distribution encoded by Bj can be written as
(2 1 )
where ôj =  (ô]j,Ô2 j , ..., Ôn^ ) is a vector of random variables 
representing the entire set of decision variables, and /?((5n.,in^„,) 
is the conditional probability of ô^ .z given its set of parent 
variables Intuitively, this conditional probability is defined
) = B(n. ) (22)
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Each K. is proportionally represented in the generation of 
G(t +  1). As S(r) contains half the solutions present in G(f), 
the number of solutions generated using each is 2\K^.
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